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PREFACE 
The experimental work described in this thesis was carried out in the 
Department of Biochemistry, University of Natal, Pietermaritzburg, from 
February 1991 to December 1996, under the supervision of Prof. Clive 
Dennison. 
These studies represent original work by the author and have not been 
submitted in any other form to another university. Where use was made of 
the work of others, it has been duly acknowledged in the text. 




A variety of proteases have been shown to promote the progression of cancer by 
virtue of their ability to degrade extracellular proteinaceous barriers, such as 
basement membrane and interstitial stroma. At the outset of this study available 
evidence strongly implicated cathepsin D in breast cancer metastasis. It was 
envisaged that an antibody inhibitory to the activity of this enzyme might retard 
invasion, and restrain a tumour from spreading. To this end anti-peptide 
antibodies were generated against a peptide sequence derived from the substrate 
capturing "flap" of the enzyme. Inhibition of enzyme activity by these antibodies 
could not be demonstrated, probably due to the lack of a suitably sensitive 
enzyme assay. However, the rationale of this study and the expertise gained from 
it could be applied, in the future, to enzymes that have since been found to be 
more relevant to tumour invasion. 
A feature of many transformed cells is an anomalous lysosomal enzyme 
trafficking system, and concomitant hyper-secretion of some enzymes. The 
distribution of low pH compartments and lysosomal enzyme-containing 
compartments was investigated in human breast epithelial cells, and their c-Ha-
ras-transformed counterparts. Immunofluorescence and immunoelectron 
microscopy showed that these compartments have a more peripheral cellular 
distribution with respect to normal cells, and cathepsins Band D were cell 
s urface-associa ted. 
Studies were undertaken to reveal the extracellular matrix degrading ability of c-
Ha-ras-transformed cells. Transformed cells exhibited increased degradation of 
fluorescein-labelled extracellular matrix in serum free medium, and increased 
iii 
motility, and degradation and disruption of extracellular matrix in serum-
containing medium. In vitro invasion through artificial basement membrane by 
transformed cells was investigated using scanning electron microscopy, and was 
further used to preliminarily identify the proteases involved in invasion by 
specific inhibition. By this means, greatest inhibition of in vitro invasion was 
obtained using a specific metalloproteinase inhibitor. Overexpression by 
transformed cells of a metalloproteinase was detecte~ by gelatin zymography. 
Together these results suggest that the increased invasive capacity of ras-
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1.1 The biology of tumour progression 
For many years there has been a tendency to classify cancer as a single disease. It 
is now clear, however, that cancer is a complex of malignancies many of which 
appear phenotypically similar, but are characterised by subtle differences in 
mol~cular mechanisms. One common denominator to all malignant cancers is 
metastasis which, despite major advances in surgical techniques and adjuvant 
therapies, is still the major cause of death in human cancer. This is reflected by 
the fact that approximately 50% of patients diagnosed with cancer will have 
distant metastases at the time of diagnosis (Crissman, 1989). Radical therapies 
directed at the primary tumour will, therefore, not improve survival for this 
subgroup of patients. Although invasion is an important component of the 
metastatic process, this process has often already been completed at the time of 
diagnosis, and is therefore not available for therapeutic intervention. It has been 
suggested, therefore, that therapeutic developmental efforts be focused on the last 
steps in metastatic dissemination, i.e., colonisation and angiogenesis (Weins tat-
Saslow and Steeg, 1994). However, mapping the proteolytic profile of human 
cancers may be useful both as a guide to the development of prognostic markers 
and in the design of anti-proteolytic strategies aimed at controlling the disease. 
Extracellular proteolysis, for instance, is implicated in growth factor activation 
and release, which in turn may enhance proliferation of malignant cells or 
trigger angiogenesis. 
Malignancy is a systemic disease in which the tumour cells' interaction with the 
vasculature forms an integral part of the pathological process. The first step in 
this process is tumour neoangiogenesis, or the development of new blood 
vasculature associated with the tumour, accomplished by the secretion of several 
angiogenic factors by tumour and host cells (Fidler and Ellis, 1994). Failure to 
recruit and establish new blood vessels to supply essential nutrients and oxygen 
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for growth, results in small, latent tumours which may remain viable for 
decades. Metastases are rarely associated with avascular tumours. Upon 
vascularisation, however, the tumour cells begin to grow in a cylindrical pattern 
around the new microvessels (Folkman and Shing, 1992), followed by tumour 
cell detachment from the primary neoplasm. Tumour cells are thought to 
separate more easily from the solid tumour mass than corresponding normal 
cells from surrounding tissue (Nicolson, 1988). 
For tumour dissemination to occur, the unconstrained malignant cells must gain 
access to a vasculature, either haematogenous or lymphatic. Tumour 
interstitium, however, generally lacks lymphatic vasculature and entry of 
tumour cells into circulation usually takes place via tumour blood vessels. 
Furthermore, tumour-induced blood vessels are fragile and permeable, thereby 
increasing the potential for penetration (Blood and Zetter, 1990). 
Upon gaining access to the vasculature, cells are subjected to a number of 
sequential or sometimes concurrent events and processes. These include (Liotta 
et al., 1986b): transport and survival of tumour cells in the vasculature, 
interactions of tumour cells with platelets and/ or leucocytes, arrest and adhesion 
to the endothelium of the target organ, tumour cell adhesion to the 
subendothelial basement membrane (BM), extravasation from the vasculature, 
~econdary tumour growth and angiogenesis. Only a small population of cells 
from the primary tumour will accomplish all stages of metastasis and form a 
secondary tumour. A secondary tumour can, in turn, initiate another round of 
metastasis to give rise to tertiary metastases down~tream from the secondary 
tumour. It is clear that the arrest of the metastatic process at any of its stages will 
have great therapeutic value in patients with actively metastasising tumours. 
The interstitial stroma and BMs of most tissues do not normally contain pre-
existing passageways for cells. Only during events such as tissue remodelling, 
wound healing, inflammation and neoplasia do these matrices become focally 
permeable to migrating cells. Liotta et al. (1986b) have proposed a three-step 
hypothesis describing the sequence of biochemical events during tumour cell 
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invasion of the extracellular matrix (ECM). In the first step the tumour cell 
attaches to components of the matrix such as . laminin, fibronectin and 
vitronectin in EM and fibronectin in stroma, a process mediated by cell adhesion 
receptors (Zetter, 1993). The anchored cells then secrete hydrolytic enzymes (or 
induce host cells to secrete enzymes) which locally degrade matrix. The third step 
is tumour cell locomotion through the region of matrix degraded by enzymatic 
action. 
The vascular endothelium plays dual and opposing roles: it provides a site for 
receptor-mediated tumour cell adhesion, but also serves as a barrier to 
extravasation. Kramer and Nicolson (1979) first demonstrated tumour cell 
adhesion to endothelial cell monolayers, and subsequent endothelial cell 
retraction (Nicolson, 1982) and tumour cell migration to the exposed underlying 
subendothelial matrix. Menter et al. (1987) demonstrated that tumour cell 
adhesion to endothelial cells and the subendothelial matrix is enhanced in the 
presence of platelets. One platelet factor that can transfer from activated platelets 
to endothelial cells is the lip oxygenase product of arachidonic acid, 12(S)-
hydroxyeicosatetraenoic acid, generated during tumour cell-platelet-endothelial 
cell interactions. This compound has been shown to induce reversible 
endothelial cell retraction, allowing tumour cells access to the subendothelial 
matrix (Bonn et al., 1989). Directed movement of tumour cells from sites of 
initial attachment on endothelial cells may be mediated initially by fibronectin 
associated with the endothelial EM, thereby creating a haptotactic gradient toward 
the BM (Kramer et aI., 1980; McCarthy and Furcht, 1984). Motivation for tumour 
extravasation through the BM appears to be a function of motility factors or 
soluble gradients of ECM derived fragments acting as chemotaxins (Hart et al., 
1989). Autocrine motility factor and scatter factor have been proposed to a playa 
major role in the local invasive behaviour of tumour cells and may also facilitate 
the concerted invasion by groups of tumour cells (Liotta et al., 1986a; Gherardi 
et al., 1989). 
During the development of invasive tumours, tumour cells disobey the social 
order of organ boundaries and cross into tissues where they do not belong. The 
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BM acts as an interface between histologically distinct tissues, separating organ 
cells, epithelia and endothelia from the interstitial stroma. The BM plays a role 
in cell adhesion, providing a support for growing cells, forming selective 
permeability barriers for proteins and is important for morphogenesis and 
mitogenesis. The biochemical components are a BM-specific collagen, type IV 
collagen, which forms the structural framework; the glycoproteins laminin and 
fibronectin; a heparin sulfate proteoglycan specific for the BM; entactin and 
nidogen (Pauli et al., 1983; Liotta et al., 1986b). The interstitial stroma is a 
complex matrix composed of cells located in a meshwork of collagen fibres (types 
I and III), glycoproteins and proteoglycans (Tryggvason et al., 1987). This is a 
widely distributed tissue that has major mechanical and supportive functions 
and is present in bone, tendons, cartilage, ligaments and as tissue stroma. 
It is clear, however, that although mechanisms exist for tumour cell arrest, 
attachment and migration out of the vasculature, the BM still constitutes a 
barrier which must be compromised for extravasation to occur. For this reason, 
degradation of the biochemically complex ECM is a hallmark of the metastatic 
~ process. The -involvement and relevance of secreted proteolytic enzymes during 
tumour invasion is now firmly acknowledged. Invasive tumour cells secrete a 
variety of matrix-degrading proteases, or induce their secretion in host cells 
(Himelstein et al., 1994), resulting in focal lysis of the BM at regions close to the 
tumour cell surface (Sloane et al., 1982; Woolley et al., 1984; DaIl0 et al., 1985; 
Rochefort et al., 1987). 
A variety of normal physiological processes also require proteolytic modification 
of the ECM. Leucocytes extravasate out of the bloodstream in response to stimuli 
associated with inflammation (Weis, 1989). Resorption of bone by osteoc1asts 
involves the secretion of proteolytic enzymes (Eeckhout, 1990), as does 
cytotrophoblast invasion of the BM of the uterus during implantation (Librach 
et al., 1991). Wound healing and tissue remodelling require proteolytic activity 
directed at ECM (Alexander and Werb, 1989), and angiogenesis by normal 
endothelial cells shares many properties in common with tumour invasion 
(Liotta et al., 1991). Rheumatoid arthritis (Weston and Poole, 1973), pulmonary 
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emphysema (Bieth, 1992) and non-neoplastic invasion by parasites (Doenhoff 
et al., 1990) are pathologies also characterised by proteolytic degradation of ECM 
barriers. 
A unifying principle of malignant neoplasms appears to be an imbalance of 
proteolysis which favours invasion. The defect in the tumour cell cannot simply 
be unbridled production of degradative enzymes, as cell migration requires 
attachment and detachment of the cell as it moves forward. Lysis of matrix 
components would remove the substratum necessary for proper cell traction. It 
is thus probable that the invading tumour cell uses proteolysis in a highly 
organised manner that is functionally little different from cells that would 
normally migrate through tissue barriers (Liotta and Stetler-Stevenson, 1991). 
The difference is that tumour cells achieve invasion by proteolysis and motility 
at times and places inappropriate for normal cells. 
The success of the invasive phenotype, however, is a function of the balance 
between active proteases and their inhibitors. In an in vitro model of tumour 
cell invasion using amniotic membranes, .a -bimodal .rElationship between 
invasion and plasminogen activator activity was demonstrated. The invasive 
behaviour of Bowes' melanoma cells, which produce large amounts of tissue-
type plasminogen activator (tP A), and HT 1080 fibrosarcoma cells, which produce 
large amounts of urokinase-type plasminogen activator (uPA), is not blocked but 
enhanced by the addition of plasmin inhibitors or anti-plasmin antibodies. 
Conversely, the invasive capacity of cells which produce low levels of these 
proteases was blocked. Excessive proteolysis in the melanoma and fibrosarcoma 
cells may cause uncontrolled matrix degradation and the interruption of cell-
matrix interactions necessary for invasion. Addition of inhibitors of proteolysis, 
would reduce degradation to a level compatible with invasion (Tsuboi and 
Rifkin, 1990). 
A large body of evidence shows increased amounts of proteinase activity and 
secretion in malignant tumour tissue samples and cultured transformed or 
tumour cells (Liotta et al., 1979; Recklies et al., 1982; Nakajima et al., 1983; Reich 
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et al., 1988). In some cases a direct correlation between metastatic potential of 
tumour cells and the production of certain proteinases has been claimed (Liotta 
et al., 1980; Sloane and Honn, 1984). Proteinases are grouped into four main 
classes depending on their catalytic site, pH optimum, susceptibility to inhibitors 
and cation requirements (Table 1). Proteinases that have most frequently been 
associated with the malignant phenotype are the collagenases, plasminogen 
activators and cathepsins, but other enzymes such as elastase (Kao and Stern, 
1986), chymotrypsin-like proteinases (Kinder et aI., 1992) and heparanase 
(Nakajima et al., 1983) have also been implicated. 
A complex set of interactions has been suggested whereby proteases of different 
classes activate other proteases thus amplifying the degradative process. In vitro 
experiments usually require a high molar excess of the activating protease 
(Goretzki et al., 1992), but if the proteases were concentrated on the plasma 
membrane in close proximity to each other, such an excess may not be necessary. 
In this way the degradation process is localised to sites where the cell surface is in 
contact with the ECM (Chen et al., 1985). Focal adhesions, responsible for 
-attachment of cells to the -ECM, are found at the periphery of the ventral cell 
surface, whereas invadopodia, cell surface extensions that protrude into the lysed 
ECM, are found at central sites of the cell, at the leading edge of invasion (Chen 
and Monsky, 1993). Invadopodia have been found to actively degrade matrix 
substrates, leading to cell invasion (Chen, 1989), and this interaction may be 
protected from the effects of protease inhibitors by peripheral focal contacts, thus 
amplifying the proteolytic cascade (Campbell and Campbell, 1988; Chen and 
Monsky, 1993). The most closely studied proteases recruited to the cell surface are 








General characteristics of the four classes of proteinases (adapted from 
Nakajima et al., 1987; Tryggvason et aI., 1987). 
*Examples pH range Inhibitor 
for activity 
collagenases, gelatinases, 7-9 metal chelators, 
stromelysin neutral TIMP 
neutral 







cathepsins B, H, L, 3-8 iodoacetate, 
5, N, T, 0 N-ethy l-maleirnide, 
cystatins 
pepsin, renin, 2-7 pepstatin A 
cathepsins D, E 
*Relationships between tumour invasiveness or metastatic activity and 
activity of tumour-associated enzymes (in italics) have been reported. 
1.2 Matrix-metalloproteinases 
The MMPs are a family of zinc metalloenzymes, which have been grouped into 
three broad categories based on substrate preference: interstitial collagenases, type 
IV collagenases (gelatinases) and stromelysins (Stetler-Stevenson et al., 1993). 
Interstitial collagenase and neutrophil collagenase are grouped because of their 
specificity for type I, II and III collagen degradation. The stromelysins are three 
related gene products, stromelysin, stromelysin 2, and matrilysin which degrade a 
variety of matrix components including proteoglycans, non-collagenous 
glycoproteins such as laminin and fibronectin and the non-collagenous domain 
of type IV collagen (Liotta and Stetler-Stevenson, 1991; Stetler-Stevenson et aI., 
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1993). The type IV collagenases are so named because of their selective ability to 
cleave type IV collagen; the 72 kDa (gelatinase B) and 92 kDa (gelatinase A) forms 
being unique gene products (Liotta and Stetler-Stevenson, 1991). 
Gelatinases are secreted as inactive zymogens and enzyme activation is thought 
to be an important control step in proteolysis . Studies have clearly demonstrated 
a positive correlation between MMP expression, invasive behaviour and 
metastatic potential in experimental systems (Liotta et al., 1980; Chen et al., 1991; 
Pyke et al., 1992; Aimes et al., 1994). These proteases are also an important 
component of the invasive phenotype in human tumours, including breast, 
prostate, colon, lung, ovarian and thyroid cancers (Stetler-Stevenson et al., 1993). 
Furthermore, antibodies (Hoyhtya et al., 1990), and other gelatinase inhibitors 
(Reich et al., 1988) prevented tumour cell invasion in vitro. It is believed, 
however, that the ratio of active enzyme species to latent proenzyme may 
provide a better correlation with invasive potential than overall levels of the 
enzyme. 
There is evidence that the latent MMPs bind to the plasma membrane where 
activation takes place. The human breast cancer cell lines MDA-MB231 and 
MCF-7 contain a cell surface, high affinity receptor for the 72 kDa MMP (Emonard 
et al., 1992) and the invadopodia of transformed chicken embryo fibroblasts 
. contain activated 72 kDa MMP (Monsky et al., 1993). Activation of this MMP has 
recently been elucidated, and is mediated by an integral plasma membrane 
protein, the first membrane-type MMP (MT-MMP) to be discovered (Sato et al., 
1994; Vassalli and Pepper, 1994). Indeed, in human gliomas increased MT-MMP 
expression correlates with increased expression and activation of the 72 kDa 
MMP during malignant progression in vivo (Yamamoto et al., 1996). In contrast, 
the 92 kDa MMP is activated by a mechanism which is cell surface associated but 
independent of the 72 kDa MMP activation mechanism. 
Secretion and activation of MMPs is not enough to ensure that they will degrade 
the target matrix substrate. Tissue inhibitor of metalloproteinases (TIMPs) 
produced by the tumour or the host can bind to latent and active MMPs (Liotta 
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and Stetler-Stevenson, 1991). Tight-binding 1:1 complexes form between TIMP-1 
and TIMP-2, and 92 kDa MMP and 72 kDa MNIP respectively. Exogenously added 
TIMPs are inhibitors of invasion through reconstituted extracellular matrix 
(Schultz et al., 1988), and overexpression of TIMP-1 in metastatic melanoma cells 
suppressed metastasis in vivo (Khokha, 1994), indicating that net invasive 
activity depends upon the balance between the levels of activated enzyme and 
TIMPs (Kishi et al., 1994). These metalloproteinase inhibitors have also been 
demonstrated to have an effect on tumour growth. TIMP-1 and TTh1P-2 have 
both been shown, in vitro, to have potent growth-promoting activities for a wide 
range of cells (Hayakawa et al., 1994). In contrast, TIMP-1 overexpressed in B16 
mouse melanoma cells resulted in a substantial decline in tumour growth in 
vivo (Khokha et al., 1992) without reducing their ability to extravasate (Koop 
et al., 1994). Several non-mutually exclusive reasons may exist for the growth 
inhibitory effect of protease inhibitors. First, many protease inhibitors have been 
shown to inhibit angiogenesis (Johnson et al., 1994), which is likely to 
significantly limit growth rate in v iv o; and secondly, proteinase inhibitors, by 
exerting control over proteolytic activity, could in turn control the bioavailability 
of matrix-bound growth factors. 
1.3 The urokinase-type plasminogen activator system 
The uP A system provides a model for the binding of secreted proteases to the cell 
surface with subsequent activation. Many cells display specific receptors for uP A 
and a single class of receptors binds both plasminogen and plasmin. Binding 
does not involve the active site and receptor bound plasmin and uP A are 
catalytically active and are not internalised. _ Co-expression of 
plasmin/ plasminogen and uP A receptors provide tumour cells with a 
mechanism to generate and localise protease activity to the cell surface (Testa and 
Quigley, 1990). It has been shown that receptor-bound uP A mediates the 
activation of plasminogen at the cell surface. The plasmin generated, in turn, 
activates surface-bound pro-uP A (Stephens et al., 1989). Pro-uP A may also be 
converted by plasma kallikrein (Schmitt et al., 1992), or the cysteine proteinases, 
cathepsins B (Kobayashi et al., 1993) and L (Goretzki et al., 1992). Receptor-bound 
uPA can be inactivated by plasminogen activator inhibitors (PAl), PAl-l and PAI-
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2, but receptor-bound plasmin is inaccessible to serum inhibitors (Stephens et aI., 
1989) and is active against a variety of ECM molecules including fibrin, 
. fibronectin and laminin (Schmitt et al. , 1992). The interaction between receptor-
bound uPA and PAl-lor PAI-2 results in internalisation and subsequent 
degradation of the enzyme/inhibitor complexes (Testa and Quigley, 1990). 
Elevated levels of uP A have been determined in almost all cancer tissues 
examined, and related to the increased invasive potential of tumour cells 
(Chucholowski et al., 1991). Tumour cell surface-associated uP A and plasmin 
mediate the degradation of tumour stroma and basement membrane (Quax et al., 
1991; Kobayashi et al., 1992) and the clinical relevance of these findings for breast 
cancer has been established, indicating uP A to be an independent prognostic 
factor for early recurrences and shorter overall survival (Chucholowski et al., 
1991). Inhibitors of uP A have been shown to inhibit in vitro invasion of the 
ECM by several neoplastic cell lines (Reich et aI., 1988; Kobayashi et al., 1995), and 
anti-catalytic antibodies delayed the onset of pulmonary metastasis by human 
carcinoma cells in the chicken embryo invasion model (Ossowski and Reich, 
1983). In fact, uP A expression alone is sufficient to confer to non-invasive mouse 
L cells an experimental invasive phenotype (Cajot et al., 1989), while highly 
invasive cells expressing recombinant P AI-2 were found to have their receptor-
bound uP A activity neutralised, resulting in suppression of matrix protein 
degradation and inhibition of invasion in vitro (Laug et al., 1993). In addition, 
the metastatic process in vivo is sensitive to uPA receptor blockade by 
catalytically inactive uP A mutants (Crowley et al., 1993), as well as antisense 
inhibi!ion of the receptor in human carcinoma cells (Kook et al., 1994). It is 
interesting to note that tP A, in contrast to uP A, appears not to playa significant 
role in tumour invasion, but is mainly involved in intravascular thrombolysis 
(Schmitt et al., 1992). 
A number of studies have shown that both uP A and type IV collagenase are 
produced by tumour cells as they invade reconstituted basement membrane, and 
inhibitors of these enzymes block invasion (Mignatti et aI., 1986; Reich et aI., 
1988). There is evidence from these studies that the cleavage of type IV collagen 
11 
is the permissive event during in vitro invasion because, a) a hydroxamic acid 
collagenase inhibitor blocks invasion, b) radiolabelled type IV collagen added to 
reconstituted basement membrane was degraded as cells invaded, c) bacterial 
collagenase increases invasion of cells, and d) the inhibition of uP A and plasmin 
could be bypassed using an organomercurial activator of procollagenase. It 
appears, in this case, that uP A-activated plasmin probably acts as an upstream 
activator of type IV collagenase, although a contributory effect of plasrnin on 
ECM lysis by virtue of its fibrinolytic and lamininolytic activities, is possible. In 
contrast, with human melanoma cells that secrete large amounts of uP A and 
interstitial collagenase, removal of glycoproteins by uP A was found to be a 
prerequisite and rate-limiting step for the degradation of interstitial collagen 
(Montgomery et al., 1993). This may reflect the implementation of different 
strategies for different environments. 
An association between levels and activities of the lysosomal cathepsins and 
invasion has also been observed. A tumour cell has, therefore, at its disposal a 
whole plethora of hydrolytic enzymes which may act individually, in concert, or 
as part of a proteolytic ·cascade (Fig. 1). Based on the heterogenous nature of tissue 
surfaces and matrices, it is unlikely that anyone enzyme is able to remove all 
ECM barriers. The activity of type IV collagenase would be of major importance 
for basement membrane disruption, but other enzymes are probably required for 
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Tumour-associated degradative enzymes and plasma proteinases: their possible roles 
in metastasis and regulation by tumour or host cell-derived inhibitors. 
Bold lines represent the release of enzymes or inhibitors, lines represent activation of 
proenzymes and broken lines represent possible inhibitory mechanisms (adapted from 
Nakajima et al., 1987; Alexander and Werb, 1989). ~M (u2-macroglobulin); serpin 
(serine proteinase inhibitor). 
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1.4 Lysosomal proteinases 
A significant body of evidence implicates lysosomal cysteine proteinases in 
neoplastic progression. In breast carcinoma patients, levels of cathepsins B, Land 
H are elevated in sera and tissue, when compared with normal sera or tissue 
(Gabrijelcic et al., 1992). Lah et al. (1992a; 1992b) found the activities of cathepsins 
Band L in breast tumours to be 20- and 50-fold higher, respectively, than in 
normal matched tissues. Furthermore, cystatins, endogenous protein inhibitors 
of cysteine proteinases (Barrett et al., 1986), reflected lower activity in two thirds 
of carcinomas, and higher activity in one third (Lah et al., 1992b). Although 
cathepsin D levels were also elevated in these studies, no correlation could be 
found between cathepsin D and cysteine proteinase inhibitor activity, negating 
the possibility of cathepsin D-mediated inactivation of cystatins (Lenarcic et al., 
1988; Lenarcic et al., 1991). In a separate study (Lah et al., 1989), cystatin A from 
human sarcoma extracts was found to have an impaired ability to inhibit 
cathepsins B, Land H, thereby providing a mechanism to shift the 
inhibitor/proteinase balance in favour of proteolysis. In contrast, in human 
colorectal carcinoma the levels of endogenous cysteine proteinase inhibitors 
remained constant, while cathepsin B- and "L-1ike activities were elevated 
(Sheahan et al., 1989). 
Of these cysteine proteinases, cathepsin B appears to be most relevant, perhaps 
due to its ability to digest basement membrane at a pH approaching neutrality 
(Guinec et al., 1993), as well as its ability to act as an initiator of protease cascades 
(Fig. 1). Increased cathepsin B activity has been detected in human lung tumours 
(Krepela et al., 1990) and, significantly, the enzyme was localised to the plasma 
membrane of a human lung cancer cell line (Erdel et al., 1990). The distribution 
on the cell surface was not even, but localised to areas of contact with the 
supporting substrate. This may facilitate directed proteolysis or activation of 
other plasma membrane-bound proteases such as uP A or type IV collagenase. 
Surface-bound cathepsin B has also been found in H-ras-transformed human 
breast epithelial cells (Sloane et al., 1994) and murine B16 melanoma variants 
(Sloane et al., 1986; Rozhin et al., 1987), in the latter characterised by a slightly 
higher pH optimum and resistance to inactivation by extracellular proteinase 
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inhibitors. In fact, Sloane et al. (1981) have demonstrated a significant correlation 
with the metastatic potential of in vivo grown variants of B16 mouse melanoma 
and cathepsin B activity. 
The possible role of cathepsin B in the degradation of extracellular matrix in 
tumour invasion is not clear, however. An increased activity in transformed 
cells may reflect an increase in the general intracellular machinery of the cells, 
allowing the enzyme to contribute to the process of matrix destruction in 
lysosomes, after internalisation of fragments generated by hydrolases outside the 
cell. Furthermore, the bulk of cathepsin B secreted by tumour cells accumulates 
as latent proenzyme, which would require activation. The only proteinases 
known to be capable of activating this enzyme, pepsin and cathepsin D, require 
acidic conditions for activity. However, Keppler et al. (1994) have recently 
described cathepsin B activation by polymorphonuclear leucocyte elastase, and 
cystatin C (the most potent cathepsin B endogenous inhibitor) inactivation with 
respect to cathepsin B activity. As tumours are most often infiltrated with 
polymorphonuclear leucocytes, this would provide a potential source of elastase, 
allowing activation to occur under physiological conditions. Activated cathepsin 
B can liberate collagenase, gelatinase and lamininase activities from the central 
domain of plasma fibronectin (Guinec et al., 1993), thereby initiating another 
proteolytic cascade. 
The lysosomal cysteine proteinase, cathepsin L, has also been ear-marked as a 
potential candidate for involvement in tumour metastasis. This is mainly due to 
its superior ability to digest a wide variety of ?CM components, including type IV 
collagen, laminin and fibronectin, when compared to other collagenolytic 
cysteine cathepsins B, Hand S. Furthermore, studies ill this laboratory have 
shown cathepsin L to be active in a medium that mimics extracellular fluid 
(Dehrmann et al., 1995), although this was only tested against synthetic substrates. 
However, relative to cathepsin B, less clinical and biochemical data exists 
demonstrating an involvement of this enzyme in tumour invasion. 
Nevertheless, cathepsin L has been demonstrated to be cell-surface associated in 
B16 melanoma cells (Rozhin et al., 1989), and was 7-fold more active in a highly 
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metastatic compared to a poorly metastatic subpopulation, whereas cysteine 
proteinase inhibitor activity was 5-fold less. Procathepsin L expression and 
secretion also correlated with the extent of H-ras expression and metastatic 
potential in H-ras transfected mouse NIH 3T3 cells (Denhardt et al., 1987). More 
direct evidence for a role for cathepsin L in invasion is revealed by the inhibition 
of invasion of the human amnion by murine mammary and melanoma cells in 
vitro (Yagel et al., 1989a). The cathepsin L-specific peptidyl diazomethyl ketone 
inhibitor, ZPhePheCHN2 (benzyloxycarbonyl-L-phenylalanyl-L-phenylalanyldiazo-
methane) was able to inhibit invasion, but not to the extent that inhibitors of 
M:MPs were able, suggesting a role for cathepsin Lin MMP activation. Recently, a 
41 kDa C3 (third component of complement)-cleaving cysteine proteinase, which 
is antigenic ally related to cathepsin L, has been identified as being membrane 
associated in DM-4 human melanoma cells Gean et al., 1996). Pretreatment of 
DM-4 cells with anti-murine procathepsin L antibodies, strongly inhibited their 
tumourgenicity and significantly decreased their metastatic potential in nude 
mice. Significantly, these effects are not due to a decrease in the ability of 
pretreated cells to penetrate the basement membrane, since incubation of DM-4 
cells with antibodies did not affect the migration of cells in an in vitro invasion 
assay. It is speculated that inhibition of the cysteine proteinase that cleaves 
human C3 renders cells more susceptible to complement lysis. 
An association between the lysosomal aspartic proteinase, cathepsin D, and 
cancer has been demonstrated in a number of independent studies. Cathepsin D 
was found by immunocytochemistry to be widely distributed in a number of 
carcinomas and lymphomas (Reid et al., 1986), and levels of the enzyme have 
been found to be elevated in both benign and malignant ductal mastopathies, but 
are very low in normal or resting mammary glands (Garcia et al., 1986). 
Furthermore, a number of clinical studies have been undertaken to assess the 
value of cathepsin D as a prognostic marker in breast cancer (Rochefort, 1990; 
Roger et al., 1994; Castiglioni et al., 1994) and endometrial adenocarcinoma 
(Nazeer et al., 1992), but the conclusions remain controversial due to the 
appearance of various articles offering different opinions. It has been suggested 
that the establishment of standardised techniques, reagents and diagnostic criteria 
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would allow for a true assessment of the value of assaymg for cathepsin D 
(Cardiff, 1994). 
A variety of reports show the presence in tumours of cathepsin D with unusual 
biochemical properties. In a comparison between cathepsin D from normal rat 
liver and that from a transplantable rat sarcoma, it was shown that although the 
two cathepsins are similar in most respects, their substrate binding sites have 
different structures (Kazakova et al., 1972). Similarly, cathepsin D isolated from 
rat Yoshida ascites hepatoma cells showed increased susceptibility to inhibition by 
pepstatin (a specific fungal inhibitor of aspartic proteases) (Knight and Barrett, 
1976), suggesting an alteration in the substrate binding cleft (Bonelli et al., 1988). 
Anomalous activity was also found in cathepsin D purified from human ascitic 
fluid. The enzyme showed similar activities against bovine serum albumin 
(BSA) and haemoglobin (Esumi et al., 1978), whereas normal human liver 
cathepsin D has an activity against BSA only 5% of that against haemoglobin 
(Barrett, 1970). Significant elevation of cathepsin D activity against haemoglobin 
was found in human hepatoma tissues when compared to normal human livers, 
probably due to increased amounts -of enzyme protein, not to the enzyme being 
more active (Maguchi et al., 1988). 
The most compelling evidence favouring the hypothesis that cathepsin D is an 
important protease facilitating metastasis and invasion, comes from the work of 
Rochefort and co-workers on human breast cancer. Westley and Rochefort (1980) 
noted that an oestrogen responsive metastatic human breast cancer cell line 
(MCF-7), when treated with oestrogen, secreted a 52 kDa glycoprotein into 
conditioned media. This protein accounts for up to 40% of the secreted proteins 
of oestrogen-stimulated MCF-7 cells, and was also found to be produced 
constitutively in large amounts in some hormone-independent breast cancer cell 
lines, relative to unstimulated oestrogen-responsive cell lines (Garcia et al., 1987). 
The protein was also found to be inducible in primary cultures derived from 
metastatic effusions of breast cancer where oestrogen also results in the export of 
the protein into the medium (Veith et al., 1983). It therefore appears that 
oestrogen regulation of the 52 kDa protein is not simply an artefact peculiar to 
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some permanent cell lines, but seems to have some biological relevance to the in 
vivo situation in breast cancer patients. 
Monoclonal antibodies against the 52 kDa protein (Garcia et al., 1985) enabled the 
purification of the protein (Capony et al., 1986), its characterisation and 
sequencing. A scheme for the glycosylation and post-translational processing was 
proposed in which a polypeptide of 48 kDa is co-translationally N-glycosylated 
with two high-mannose oligosaccharide chains to yield a 52 kDa glycoprotein. 
The protein was found to be phosphorylated mostly on the mannose side chains 
and mannose-6-phosphate (M-6-P) signals were identified (Capony et al., 1987), 
suggesting that the protein is normally routed to lysosomes where it exerts its 
usual metabolic functions (von Figura and Hasilik, 1985). Pulse-chase 
experiments showed that the 52 kDa protein is a precursor of a lysosomal enzyme 
where, after oestrogen treatment, about 40% of the cellular pool is secreted and 
60% successfully processed into an intermediary 48 kDa and a stable 34 kDa + 
14 kDa protein (Morisset et al., 1986a). 
Enzymatic activity -studies showed that both the purified secreted 52 kDa protein 
and the corresponding cellular proteins (52 kDa, 48 kDa, 34 kDa + 14 kDa) 
displayed strong proteolytic activity against haemoglobin at acidic pH, where the 
52 kDa proform is autoactivated (Morisset et al., 1986b; Capony et al., 1987). 
Molecular weights, immunoreactivity, pH and inhibitor sensitivities showed 
strong homology with cathepsin D. 
Cloning an~ sequencing of cDNA showed complete sequence homology with 
human kidney procathepsin D (Faust et al., 1985) except for a 5 nucleotide change, 
involving only one amino acid substitution (A to V) in the profragment 
(Augereau et al., 1988). The amino acid structure of the 52 kDa cathepsin D of 
breast cancer thus appears to be almost identical to that of the lysosomal 
cathepsin D of normal tissues. The structure of the oligosaccharide chains is not 
yet known, and differences at this level are possible. This is suggested by 
isoelectric focusing analysis of procathepsin D from normal and mammary 
cancer cells, the latter containing more acidic forms (Capony et al., 1989). 
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Major differences in the intracellular processing of the 52 kDa procathepsin D 
were found in a comparative study between normal human mammary epithelial 
cells and breast cancer cell lines (Capony et al., 1989). In normal mammary cells, 
as in human fibroblasts (Hasilik and Neufeld, 1980), negligible amounts of the 
proform were secreted or accumulated in the cells. The precursor was trafficked 
to lysosomes and rapidly processed into the mature form (34 kDa+ 14 kDa) via 
production of the intermediate form (48 kDa). In several hormone-dependent 
cell lines (including MCF-7) and hormone-independent cell lines, however, 
processing was delayed and there was an accumulation of the 52 kDa and 48 kDa 
forms in cells. Furthermore, secretion of the 52 kDa form was 30 times higher in 
cancer cells. 
Pro cathepsin D secretion was originally detected due to its oestrogen-specific 
induction (Morisset et al., 1986a). Oestrogen treatment causes an approximately 
10-fold increase in cathepsin D mRNA in MCF-7 cells (Cavailles et al., 1988). 
Other mitogens, such as insulin-like growth factor-I, epidermal growth factor 
(EGF) and insulin are also able to increase cathepsin D mRNA (Cavailles et al., 
1988). Mitogen regulation in breast cancer cells appears to be complex, however, 
as oestrogen can induce both growth factors and cathepsin D, which in turn can 
also be induced by these growth factors (Rochefort, 1990). 
Evidence, to date, has pointed to an extracellular role for proteolytic enzymes 
such as uPA and MMPs in invasion. However, this is more debatable for 
intracellular proteinases, like some cathepsins, which require acidic pH' for 
activation. Briozzo et al. (1988) demonstrated pepstatin-sensitive ECM 
degradation by breast cancer cell-conditioned medium, but only when the 
medium was acidified to facilitate procathepsin D autoactivation. An 
extracellular role for cathepsin D was more directly investigated by assessing the 
inhibition of invasion, bypepstatin, of a series of cathepsin D secreting breast 
cancer cell lines (Johnson et al., 1993). Neither the addition of pepstatin or 
chloroquine, which neutralises the pH in acidic compartments of cells, were able 
to inhibit invasion In vitro . Indeed, a novel matrix-degrading, 
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ethylenediaminetetra-acetic acid (EDTA) and leupeptin inhibitable protease has 
been identified in the conditioned medium of hormone-dependent breast cancer 
cell lines (Shi et al., 1993; Dickson et al., 1994), although it remains to be seen to 
what extent this protease contributes to the metastatic progression of human 
breast cancer. Extracellular proteolysis by cathepsin D has, in fact, been implicated 
in proteoglycan metabolism of cartilage matrix (Poole and Mort, 1981), although 
the nature of this extracellular activity was not resolved. 
Matters are far from clear, however, as a direct role in metastasis for cathepsin D 
has actually been demonstrated. A tumourigenic but low-metastatic transformed 
rat embryo cell line that does not secrete cathepsin D, was transfected with the 
enzyme. Overexpression of human cathepsin D in transfected clones increased 
the malignant phenotype in vitro, and the metastatic activity of clones injected 
into athymic mice was significantly higher than control clones (Garcia et aI., 
1990). This study was extended to assess the effects on experimental metastasis of 
retention of the enzyme in the endoplasmic reticulum (Liaudet et al., 1994). The 
transformed rat cell line was transfected with mutated human procathepsin D 
that was obtained by an insertion -of a KDEL peptide signal responsible for 
endoplasmic reticulum retention. In contrast to wild-type human procathepsin 
D transfected clones, procathepsin D-KDEL clones had no ability to metastasise in 
athymic mice. Furthermore, high producer KDEL clones, where KDEL receptors 
were saturated, resulting in the secretion of mutated procathepsin D, showed no 
increase in metastatic activity. This indicates that procathepsin D secretion alone 
is not sufficient to manifest the invasive phenotype, but maturation of the 
enzyme into proteolytic ally active forms is a prerequisite. 
Secreted procathepsin D could still, however, playa role in tumour progression 
by virtue of its proposed mitogenic activity. Vignon et al. (1986) first 
demonstrated autocrinal growth stimulation of MCF-7 breast cancer cells by 
procathepsin D, and this has been further shown in clones of transformed rat cell 
lines hyper-expressing procathepsin D (Garcia et al., 1990; Liaudet et al., 1994) and 
a variety of breast cancer cell lines (Fusek and Vetvicka, 1994). Mitogenic activity 
cannot be blocked by inhibition of proteolytic activity nor by the inhibition of the 
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interaction of procathepsin D with M-6-P receptors . The addition of antibodies 
raised against the propeptide sequence impaired the mitogenic activity of 
procathepsin D, and a synthetic peptide corresponding to the propeptide of 
procathepsin D produced a mitogenic effect (Fusek and Vetvicka, 199-1). 
Conflicting results have been reported where no mitogenic effect by 
procathepsin D was found (Stewart et al., 1994), although no adequate 
explanation is given for this discrepancy. It remains to be seen if this mitogenic 
activity has any role in vivo in breast cancer, though. Interestingly, a single 20 ~g 
intraperitoneal injection of cathepsin D induced significant stimulation of DNA 
synthesis and mitosis in the liver but not kidney (Morioka and Terayama, 1984), 
while the propart peptide was also able to effectively inhibit the enzyme (Fusek e t 
al., 1991; Puizdar and Turk, 1981). 
Taken together, the lack of inhibition of invasion of cathepsin D secreting breast 
cancer cells by pepstatin, a requirement for intracellular maturation of 
cathepsin D for experimental metastasis to occur, and lack of direct evidence for 
low pH microenvironments at the cell-substrate interface of breast cancer cells 
(Montcourrier -et al., 1990), mitigates for an intracellular role for the enzyme in 
tumour progression. This is supported by evidence of large acidic vesicles in 
breast cancer cells that contain endocytosed extracellular matrix, high cathepsin D 
concentrations, resemble phagolysosomes and are correlated with an increased 
ability to invade through reconstituted basement membrane (Montcourrier et al., 
1990; Montcourrier et al., 1994). Perturbation of cathepsin D maturation into an 
active enzyme could, therefore, result in dysfunctional digestive vesicles which 
become 'constipated' with extracellular matrix, thereby compromising invasion. 
Thus it appears that the balance between proteases and their inhibitors, rather 
than over expression of proteases, is the key determinant in tumour progression. 
The activity of protease inhibitors is not restricted to inhibition of invasion and 
metastasis, but preserves the delicate equilibrium between cells and the 
extracellular matrix, matrix components and matrix-associated growth factors, all 
of which can have a profound effect on cell behaviour. 
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In this thesis a study is detailed of some of the proteinases thought to be involved 
in tumour progression, and some of the characteristics of tumour cells with 
respect to normal cells. At the outset of this work cathepsin D was viewed as the 
primary malevolent proteinase in breast cancer metastasis and, as such, attempts 
were made to develop an anti-peptide antibody to neutralise its activity. Later it 
became clear that cathepsin D is only part of a complex interaction, and so the 
study was broadened to encompass other proteinases. This included a study of 
the distribution of lysosomal proteinases in transformed and normal celis, and 
initial characterisation of the extracellular degradative processes displayed by 
these cell lines. 
CHAPTER 2 
MATERIALS AND METHODS 
This chapter will detail methods that are considered in biochemical terms as 
being fundamental and are used throughout this study. This chapter also 
contains methods, especially immunological methods, which could be 
considered relatively specialised but would hinder the intended structure of the 
relevant chapter. 'Reagents' sections in this chapter only describe those reagents 
that were prepared before use, reagents that were used as-is are referred to at the 
relevant point in the 'Procedure' section. 
2.1 Materials 
The source of all specialised products used in this study is detailed here. Most 
common chemicals used were from Boehringer Mannheim, BDH or Merck, and 
were of the highest purity available. Denatured bovine haemoglobin was from 
Nutritional Biochemicals; Serva Blue G was from Serva; ovalbumin (Grade V), 
4-Chloro-l-napthol, pepstatin-diaminohexane-Sepharose, polyacrylhydrazido-
agarose, Sephadex G-2S and standard electrophoretic proteins were from Sigma 
Chemical Co., St. Louis, Mo. Coomassie Brilliant Blue R-2S0 was from Merck; 
.' acrylamide and N,N'-methylenebisacrylamide were from BDH; N,N,N',N'-
tetramethyl-ethylenediamine (TEMED) was from Bio-Rad; BSA (Fraction V) and 
2,2'-azino-di-(3-ethyl)-benzthiozoline sulfonic acid (ABTS) were from Boehringer 
Mannheim, SA; Elite fat-free milk powder was from NCD; horseradish 
peroxidase -(HRPO) was from Seravac and enzyme-linked immunosorbent assay 
(ELISA) plates were Nunc-Immuno Maxisorp F96 plates. Sheep anti-rabbit IgG 
and rabbit anti-chicken IgY secondary antibodies were prepared by Dr Theresa 
Coetzer, Department of Biochemistry, University of Natal. 
2.2 Protein assays 
Protein purification procedures require methods of protein quantification which 
are rapid, specific and yet sensitive. Spectrophotometry using specific protein 
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extinction coefficients at 280 run fulfil these criteria but lack general applicability, 
whereas assays based on features common to most proteins are often subject to 
interference, response variation or insensitivity. An assay that to a large extent 
overcomes such problems, is the Bradford dye-binding assay (Bradford, 1976). 
2.2.1 Bradford dye-binding assay 
The Bradford assay is based on the observation that Coomassie Brilliant Blue 
G-250 dye exists in two colour forms, red and blue, the red form predominates at 
low pH but converts to the blue form upon binding of dye to protein. The high 
extinction coefficient of the blue protein-dye complex at 595 run results in great 
sensitivity in protein measurement. Due to its rapidity, the assay is suitable for 
processing large sample numbers. Colour development is essentially complete 
within 2 min of the addition of the dye reagent to the protein sample and 
remains stable for up to 1 h. The important advantage of the assay is the lack of 
interference by most chemicals tested. Small effects due to Tris, acetic acid, 
2-mercaptoethanol, sucrose, glycerol, EDTA, and trace amounts of Triton X-100 
and sodium dodecyl sulfate can be eliminated by using the appropriate buffer 
blank. Detergents at concentrations of 1% or greater, however, produce 
abnormalities too great to overcome. 
The greatest disadvantage of the dye-binding assay is the wide variation of 
colour-yield in response to different standard proteins (Read and Northcote, 
1981). This would affect the validity of measurements extrapolated from the 
standard protein. When determining the concentration of purified proteins, this 
problem is best overcome by using the pure protein as its own standard, although 
this is seldom feasible due to the wastefulness of such an approach. To reduce 
response variation, Read and Northcote (1981) modified the method by 
substituting Coomassie Brilliant Blue G-250 with Serva Blue G, and by increasing 
the dye concentration or decreasing the phosphoric acid concentration. In this 
study it was found, however, that modification of dye and phosphoric acid 
concentrations caused the dye to precipitate. The reagent finally employed in this 
study was the same as that of Bradford (1976), except that Coomassie Brilliant 
Blue G-250 was replaced by Serva Blue G. The extent of variation between 
ovalbumin, the chosen standard protein, and cathepsin D, a major protein of 
interest in this study, was tested by comparing the concentration of a suitable 
sample of purified cathepsin D as derived from the Bradford assay with that 
derived from its extinction coefficient at 280-nm. The relative concentration 
difference was found to be 6.6%, which was deemed within acceptable limits. 
The only disadvantage of the reagent employed compared to that of Read and 
Northcote (1981), is evidence of non-linearity at protein levels beyond 25 Ilg, 
presumably due to dye depletion. This can easily be overcome by diluting protein 
samples to within the 5-25 Ilg working range of the assay. For the determination 
of lower protein concentrations (1-5 Ilg), a micro-assay procedure (Read and 
Northcote, 1981) was used. 
2.2.1.1 Reagents 
Dye reagent. Serva Blue G (50 mg) was dissolved with stirring in 89% phosphoric 
acid (50 ml). Absolute ethanol (23.5 ml) was added and stirred for 1 h. The 
solution was made up to 500 ml with distilled water (dist.H20), stirred for a 
further 30 min and filtered through Whatman No. 1 filter paper. The dye 
reagent can be stored in a brown bottle at room temperature for several months. 
Standard protein solution. Ovalbumin was dissolved at 1 mg/ml In dist.H
2
0. 
This was diluted to 100 Ilg/ml for the micro-assay. 
2.2.1.2 Procedure 
Macro-assay. Standard protein solution (0-25 Ill), or sample protein, was diluted 
with dist.H20 or buffer to a final volume of 100 III to give the desired 
concentration levels (0-25 Ilg)· Dye reagent (5 ml) was added to standard 
solutions, samples and blanks (100 Ill), vortexed and allowed to stand for 2 min. 
The absorbance was read at 595 nm against the buffer blank, for sample, or water 
for the ovalbumin standard solutions. Assays for a standard curve were carried 
out in triplicate at five concentrations of ovalbumin. Plastic cuvettes (3 ml) were 
used as the dye-reagent binds to quartz (Bradford, 1976) although it can be easily 
removed with dilute sodium hypochlorite. 
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1-Iicro-assav. Standard protein solution (0-50 ~l of the 100 ~g/ml solution, i.e. 1-5) , 
or sample was diluted with dist.H20 or buffer to a final volume of 50 ~l. Dye 
reagent (950 ~l) was added to standard solutions, samples and blanks, vortexed 
and allowed to stand for 2 min. The absorbance was read at 595 nm against the 
buffer blank, for sample, or water for the ovalbumin standard solutions, in 1 ml 
plastic micro-cuvettes as above. A standard curve was generated for each batch of 
reagent made up, and subjected to linear regression analysis from which protein 
concentrations were calculated. 
2.2.2 Spectrophotometry using protein extinction coefficients 
Spectrophotometry using extinction coefficients represent a highly specific 
method of protein concentration determination but is, by definition, inherently 
impractical for general protein quantification. The extinction coefficient of 
1.05 mllmg/cm at 280 nm for bovine spleen cathepsin D (Lah et aI., 1984) was 
used, where possible, for pure preparations of this enzyme. Determination of the 
concentrations of pure immunoglobulin G and Y (IgG and IgY) were also 
facilitated by using extmction coefficients at 280 nm of 1.43 and 1.25 mll mg/ cm 
respectively (Hudson and Hay, 1980; Coetzer, 1985). 
2.2.2.1 Procedure 
The absorbance of the relevant sample at 280 nm was read in a quartz cuvette 
against the appropriate blank and the concentration calculated as follows: 
A = £ xc 
where A = absorbance at 280 nm 
£0,1,),, = absorbance of a 0.1% solution (i.e. 1 mg/ml) 
solution in a 1 cm cuvette pathlength 
c = protein concentration in mg/ml. 
Cathepsin D solutions were generally not diluted prior to reading, while IgG and 
IgY were diluted 1/40 (Section 2.5) . 
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2.3 Methods of protein concentration 
During some procedures it was necessary to concentrate proteins for protein 
assays, or for further analysis such as sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). 
2.3.1 Concentrative dialysis 
Where concentration of large volumes of dilute protein solutions was required, 
dialysis against a substance, which has high osmotic pressure when in solution, 
such as sucrose or polyethylene glycol (PEG) was utilised. Sample concentration 
is based on the fact that a gradient of water concentration is established between 
the protein solution in the dialysis membrane and the substance at the exterior 
surface of the membrane. Water and buffer ions will thus move out of the 
membrane, slowly saturating the material, while proteins larger than the 
membrane molecular weight cut-off limit, are retained. The overall volume in 
which the protein is dissolved is thus reduced, and the process can be halted 
when the required degree of concentration has been reached. 
Sucrose, which is inexpensive, was most often used but suffers from the 
disadvantage that it is small enough to diffuse into the dialysis tubing. When 
concentrated sucrose-free protein solutions were required, as is the case of protein 
assays where a corresponding reagent blank is required, dialysis against PEG 
(20 kDa) was employed. This substance has a molecular weight greater than the 
size cut-off of the dialysis membrane and will thus not move into the bag. 
2.3.2 Sodium dodecyl sulfate/potassium chloride precipitation 
The most often used method of qualitative analysis of proteins was SDS-P AGE 
and precipitation with sodium dodecyl sulfate (SDS) and KCI provided a quick 
and simple method to concentrate proteins prior to electrophoretic analysis. The 
potassium salt of dodecyl sulfate is insoluble, and hence when dodecyl sulfate is 
bound to a protein molecule, the protein will precipitate with the anion upon 
addition of KCl. 
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2.3.2.1 Reagents 
5% (m/v) Sodium dodecyl sulfate. Sodium dodecyl sulfate (0.5 g) was dissolved 
in dist.H
2
0 by gentle warming, cooled, made up to 10 ml. 
3 M Potassium chloride. Potassium chloride (2.24 g) was dissolved in dist.H20 
and made up to 10 ml. 
2.3.2.2 Procedure 
5% SDS (10 Ill) was added to the sample (100 Ill) in a polyethylene microfuge tube. 
The tube was inverted several times, 3 M KCl (10 Ill) was added and the tube 
again inverted. The white SDS-protein precipitate was sedimented by 
centrifugation (12 000 x g, 2 min, RT), the supernatant fluid discarded and the 
pellet redissolved in stacking gel buffer (10 Ill) and reducing SDS-PAGE treatment 
buffer (Section 2.4.1). The procedure afforded an approximately 5-fold 
concentration of protein. 
2.4 Sodium dodecyl sulfate polyacrylamide _gel electrophoresis 
Analysis of the composition of protein mixtures is most conveniently performed 
by polyacrylamide gel electrophoresis (PAGE) in the presence of SDS. This 
system is designed, in the presence of a disulfide bond reducing agent, to 
dissociate all proteins into · their individual polypeptide subunits. Most proteins 
interact with and are denatured by SDS in a similar manner, each gram of 
polypeptide binding a constant 1.4 g of SDS (Reynolds and Tanford, 1970). The 
SDS-protein complexes assume a rod-shaped random coil configuration and 
behave as though they have uniform shape. The intrinsic charges of the 
polypeptide are masked by the negative charge provided by the bound ionic 
detergent, so that the SDS-polypeptide complexes have essentially identical 
charge densities and migrate in SDS-P AGE gels, which have molecular sieving 
properties, according to polypeptide size (Weber and Osborn, 1969). The 
molecular weight of the sample polypeptides can then be determined by reference 
to the mobility of polypeptides of known molecular weight separated under the 
same electrophoretic conditions. 
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The most commonly-used SDS-PAGE system makes use of the discontinuous 
P AGE buffer system of Ornstein (1964) and Davis (1964) with the modification of 
Laemmli (1970) which introduces SDS. Compared to continuous buffer systems, 
discontinuous systems employ buffer ions of different composition and pH in the 
gel relative to those in the electrode reservoirs. Furthermore, sample is loaded 
onto a large pore stacking gel through which it migrates to enter the small pore 
running gel. The major advantage of such a system over a continuous system, is 
that relatively large volumes of dilute protein can be applied to the gel without 
compromising resolution. During migration through the large-pore staking gel, 
proteins are concentrated into extremely narrow stacks, after which they enter the 
running gel where band resolution can occur. 
2.4.1 Reagents 
(A): Monomer solution (30% T; 2.7% C). Acrylamide (58.4 g) and N,N'-
methylene-bisacrylamide (1.6 g) were dissolved in dist.H20 and made up to 
200 ml. 
(B): 4 x Running gel buffer (1.5 M Tris-HCL pH 8.8). Tris base (36.3 g) was 
dissolved in about 150 ml dist.H20, adjusted to pH 8.8 with NaOH and made up 
to 200 ml. 
(Q: 4 x Stacking gel buffer (500 mM Tris-HCL pH 6.8). Tris base (3.0 g) was 
dissolved in about 30 ml dist.HzO, adjusted to pH 6.8 with NaOH and made up to 
50 rol. 
(D): 10% (m/v) Sodium dodecyl sulfate. Sodium dodecyl sulfate (50 g) was 
dissolved in dist.HzO with gentle warming and made up to 500 ml. 
(E): 10% (m/v) Ammonium persulfate. Ammonium persulfate (0.5 g) was 
dissolved in dist.H20 and made up to 5 ml. Fresh reagent was made up every two 
weeks. 
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(F): Reservoir tank buffer (25 mM Tris base, 192 mM glycine, 0.1% (m / v) SDS, 
pH 8.3). Tris base (12.0 g), glycine (57.6 g) and 10% SDS (D) (400 ml) were 
dissolved in dist.H20 and made up to 4 litres. The pH is automatically 8.3. 
Treatment buffer (125 mM Tris-HCL pH 6.8, 4% (m/v) SDS, 20% (v Iv) glycerol, 
10% (v Iv) 2-mercaptoethanol). Stacking gel buffer (C) (2.5 ml), 10% SDS (D) 
(4.0 ml), glycerol (2 ml) and 2-mercaptoethanol (1.0 ml) were made up to 10.0 ml 
with dist.H20. 
Stain stock (1 % (m/v) Coomassie Brilliant Blue R-250). Coomassie Brilliant Blue 
R-250 (2.0 g) was dissolved in about 150 ml of dist.H20 with overnight stirring. 
The solution was made up to 200 ml and filtered through Whatman No. 1 filter 
paper. 
Stain (0.125% (m/v) Coomassie Brilliant Blue R-250, 50% (v Iv) methanol, 10% 
(v Iv) acetic acid). Coomassie Brilliant Blue R-250 stain stock (62.5 ml), CP 
methanol (250 -ml) and CP acetic acid (50 ml) were -made up -to -SOO ml with 
dist.H20 . 
Destaining solution I (50% (v Iv) methanol, 10% (v Iv) acetic acid). CP Methanol 
(500 ml) and CP acetic acid (100 ml) were made up to 1 litre with dist.H20. 
Destaining solution II (5% (v Iv) methanoL 7% (v Iv) acetic acid). CP Methanol 
(50 ml) and CP acetic acid (70 ml) were made up to 1 litre with dist.H20. 
Molecular weight markers (1 mg standard protein/ml). Bovine serum albumin 
(1 mg), ovalbumin (1 mg), carbonic anhydrase (1 mg) and lysozyme (1 mg) were 
dissolved in treatment buffer (1.0 ml), placed in a boiling waterbath for 90 sand 
bromophenol blue tracking dye (0.1 % (m/v) in stacking gel buffer C) was added 
(15 Ill). 
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Table 2. Preparation of running (12.5%) and stacking gels (4.0%) for two 
1.5 mm thick polyacrylamide gels. 
Reagent Running gel (ml) Stacking gel (ml) 
A 6.25 0.94 
B 3.75 
C 1.75 
D 0.15 0.07 
E 0.75 0.35 
dist.H2O 3.50 4.20 
TEMED 0.075 0.015 
2.4.2 Proced ure 
Protein samples to be electrophoretically analysed were combined 1:1 with 
treatment buffer, boiled (90 s) and 0.1% (m/v) bromophenol blue tracking dye 
added to 0.005% (v Iv). Typically, pure enzyme preparations were loaded at about 
10 ~g per well (at least 2 ~g of protein per band), crude protein fractions at 50-
200 ~g per well and molecular weight markers at 4 ~l per well. 
The running gel pore size and hence the molecular weight resolving range can 
easily be manipulated by changing the concentration of monomer solution in the 
gel preparation. For the purposes of this study it was found that a running gel 
concentration of 12.5% acrylamide was optimal both in terms of molecular 
weight range (roughly from 12 kDa to 75 kDa) and band resolution. 
For all polyacrylamide gel electrophoretic procedures a Hoefer Scientific 
Instruments SE 250 ('Mighty Small') vertical slab gel unit was employed. The 
vertical slab gel unit was assembled essentially according to the Hoefer 
instruction manual. Aluminium plates were separated from glass plates by two 
vertical 1.5 mm spacers and clamped against both sides of the electrophoresis pod. 
Two lines of molten agarose (1% (m/v) in dist.H20) were poured on a glass base a 
distance from each other corresponding to the distance between the two gel 
chambers. The unit was lowered into the agarose, the agarose being drawn up 
into the gel chamber sandwich to polymerise into a plug gel. The prepared 
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running gel was gently expelled from a syringe, with a needle attached , into the 
top of the sandwich to a distance about 3 cm from the top of the glass p lates, care 
beiner taken not to allow air bubbles to be trapped in the viscous running gel. The 
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running gel was carefully overlayered with dist.H20 to exclude atmospheric 
oxygen from the gel as it prevents polymerisation. Completion of running gel 
polymerisation is indicated by the formation of a visible gel-water interface. The 
water was poured off and prepared stacking gel was added into the sandwich to 
the top of the aluminium plates. Combs, either 15 well or 10 well, were inserted 
forming an oxygen-proof barrier with the atmosphere, allowing the stacking gel 
to polymerise. Running gel should be allowed to polymerise for a total of at least 
2 h, while 30 min is sufficient for the stacking gel. 
Upon completion of polymerisation, the combs were carefully removed, the 
wells rinsed with dist.H20 and cold reservoir buffer (F) poured into the wells and 
cathodic and anodic compartments. Treated samples were carefully underlayered 
into wells with a fine-tipped Hamilton syringe and the electrophoresis pod 
connected to a circulating water-bath set to 10°e. The safety lid was placed on the 
unit, attached to a power supply and electrophoresis-was-run at a constant current 
of 18 rnA per gel. When the bromophenol blue tracking dye had reached the 
bottom of the gel sandwich, the power supply was turned off, the pod 
disassembled and the gels carefully removed and placed into stain for 4 h . The 
gels were then placed into destain solution I overnight and destain solution n 
thereafter until the background staining had faded to acceptable levels. Gels were 
photographed and stored in sealed plastic bags at room temperature. 
2.5 Fractionation of IgG and IgY 
A simple and convenient method of purification of IgG and IgY was found in the 
protein precipitating properties of PEG, a water-soluble linear polymer. Polson 
et al. (1964) found that relatively low concentrations of high molecular weight 
polymers were able to precipitate proteins, but high concentrations of low 
molecular weight species are required to effect the same degree of precipitation. 
The conclusion drawn was that precipitation by PEG was not due to dehydrating 
effects of the polymer on the protein molecules as is the case with ammonium 
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sulfate precipitation. It was apparent, however, that the concentration of the 
pol ymer required to precipitate a protein is a function of the net charge on the 
protein as determined by the pH of the medi~ in which it is dissolved. 
The protocol used to purify IgG from rabbit serum was that of Polson et al. (1964) 
while the method used for IgY purification from chicken egg yolks was as a result 
of more recent developments in the investigation of antibodies from chicken 
eggs (Polson et aI., 1985; Rowland et aI. , 1986) . 
2.5.1 Reagents 
10 mM sodium borate buffer, pH 8.6. Boric acid (2.16 g), NaOH (0.2g), 37% (v Iv) 
HCI (0.62 ml) and NaCI (2.19 g) were added to dist.H20 and made. up to 1 litre. 
The pH should automatically be 8.6. 
100 mM phosphate buffer, 0.02% (m/v) NaN1, pH 7.6. NaH2P04 (13.8 g) and NaN3 
(0.2 g) were dissolved in about 800 ml of dist.H20, titrated to pH 7.6 with NaOH 
and made up to 1 litre. 
2.5.2 Isolation of IgG from rabbit serum 
Rabbits were bled from the marginal ear vein and the blood allowed to clot 
overnight at 4°C. Supernatant serum was carefully drawn off the clot, and 
remaining serum recovered by centrifugation (3000 x g, 10 min, RT) of the clot. 
The serum was preserved with NaN3, added to 0.02% (m/v). Rabbit serum 
(1 volume) was diluted with borate buffer (2 volumes). Polyethylene glycol (15% 
(m/v) 6 kDa) was dissolved in the protein solution with stirring and the 
resulting IgG precipitate sedimented (12000 x g, 10 min, RT). The pellet was 
redissolved in phosphate buffer (3 volumes) and the precipitation procedure 
repeated to remove remaining contaminants. The final pellet was redissolved in 
half the initial serum volume with phosphate buffer. In determination of IgG 
concentration, a 1/40 dilution of IgG in phosphate buffer was made and the 
absorbance read at 280 nrn in a quartz cuvette against a buffer blank. To calculate 
the protein concentration an extinction coefficient of 1.43 ml/mgl em 
(Section 2.2.2) was used. 
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2.5.3 Isolation of IgY from chicken egg yolk 
Individual yolks were freed of adhering albumin (egg white) by careful washing 
in a stream of water. The yolk sac was punctured, the yolk volume measured 
and phosphate buffer, equivalent to 2 volumes of yolk, was added and 
thoroughly mixed. Solid PEG (6 kDa) was added to a final concentration of 3.5% 
(m/v of diluted yolk). The PEG was dissolved with stirring and the mixture was 
centrifuged (4420 x g, 30 min, RT) to separate three phases, a casein-like vitellin 
fraction, then a clear fluid, and a lipid layer on the surface. The supernatant fluid 
contaminated with some of the lipid layer was filtered through a loose plug of 
cottonwool in the neck of a funnel. The volume of clear filtrate was measured 
and the PEG concentration increased to 12% (m/v). The precipitated IgY fraction 
was centrifuged (12 000 x g, 10 min, RT), the pellet redissolved in phosphate 
buffer to the volume after filtration and the IgY again precipitated 'with 12% 
(m/v) PEG and centrifuged. The final IgY pellet was dissolved overnight in a 
volume of phosphate buffer equal to one sixth of the original yolk volume. 
Immunoglobulin Y concentration was determined as in Section 2.5.2 using an 
extinction coefficient of 1.25 ml/mgl ern (Section 2.2.2) . 
2.6 Enzyme-linked immunosorbent assay 
Immunoassays use the specific interaction of an antibody with antigen to provide 
information about antibody (or antigen) concentration in unknown samples. In 
principle, the labelling by chemical conjugation of an enzyme to either antibody 
or antigen allows the detection of immune complexes.. formed on a solid phase. 
This forms the basis of the ELISA, first introduced by Engvall and Per lmann 
(1971) . One of the simplest and most commonly used ELISAs for the detection of 
antibodies, is a three layer system. Briefly, antigen is coated to the plastic surface 
of the wells of polystyrene microtitre plates, and the primary antibodies to be 
quantified allowed to form a complex with the immobilised antigen. After excess 
antibody has been washed away, the degree or amount of reactivity is quantified 
with an appropriate detection system. In an ELISA this would take the form of 
an enzyme conjugated to a secondary antibody which will recognise the primary 
antibody bound to the immobilised antigen. The enzyme reacts with a substrate 
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which yields a coloured product which can be measured spectrophotometric ally. 
This quantitative system complements western blotting (Section 2.7), which gives 
qualitative information about antibody specificity. 
During the course of this work, an ELISA was most commonly used as a means 
to monitor the progress of immunisation of rabbits and chickens, and in enzyme 
cross-species reactivity studies. It also aided in the determination of suitable 
antibody dilutions for use in western blot analysis (Section 2.7) . 
2.6.1 Reagents 
Phosphate buffered saline (PBS). NaCl (8.0 g), KCl (0.2 g), Na2HP04 (1.15 g) and 
KH2P04 (0.2 g) were dissolved in about 800 ml of dist.H20, adjusted to pH 7.4 with 
HCl and made up to 1 litre. 
0.5% (m/v) Bovine serum albumin in PBS (BSA-PBS). Bovine serum albumin 
(0.5 g) was dissolved in PBS and made up to 100 ml. 
0.1 % (v Iv) Tween 20 in PBS (PBS-Tween) . Tween 20 (1 ml) was diluted to 1 litre 
in PBS. 




(2.84 g) and citric 
acid (2.29 g) were each dissolved in dist.H20 and ma?e up to 100 ml. The citric 
acid solution was titrated against the Na2HP04 (50 ml) solution to pH 5.0. 
Substrate solution (0.05% (m/v) ABTS and 0.0015% (v Iv) H
2
0, in citrate-
phosphate buffer). ABTS (7.5 mg) and H 20 2 (7.5 ~) were dissolved in citrate-
phosphate buffer, pH 5.0 (15 ml), for one ELISA plate. 
0.1% (m/v) Sodium azide in 150 mM citrate-phosphate buffer, pH 5.0. For each 
ELISA plate NaN3 (15 mg) was dissolved in citrate-phosphate buffer (15 ml) . 
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2.6.2 Procedure 
Wells of microtitre plates (Nunc Immunoplate) were coated with antigen (150 Ill) 
at predetermined dilutions (2 Ilg/ ml for cathepsin D and 1.0 Ilg/ ml for peptide 
(Chapter 3) as determined by a checkerboard ELISA) in PBS overnight at room 
temperature. Wells were blocked with BSA-PBS (200 Ill) for 1 h at 37'C and 
washed 3 times with PBS-Tween. Dilutions of the primary rabbit antiserum, IgG 
or I(7Y solution in BSA-PBS were added (100 Ill), incubated for 1 h at 37'C and 
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excess antibody washed out 3 times with PBS-Tween. A suitable dilution of 
sheep anti-rabbit IgG-HRPO conjugate or rabbit anti-chicken IgY-HRPO conjugate 
in BSA-PBS, was added (120 Ill) and incubated (30 min) at 37°C. The ABTS 
substrate (150 Ill) was added and incubated in the dark for optimal colour 
development (usually 10-20 min) . The enzyme reaction was stopped by the 
addition of 50 !ll of 0.1 % (m/v) NaN3 in citrate-phosphate buffer and absorbances 
read at 405 nm in a Bio-Tek E1307 ELISA plate reader. Titration curves were 
constructed from the spectrophotometric values. 
2.7 Western blotting 
Polyacrylamide gel electrophoresis is a powerful tool for the analysis of complex 
protein mixtures. The value of this method is, however, restricted in that 
resolved proteins remain buried within the gel matrix and are not readily 
available for further investigation. A protein blotting technique devised by 
Towbin et al. (1979) can alleviate this problem. 
The technique involves the electrophoretic transfer of proteins from a 
polyacrylamide gel to an adjacent nitrocellulose filter. This is achieved by placing 
the polyacrylamide gel-nitrocellulose stack between two electrodes, the gel closest 
to the cathode and the nitrocellulose closest to the anode. The electrodes and gel-
nitrocellulose stack are submersed in a blotting buffer of relatively high pH and 
also containing SDS, the principles of transfer thus being essentially the same as 
thos.e in SD5-PAGE. While the presence of SDS in the blotting buffer does give 
the proteins a high mobility, resulting in very efficient transfer out of the gel, 
some proteins do not adhere well to nitrocellulose membranes . This is probably 
due to the detergent action of SDS which disrupts hydrophobic interactions 
36 
between protein and nitrocellulose. The absence of SDS, on the other hand, 
while maxlInlsmg protein-nitrocellulose binding, compromises transfer. 
Methanol is often included in the blotting buffer as it improves adsorption of 
proteins onto nitrocellulose by virtue of its fixing properties. 
The accessibility of a resolved protein mixture on the surface of a nitrocellulose 
membrane allows the use of a variety of detection methods, otherwise limited by 
the gel matrix structure. In this study it allowed for the targeting of antigens, 
both pure and in crude fractions, via an antibody specific for the antigen in 
question. The bound antibody is then recognised by a secondary antibody, 
conjugated to an enzyme whose coloured reaction product precipitates on the 
nitrocellulose and can easily be visualised against the white background of the 
membrane. 
Such an immunoblot system is critical for characterising an antibody's specificity 
for purified antigen when tested alongside a crude preparation, and also for its 
ability to detect the antigen in the crude sample itself. 
2.7.1 Reagents 
Blotting buffer. Tris base (27.23 g) and glycine (64.8 g) were dissolved in about 
3litres of dist.B:zO. To this was added 10% (m/v) SDS (4.5 ml) and CP methanol 
(900 ml) and the volume made up to 4.5 litres with dist.H20. The pH is 
automatically 8.3. 
Tris buffered saline (TBS; 20 mM Tris-HCL 200 mM NaCL pH 7.4). Tris base 
(2.42 g) and NaCl (11.68 g) were dissolved in about 900 ml of dist.H
2
0, titrated to 
pH 7.4 with HCl and made up to 1 litre. 
Blocking agent (5% (m/v) fat-free milk powder in TBS) . Fat-free milk powder 
(5 g) was dissolved in about 90 mI of TBS and made up to 100 ml. 
0.5% (m/v) Bovine serum albumin in TBS (BSA-TBS). Bovine serum albumin 
(0.4 g) was dissolved in about 50 ml of TBS and made up to 80 mI. 
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0.1 % (v Iv) Tween 20 in TBS (TBS-Tween) . Tween 20 (0.5 ml) was diluted to 
500 ml in TBS. 





1 4-chloro-1-napthol (0.03 g) was dissolved in methanol (10 ml). 2 ml 
of this solution was diluted to 10 ml with TBS, with the addition of 35% peroxide 
(4 ~). 
0.1 % (m/v) Sodium azide in TBS. NaN3 (0.03 g) was dissolved in TBS (30 ml). 
2.7.2 Procedure 
After the electrophoretic separation of proteins m the presence of SDS 
(Section 2.4), the polyacrylamide gel was removed, placed on 3 layers of filter 
paper and the pre-cut nitrocellulose membrane (Schleicher and Schuell, BA 85, 
0.45 /lm) laid squarely on the gel, care being taken to dislodge all air bubbles. 
Three further layers of wetted filter paper were placed over the nitrocellulose and 
placed in the blotting apparatus sandwich. The complete sandwich was 
transferred to the TE Transphor electroblotting unit (Hoefer Scientific 
Instruments), placed vertically between two electrodes and submerged in blotting 
buffer, ensuring that the nitrocellulose is on the anodal side. Electroblotting was 
accomplished after 1.5 h at 200 rnA constant current, the apparatus being cooled 
to 4°C by a circulating water-bath. 
Upon completion of blotting the apparatus was disassembled, the nitrocellulose 
marked with the positions of relevant wells and hung up to air-dry (1.5-2 h). The 
membrane was cut with scissors into pieces corresponding to the sample wells, 
each piece being placed into a separate container and soaked with gentle rocking 
(1 h) in blocking agent to saturate additional protein binding sites. The 
membranes were washed with TBS (3 x 5 min) and antibody diluted in BSA-TBS 
added. Controls consisted of substituting a non-immune preparation for an 
immune antibody for each different antibody, antibody concentration or blotted 
protein sample tested. After incubation in the primary antibody (2 h or 
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overnight), the nitrocellulose was washed with TBS-Tween (3 x 5 min) . The 
presence of detergent decreases non-specific binding of antibody molecules to the 
nitrocellulose surface by acting as a further blocking agent, or by decreasing non-
specific hydrophobic binding of the antibody. The nitrocellulose was then 
incubated (1 h) in the appropriate secondary antibody-HRPO conjugate 
(Section 2.6.2) diluted in BSA-TBS, again washed in TBS-Tween (3 x 5 min) and 
incubated in the dark with freshly prepared substrate solution. Incubation in 
substrate was allowed to proceed until an optimal colour differential between 
specifically targeted bands, and non-immune incubations was found. The 
reaction was stopped by briefly rinsing the membranes in 0.1% (m/v) NaN3 in 
TBS and then allowing these to dry on a piece of filter paper. Blots were 
photographed, and stored in the dark to prevent yellowing. 
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CHAPTER 3 
PRODUCTION AND CHARACTERISATION OF ANTI-PEPTIDE ANTIBODIES 
AGAINST CATHEPSIN D 
3.1 Introduction 
Modulation of enzyme activity is normally achieved with enzyme inhibitors, but 
the binding of antibodies to an enzyme can also influence enzyme activity. The 
use of specific anti-catalytic antibodies may have important implications in the 
study of extracellular proteolysis by live cells, as it permits systematic dissection of 
the reactions utilised by living cells, in particular invading tumour cells, in the 
degradation of extracellular matrices. Furthermore, a number of novel 
therapeutic roles can be envisaged for inhibitory molecules. Blockage of 
proteolytic activity in tumours could stimulate the encapsulation of invasive and 
unresectable tumours, allowing later resection that would preserve organ 
structures in the vicinity of the tumour. Inhibitory antibodies could also be 
tested for their anti-angiogenic activity, and utilised to prevent the _growth of 
micrometastases that require an angiogenic response for macroscopic 
development. 
Although synthetic and naturally occurring inhibitors have been used in such 
studies, conclusions are not clear. In some studies anti-tumour effects were 
clearly demonstrated, but in most other studies, limited or no effects were 
observed. In some instances opposite, or tumour-enhancing, effects of proteinase 
inhibitors were noted (Nelles and Schnebli, 1982). - Furthermore, therapy may 
require prolonged administration of inhibitors which may lead to unacceptable 
toxicity (DeClerck and Imren, 1994). Inhibitors to serine proteinases may be 
problematic if administered systemically, because of their role in blood 
coagulation. Matrix metalloproteinases are involved in many physiological 
functions, such as tissue repair and reproduction, and inhibition of these 
proteinases could have serious consequences. A systemic immune response, 
however, generating antibodies capable of specific enzyme inhibition, may find 
application as an adjuvant tumour therapy. Indeed, a number of in vitro 
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experiments have shown significant inhibition of invasion of tumour cells by 
anti-catalytic antibodies (Ossowski and Reich, 1983; Hoyhtya et al., 1990). 
Immunoinhibition of catalysis of a number of enzymes has been studied, 
including lysozyme (Arnon, 1968), papain (Arnon and Shapira, 1967), a tyrosine-
specific protein kinase (Sen et al., 1983), type IV collagenase (Hoyhtya et al., 1990), 
cathepsin L (Coetzer et al., 1992) and cathepsin D (Dingle et al., 1971; vVeston and 
Poole, 1973). Inhibitory antibodies to cathepsin D have been used to elucidate the 
role of this enzyme in cartilage breakdown (Dingle et al., 1971; Poole et al., 1974) 
while inhibitory antibodies to uP A and interstitial collagenase indicated a specific 
role for these enzymes in fibrin and type I collagen breakdown in human 
HT-1080 cells (Birkedal-Hansen et al., 1989). 
A distinction, however, needs to be made between true immunoinhibition and 
inhibition due to immunoprecipitation. True immunoinhibition occurs either 
by virtue of a bound antibody interfering directly with the catalytic mechanism of 
the enzyme, or changing the protein's conformation or flexibility, or by sterically 
hindering access of a substrate to the active site. An antibody generated to inhibit 
cathepsin L binds an active-site associated peptide length, including the active-
site histidine residue (Coetzer et al., 1992), an interaction which probably disrupts 
the catalytic machinery of the enzyme, although simple sterk hindrance cannot 
be ruled out. In immunoprecipitation, optimal proportions of antibody and 
antigen interact to form a cross-linked lattice which may render the enzyme 
inactive by being locked in an insoluble complex. Precipitation, however, is not 
_ always synonymous with inhibition as enzyme in a precipitate may still be active 
(Branster and Cinader, 1969), at least against soluble substrates. Precipitation 
requires at least two epitopes and polydonal antibodies, therefore monoclonal 
and anti-peptide antibodies will not be precipitating. 
A protein's antigenicity refers to its capacity to bind specifically to paratopes 
(binding sites) of immunoglobulin molecules. The portion of the antigen with 
which the antibody binds is the epitope or antigenic determinant (Novotny et al., 
1983). Not all epitopes are able to elicit an immune response, however, and the 
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property of an epitope whereby it is able to induce such a response is known as its 
immunogenicity (Atassi, 1984). Epitopes can be further discriminated on the 
basis cif structural criteria: a stretch of amino acid residues directly linked by 
peptide bonds constitutes a continuous epitope, while a group of residues 
brought into apposition by virtue of polypeptide chain folding or interchain 
interaction is defined as a discontinuous epitope (Atassi and Smith, 1978). 
To produce an immune response in vivo that generates antibodies inhibitory to 
selected non-immunogenic proteases, requires a strategy that will break immune 
self-tolerance. This can be achieved by producing antibodies to a peptide 
corresponding to an accessible portion of the enzyme, thereby allowing such 
antibodies to bind to the common, non-immunogenic epitope of the enzyme 
(Dennison, 1989). This approach also has the advantage of allowing for the site of 
binding of the antibody to the enzyme to be pre-selected according to criteria 
maximising the chances of immunoinhibition. Furthermore, prediction 
algorithms based on empirical observations of the location of continuous 
epitopes in proteins and structural parameters such as hydrophilicity (Hopp and 
Woods, 1981; 1983) and segmental mobility (Westhof et al., 1984), can be used to 
aid peptide selection. 
The work described in this chapter was aimed at production of an anti-peptide 
antibody capable of immunoinhibiting cathepsin D. Cathepsin D, as discussed in 
the general introduction, has been implicated in breast malignancy. At the outset 
of this work, an extracellular, proteolytic role for cathepsin D was envisaged, 
although evidence now seems to indicate that, in the context of tumour 
progression, the enzyme's proteolytic role may be intracellular (Montcourrier 
et al., 1994). However, endocytosed immunoinhibitory polyclonal antibodies to 
cathepsin D have been found to significantly reduce intracellular cathepsin D-
dependent proteolysis in lysosomes of macrophages (Dingle et al., 1973). 
Moreover, ablation by antibodies, of the suggested extracellular mitogenic activity 
of cathepsin D on breast cancer cells (Fusek and Vetvicka, 1994) is not precluded. 
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Anti-cathepsin D anti-peptide antibodies were raised in rabbits and chickens, 
against either free or conjugated peptide immunogens. These antibodies were 
characterised for binding to the peptide and to cathepsin D purified from various 
species, as well as for immunoinhibitory activity. 
3.2 Purification of cathepsin D 
Cathepsin D was purified from human, porcine and bovine spleen for 
characterisation of the anti-peptide antibodies generated. High levels of the 
enzyme are present in spleen (Cunningham and Tang, 1976). Its reversible but 
strong and stable association with pepstatin, a fungally derived aspartic 
proteinase inhibitor (Aoyagi et al., 1972; Knight and Barrett, 1976), was used to 
purify the enzyme by affinity chromatography (Kazakova and Orekhovich, 1976; 
Takahashi and Tang, 1981), a procedure now ubiquitously used. Prior to affinity 
chromatography, the crude spleen homogenates were subjected to three-phase 
partitioning (TPP) (Pike and Dennison, 1989a) in t-butanol/water / ammonium 
sulfate (Jacobs et al., 1989), a fractionation technique also successfully used for the 
purification of cathepsin L (Pike and Dennison, 1989b). 
3.2.1 Materials 
Spleens. Fresh porcine and bovine spleens were obtained from the Cato Ridge 
Abattoir. A human spleen was obtained from the University of Natal Medical 
School, Durban, after a splenectomy due to portal hypertension resulting in 
congestive splenomegaly. The spleen was human immunodeficiency virus and 
hepatitis B negative (tested by the Natal Institute of Immunology, Pinetown). 
Loading buffer (50 mM sodium acetate, 200 rnM NaC!' 0.02% (m/v) NaN3.< 
pH 3.5). AR acetic acid (2.86 rnl), NaCl (11.69 g) and NaN3 (0.2 g) were dissolved in 
about 900 ml of dist.H20, titrated to pH 3.5 with NaOH, and made up to 1 litre. 
Elution buffer (50 rnM Tris-HC!' 200 rnM NaCL 0.02% (rn/v) N aN3! pH 8.5). Tris 
base (6.06 g), NaCl (11.69 g) and NaN3 (0.2 g) were dissolved in about 900 ml of 
dist.H20, titrated to pH 8.5 with HCl and made up to 1 litre. 
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3.2.2 Procedures 
3.2.2.1 Spleen preparation 
Spleens were prepared essentially according to Takahashi and Tang (1981) . 
Porcine and bovine spleens were freed from connective tissue, but the human 
spleen was found to have almost no connective tissue associated with it. Spleens 
were diced into 2 x 2 cm cubes and stored frozen (-70°C). Diced spleen was 
allowed to thaw overnight to 4°C and homogenised in a Waring blendor with 
cold dist.H20 . Ratios of 1:1 or 1:2 (mass of spleen to volume of water) were used, 
and spleens were homogenised for 1 or 2 min. The homogenate was centrifuged 
(10000 x g, 30 min, 4°C), the supernatant decanted and adjusted to pH 3.7 with 
dilute HCI with stirring, and centrifuged as before. The supernatant was poured 
off and subjected to TPP (Section 3.2.2.2). 
3.2.2.2 Three-phase partitioning 
All procedures were performed at 4°C. Three-phase partitioning ·was effected on 
the pH 3.7 acid supernatant by the addition and mixing in of 2-methylpropan-2-o1 
(t-butanol) to 30% (v /v of final volume). 
The volume of t-butanol to be added was calculated as follows: 
where 
x 
x+y = 0.3 
x = volume of t-butanol 
y = volume of pH 3.7 supernatant. 
t-Butanol was first warmed to 30°C (above its crystallisation temperature of about 
25°C). Solid (~)2S04 (20% (m/v) based on the volume of pH 3.7 supernatant 
and t-butanol) was added and dissolved with stirring. The mixture was 
centrifuged (6000 x g, 10 min, 4°C) in a swing-out rotor and the supernatant 
t-butanol and subnatant aqueous phases decanted, leaving behind the third phase 
of interfacial protein precipitate, which was discarded. Further (NH
4
) :S04 was 
added to the aqueous and solvent phases to bring the concentration to 35% (m/v) 
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(based on the volume of pH 3.7 supernatant and t-butanol) and was dissolved 
with stirring. The solution was again centrifuged (6000 x g, 10 min, 4°C) and the 
interfacial protein l~yer collected by decantation of the super- and subnatants. 
The precipitate was redissolved in loading buffer at approximately one-tenth of 
the volume of the acid supernatant. The solution was centrifuged (25000 x g, 
15 min, 4°C) and filtered through Whatman No. 4 filter paper to remove 
undissol ved protein. 
3.2.2.3 Pepstatin affinity chromatography 
The sample was loaded onto a column of pepstatin-diaminohexane-Sepharose 
(1.0 x 3.0 cm = 2.4 ml) that had previously been equilibrated with loading buffer at 
10 ml/h. Unbound material was washed off the column with loading buffer and 
cathepsin D was eluted with elution buffer. · 
3.3 Assay of cathepsin D 
Cathepsin D activity is routinely measured using acid-denatured haemoglobin as 
a substrate. The distribution of molecular weights -of released pep tides -depends 
on the nature of the substrate and the specificity of the proteinase, while the 
extent of proteolysis depends on the amount of enzymatic activity. Activity is 
measured spectrophotometrically by quantifying the total amount of peptide 
product separable from the parent substrate protein by acid precipitation. The 
method of Anson (1938) utilising trichloroacetic acid (TCA), as modified by 
Takahashi and Tang (1981), is widely used. A linear relationship between change 
in absorbance and incubation time in the range of 10-120 min has been 
demonstrated (Barrett, 1970). 
3.3.1 Reagents 
5% (m/v) Haemoglobin substrate. Bovine haemoglobin powder (0.5 g) was 
placed on top of dist.H20 (10 ml) in a small beaker and gently shaken by hand at 
regular intervals until all protein had dissolved. Excessive stirring entraps air 
bubbles and slows dissolution of the haemoglobin. 
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Assay buffer (250 mM sodium citrate buffer. pH 3.2). Citric acid (5.26 g) was 
dissolved in about 80 ml of dist.H20 , titrated with NaOH to pH 3.2 and made up 
to 100 ml. 
5% (m/v) Trichloroacetic acid. Trichloroacetic: acid (5 g) was dissolved in dist.H20 
and made up to 100 ml. 
3.3.2 Procedure 
The reaction mixture, consisting of assay buffer (506 ~l), substrate (133 ~l) and 
enzyme sample (26 ~l), was prepared in a polyethylene microfuge tube. After 
incubation at 37°C for 30 min, a sample (300 ~l) was removed and added to a 
polyethylene microfuge tube containing TCA (240 ~). For a zero-time control, a 
sample (300 ~) was removed and mixed with TCA immediately after addition of 
the enzyme. The precipitated protein, in both reaction mixtures and blanks, was 
centrifuged to a pellet using a horizontally orientated microfuge tube rotor. The 
absorbance of the reaction mixture supernatant was read against the blank 
supernatant in a 1 ml quartz cuvette at 280 nm. Tr~plicate assays were carried out 
for both samples and controls. For the purposes of this study, 1 unit of activity is 
defined as the quantity of enzyme producing an increase of absorbance of 1.0 in 
excess of the control in 60 min (Barrett, 1970). 
3.4 Selection and synthesis of peptide 
A comparison of available high resolution crystal structures of aspartic 
proteinases, indicated a considerable degree of structural similarity (Davies, 1990). 
This suggested, at the outset of this study, when the tertiary structure ~f 
cathepsin D was not yet elucidated, that related aspartic proteinase structures 
could be used as models of cathepsin D. Penicillopepsin is probably the best 
characterised aspartic proteinase in terms of catalytic mechanism and structure 
(Hsu et al., 1977; James et al., 1982), and was thus used for peptide selection. 
Aspartic proteinases contain two lobes symmetrical in peptide chain 
conformation. A large binding cleft (40 A), which can accommodate about eight 
substrate amino acid residues, runs across. the molecule, separating the two 
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domains. The active site residues, Asp-21S, Asp-32 and Ser-3S (penicillopepsin 
numbering), are found near the midpoint of the active site cleft (Tang, 1979; 
Davies, 1990). In the middle of the cleft, the structures of all aspartic proteinases 
are very similar; superimposition of this core region of human renin and that of 
three fungal aspartic proteinases shows differences of only 0.45 A (Sielecki et al., 
1989). Unlike some lysosomal cysteine proteinases, the active site lies buried 
between the two lobes, and would be inaccessible to an antibody. However, 
another structurally conserved region is the ~-hairpin structure known as the 
"flap", composed of residues 71-83 in penicillopepsin (James et al., 1982; Sielecki 
et al., 1989; Sielecki et al., 1990). A difference electron density map at 1.8 A 
resolution of crystals of a molecular complex between the esterified tripeptide 
fragment of pepstatin and penicillopepsin, indicated a major conformational 
change involving the flap as a result of inhibitor binding. There are 82 
nonbonded contacts less than 4.0 A that the atoms of the tripeptide make with IS 
residues of the enzyme. Of the 82 contacts, 40 are made by the PI statine residue to 
10 residues of penicillopepsin, and 3 of these are with the flap, i.e. Tyr-75, Asp-77 
and Ser-79. The P2 amino acid of pepstatin, valine, also makes a major contact 
with Asp-77. 
Mobility of the flap is a prerequisite to accommodate substrates in the binding 
cleft. A conformational change is indicated by the negative electron density on 
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the difference map between the enzyme and enzyme-inhibitor complex. A 
hinge-like rotation around an axis connecting the ex atoms of Trp-71 and Gly-83 
provides movement to the flap such that the tip of the flap is able to move by 
about 2.2 A (James et al., 1982). A recently completed crystallographic study by 
Baldwin et al. (1993) (Fig. 2) and a rule-based model by Scarborough et al. (1993), 
detailing the structure of native and inhibited forms human cathepsin D, 
confirms the analogous studies done on penicillopepsin. 
Figure 2 
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Calpha backbone of two-chained human cathepsin D determined from the crystal 
structure (Baldwin et a I., 1993). 
The "flap" (magenta) is situated in the human cathepsin D light chain (cyan). The 
heavy chain is shown in white, and side chains are shown for the disulfide bonds 
(yellow) and the two active-site aspartate residues (red). The parent image 
(reference 1L YB) was retrieved from the Protein Data Bank, Brookhaven National 
Laboratory, Upton, New York. This image was modified in RasMol version 2.5 for 
Windows. 
Binding of pepstatin to cathepsin D induces residues Gly-79 and Ser-80 at the tip 
of the flap to move about 1.7 A toward the inhibitor, accompanied by a decrease 
of flexibility of the tl-bend as result of hydrogen bonding between the backbone of 
the inhibitor and side-chain atoms of the enzyme (Fig. 3). 
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Schematic hydrogen-bonding diagram for pepstatin bound to cathepsin D. 
Inhibitor side-chain numbering is according to the nomenclature of Schechter and 
Berger (1967) and flap residues are numbered according to human cathepsin D. 
It was envisaged that an antibody binding to the flap would disrupt its flexibility 
of movement and/or its hydrogen bonding interactions with a good substrate. 
This approach was independently used with human renin (Bouhnik et al., 1987), 
where 7 peptide sequences were selected, based on the three-dimensional model 
of renin. Antibodies against these pep tides were tested for immunoinhibitory 
activity, and the antibody based on the renin flap sequence proved to be the most 
potent inhibitor. 
Based on the considerations outlined above, an amino acid sequence 
corresponding to residues 73-84 (D73-84) in the human cathepsin D sequence 
(Faust et al., 1985), was selected (Fig. 4). Despite a high degree of structural 
conservation, the flap region has a remarkable lack of sequence homology 
between aspartic proteinases (Fig. 4), and anti-peptide antibodies produced against 
this sequence would be unlikely to cross-react with other aspartic proteinases. In 
contrast, the sequence is relatively well conserved across species (Fig. 5), being 





human cathepsin Dl: S F D I H Y G S G S L S 
human renin2: E L T L R S T - T V -
human pepsinogen3: T V S T - - T - - M T 
porcine pepsinogen4: E L S T - - T - - M A 
bovine chymosins: p L S - - - - T - - M Q 
penicillopepsin6: T W S S - - D - - S A 
Amino acid sequence homology of the flap region of human cathepsin D with that of 
other aspartic proteinases. 
Dashes in the lower five sequences indicate identity with the human cathepsin D 
sequence. lFaust et al., 1985; 2Imai et al., 1983; 3Sogawa et al., 1983; -trang et al., 1973; 
sHarris et al., 1982 and 6Hsu et al., 1977. 
human1 cathepsin D: 
porcine2 cathepsin D: 
chicken3 cathepsin D: 
ra~/mouses cathepsin D: 
mosquito6 cathepsin D: 
Schistosoma japonicum7 
aspartic proteinase: 
S F D I H Y G S G S L S 
T - - A 
E - A - - - -
A - H - Q 
D - S - R - - T - - - -
Cross-species amino acid sequence homology of the flap region of cathepsin D. 
Dashes in the lower five sequences indicate identity with the human cathepsin D 
sequence. lFaust et al., 1985; ~hewale and Tang, 1984; 3Retzek et aI., 1992; ~Birch and 
Loh, 1990; sGrusby et al., 1990; 6Cho and Raikhel, 1992 and 7Becker et al., 1995. 
The flap sequence is more than 10 amino acids long, thereby enhancing 
immunogenicity (Van Regenmortel, 1988). It is relatively hydrophobic but quite 
mobile, the region corresponding to the tip of the flap (residues 78-81) being more 
rigid (Fig. 6). The N-terminus is also relatively constrained, enhancing its 
suitability for coupling to a carrier molecule prior to inoculation, leaving the 
more mobile C-terminus free to interact with the immune system. The peptide 
was, however, also inoculated in the unconjugated, free form. 
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Peptide D73-84 was custom synthesised by Multiple Peptide Systems, San Diego, 
Ca. The C-terminal carboxyl residue was amidated to remove the charge 
associated with the carboxyl group, thereby mimicking more closely the peptide 
bond in the protein. This modification .also ensures a higher yield from peptide 
synthesis (Multiple Peptide Systems technical bulletin). The N-terminus was left 
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Hydrophilicity and segmental mobility profiles of human D73-84. 
Hydrophilicity (0) was calculated according to Hopp and Woods (1981; 1983) and 
segmental mobility (+) calculated according to Westhof et al. (1984) . 
3.5 Conjugation of peptide D73-84 to ovalbumin 
Conjugation was effected with the homobifunctional reagent, glutaraldehyde, 
between the N-terminus of D73-84 and the carrier protein, ovalbumin, by the 
method of Briand (1985). Both tyrosine and histidine, present in D73-84, are 
capable of secondary reactions with glutaraldehyde (Muller, 1988), while 
ovalbumin contains 20 e-NH2 groups, although not all necessarily available for 
coupling (Nisbet et al., 1981). A peptide:carrier molar ratio of 1:40 was used and 
conjugation effected with 1% glutaraldehyde. A 50% coupling efficiency was 
assumed (Bulinski and Gundersen, 1986). 
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The peptide was insoluble in buffer at a neutral pH, but NaOH effected 
solubilisation at ca. pH 12. This pH, however, is beyond the optimal range for 
glutaraldehyde conjugation, so amine-free dimethyl formamide (DMF), which 
was also able to effect solubilisation, was used as a solvent. 
3.5.1 Reagents 
Synthetic peptide D73-84. The peptide, SFDIHYGSGSLS, IS described In 
Section 3.4. 





(13.8 g) and NaN3 (0.2 g) were dissolved in about 800 ml of dist.H20, 
titrated to pH 7.0 with NaOH and made up to 1 litre. 
Glutaraldehyde (2% (v Iv) in conjugation buffer). Glutaraldehyde (80 ~ of a 25% 
solution, Merck, E. M. grade) was made up to 1 ml with conjugation buffer. 
3.5.2 Procedure 
Peptide (5 mg, 3.9 llmoles, 1270 Da) was dissolved in amine-free DMF (100 jll) and 
made up to 1 ml with PBS. Ovalbumin (4.6 mg, O.l11moles, 45 kDa) was added to 
the solution and allowed to dissolve. Glutaraldehyde (1 ml) was added dropwise, 
with stirring, over a period of 5 min, and allowed to react for a further 2 h at 4°C. 
The reaction was stopped by the addition of NaBH4 (20 mg) and the mixture 
incubated for a further 1 h at 4°C. Conjugated peptide was separated from free 
peptide by dialysis against several changes of conjugation buffer at 4°C. 
3.6 Production of anti-D73-84 anti-peptide antibodies in rabbits and chickens 
Antibodies to peptide D73-84 were produced in rabbits and chickens. Rabbits were 
each injected subcutaneously at 4-6 sites on the back with 100 llg conjugated 
peptide per animal, emulsified (1:1, v Iv) in Freund's complete adjuvant (Difco, 
Detroit, Mi.). Further inoculations were administered in the same manner in , 
Freund's incomplete adjuvant (Difco) at week 2, followed by monthly boosters. 
Antibodies to free peptide (200 llg per animal, dissolved in pH 11.25 NaOH) were 
52 
similarly raised except that Freund's complete adjuvant was used throughout. 
Blood was collected from the marginal ear vein of rabbits at 3 and 8 weeks, and by 
non-lethal cardiac puncture at 12 weeks. Serum was separated from blood clots 
and IgG isolated (Section 2.5) and stored in glycerol (1:1, v Iv) at -20°e. 
Chickens were inoculated intramuscularly, at two sites in their large breast 
muscles, with either conjugate (100 Ilg conjugated peptide per animal) or free 
peptide (200 Ilg free peptide per animal, dissolved in pH 11,25 NaOH). For the 
conjugate, Freund's complete adjuvant (1:1, v Iv) was used at week 0, and 
Freund's incomplete adjuvant (1:1, v Iv) at weeks 2,4, 6 and for monthly boosters 
thereafter. A similar schedule was used for free peptide except that complete and 
incomplete adjuvants were alternated from week o. Eggs were collected and IgY 
isolated (Section 2.5) and stored in glycerol (1:1, v Iv) at -20°e. 
3.7 Enzyme-linked immunosorbent assay with peptide and enzyme 
To test anti-peptide antibodies against peptide, an ELISA protocol (Section 2.6) 
was used, with peptide coated at 1.0 Ilg/ml. To test the across-species reactivity of 
anti-peptide antibodies against cathepsin D from human, bovine and porcine 
spleens, the same protocol was followed using IgY and substituting whole serum 
in the place of IgG. Cathepsin D, purified from various sources, was coated at 
2 Ilg/ml. 
3.8 Competition ELISA for native cathepsin D 
The binding affinity of the anti-peptide antibody for native cathepsin D was tested 
by competition between coated peptide and free enzyme for the anti-peptide 
antibody. A decrease in the binding of antibody to peptide indicates a positive 
reaction with the native enzyme. Antibody (2 mg/ml) was pre-incubated (pH 7.2, 
30 min, 37°C) with different levels of enzyme (molar ratios of peptide-to-enzyme 
from 1:32 to 1:0.5) and transferred to peptide coated plates (Section 3.7). The 
mixture was allowed to incubate for 1 h at 37°C and developed as previously 
described (Section 2.6). 
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3.9 Immunoinhibition assays 
A major problem associated with cathepsin D is the lack of a sensitive assay. To 
measure enzyme immunoinhibition by polyclonal anti-peptide antibodies, a 
large ~olar excess of antibody over enzyme is required, as only a small 
proportion of the antibody population will recognise the native enzyme. This 
necessitates the use of as small an amount of enzyme as possible. Synthetic 
fluorogenic substrates, which are normally highly sensitive to detection, are not 
in wide use for cathepsin D, and therefore not well characterised. Use is almost 
exclusively made of the traditional haemoglobin assay (Anson, 1938), which lacks 
sensitivity and specificity. In this study, use was made of the haemoglobin assay 
and the azocasein assay in the presence of urea (Wiederanders et al., 1985). 
3.9.1 Modified haemoglobin assay 
The routinely used haemoglobin assay was modified to accommodate larger 
sample volumes, necessitated by the preincubation of enzyme with antibody. 
Furthermore, it has been observed that maximum pepsin activity was obtained 
with a substrate concentration of 0.5% haemoglobin, while a concentration of 
1.67% elicited 35-40% less activity. A similar inhibition by haemoglobin substrate 
above a concentration of 1.25% has been reported for cathepsin E (Simonarson 
et al., 1985). The concentration of haemoglobin was, therefore, maintained at 
0.9% (Muto et al., 1988), and not at 1.67% as in the original Anson (1938) assay. 
3.9.1.1 Reagents 
Assay buffer (250 mM sodium citrate buffer, pH 5.0). Citric acid (5.26 g) was 
dissolved in about 80 ml of dist.H20, titrated with NaOH to pH 5.0 and made up 
to 100 ml. 
1 % (m/v) Haemoglobin substrate. Denatured bovine haemoglobin powder (0.1 g) 
was placed on top of assay buffer (10 ml) in a small beaker and gently shaken by 
hand at regular intervals until all protein had dissolved. 
10% (m/v) Trichloroacetic acid. Trichloroacetic acid (10 g) was dissolved In 
dist.HzO and made up to 100 ml. 
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3.9.1.2 Procedure 
Enzyme (400 ng) was preincubated wi_th immune or non-immune antibody 
(0.1 mg - 9.0 mg) in assay buffer (total volume of 200 Ill, 15 min, 37°C). To start 
the assay, substrate (2000 Ill) was added and the mixture incubated in glass test 
tubes. For a zero-time control, a sample (1100 jll) was removed and mixed with 
TCA (1000 Ill) immediately after addition of the enzyme. After incubation at 37°C 
(2 h), TCA (1000 Ill) was added to the reaction mixtures. The precipitated protein 
in both reaction mixtures and blanks, was spun to a pellet in a benchtop 
centrifuge. Supernatants were clarified by filtration through Whatman No. 4 
filter paper. The absorbance of the reaction mixture supernatant was read against 
the blank supernatant in a 3 ml quartz cuvette at 280 nm. Triplicate assays were 
carried out for both samples and controls. Immunoinhibition can be calculated 
as the percentage inhibition due to the presence of antibody relative to a parallel 
non-immune control. 
3.9.2 Azocasein assay 
Azocasein in the presence of 3 M urea is a more sensitive substrate for 
cathepsin D than denatured haemoglobin (Wiederanders et al., 1985). Urea has 
the effect of increasing the susceptibility of azocasein to attack by the enzyme and 
increases the solubility of hydrolysed products in TCA. Furthermore, the 
optimum for hydrolysis of azocasein is shifted to pH 5.0 in comparison to that of 
. pH 3.2 in the haemoglobin assay (Anson, 1938). This is advantageous for 
immunoinhibition assays where pH 5.0 is used to ensure adequate binding of 
antibody to enzyme. The effect of the presence of urea in the assay system was 
ascertained by an ELISA (Section 3.9.3). Although there was a reduction in titre, 
at high antibody levels comparable amounts of antibody bound immobilised 
enzyme as in urea-free controls. 
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3.9.2.1 Reagents 
Assay buffer (250 mM sodium citrate buffer, pH 5.0). Citric acid (5.26 g) was 
dissolved in about 80 ml of dist.H20, titrated with NaOH to pH 5.0 and made up 
to 100 ml. 
6% (m/v) Azocasein. Azocasein (3 g) was weighed into a glass beaker and 
dissolved in 50 m1 dist.H20 with gentle magnetic stirring at room temperature for 
about 1 h. 
Azocasein/3 M urea solution. Urea (10.8 g) was dissolved in 6% azocasein 
solution (10 ml) by stirring on a magnetic stirrer at about 30°C. The volume was 
made up to 30 m1 with assay buffer. 
5% (m/v) TCA. Trichloroacetic acid (5 g) was dissolved in dist.H20 and made up 
to 100 ml. 
3.9.2.2 Procedure 
Enzyme (100 ng - 400 ng) was preincubated with non-immune or immune 
antibody (0.5 mg - 1.0 mg) in assay buffer (total volume of 200 ~, 15 min, 37°C). 
Sample (200 /-ll) was mixed with assay buffer (200' /-l1) and azocasein/urea solution 
. (400 ~l), and an aliquot (200 ~) immediately withdrawn-and mixed with 5% TCA 
(1000 ~). This served as a blank for the. reaction. After a specified time (30 min-
2 h) a further aliquot was withdrawn (200 /-ll) and mixed with TCA (1000 /-ll). 
Samples were centrifuged in a microcentrifuge and the absorbance at 366 run read 
in glass micro-cuvettes, with blacked-out sides to prevent transmission of light 
around the sample. Triplicate assays were carried out for both samples and 
controls. Immunoinhibition can be calculated as the percentage inhibition due to 
the presence of antibody relative to a parallel non-immune control. 
3.9.3 Enzyme-linked immunosorbent assay in the presence of 3 M urea 
The binding of the chicken anti-peptide antibodies in the presence of 3 M urea 
was established at pH 5.0 and 6.0 using assay buffer (Section 3.9.1) and at pH 7.4 as 
before (Section 2.6 and 3.7). 
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3.10 Affinity purification of chicken anti-D73-84 anti-peptide antibodies 
Preliminary assays demonstrated a lack of enzyme inhibition by'the antibodies 
tested, which prompted the decision to affinity purify antibodies using bovine 
cathepsin D immobilised via its carbohydrate groups on polyacrylhydrazido-
agarose (Bio-Rad Bulletins 1099, 1298). This ensures, firstly, that the immobilised 
enzyme is optimally available for antibody binding by virtue of the carbohydrate 
group acting as a spacer arm and, secondly, that the enzyme remains as native as 
possible by avoiding immobilisation via protein residues as occurs when 
cyanogen bromide-activated agarose is used. This should yield an antibody 
preparation that is essentially monoclonal in its specificity for binding the flap 
region of the enzyme. Bovine cathepsin D was used due to the similarity of 
recognition of the bovine and human enzyme in an ELISA, and the availability 
of suitable source material for its purification. 
3.10.1 Reagents 
Coupling buffer (100 mM -sodium acetate, 150 mM NaCL pH 5.5). AR acetic acid 
(5.72 ml) and NaCl (8.76 g) were dissolved in about 900 ml of dist.H20, titrated to 
pH 5.5 with NaOH, and made up to 1 litre. 
Bovine cathepsin D. Cathepsin D was purified from bovine spleen as described 
in Section 3.2. 
20.8 mg/ml Sodium periodate. Sodium periodate (20.8 mg) was dissolved in 
dist.H20 (1 ml). 
Equilibration buffer (20 mM sodium phosphate, 500 mM NaCL 0.02% (m/v) 
NaN3, pH 7.2). NaH2P04 (2.76 g), NaCl (29.23 g) and NaN3 (0.2 g) were dissolved 
in about 800 ml of dist.H20, titrated to pH 7.2 with NaOH and made up to 1 litre. 
Elution buffer (20 mM sodium phosphate, 500 mM NaCL 3.5 M potassium 
thiocyanate, pH 7.2). NaH2P04 (0.28 g), NaCl (2.92 g) and potassium thiocyanate 
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(34.01 g) were dissolved in about 80 ml of dist.H20, titrated to pH 7.2 with NaOH 
and made up to 100 ml. 
3.10.2 Procedure 
Bovine cathepsin D (10.9 mg) was dialysed into coupling buffer to a volume of 
5 ml. Cathepsin D sugar moieties were oxidised with sodium periodate 
(0.1 volumes) by gentle stirring (1 h, in the dark). To stop the reaction glycerol 
(8 JlI, 20 mM final conc.) was added and mixed in (10 min). Oxidised cathepsin D 
(5 ml) was applied to a Sephadex G-25 column (2.5 cm x 25 cm = 120 ml), 
equilibrated in coupling buffer (50 ml/h), to remove excess periodate and 
glycerol. Eluted cathepsin D (10.2 mg, 14 ml) was coupled in an end-over-end 
mixer to polyacrylhydrazido-agarose (3 ml, 24 h, RT), previously washed with 
coupling buffer. The gel was washed alternately with high and low pH buffer 
(elution and equilibration buffers respectively, Section 3.2.1), coupling buffer and 
elution buffer and again with equilibration buffer. Determination of the amount 
of enzyme left uncoupled, gave a coupling efficiency of 95%. 
An appropriate antibody preparation (10 mg) was twice passed through the 
affinity gel (1.0 em x 3.3 cm = 2.6 ml, 10 ml/h) and unbound material washed off 
with equilibration buffer. Bound antibody was eluted with elution buffer 
(5.6 ml), and the eluted fraction desalted into equilibration buffer on a column of 
Sephadex G-25 as described above. 
3.11 Results 
3.11.1 Purification of cathepsin D from bovine, porcine and human spleen 
Cathepsin D was purified from bovine (200 g), porcine (330 g) and human (250 g) 
spleens using the procedure described in Section 3.2.2. A comparison of the 
purification of cathepsin D from the three species is presented in Table 3. 
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Table 3. The purification of cathepsin D from bovine, porcine and human 
spleens. 
Step Vol. Total Total / Specific Purilic- Yield 
(ml) Protein Activity Activity ation (%) 
(mg) (units) (units/mg) (fold) 
Bovine 
crude 
supernatant 352 17 632 13 084 0.742 (1 ) (100) 
acid supernatant 296 5 957 7 556 1.268 1.7 58 
IPP 38 92 5437 59.09 79.6 42 
pepstatin-
Sepharose 7.7 5.951 4082 685.94 924.5 31 
Porcine 
crude 
supernatant 540 25 193 15 229.3 0.605 (1) (100) 
acid supernatant 453 9 931 13 798.9 1.389 2.3 90.61 
IPP 56 292.8 6 644.32 22.69 37.5 43 .63 
pepstatin-
Sepharose 4.5 4.515 564.02 124.92 206.7 3.7 
Human 
acid supernatant 457 3- 950 30 384.6 7.69 (1) (100) 
IPP 40 161.6 5 736.6 <- 35.5 4.6 18.8 
pepstatin-
Sepharose 10.1 4.51 2 518.1 558.3 72.6 8 
Freezing of tissue prior to homogenisation is essential to disrupt lysosomes and 
facilitate the release of lysosomal enzymes. Better recoveries were obtained using 
twice the volume of dist.H20 per mass of spleen for homogenisation and twic'e 
the homogenisation time recommended by Takahashi and Tang (1981). Different 
buffers have no effect on cathepsin D extraction (Press et al., 1960). 
Cathepsin D eluted from pepstatin-Sepharose in a single peak (Fig. 7). The low 
pH of the loading buffer allows the enzyme to assume an enzymatically active 
conformation, and it is thus able to bind to the immobilised inhibitor. By virtue 
of the reversibility of the enzyme-inhibitor interaction, a change to a higher 
buffer pH, which induces conformational deactivation, causes the enzyme to 
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release the inhibitor and it is thus eluted. Enzyme activity in the breakthrough 
peak was low and probably attributable to non-aspartic protease proteolytic 
activity against haemoglobin substrate (results not shown). Activity in the eluted 
peak should be quantitative by virtue of the specificity of the enzyme-inhibitor 
interaction. Figs 8-10 illustrate the SDS-PAGE analysis of the purification of 
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Elution of cathepsin D from pepstatin-Sepharose after application of the TPP 
fraction. 
Pepstatin-Sepharose was equilibrated with loading buffer and oound cathepsin D 
was eluted with elution buffer, applied at point -1.. The flow rate was 10 ml/h and 
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Reducing SDS-PAGE analysis of the purification of bovine spleen cathepsin: D. 
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Fractions were reduced and loaded onto a 12.5% gel. (a) cathepsin D; (b) molecular 
I 
weight markers (BSA, 68 kDa; ovalbumin, 45 kDa; carbonic anhydrasj' 29 kDa; 
lysozyme, 14 kDa); (c) TPP fraction; (d) acid supernatant and (e) crude supernatant. 
I 







Reducing SDS-PAGE analysis of the purification of porcine spleen catheps'in D. 
Fractions were reduced and loaded onto a 12.5% gel. (a) crude supernataht; (b) acid 
supernatant; (c) TPP fraction; (d) cathepsin D and (e) molecular weight karkers (as 
I 
in Fig. 8). 




Figure 10. Reducing SDS-PAGE analysis of the purification of human spleen cathepsin D. 
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Fractions were reduced and loaded onto a 12.5% gel. (a) acid supernatant; (b) TPP 
fraction; (c) molecular weight markers (as in Fig. 8) and (d) cathepsin D. I 
Lane e of fig. 8 and lane a of Fig. 9 show the extent of cytosolic proteins in the 
homogenate supernatant, and lane d and b respectively ·the correspohding 
supernatants after the acid precipitation step. Note the degree of purification 
achieved by the TPP step and the concomitant disappearance ·of thef very 
prominent band corresponding to haemoglobin. I 
I 
Bovine cathepsin D was purified as a mixture of single- (45 kDa) and lw04ained 
forms (30 kDa + 15 kDa) (Fig. 8). The light chain component of the two-chain 
enzyme is present as a doublet, and a band is visible at a molecular wei~ht of 
about 39 kDa. This band was a feature of all cathepsin D purifications I from 
bovine spleens, and was assumed to be a proteolysis product of the single I chain 
enzyme (Whitaker, 1980). 
Cathepsin D from porcine spleen was similarly found to run as a mixture of 
single- (45 kDa) and two-chain forms on (30 kDa + 15 kDa) on SDS-PAGE (Fig. 9). 
The proportion of single- to two-chain enzyme appears to be lower relative to 
bovine cathepsin D. The 15kDa light chain appeared as a triplet for Jorcine 





enzyme was purified only as a two-chain form with 30 kDa and 15 kDa 
components. 
3.11.2 Production and characterisation of anti-peptide antibodies against the 
human cathepsin D peptide 
Use of glutaraldehyde as a coupling agent can give a coupling yield of 35-50% 
(Bulinski and Gundersen, 1986). Previous studies in this laboratory have yielded 
coupling efficiencies of 47.5% (Pike, 1990) and 45% (Coetzer, 1992) for two 
different peptides coupled by this method. The coupling efficiency for D73-84 was 
thus assumed to be 50%, and this was used to determine the amount of 
immunogen required for inoculation. 
To monitor the progress of antibody production in host animals, an ELISA was 
developed in which peptide was coated directly to the wells of the microtitre 
plate. Many workers prepare conjugate antigens for use in ELISAs, consisting of a 
carrier and a coupling method different from those used to prepare the 
immunogen. Most coupling reactions lead to the modification of many residues 
of the carrier that are not involved in the formation of peptide-carrier bridges. 
When animals are immunised with peptide conjugates, such coupling agent-
modified residues (CAMOR) may elicit the formation of CAMOR antibodies that 
recognise only the modified carrier molecule, but not the untreated carrier or 
peptide moiety (Briand et . al., 1985). By coating directly with peptide, only the 
contribution of anti-peptide antibodies is measured and the need to prepare the 
peptide coupled to a different carrier by means of another coupling agent is 
obviated. 
The chickens responded very similarly during the course of the inoculation 
programme, and the response of only one chicken is, therefore, shown. Antibody 
production against conjugated peptide reached a maximum at eight weeks, with 
the levels at twelve weeks being almost unchanged (Fig.llA). The antibody did 
not show appreciable non-specific binding (results not shown) to the unrelated 
peptide D1l2-122 from porcine cathepsin D (Coetzer et al., 1,991). Free peptide, 
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however, did not elicit a comparable immune response, although there was 
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Figure 11. ELISA of the progress of immunisation with conjugated and free peptide D73-84 in 
chickens. 
Human cathepsin D peptide D73-84 was coated at 1.0 Jlg/ml to microtitre plates and 
incubated with serial two-fold dilutions of chicken anti-human cathepsin D peptide 
D73-84 IgY collected after 3 (+), 8 (A) and 12 weeks (0) and non-immune IgY (L\). 
Immunisation was with (A) ovalbumin-conjugated peptide and (B) free peptide. 
Binding was visualised by incubation with rabbit anti-chicken IgY-HRPO secondary 
antibodies as described in Section 2.6. 
The reactivity of the IgY anti-peptide antibodies toward whole enzyme was tested 
in an ELISA where bovine, porcine and human cathepsin D were immobilised 
(Fig. 12). Using antibodies to the conjugated peptide, the human and bovine 
enzymes were equally well targeted, while porcine cathepsin D was less well 
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recognised. A similar trend was found with IgY antibodies against the free 


















-1 o 1 2 3 4 
logUIg Yl <llglm1)} 
Figure 12. ELISA of the cross-species reactivity of chicken anti-human cathepsin D peptide 
(conjugated and free) antibodies with bovine, porcine and human cathepsin D. 
The enzyme preparations were coated at 2.0 ~g/ml to microtitre plates and incubated 
with serial two-fold dilutions of chicken anti-human cathepsin D peptide D73-84 
IgY. Cross-reaction of anti-conjugated D73-84 IgY (A) and anti-free D73-84 IgY (B) 
with bovine (+), porcine (.~) and human (0) cathepsin D. Non-immune IgY (~) . 
Binding was visualised by incubation with rabbit anti-chicken IgY-HRPO secondary 
antibodies as described in Section 2.6. 
Immunisation of conjugated peptide into rabbits elicited a similar response that 
peaked at 8 weeks and remained constant at 12 weeks (Fig. 13A). Free peptide, 
however, provoked a very rapid response; the titre had reached maximum at 
65 



















-4.5 -3.5 -2.5 -1.5 -0.5 
-log(antiserum dilution) 
Figure 13. ELISA of the progress of immunisation with conjugated and free peptide D73-84 in 
rabbits. 
Human cathepsin D peptide D73-84 was coated at 1.0 Jlg/ml to micro titre plates and 
incubated with serial two-fold dilutions of rabbit anti-human cathepsin D peptide 
- D73-84 serum collected after 3 (+), 8 (A) and 12 weeks (0) and non-immune serum (~) . 
Immunisation was with (A) ovalbumin-conjugated peptide and (B) free peptide. 
Binding was visualised by incubation with sheep anti-rabbit IgG-HRPO secondary 
antibodies as described in Section 2.6. 
Reactivity of rabbit serum against conjugated or free peptide, in contrast to serum 
against free peptide incubated with immobilised peptide (Fig. 13B), was similar 














Figure 14. ELISA of the cross-species reactivity of rabbit anti-human cathepsin D peptide 
(conjugated and free) serum with bovine, porcine and human cathepsin D. 
The enzyme preparations were coated at 2.0 J.lg/ml to microtitre plates and incubated 
with · serial two-fold dilutions of rabbit anti-human cathepsin D peptide D73-84 
serum. Cross-reaction of anti-conjugated D73-84 serum (A) and anti-free D73-84 serum 
(B) with bovine (+), porcine (A) and human (0) cathepsin D. Non-immune serum (A). 
Binding was visualised by incubation with sheep anti-rabbit IgG-HRPO secondary 
antibodies as described in Section 2.6. 
The reactivity of anti-peptide D73-84 antibodies against fully denatured 
cathepsin D was tested by western blotting (Section 2.7) subsequent to reducing 
SDS-PAGE, and by a blotting method designed to minimise protein denaturation 
(Dunn, 1986). To this end non-reducing SDS-PAGE was followed by incubation 
of the gel in glycerol to facilitate SDS removal and enzyme renaturation. 
Transfer of the protein to nitrocellulose membrane was effected in the absence of 
SDS at pH 8.3, and the membrane was not allowed to dry prior to probing. No 
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reaction was found by either method, suggesting that a conformation-dependent 
epitope may be recognised on the enzyme. 
The recognition of native cathepsin D by anti-peptide D73-84 antibodies at pH 7.2 
was evidenced by competitive inhibition by the enzyme of binding of antibody to 
immobilised peptide (Fig. 15). Maximum competition at 566 ~g/ml corresponds 
to an approximately 32-fold molar excess of enzyme over immobilised peptide. 
Binding of antibody to native enzyme could not be detected at pH 5.0, the pH 
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Figure 15. Competition ELISA determination of the ability of anti-peptide D73-84 to bind to 
native cathepsin D. 
Chicken anti-D73-84 was preincubated with different levels of cathepsin D before 
transfer to peptide-coated microtitre (peptide to enzyme ratio of 1:0.5 to 1: 32) where 
inhibition of binding of IgY to immobilised peptide was measured at pH 7.0 
(Section 3.7). The ELISA was developed as in Section 2.6. Control incubations 
containing either non-immune IgY or no competing cathepsin D were included. 
3.11.3 Cathepsin D immunoinhibition 
Immunoinhibition of cathepsin D by anti-peptide antibodies was tested against 
the protein substrates haemoglobin and azocasein, at pH 5.0. A molar excess of 
up to 625-fold and 1875-fold of antibody over enzyme was used for the 
haemoglobin and azocasein assays respectively. No inhibition of enzyme activity 
was detected in either case. To ascertain whether the presence of 3 M urea in the 
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assay buffer for azocasein assays affects antibody-antigen interactions, an ELISA 
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Figure 16. ELISA of the binding of anti-peptide D73-84 to cathepsin D in the presence and 
absence of 3 M urea. 
The enzyme preparations were coated at 2.0 J.lg/ml to micro titre plates, and incubated 
with serial two-fold dilutions of chicken anti-human cathepsin D peptide D73-84 IgY 
in 250 mM citrate buffer, pH 5.0 (Section 3..3) in the presence oi.3..M_urea, or.phosphate 
buffer, pH 7.4 (Section 2.6). Reaction of cathepsin 'D with anti-D73-84 at pH 5.0 (~), 
pH 5.0 + 3 M urea (0), pH 7.4 (0) and non-immune IgY at pH 5.0 (A), pH 5.0 + 3 M urea 
(_) and pH 7.4 (+). Binding was visualised by incubation with rabbit anti-chicken 
IgY-HRPO secondary antibodies as described in Section 2.6. 
Binding of the antibody at pH 5.0 in the presence of 3 M urea was found to be 
slightly less than at pH 7.4, but still significant. It is unlikely, therefore, that the 
presence of 3 M urea in the azocasein assay buffer was responsible for perturbing 
antibody-enzyme interaction, thereby compromising inhibition. 
In an attempt to obtain anti-peptide antibodies of a higher potency, antibodies 
were affinity purified against cathepsin D immobilised by its carbohydrate 
residues. This procedure yielded approximately 70.0 ~g/ml purified antibody per 
100 mg IgY preparation applied. The titre of the affinity purified antibody was 
tested in an ELISA (Fig. 17). Immobilised human cathepsin D was still recognised 
at four dilutions more than the crude IgY preparation. The affinity purified 
69 
antibody, however, still failed to produce enzyme immunoinhibition. Attempts 
to produce immunoinhibition by using protein substrates with fluorescent 
leaving groups, such as fluorescein-haemoglobin and fluorescein-casein, were 
also unsuccessful. These assays did not produce a significantly greater degree of 
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Figure 17. ELISA of the binding of affinity purified anti-peptide D73-84 to human cathepsin D. 
Human cathepsin D was coated at 2.0 ~g/ml to microtitre plates, and incubated with 
serial two-fold dilutions of chicken anti-cathepsin D peptide D73-84 IgY 
preparations. Reaction of affinity purified antibody (A), crude IgY (.) and non-
immune IgY (il) . Binding was visualised by incubation with rabbit anti-chicken IgY-
HRPO se~ondary antibodies as described in Section 2.6. 
3.12 Discussion 
This chapter is divided into two complementary parts; first the purification of the 
aspartic proteinase, cathepsin D, and second, the raising and characterisation of 
anti-peptide antibodies against a sequence selected from cathepsin D. It was 
envisaged that anti-peptide antibodies could be generated so as to exhibit 
inhibition of enzyme activity, as has been demonstrated for other proteinases 
such as cathepsin L (Coetzer et al., 1991) and renin (Bouhnik et al., 1987). Such 
antibodies could find applicability in in vitro tumour invasion studies and, it was 
initially envisaged, in tumour immunotherapy. 
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A major advancement of the cathepsin D purification procedure used, is the use 
of TPP as the pre-affinity chromatography step. Almost all other procedures 
encowl.tered appeared to be more costly, and labour and time intensive. The 
commonly used method of Takahashi and Tang (1981) involves a 40 h dialysis 
step followed by ion-exchange chromatography and pepstatin-Sepharose affinity 
chromatography, while the method of Afting and Becker (1981) employs 
chromatography on concanavalin A-Sepharose and pepstatin-Sepharose affinity 
chromatography. 
Three-phase partitioning was discovered serendipitously during the course of 
studies on the effects of water-miscible organic solvents on the activity of 
enzymes (Tan and Lovrien, 1972). It was found that t-butanol, normally 
completely miscible in water, separated from the aqueous phase on the addition 
of a salt such as ammonium sulfate. Protein in solution was precipitated into a 
third phase between the t-butanol and aqueous phases. A systematic study of TPP 
(Pike and Dennison, 1989) indicated that proteins precipitate into the third phase 
most readily at or below their pI, but are most soluble after TPP when carried out 
above the pI. The amount of salt required to precipitate a protein was found to 
vary inversely with the protein molecular weight. Three-phase partitioning 
differs from conventional salting-out with ammonium sulfate in that the 
protein precipitate is largely dehydrated and has a low salt content. t-Butanol, 
unlike other organic solvents, does not tend to denature proteins, and TPP can 
therefore be done at room temperature . 
.!'Jon-covalently bonded proteins such as haemoglobin and myoglobin, are 
completely denatured by TPP, while single-chain proteins are denatured to a 
variable extent dependent partly on the pH at which TPP is carried out, relative to 
the pI of the protein. Three-phase partitioning, therefore, constitutes a method 
where single chain proteins can be separated from oligomers which, in the case of 
cathepsin D, results in the removal of haemoglobin, a major contaminant of 
spleen homogenates, at an early stage of the purification. Indeed, the continuous 
presence of haemoglobin during the purification is probably the source of a major 
loss of cathepsin D. Haemoglobin found in tissue homogenates would act as a 
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substrate for cathepsin D, especially since the purification is performed at a low 
pH. Procedures where haemoglobin is removed in soluble form probably deplete 
cathepsin D concomitantly, as is implied by the affinity purification of the 
enzyme on haemoglobin-Sepharose (Smith and Turk, 1974). The introduction of 
TPP, which precipitates haemoglobin and, presumably, leaves most cathepsin D 
in solution, circumvents this problem. 
Resolution of the phases requires only low speed centrifugation, resulting in a 
relatively salt-free fraction, unlike equivalent preparations from ammonium 
sulfate precipitation. Three-phase partitioning is a cheap and rapid pre-affinity 
chromatography step that is suited to macro-scale purification of cathepsin D, 
with competitive enzyme yields. Takahashi and Tang (1981) report the 
purification of 4.65 mg of cathepsin D/100 g of bovine spleen, while with this 
procedure up to 5 mg of enzyme/100 g of spleen has been isolated within a far 
shorter time. 
Cathepsin D was purified, using this protocol, from bovine spleens and, for the 
first time, from porcine and human spleens. Bovine and porcine enzymes were 
purified as a mixture of single (45 kDa) and two-chained (30 kDa and 15 kDa) 
forms . This is in agreement with published sizes of bovine cathepsin D (Lah 
et al., 1984), but differs slightly from the porcine cathepsin D purified by 
Takahashi and Tang (1981). This group describe the purification of a 35 kDa and 
15 kDa two-chain form and a 50 kDa single-chain enzyme. Mting and Becker 
(1981) have purified from pig myometrium 43 kDa and 30 kDa forms, a result in 
agreement with that obtained in this study. Human cathepsin D was purifi~d as a 
two-chained form with 30 kDa and 15 kDa components. These values are the 
same as those reported by Barrett (1979). The light chain of all species of 
cathepsin D was consistently detected as a doublet or triplet, a finding also 
reported by Barrett (1977). 
Purified cathepsin D was used either as an immunogen for antibody production 
(Chapter 4) or, as described in this chapter, for the characterisation of anti-peptide 
antibodies generated against a peptide sequence derived from cathepsin D. 
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The use of synthetic pep tides as immunogens is an area of immunochemistry 
characterised by loose terminology and, as a result, is prone to differing 
interpretation which should be clarified. Some authors, for instance, define the 
antigenic reactivity of a protein as its capacity to bind specifically to the functional 
binding sites or paratopes of immunoglobulin molecules (Van Regenrnortel, 
1988). The epitopal nature of a set of amino acids in a protein can be defined only 
when an antibody has bound to it. The origin of the antibody used to identify an 
epitope is, by this definition, irrelevant. Others consider the property of 
immunogenicity as intrinsic to the concept of epitopes (Atassi, 1984). 
Immunogenicity refers to the ability of a protein to induce an immune response. 
An epitope, therefore, refers to a region of a protein that is recognised during the 
immune response when the whole protein is used as an immunogen. This 
viewpoint will adhered to in this thesis. 
Epitopes have been divided into several conceptual categories that are not easily 
experimentally shown (Shinnick et al., 1983; Van Regenrnortel and Daney de 
-Marcillac, 1988). Sequential epitopes are defined by peptide regions in their 
random coil form, while conformational epitopes require a specific conformation 
to be recognised by complementary paratopes. This distinction may be somewhat 
artificial, however, as it is unlikely that a paratope could recognise a sequence of 
residues independently of any conformation. A further distinction is between 
continuous and discontinuous epitopes. Continuous epitopes are defined as a 
length of contiguous residues in direct peptide linkage while discontinuous 
epitopes consist of ~ group of residues that are not contiguous but are brought 
together by the folding of the polypeptide chain. 
In practice, any linear peptide fragment of a protein that is found to react with 
antibodies raised against the intact protein is termed a continuous epitope. 
However, this does not imply that the fragment accurately mimics the structure 
in the protein. The linear peptide may only be part of a larger discontinuous 
epitope but still reacts with antibodies against the larger discontinuous epitope. 
Also, not every residue in the continuous epitope will necessarily be able to make 
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contact with the paratope. The linear epitope is, then, antigenically 
discontinuous and the division between continuous and discontinuous epitopes 
is also artificial. 
It is generally believed that the majority of epitopes are discontinuous, mainly 
due to the lack of contiguous stretches in direct peptide linkage at protein 
surfaces, as ascertained from space-filling models of globular proteins. It is, 
however, useful to label some antigenic sites as continuous, especially in the 
context of peptides that cross-react antigenically with a protein. 
Most available information on protein immunogenicity IS based on the 
identification of continuous epitopes (Atassi, 1986). This concerns primarily 
identifying paratope interactions with peptides, which retain only part of their 
activity after protein fragmentation. This concept has been extended by 
producing antibodies against synthetic peptides that correspond to linear 
segments of proteins. These anti-peptide antibodies are often able to cross-react 
with the complete protein molecule. Furthermore, the immune system can be 
manipulated to produce antibodies against peptide immunogens that represent 
'self' protein antigens, thereby generating an essentially auto-immune response 
(Dennison, 1989). 
Candidates for peptide synthesis may be selected from the protein sequence on 
the basis of prediction algorithms derived from the observed correlation between 
the location of continuous antigenic sites and structural parameters. For 
maximum antibody accessibility, selected sequences should be located on the 
. surface of the protein molecule. Hydrophobic amino acid residues make up the 
internal part of a protein while hydrophilic side-chains are on the exterior, where 
they can interact with water. Thus by evaluating relative amino acid 
hydrophilicities and hydrophobicities in a polypeptide chain, a hydrophilicity 
profile can be generated. Hopp and Woods (1981, 1983) used such an approach to 
show that the most hydrophilic portions of a protein tend to correspond with 
continuous epitopes. Further prognostic information comes from the observed 
link between peptide chain mobility and antigenicity. Crystallographic 
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determination of protein structure and nuclear magnetic resonance studies of 
protein side chains has provided atomic temperature factors or B-values as a 
measure for mobility. When plotted against residue numbers, B-values provide 
a profile of high and low mobility, high B-values corresponding to high mobility 
(Westhof et al., 1984). It appears that the more mobile peptide segments make 
better candidates for immunisation because recognition of protein epitopes in the 
form of peptides would occur at such flexible stretches. A variety of other 
antigenic predictors have been developed, including protein secondary structure, 
static surface accessibility, sequence variability and chain termination (Van 
Regenmortel, 1988). 
Attention has also been afforded to the role of T cell responses leading to the 
expression of cytotoxic T lymphocytes, which play an important role in the 
recovery from viral infection. Band T cells differ in the way they recognise 
antigens, and the majority of T cells do not recognise the native conformation of 
protein antigens, but bind to fragments of the antigen (Berzofsky, 1985). Attempts 
have been made to correlate the structural properties of T cell epitopes with T cell 
immunogenicity. It appears that T cell epitopes tend to correspond to 
amphipathic helices and avoid random coiled conformations (DeLisi and 
Berzofsky, 1985). 
Examination of peptide D73-84 indicates generally poor mobility and very poor 
hydrophilicity, as reflected by its solubility in DMF. According to these predictors 
peptide D73-84 would be a poor candidate for generating protein-reactive 
antibodies, yet this was found not to be the ~ase. Indeed, of the 7 different peptide 
immunogens used in this laboratory, all but one were found to be protein-
reactive. In each case, as with peptide D73-84, peptide selection was based on 
considerations of 3-dimensional structure and function of protein motifs, rather 
than prediction algorithms. It is now generally believed that a peptide 
corresponding to virtually any accessible region of a protein can elicit antibodies 
reactive with that protein (Sutcliffe et al., 1982). An explanation for this is to 
suggest that in solution a peptide can adopt a variety of interchangeable 
conformations, some of which mimic those found in the native protein 
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(Crumpton and Small, 1967). However, since pep tides in solution lack any 
ordered structure (Crumpton and Small, 1967; Atassi and Singhal, 1970), only a 
small fraction of the fragments can be in the proper conformation. Indeed, the 
fraction of staphylococcal nuclease fragments in a given conformation at anyone 
time is too small to detect (Sachs et al., 1972). Furthermore, some relatively 
short-range interactions within a peptide can influence the frequency with which 
some conformations are adopted. If a peptide can adopt many conformations, 
what kinds of conformations will elicit antibodies that cross-react with the native 
protein? A peptide that exactly mimics its native conformation in a protein will 
bind with high affinity to the immunoglobulin receptor on the appropriate B cell. 
Conformations resembling the native one may bind with lower affinity, but once 
in the antibody binding site may be locked into the high affinity conformation. 
Triggering of an appropriate B cell may thus be accomplished by several of the 
possible peptide conformations. Also, proteins are not static structures, and 
individual regions can adopt a limited number of conformations. Therefore, to 
elicit protein-reactive antibodies, it is probably not necessary to exactly reproduce 
the native conformation. This may, however, not hold for highly constrained 
regions in a protein such as a loop, where it may be necessary to mimic 
conformation more closely. 
Peptide D73-84 forms an anti-parallel loop, constituting the active-site associated 
"flap" of cathepsin D. Despite this obvious conformational restraint, antibodies 
generated against the peptide were able to recognise the protein coated onto 
microtitre plates and in free solution, as in the competition ELISA. Lack of 
targeting of the enzyme on western blots, even under optimally renaturing 
conditions, may reflect some degree of conformational dependence of antibody 
binding. Indeed, the better binding found with antibodies generated from 
conjugated peptide in chickens could, in part, be due to the envisaged higher 
degree of restraint after conjugation. 
Antibodies to peptide D73-84 were also characterised by a lack of detectable 
inhibition of enzyme activity. This could probably not be attributed to a lack of 
antibody-antigen binding at the low pH used in the azocasein assay, as shown by 
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binding under similar conditions in an ELISA. Given the functional importance 
of the "flap" region in cathepsin D catalysis, and the proven inhibitory activity of 
antibodies to the "flap" region of renin (Bouhnik et al., 1987), lack of detectable 
inhibition appears to be anomalous. However, when one considers that more 
than a 450 ODD-fold molar excess of antibody over renin was required for 40% 
inhibition, and at best an excess approaching only 2 ODD-fold was attainable using 
the azocasein assay, it becomes apparent that enzyme assay sensitivity may be a 
major limiting factor. This problem may be alleviated by using more potent 
antibodies. Monoclonal antibodies that putatively recognise the "flap" region of 
renin (de Gasparo et al., 1987), inhibit the enzyme 100% at an only 8-fold molar 
excess over enzyme. However, attempts to demonstrate inhibition using high 
titre affinity purified anti-D73-84 antibodies were unsuccessful. 
Highly sensitive lysosomal cysteine proteinase substrates are those based on the 
amino methyl coumarin leaving group (Barrett and Kirschke, 1981), where a 
short 2-3 amino acid peptide separates a blocking group from the fluorescent 
leaving group. These substrates were used to demonstrate 80% inhibition of 
cathepsin L activity at a 3 235-fold molar excess of antibody over enzyme (Coetzer 
et al., 1991). Cathepsin D, however, has an extended active site, sufficient to 
accommodate 7-8 amino acid residues of a peptide substrate (Tang, 1979). Indeed, 
the rate of peptide hydrolysis shows marked dependence on the amino acid 
composition and length of the peptide substrate. An induced fit model of 
catalysis suggests that, within a series of related substrates of varying length, the 
rate of hydrolysis (kcaJ can vary by several orders of magnitude, in contrast with 
the binding constant (Km) which is comparatively insen~itive (Pearl, 1985). 
Generally, the rate enhancement for a larger substrate over that observed for a 
smaller substrate is cumulative. 
To accommodate the requirements of the extended substrate binding cleft of 
cathepsin D, larger peptide substrates, which include the fluorescent methoxy 
naphthyl amine and amino methyl coumarin · leaving groups, have been 
developed. The company holding these substrates, however, no longer exists and 
no alternative source could be found. Another potential fluorescent substrate is 
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that utilised for the renin assay. Renin specifically hydrolyses angiotensinogen to 
form angiotensin I, and a fluorogenic peptide substrate was developed to 
incorporate the renin cleavage site that occurs in angiotensinogen (Wang et al., 
1993). Cathepsin D has been assayed with a radioimmunoassay version of this 
assay (Takahashi and Tang, 1981), implying that the fluorescent substrate should 
also be suitable. The cost of this substrate, however, rendered such an approach 
prohibitive. Proteinaceous substrates chemically modified by the addition of 
fluorescent groups (haemoglobin-fluorescein isothiocyanate (mC) and casein-
FITC) were also tested for enhanced sensitivity, but were found to be no better 
than the azocasein in the presence of urea (results not shown). A synthetic 
chromophoric substrate extensively used for the kinetic characterisation of 
aspartic proteinases (Dunn et al., 1986) was also found unsuitable due to lack of 
sensitivity. Radio-labelled protein substrates may have offered a more sensitive 
alternative, but financial constraints prohibited this avenue being explored. 
The rationale used for choosing a peptide which would elicit immunoinhibiting 
antibodies, was based on sound consideration of the three-dimensional and 
physico-functional characteristics of cathepsin D. The antibodies generated were 
ultimately unable to produce demonstrable enzyme inhibition, but this aspect 
remains inconclusive until a more sensitive assay can be used. 
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CHAPTER 4 
THE DISTRIBUTION OF LYSOSOMAL PROTEINASES IN A HUMAN BREAST 
EPITHELIAL CELL LINE AND ITS c-Ha-Ras 1RANSFORMED COUNTERPART 
4.1 Introduction 
The study of biological processes has been greatly enhanced with the 
development of in vitro cell culture techniques, and indeed the field of cancer 
biology has profited greatly from such developments. Tumour cell lines can be 
finely characterised in terms of their genetic make-up, growth characteristics, 
ultrastructure, metabolism, enzymology and invasiveness. Much of what is 
known about the significant role played by uncontrolled proteolysis, during 
tumour metastasis, was elucidated in this way. A singular drawback in breast 
cancer research has, however, been the lack of a reliable source of normal human 
epithelial cells to delineate the sequential states of progression to the malignant 
state, and to act as true control cells under experimental conditions. Until 
recently the available immortal human (mammary epithelial) cell lines have 
been altered in some way, e.g. by exposure to benz(a)pyrene, by SV-40 (simian 
virus-40) genetic information, or by isolation of cell lines from patients with 
tumours (Soule et al., 1990). The establishment of the immortal MCF-10 cell line, 
that arose spontaneously (Soule et al., 1990) without chemical or viral 
intervention, has finally provided the ideal J/normal" control and a cell line into 
which various oncogenes may be transfected to allow the progression to the 
malignant phenotype to be studied. 
The work reported in this chapter, as that in Chapter 5, focuses on the use of this 
cell line, and its oncogenic ally transformed sister cell line, in studies of the 
intracellular distribution of proteinases and their role played in invasion. This 
study was undertaken in collaboration with Dr Bonnie Sloane (Department of 
Pharmacology, Wayne State University, Detroit, Mi.), who provided the cell 
lines, and Dr Edith Elliott (Department of Biochemistry, University of Natal, 
Pieterrnaritzburg). 
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Mortal human diploid mammary epithelial cells (MCF-I0M) were obtained from 
a mastectomy performed on a 36 year old parous premenopausal woman with 
extensive fibrocystic disease, and no evidence of atypia (Soule et al., 1990). 
Spontaneous immortalisation occurred during growth of these cells in a low 
calcium medium, giving rise to attached (MCF-I0A) and floating (MCF-10F) cell 
lines, both of which continued to proliferate at normal calcium concentrations. 
Cytogenetic analysis prior to immortalisation showed normal diploid cells, 
although later passages showed minimal rearrangement and near-diploidy. The 
MCF-I0A cell line is oestrogen receptor negative, and was characterised as 
normal breast epithelium by the following characteristics: lack of tumourgenicity 
in nude mice; growth in culture that is controlled by hormones and growth 
factors; three-dimensional growth in collagen; lack of anchorage independent 
growth; and dome formation in confluent cultures (Soule et al., 1990). The MCF-
10 cell line is the first spontaneous line of cultured breast epithelium (Tait et al., 
1990) for which there is direct evidence that the normal diploid chromosome 
pattern of the original explanted tissues was retained for over a year of growth in 
culture. 
Transfection of MCF-I0A with the activated (mutated) c-Ha-ras oncogene 
resulted in cell transformation (Basolo et al., 1991), the new cell line being 
designated MCF-I0AneoT. A possible link between the expression of the 
activated ras oncogene and the appearance of in vitro migratory and invasive 
capacities was explored. MCF-I0AneoT cells exhibited increased transforming 
growth factor-a expression and secretion (Ciardiello et al., 1990), anchorage-
independent growth, hormone and growth factor independence, alterations in 
the three-dimensional pattern of growth in collagen matrix, increased 
collagenolytic activity, and tumourgenicity in nude mice (Basolo et al., 1991). 
Furthermore, another study indicated enhanced chemotactic and chemokinetic 
activities, an increased ability to invade matrigel barriers, and the ability to form 
large colonies in matrigel, in contrast to MCF-I0A cells transfected with the 
neomycin resistance gene alone or with the normal ras proto-oncogene (Ochieng 
et al., 1991). The insertion of activated c-Ha-ras alone is sufficient to induce these 
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phenotypes, which is consistent with full malignant transformation. It has been 
shown that the ras gene family induces invasive phenotypes in human breast 
tissues (Clark et al., 1988) and MCF-7 human breast carcinoma cells transfected 
with v-Ha-ras bypass the oestrogen requirement for tumourgenicity and show 
higher invasive properties than non-transfected cells (Albini et al., 1986). 
Moreover, human bronchial epithelial cells transformed with v-Ha-ras express 
more type IV collagenase with a concomitant increase in their invasive 
properties (Ura et al., 1989). However, transfection of the activated ras oncogene 
does not confer the metastatic phenotype to C127, a non-metastatic mouse 
carcinoma cell line, indicating the dependence of the developed phenotype and 
transformation on the recipient cell type (Muschel et al., 1985). The 
enhancement of the chemotactic potential of ras-transformed human breast 
epithelial cells is probably due to an increase in the signal level of the transducing 
pathway mediated by the ras protein, p21. Chemoattractants bind to receptors on 
the surface of tumour cells and activate the phosphatidylinositol signal 
transduction pathway, for which p21 is a likely transducer (Okajima and Ui, 
1984). 
The transition from normal breast epithelium to fully malignant, invasive · 
tumours occurs via a sequence of stages from benign hyperplasia through a typical 
hyperplasia to carcinoma in situ and eventually to the metastatic cell type, this 
spectrum of pathological change being termed proliferative breast disease. 
MCF-10AneoT cells transplanted into nude mice and maintained for more than a 
year, gave rise to a sequence of histological changes that resemble proliferative 
breast disease in humans, including the development of carcinomas (Miller et al., 
1993). This model for proliferative breast disease has been extended by successive 
transplantations of cells derived from the xenografts, such that a grading system 
of proliferative breast lesions could be established, from grade 0 (simple 
epithelium) to grade 5 (invasive carcinoma) (Dawson et al., 1996). This xenograft 
model provides a system for the study of the conversion of breast epithelial cells 
to malignant cells. It must, however, be borne in mind, in the context of the 
present study also, that MCF-10AneoT cells contain the activated Ha-ras 
oncogene, which is not highly characteristic of female or male breast carcinoma 
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(Rochlitz et al., 1989), although over-expression of normal ras is common In 
breast cancer (Miller et al., 1993) . 
Malignant progression, as reflected by the MCF-10AneoT xenograft model, is 
associated with increases in expression, alterations in subcellular distribution and 
increases in secretion of lysosomal proteases. The stage at which these alterations 
occur and whether they are causally linked to progression remains in question. 
Transfection of murine 3T3 fibroblasts with the ras oncogene leads to an increase 
in the expression of cathepsin L mRNA and protein, and secretion of 
procathepsin L is observed (Denhardt et al., 1987). In the same cells mRN A 
transcripts for cathepsin B are increased (Zhang and Schultz et al., 1992), as is the 
case for murine (Qian et al., 1989) and human tumours (Moin et al., 1992). 
Similar findings were revealed in an analysis of aspartic and cysteine proteinases 
in sequentially immortalised and c-Ha-ras-transformed rat embryo fibroblasts. 
The expression of proteinases increased with each degree of transformation, 
cathepsin D accounting for most of the secreted activity, and cathepsin L and, to a 
lesser extent, cathepsin B accounting for most of the intracellular activity 
(Solovyeva et al., 1995). It is notable that the p21 ras oncoprotein is a potent 
inhibitor of cathepsins B and L (Hiwasa et al., 1987), and shows sequence 
homology with the cysteine proteinase inhibitors, the cystatins, although the 
significance of this inhibition is unknown. 
Changes in the levels of proteases expressed after ras transformation is the result 
of a series of poorly understood events, beginning with the expression of ras 
proteins and their subsequent association with the inner cell membrane, 
resulting in the induction of ras-mediated signal pathways. Ras-induced events 
occur under serum-free conditions (Bar-Sagi and Feramisco, 1986), indicating that 
ligand-binding is not a prerequisite, a finding substantiated by the growth factor-
independence of MCF-10AneoT cells. Ras regulates at least two downstream 
signal transduction pathways. The first induces the constitutive reorganisation 
of actin (Bar-Sagi and Ferarnisco, 1986), mediated downstream through members 
of the rae and rho family of guanosine triphosphate-binding (GTP) proteins, 
which are implicated in the control of cell architecture (Symons, 1996). The rho 
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family of proteins increases stress fibre formation (Prendergast and Gibbs, 1993) 
(stress fibres extend into the cell from cell-surface focal adhesions where integrins 
make contact with the extracellular matrix), while rae induces the appearance of 
membrane ruffles and fluid-phase pinocytosis (Ridley et al., 1992). Induction of 
the rho/rae pathway by ras suggests that actin cytoskeletal rearrangement may 
playa key role in ras transformation. The second, the mitogen-activated protein 
kinase pathway, regulates a wide variety of cellular processes such as translation, 
transcription, differentiation and the cell cycle (Prendergast and Gibbs, 1993). 
Perturbation of any of the events affected by ras is consistent with cell 
transforma tion. 
In this chapter the effects of ras-transformation of normal human breast 
epithelial cells on the distribution of selected lysosomal proteinases and, by 
association, of lysosomes themselves, will be reported. This, however, should be 
preceded by an understanding of the trafficking of lysosomal enzymes under 
'normal' conditions. Lysosomal enzymes, secretory proteins and plasma 
membrane proteins, are synthesised by membrane-bound polysomes on the 
rough endoplasmic reticulum (RER) , and are vectorially transported across the 
RER membrane into the lumen, a process mediated by a signal peptide on the 
nascent polypeptide (Walter et al., 1984). Lysosomal enzymes, as well as most of 
the secretory proteins and plasma membrane proteins, undergo cotranslational 
glycosylation of selected asparagine residues, involving the en bloc transfer of a 
large pre-formed oligosaccharide. In the RER the signal peptide is cleaved and 
the oligosaccharide is trimmed (Kornfeld and Kornfeld, 1985). The proteins then 
move, by vesicular transport, to the Golgi stack where they undergo a variety of 
post-translational modifications and are sorted to their proper destinations. 
Lysosomal enzymes acquire phosphomannosyl residues (Kornfeld, 1986), .the 
resultant phosphomonoesters serving as a recognition marker that leads to high 
affinity binding to M-6-P receptors in the Golgi (von Figura and Hasilik, 1986). In 
this way the lysosomal enzymes are segregated from the proteins destined for 
secretion. The ligand-receptor complex exits the Golgi via a coated vesicle which 
fuses with an acidic pre-lysosomal sorting compartment (late endosome) where 
the low pH facilitates dissociation of enzyme from the receptor (Geuze et al., 
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1985). The receptor is then free to recycle to the Golgi for further rounds of 
enzyme transport, while the dissociated enzymes are transferred to the lysosome 
(Brown et al., 1986). A small proportion of lysosomal enzymes, usually 5-20%, is 
secreted before delivery to lysosomes. A portion may bind to M-6-P receptors on 
the cell surface and be internalised and delivered to lysosomes (Valdutiu and 
Rattazzi, 1979). 
In addition to oligosaccharide processing, lysosomal enzymes undergo further 
proteolytic processing. All lysosomal enzymes studied to date are synthesised as 
preproenzyrnes. The pre-piece or signal peptide is cleaved after transport into the 
RER, while removal of the propiece appears to be initiated in the pre-lysosomal 
compartments (Gieselmann et al., 1983), a process generally synonymous with 
enzyme activation. 
Studies have shown that transfection of normal breast epithelial cells with the 
activated ras oncogene results in transformed cells capable of growth in nude 
mice (Miller et al., 1993) and, in some cases progression to invasive carcinoma 
(Dawson et al., 1996). The intra- and extracellular events leading to full 
transformation by ras are complex and poorly understood. In this chapter an 
aspect of this event which has been found to be critical to invasion and 
metastasis, namely abnormal enzyme trafficking that results in inappropriate and 
uncontrolled proteolysis, is described. 
4.2 Cell culture 
The MCF-I0A and MCF-10AneoT cell lines were cultured exactly as in the Sloane 
laboratory to ensure a cell phenotype consistent with that laboratory, as this 
protocol differs slightly from that used by other workers. 
4.2.1 Reagents 
The MCF-10A and MCF-I0AneoT cell lines were donated by Dr Bonnie Sloane 
(Wayne State University, Detroit, Mi.) as part of a research collaboration. 
Dulbecco's minimal essential medium (DMEM):Ham's F-12 medium, 
hydrocortisone, insulin, penicillin G:streptomycin (10 000 units and 10 mg/ml 
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respectively), trypsin-EDTA solution (X 1) and Hanks' balanced salt solution 
(HBSS) were from Sigma Chemical Co., St. Louis, Mo.; fungizone (0.25 mg/ ml) 
and equine serum were from Gibco, Paisley, U.K. and EGF was from Biomedical 
Technologies, Inc., Stoughton, Ma. Where applicable, components were 
reconstituted and sterilised by filtration through a 0.22 11m filter. Sterile plastic 
culture-ware was from approved suppliers. Glassware was washed in 7X-PF (lCN 
Biomedicals Ltd, Irvine, Scotland) detergent solution and copiously rinsed in tap 
water and double distilled water before autoc1aving. 
Complete medium (DMEM:Ham's F-12, hydrocortisone (0.5 ug/ml), insulin 
(10 Ug/ml), EGF (20 ng/ml), equine serum (5%, v Iv), penicillin G:streptomycin 
(100 unitslml and 100 Ug/ml respectively), fungizone (0.25 Ilg Iml), pH 7.3). 
Powdered medium and sodium hydrogen carbonate (1.2 g) were consecutively 
dissolved in about 900 ml of ultra-pure water (Milli-Q Plus, Millipore, Microsep, 
Durban), adjusted to pH 7.3 with NaOH and made up to 1 litre. Medium was 
sterile filtered through a 0.22 11m filter and equine serum (52.6 ml), 
hydrocortisone (2.14 ml), insulin (4.2 ml), EGF (0.43 ml), penicillin 
G:streptomycin (10.0 ml) and fungizone (1.1 ml) were aseptically added. 
Complete medium was stored at 4°C. 
4.2.2 Procedure 
Cells were maintained in 25 cm2 flasks in complete medium in a humidified 
atmosphere containing 5% CO2 at 37°C. Cells were fed every 3-4 days and 
passaged upon reaching confluence. To this end cells were washed with HBSS 
(3 X) rinsed in a small amount of trypsin-EDTA, leaving a thin film covering the 
monolayer, and incubated at 37°C until microscopic inspection showed that cells 
had detached. Cells were diluted in complete medium and split in a ratio of 1:3. 
4.3 Antibodies 
Antibodies to cathepsin D were raised in chickens to take advantage of the 
extremely high antibody yield from eggs and, as found in our laboratory, the 
relatively higher titre antibody generated by chickens as compared to rabbits. 
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Two chickens were each immunised with 100 Ilg of porcine cathepsin D 
(Section 3.2), 50 Ilg into each breast muscle. The antigen was triturated in a 1:1 
ratio with Freund's complete adjuvant (Difco) at week a, and in Freund's 
incomplete adjuvant (Difco) at I, 2,4 and 6 weeks and for the monthly boosters, 
thereafter. Eggs were collected on a daily basis and IgYextracted from the yolks 
(Section 2.5) at the time points required. Progress of immunisation was 
monitored by the ELISA (Section 2.6) and specificity ascertained by western 
blotting (Section 2.7). 
Examination of the progress of immunisation curve for a representative chicken 
indicates a peak of antibody production after 8 weeks (Fig. 18), with a titre of 
0.061Ilg/ml. Antibody specificity as determined by western blotting indicated 
specific targeting of single-chain cathepsin D in the TPP fraction, and the 30 kDa 
heavy-chain component in all fractions (Fig. 19). Non-immune IgY displayed no 
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Figure 18. ELISA of the progress of immunisation with porcine cathepsin D in a chicken. 
Porcine cathepsin D was coated at 2,0 ~g/ml to a microtitre plate and incubated with 
serial two-fold dilutions of chicken anti-porcine cathepsin D IgY collected after 
4 (+), 8 ( .... ) and 12 weeks (0) and non-immune IgY (.1) . Binding was visualised by 







D incubated wi th Western blot of pure and crude fractions of porcine cathepsin 
chicken anti-porcine cathepsin D IgY. 
Fractions were electrophoresed on a reducing SDS 12.5% gel (Section I 2.4) and 
electroblotted onto nitrocellulose. The blot was incubated in 20 f..1.g/ml of chi~ken anti-
I 
porcine cathepsin D IgY, and developed with rabbit anti-chicken IgY-HRPO 
(Section 2.7). Samples were: a) crude supernatanti b) acid supernatanti c) TPP fraction 
and d) purified porcine cathepsin D (Section 3.2). I 
For immunofluorescence microscopy (Section 4.5), the following antibodies, 
which were generous gifts from a number of differ.ent _res.earchers, weke used: 
I 
affinity purified rabbit anti-human cathepsin B was from Dr Luka~ Mach 
I 
(Universihit fur Bodenkultur, Vienna), rabbit anti-peptide antibodies recognising 
the human cathepsin H active site region, CHKTPDKVNHA V (Coetzek, 1992), 
I 
was from Dr Theresa Coetzer (Department of Biochemistry, University of Natal), 
chicken anti -sheep cathepsin L-stefin B complex antibodies were froJ Frieda 
Dehrmann (Department of Biochemistry, University of Natal), and rabbit anti-
pro cathepsin D was from Dr Bonnie Sloane (Department of Pharmacology, 
Wayne State University, Detroit, Mi.). Secondary antibodies (FITC-labelJd rabbit 
I 
anti-chicken IgG and tetramethylrhodamine isothiocyanate (TRITC)-labeled goat 
I 
anti-rabbit IgG) and saponin were from Sigma Chemical Co., St. Louis, Mo.; BSA 
I 
(Fraction V) was from Boehringer Mannheim and Anti-Fade0 
immunofluorescence mounting medium was from Molecular prob!es Inc., 
Eugene, Or. 
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For immunoelectron microscopy (Section 4.9) the following antibodies were 
used: antibodies to cathepsin D and cathepsin B (as described above); antibodies to 
LAMP-2 (lysosome-associated membrane protein), a lysosome-specific marker 
(Chen et al., 1985), were kindly donated by Dr Gareth Griffiths, EMBL, Heidelburg, 
Germany; and the anti-serum to chicken IgY was prepared by Dr Theresa Coetzer, 
Department of Biochemistry, University of Natal. 
4.4 LysoTrackerTM labeling of cells 
LysoTrackerTM probes are a series of fluorescent acidotropic probes for labeling 
and tracing acidic organelles in cultured cells. They selectively accumulate in 
cellular compartments with low internal pH, and exhibit bright fluorescence and 
good photostability (Bioprobes Bulletin #21, Molecular Probes Inc., Eugene, Or.). 
4.4.1 Reagents 
Complete medium. Prepared as in Section 4.2.1. 
LysoTrackerTM in -complete ·medium (1:7157). LysoTrackerTM (Red DND-99, 
Molecular Probes Inc., Eugene, Or.) (2 Ill) was added to complete medium (1 ml), 
and 35 III of this stock solution added to complete medium (465 Ill). 
4.4.2 Procedure 
Cells were seeded (Section 4.2) at a low density into 12-well Nunc Multiwell 
plates, each well containing a 15 mm sterile glass coverslip. Before confluence 
was reached, medium was aspirated from the cells, diluted LysoTracker added to 
the cells (300 Ill) and allowed to incubate (30 min). Incubation medium was 
aspirated and LysoTrackerTM allowed to wash out in complete medium (2 min). 
Coverslips were inverted onto a small drop of complete medium on a glass slide, 
sealed with clear nail varnish, and viewed ·in an Olympus BID microscope 
equipped with a BH2-RFC epifluorescence attachment, fitted with a 460 nm 
interference filter and a 520 nm barrier filter. Representative cells were 
photographed with llford XP2 400 film (Section 4.11). 
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4.5 Immunofluorescence microscopy 
Immunofluorescence microscopy allows for the assessment of the distribution of 
an antigen in a tissue or cell, by combining the high selectivity of antigen 
detection with low magnification light microscopy. This technique was used to 
determine the relative distributions of proteolytic enzymes in MCF-10A cells. 
The antibodies used are described in Section 4.3. 
4.5.1 Reagents 
Phosphate buffered saline (PBS-F) (8.06 mM N azlll'O~. 1.47 mM KH2P01.L 
136.89 mM NaCL 2.68 mM KCL 1.0 mM CaClz• 0.5 mM MgCIl,. pH 7.3). Na2HP04 
(1.145 g), KH2P04 (0.2 g), NaCI (7.99 g), KCI (0.199 g), CaCl2 (0.147 g) and MgCl2 
(0.1015 g) were dissolved in about 800 ml of dist.H20, adjusted to pH 7.3 if 
necessary and made up to 1 litre. The PBS used in immunofluorescence labeling 
studies differed from that used in electron microscopy immunolabeling, in that 
calcium and magnesium were included, and it will therefore be referred to as 
PBS-F. 
16% (m/v) Paraformaldehyde stock solution. Paraformaldehyde (BDH, Poole, 
England) (16 g) was dissolved in dist.H20 (100 ml), warmed to 60°C and cleared 
with a minimum amount of 1 M NaOH. The solution was stored at -10°C until 
required. 
3.7% (v Iv) Paraformaldehyde in PBS-F. Stock solution (3.47 ml) was added to 
PBS-F (11.53 mI) and adjusted to pH 7.3 with 1 M HCl. 
2% (m/v) Bovine serum albumin in PBS-F (BSA-PBS-F). Bovine serum albumin 
(0.8 g) was dissolved in PBS-F and made up to 40 mI. 
0.1 % (m/v) Saponin in PBS-F. Saponin (0.1 g) was dissolved in PBS-F and made 
up to 100 ml. 
5% Foetal calf serum. Foetal calf serum (0.5 ml) was mixed with PBS-F and made 
up to 10 ml. 
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Antibodies. Chicken anti-porcine cathepsin D IgY was used at 200 Ilg/ml, rabbit 
anti-human cathepsin B IgG at 40 Ilg/ml, rabbit anti-human cathepsin H peptide 
at 300 Ilg/ml, chicken anti-sheep cathepsin L-stefin B complex at 300 Ilg/ml, rabbit 
anti-pro cathepsin D at 300 Ilg/ml, rabbit anti-chicken IgG-FITC at a 1/320 
dilution, and goat anti-rabbit IgG-TRITC at a 1/250 dilution. 
4.5.2 Procedure 
Cells were seeded (Section 4.2) at a low density into duplicate 12-well Nunc 
Multiwell plates, each well containing a 15 mm sterile glass coverslip. Before 
confluence was reached, cells were washed three times with warmed (37°C) PBS-
F, fixed (10 min., RT) with 3.7% formaldehyde in PBS-F and washed again in PBS-
F (3 X). Non-specific binding sites were blocked by incubating cells in BSA-PBS-F 
(45 min., RT). Coverslips were incubated in the primary antibody (1 h, RT) 
diluted in saponin in PBS-F. After six rapid washes with saponin in PBS-F, 5% 
foetal calf serum block solution was applied (30 min., RT). Cells were then 
incubated in the appropriate secondary antibody (1 h, RT) washed six times in 
saponin in PBS-F, refixed in 3.7% formaldehyde (10 min., RT), washed three 
times in PBS-F followed by dist.H20 and the coverslips allowed to dry. The 
coverslips were mounted face-down in a minimum amount of Anti-Fade<8, 
sealed with clear nail varnish, and viewed in an Olympus BH2 microscope 
equipped with a BH2-RFC epifluorescence attachment, fitted with a 460 nm 
interference filter and a 520 nm barrier filter. Representative cells were 
photographed with Agfacolour XRG 200 or llford XP2 film (Section 4.11). A non-
immune antibody preparation was substituted for immune - antibody at a 
concentration equal to the lowest dilution used for the immune antibody. Non-
immune incubations were assessed for acceptably low background fluorescence; 
since this was generally obtained, non-immune controls are not shown in the 
Results (Section 4.11). 
4.6 In situ embedding in Lowicryl of cultured cells 
The use of immunocytochemical methods has traditionally been the domain of 
cell biologists, probably due to the apparent complexity and expense of such 
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methodology. Recent advances in these techniques, and the commercial 
availability of almost all relevant reagents, has made this technology easily 
accessible. It remains, however, that many biochemical laboratories are resistant 
to this fundamental expertise, and for this reason a review of some aspects of 
immunocytochemistry is offered. 
Lowicryl resins are acrylate-methacrylate mixtures that form a vinyl type of 
carbon backbone during polymerisation (Carlemalm et al., 1982; Carlemalm et al., 
1985). The resins were developed to obtain embedding media of low viscosity 
that can be used at low temperatures to examine the fine structure of minimall y 
fixed tissue by scanning transmission electron microscopy. Subsequently, the 
Lowicryl resins were found to be eminently suited to colloidal gold methods . 
Implicit to this approach, is the concept of antigenicity and the belief that 
maintenance of low temperature during the processing of specimens is a 
valuable aid to not only the preservation of ultrastructure, but also the retention 
of soluble components in their in vivo positions and conformations. 
It is commonly believed that lowering the temperature prevents protein 
denaturation. In fact, proteins are most stable at a temperature close to that at 
which they are thermally denatured, and the thermodynamic force which 
imposes the native conformation upon a protein (hydrophobic "bonding"), is 
weakened at lower temperatures. This makes proteins more susceptible to the 
denaturing action of organic solvents (Sj6strand, 1990). Paradoxically, 
experiments have revealed that low temperatures do reduce the rearrangement 
of proteins in non-aqueous liquids (Carlemalm et al., 1982), and have a positive 
effect on immunolabeling by increasing labeling density and decreasing 
background staining (Roth et al., 1981; Armbruster et al., 1983). This can be 
explained by taking into account the effects of the increased viscosity of the 
medium at a lower temperature. Denaturation (unfolding) of a protein is caused 
by the translational motions of parts of the polypeptide chain, the motion being 
restricted by the peptide bonds. Denaturation is therefore a diffusion 
phenomenon, and increasing the viscosity of the denaturing solvent or resin 
would therefore slow down protein denaturation by slowing down diffusion. It 
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stands to reason, therefore, that the length of exposure to denaturing media that 
tissues can tolerate without extensive protein denaturation is limited. The 
shortest possible dehydration and embedding time should be used to limi t 
diffusion/ denaturation. The viscosity of the medium probably delays protein 
denaturation more than it hinders diffusion of organic solvents and resin 
molecules, due to the large difference between the mean mass of the mobile parts 
of the crosslinked polypeptide chain and that of the solvent and resin molecules 
(Sjostrand, 1990). 
Lowicryl resins have properties that lend themselves well to use at low 
temperatures: miscibility with different organic solvents, low viscosity, and 
ability to be polymerised by ultraviolet light. Lowicryl K4M is polar and Lowicryl 
HM20 is apolar, and these can be used at -35°C and -50°C respectively, while 
Lowicryl KllM and Lowicryl HM23 are the respectively polar and non-polar 
ultra-low temperature equivalents (Acetarin et al., 1986). Lowicryl K4M can be 
kept in a partially hydrated state during dehydration and infiltration, since the 
resin can be polymerised with up to 5% (m/ m) water in the block. Low 
temperature embedding may be achieved by the progressive lowering of 
temperature (PLT) technique (Kellenberger, 1985), which involves stepwise 
reductions in temperature as the concentration of the dehydrating agent is 
increased. A temperature is selected which is just above the freezing point of the 
concentration used in the step before, as this is the concentration of the 
dehydrating agent contained in the specimen when introduced into the next 
higher concentration of the dehydration series. The PLT method gives good 
ultrastructural preservation of tissue (Roth et al., 1981); indeed, rat liver 
embedded in Lowicryl K4M using PLT showed for the first time the presence of 
an extensive trans-Golgi tubular network (Roth et al., 1985). Furthermore, the 
extraction of proteins and membrane lipids from biological materials embedded 
at low temperature is reduced (Weibull and Christiansson, 1986), and the 
Lowicryls can be used with very low glutaraldehyde concentrations for short 
times (Hobot, 1989). 
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Although there are good theoretical reasons for the use of low temperature 
during embedding, when it is desired to preserve the structure and activity of 
particular proteins in biological specimens, there are also more practical 
considerations to address. Polymerisation is an exothermic reaction, and a 
comprehensive study (Ashford et al., 1986') showed that there is a significant 
release of thermal energy during this process. At -38°C there is an 8-12°C rise in 
temperature in 7.5 ml of polymerising resin. Unexpectedly, however, a further 
more dramatic temperature rise occurs when the apparently polymerised resin 
block is taken out of the low temperature polymerisation apparatus. Here the 
temperature rises rapidly to ambient and overshoots to as much as 37°C. This 
was unaffected by the length of time that the specimens had been left under 
ultraviolet light, but was influenced by the temperature at which polymerisation 
had initially been carried out, being most pronounced after polymerisation at the 
lowest temperatures. It appears that in Lowicryl K4M one of the polymerisation 
reactions remains incomplete at low temperatures, and then proceeds rapidly 
when the temperature rises above a certain level. Such brief but dramatic rises in 
temperature can be potentially damaging to proteins, but can be avoided by 
warming specimens up slowly in contact with heat sinks, and is most easily 
controlled with small volumes of resin (Weibull, 1986). In this study only 3 ml 
of resin was polymerised in a 35 mm dish, allowing the approximately 0.3 m m 
deep resin a large surface area in contact with the heat sink. 
An important distinction should be made between Lowicryl K4M (and HM20) 
and epoxide resins such as Epon, and that is the effect of specimen-related relief 
in Lowicryl sections (Kellenberger et al., 1986). Thin Lowicryl sections of 
aldehyde-fixed biological material show a relief estimated to be 2-6 nID, whereas 
those in Epon are two to three times smoother (Kellenberger et al., 1987). Epoxy 
resins are able to form covalent bonds with biological material, particularly 
proteins, and therefore co-polymerisation occurs instead of polymerisation of the 
resin. Without co-polymerisation, section cutting resembles surface cleavage, 
which tends to follow the areas of least resistance, i.e, the interfaces between resin 
and protein, which would expose epitopes. This is probably an important reason 
for the success of Lowicryl in immunolabeling procedures. 
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Comparison of labeling after PLT and embedding in Lowicryl K4M with that 
achieved after optimal embedding in a popular hydrophilic resin, LR White, 
indicated very little difference in either ultrastructure or gold particle count 
when high glutaraldehyde (>1%) concentrations were used, even for a short time 
(15 min). However, this was not true after minimal glutaraldehyde 
concentrations «0.1% for 15 min), where PLT and Lowicryl K4M gave superior 
ultrastructural preservation, and would thus be the choice for labile antigens 
(Newman and Hobot, 1989). It is interesting to note that theoretical predictions 
for labeling on melted cryosections, where the biological material is in a fully 
hydrated and therefore in an antigenic ally optimal state, are that 10 to 30 times 
more labeling should be obtained. Yet, for reasons not fully understood, only 
factors between 0.5 and 2 have thus far been observed (Kellenberger et aI., 1987) . 
A newly commercialised hydrophilic, methacrylate resin, Unicryl, has been 
purported to give superior ultrastructure (Scala et al., 1992), as well as 
significantly stronger immunolabeling than Lowicryl K4M, perhaps providing a 
resin alternative to ultracryomicrotomy (Bogers et al., 1996), which still requires a 
high enough degree of manual skill so as not yet to be considered a routine 
technique. 
During this investigation exclusive use was made of in situ flat embedding of cell 
monolayers in culture dishes. A more accurate picture of protease distribution 
can thus be obtained, than would be the case if cells were released from the 
plastic, allowed to round up and processed as a pellet. Flat embedding with 
Lowicryl, as opposed to embedding in gelatin capsules, however, presents special 
problems, most notably the inhibition of polymerisation by atmospheric oxygen 
due to the large resin surface in contact with the air. A variety of methods have 
been used to overcome this problem, including growing cells on detachable 
chamber tissue culture slides (Ballou et al., 1985) or in Lab-Tek flaskettes (Bou-
Gharios et al., 1986), but the detachment of the polymerised cell layer and resin 
from the glass is difficult (Carlemalm and Villiger, 1982). For the present 
investigation, a relatively airtight polymerisation chamber was constructed with 
N 2 entry and exit ports, so as to create an anaerobic environment within the 
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chamber itself. It has been suggested (Carlemalm and Villiger, 1982) that 
routinely used cell culture plasticware is unsuitable for in situ embedding, due to 
the susceptibility of the plastic to corrosion by Lowicryl resin. This problem was 
not experienced during these investigations, and no corrosion-resistant 
alternative was used. 
In their comprehensive study to find the optimal conditions for specimen 
processing, embedding and labeling, Robertson et al. (1992) addressed the 
question of fixation, i.e. the concentrations and duration of fixation which will 
result in the preservation of adequate morphology and antigenicity and hence be 
suitable for immunocytochemistry. Specimens (induding a cell monolayer) fixed 
for 60 min in a mixture of 2% (v Iv) paraformaldehyde and 0.05% (v Iv) 
glutaraldehyde gave uniformly good preservation and labeling characteristics, 
while specimens fixed for 30 min or 60 min in 4% paraformaldehyde often 
showed similar but non reproducible results. A mixture of 2% (v Iv) 
paraformaldehyde and 0.05% (v Iv) glutaraldehyde for 60 min was therefore 
chosen for fixation. 
Immunolabeling at the electron microscopic level allowed for the precise 
subcellular localisation of proteinase antigens in MCF-10 cells. This data was 
used to confirm and expand on that gained from immunofluorescence studies. 
4.6.1 Reagents 
Phosphate buffered saline (PBS-E, 0.01 mM NaH2PO~, 0.15 mM NaCL 2.5 mM KCL 
pH 7.3). NaH2P04 (1.38 g), NaCI (8.76 g) and KCI (0.186 g) were dissolved in about 
800 ml of dist.H20, adjusted to pH 7.3 if necessary and made up to 1 litre. The PBS 
used in immunolabeling for electron microscopy is referred to as PBS-E. 
400 mM HEPES stock (N-2-hydroxyethyl-piperazine-N'-2-ethane sulfonic acid), 
pH 7.3. HEPES (10.92 g) was dissolved in 90 ml of dist.H
2
0, adjusted to pH 7.3 
with NaOH and made up to 100 m!. The solution was aliquotted and stored 
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frozen. Prior to use, the buffer was diluted to 200 mM, and the pH adjusted if 
necessary. 
Fixative (2% (v Iv) paraformaldehyde, 0.05% (v Iv) glutaraldehyde in 200 mM 
HEPES, pH 7.3) . Paraformaldehyde (1.25 ml of 16% stock, Section 4.5.1) and 
glutaraldehyde (20 ~l of 25% stock, Merck, Darmstadt) were added to about 8 m I 
of 200 mM HEPES, the pH adjusted to 7.3 if necessary and the solution made up 
to 10 ml with 200 mM HEPES. 
30% (v Iv) Ethanol. Ethanol (3 ml, AR) was made up to 10 ml with dist.H20. 
50% (v Iv) Ethanol. Ethanol (5 ml, AR) was made up to 10 ml with dist.H20. 
75% (v Iv) Ethanol. Ethanol (7.5 ml, AR) was made up to 10 ml with dist.H20. 
95% (v Iv) Ethanol. Ethanol (9.5 ml, AR) was made up to 10 ml with dist.H20. 
Lowicryl K4M resin. Lowicryl K4M resin (Chemische Werke Lowi, Germany) 
was formulated essentially as described in the manufacturers handbook. Cross-
linker A (2.7 g) and Monomer B (17.3 g) were pipetted into a darkened glass 
container on a balance in a fume-hood . Initiator C (0.1 g of soEd) was weighed 
separately, added to the mixture and dissolved by bubbling N 2 through the resin, 
which serves also to expel O2• Care was taken to avoid inhalation or resin fumes 
and skin contact with the resin as dermatitis is common. It was found that a 
lJatch of resin could be stored for at least 3 months in the dark at room 
temperature. 
4.6.2 Procedure 
Cells were grown (Section 4.2) in 35 mm petri dishes and upon reaching 
confluence were washed with PBS-E (3 X), fixed (RT, 60 min) and washed with 
200 mM HEPES (3 X). Cells were subjected to progressive lowering of 
temperature dehydration: 30% ethanol (O°C, ice bath in a cold-room, 10 min, 
3 ml), 50% ethanol (-20°C,3 parts crushed ice + 1 part NaCI placed in a freezer-
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room, 10 min, 3 ml), 75% ethanol (-35°C, 1.2 parts ice + 2 parts CaC12·6H20 placed 
in the pre-cooled polymerisation unit, 10 min, 3 ml), 95% ethanol (-35°C, as 
before, 10 min,3 ml), 100% ethanol (-35°C, as before, 10 min, repeated once, 3 ml). 
Petri dishes were agitated at least twice during each 10 min step. Cells were 
infiltrated with a 1:1 mixture of resin and 100% alcohol (-35°C, 30 min, 2 ml) 
followed by a 2:1 mixture of resin and 100% alcohol (-35°C, 1 h, 2 ml), pure resin 
(-35°C, 1 h, 2 ml) and again pure resin (-35°C, overnight, 2 ml). The following day 
the petri dishes were placed in heat sinks, resin was replaced (3 ml) and the uni~ 
flooded with N2. Resin was allowed to polymerise in a N2 atmosphere at -35°C in 
indirect ultraviolet radiation (360 nm, 24 h) followed by direct ultraviolet 
radiation (48 h). Petri dishes were placed on a sunny windowsill for at least 
3 days until the resin had properly hardened. 
Heat sinks consisted of aluminium discs (8 cm <I> x 2 cm) with a 3 mm deep 
excavation, slightly larger in diameter than a 35 mm petri dish, turned out of the 
middle of the disc. Alcohol was used to provide thermal conduction between the 
dish and heat sink. The polymerisation unit was constructed by the Mechanical 
Instrument Workshop, University of Natal, Pietermaritzburg. It consists of a 
small, top-loading chest freezer, fitted with a cooling unit calibrated to -35°C and a 
slow-speed fan to dissipate heat gradients within the unit. All six inside surfaces 
of the chest were covered in aluminium foil to provide a reflecting surface for 
incident · ultraviolet radiation and the lid was fitted with two ultraviolet tube 
lamps (43 cm, Hitachi) lying parallel to each other. The lamps were installed only 
as they were about to be switched on, as it was found that they would not start if 
pre-cooled. An N2 entry port was fitted on the side near the bottom of the chest 
and an exit port on the opposite side also near the bottom. This port was 
connected to a vertical hose up to a height corresponding to the top of the 
interior of the chest. N 2 is heavier than air and will thus fill from the bottom, 
displacing air out from the top through the tube. A framework with an height-
adjustable wire shelf was installed into the unit, and an optimal distance (25 cm) 
of sample from lamps for resin polymerisation was used. A thin bar was fitted 
lengthways near the top of the unit to provide a support for an aluminium foil-
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covered sheet of metal, bent midway and lengthways to 90°. This acts as a 
removable shield which provides indirect ultraviolet radiation, when required. 
4.7 Sectioning of Lowicryl K4M blocks 
Lowicryl K4M is a hydrophilic resin, therefore precautions should be taken to 
ensure that the block face does not become wet during sectioning. This is 
accomplished by sectioning with the level of fluid in the knife-trough slightly 
below normal, while still maintaining a wet knife-edge. Nickel or gold grids are 
used for labeling, as copper tends to oxidise in the labeling solutions. The 
stability of sections on the grid during labeling and in the electron microscope can 
be improved by coating grids with formvar. 
4.7.1 Reagents 
0.25% (m/v) Formvar in chloroform. Formvar (0.25 g) was dissolved In 
chloroform (100 ml). 
4.7.2 Procedure 
A dish (20 cm <l> x 10 cm) was completely filled with dist.H20. A clean glass 
microscope slide was dipped its length into the formvar solution, the excess 
allowed to drain and the remaining film dried. The dried film was loosened 
around the edges of the slide with a razor-blade, and floated onto the surface of 
the water. Nickel grids (hexagonal, 200 mesh) were placed, shiny side up, on the 
floating film. Using a rectangular piece of wire mesh as a support, the film was 
recovered by a scooping motion through the water leaving the film covering the 
mesh. The grids, adhered to the underside of the film and supported by the mesh 
were allowed to dry. Individual formvar-coated grids can then be torn away from 
the film as required. 
Small blocks (about 5 mm3) were cut with a hacksaw from a petri dish containing 
in situ embedded cell monolayers. In most cases the layer of resin did not 
separate from the dish, and the block was mounted onto a plastic stub with 
superglue, the layers of resin, cells and dish plastic perpendicular to the stub. The 
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block was trimmed on a microtome to a pyramidal face and ultrathin sections cut 
with a diamond knife and collected as soon as possible onto formvar-coated grids. 
Grids were dried and could be stored indefinitely before immunolabeling. 
The level of water in the knife-trough was lower than normal, producing a dark 
silver reflection along the knife edge. This ensures that the block face does not 
become wet during sectioning. Sectioning through two plastics of different 
hardnesses and polarities was not problematic, in fact this double layer helps the 
rapid location, in the electron microscope, of the resin edge along which the cell 
monolayer should be found. Furthermore, it protects the cell monolayer in the 
block from damage, as may be the case if the dish plastic was stripped away from 
the resin, exposing the cell monolayer at its surface. 
4.8 Production of protein A-gold probes by the tannic acid-citrate method 
The protein A-gold probes used in this study were either produced in this 
laboratory or supplied by Dr Jan Slot, University of Utrecht, Utrecht, Netherlands. 
The production of protein A-gold probes is divided into three stages: formation 
of the gold colloid, determination of the minimum amount of protein A 
required to stabilise the colloid and production of the gold probe, and purification 
and characterisation of the gold probe. 
4.8.1 Production of gold colloid 
Colloidal gold particles as a marker system have come into widespread use for a 
number of reasons: (1) high contrast in the electron microscope allows easy 
detection of small electron dense particles; (2) particles are homogenous in shape 
and size and this avoids confusion with cell structures; (3) populations of 
colloidal gold particles of differing size can be produced using relatively simple 
methods; (4) the non-specific adsorption properties of colloidal gold particles 
allows for their use as markers for a wide range of molecules differing in physical 
characteristics (Baudhuin et al., 1989; Leunissen and De Mey, 1989). However, it 
was the landmark work of Frens (1973) which, because of its simple methodology, 
allowed the introduction of particle science in cell biology. 
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Synthesis of colloidal gold is based on the controlled reduction of an aqueous 
solution of tetrachloroauric acid. The type of reducing agent used and the 
concentration of the reacting components, largely· determine the ratio between 
nucleation and growth, and thus the final particle size and size distribution. 
Rapid reduction results in formation of a greater number of nuclei, thereby 
consuming much of the tetrachloroauric acid and limiting the amount 
remaining for shell growth (Handley, 1989). Slot and Geuze (1985) used mixtures 
of a strong reducing agent (tannic acid) and a weaker reducing agent (citrate), to 
allow the production of particles of different size. For the range 2-10 nm an 
excess of tannic acid is used, and the reduction is almost exclusively 
accomplished by tannic acid. In the larger size range (10 nm-20 nm), tannic acid is 
limiting, so the reduction necessary for particle growth is effected by citrate. 
Therefore, by varying the amount of tannic acid, there is a corresponding 
variation in the rate of nucleation and the number of nucleation points. This 
affects the diameter of the resulting particles, for a constant amount of 
tetrachloroauric acid. In this way gold particles in the 2 nm-20 nm size range can 
be produced. 
4.8.1.1 Reagents 
At all times scrupulously clean, scratch-free glassware was used. All reagents, 
including water, were of the highest purity available and filtered through 
0.22 11m membranes. 
1 % (m/v) Chloroauric acid. HAuCl4 (Merck, Darmstadt) (0.1 g) was dissolved in 
dist.H20, made up to 10 ml and stored in the dark at 4°C until used. 
1 % (m/v) Trisodium citrate. Trisodium citrate.2H20 (1.14 g) was dissolved in 
dist.H20, made up to 100 ml and used freshly prepared. 
1% (m/v) Tannic acid. Tannic acid (Mallinckrodt #1764) (0.1 g) was dissolved in 
dist.H20, made up to 10 ml and used freshly prepared. 
100 
4.8.1.2 Procedure 
To prepare 200 ml of gold sol the following solutions were prepared: A) 1% 
HAuC1
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(2 ml) was added to dist.H20 (160 ml), B) 1% trisodium citrate (8 ml) and 
1 % tannic acid (1 ml for 5 nm probes, 80 III for 10 nm probes) were added to 
dist.H20 (32 ml). Solutions A) and B) were protected from exposure to light, 
warmed to 60°C and mixed rapidly while stirring. Upon formation of a red 
colour, the solution was warmed to 90°C and cooled on ice. Larger probes take 
longer to form and the red colour can take up to 1 h to develop. 
4.8.2 Formation of gold probe with a minimum amount of protein A 
Colloidal gold particles carry a net negative surface charge; they are composed of 
an internal core of pure gold surrounded by a surface layer of adsorbed AuCI2-
ions. It is these ions that confer a negative charge to the colloidal gold and 
prevent particles aggregating by electrostatic repulsion. The gold colloid is 
sensitive to electrolytes (chloride> bromide > iodide) that reduce electrostatic 
repulsion by -compressing -the ionic lay.er. This allows the van der Waal's 
attractive forces between the particles to dominate causing particle aggregation, 
which is accompanied by a colour change and eventual sedimentation of the 
gold. 
Gold colloids are also lyophobic, the surface of the particles displays not only 
electrostatic characteristics, but also has hydrophobic properties. The latter may 
be exploited to bind proteins to the particle surface, and thereby form a specific 
probe. To achieve this, it is important to know the isoelectric point (pI) of the 
protein to be coupled. This value, or 0.5 pH units higher, is considered to be the 
optimum pH for probe preparation. Under these conditions the net protein 
charge is zero or slightly negative, thus preventing aggregation with gold 
particles due to electrostatic attraction. To determine whether adsorption has 
been successful or not, electrolyte is added to a protein/ gold colloid mixture. A 
change in colour (red to blue) upon electrolyte addition indicates incomplete 
stabilisation. The stabilising amount is the lowest amount of protein added to 
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the gold colloid that will prevent a colour change upon challenge with an 
electrolyte. 
After the addition of the specific probe protein, bare areas on the- surface of 
particles may be present. Such areas may cause aggregation, and interact with 
components of biological material in an immunolabeling experiment, giving rise 
to non-specific background labeling. By adding secondary stabilisers, such as BSA, 
exposed areas can be masked (Bendayan, 1989; Leunissen and De May, 1989). 
The immunolabeling experiments described here make use of the protein A-gold 
probe. Protein A belongs to a group of proteins, located at the surface of bacteria, 
that are thought to play a role in pathogenesis and in the host-parasite 
relationship. Protein A is found in the cell wall of Staphylococcus aureus, its 
most relevant property being its affinity toward IgG through binding to the 
crystallisable fragment (Fc) (Forsgren and Sjoquist, 1966) on the CH2 and CH3 
domains (Deisenhofer, 1981). It is, thus, a pseudo-immune reaction that does not 
interfere with the binding of the immunoglobulin to its antigen. Protein A 
interacts strongly with most IgG classes of several mammalian species, such as 
human, rabbit, guinea pig and dog, and less strongly with IgG classes from goat, 
sheep, rat and chicken (Forsgren and Sjoquist, 1966; Langone, 1982). Where 
primary antibodies from weaker reacting species are used, a "linker" secondary 
antibody from a strongly reacting species may be used, followed by the protein A-
gold probe. Indeed, immunogold probes, where the secondary antibody is 
adsorbed onto the gold surface instead of protein A, would also be a viable 
alternative. This offers the further advantage of sign'll amplification, because 
more than one immunogold probe may bind to a single tissue-bound primary 
antibody (Merighi et al., 1992). Protein A binds immunoglobulin in a one-to-one 
ratio (Slot et al., 1989), an important factor when quantitative 




1 rna Iml Protein A. Protein A (1 mg, Sigma Chemical Co., St. Louis, Mo.) was 
s-
dissolved in dist.H20 (1 ml). 
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Colloidal gold. Prepared as in Section 4.7.1. 
10% (m/v) NaCl. NaCI (1 g) was dissolved in dist.H20 (10 ml). 
0.1 M NaOH. NaOH (0.04 g) was dissolved in dist.H20 (10 ml). 
10% (m/v) BSA in PBS-E. BSA (globulin-free, Sigma Chemical Co., St. Louis, 
Mo.) (1 g) was dissolved in PBS-E (Section 4.6) (10 ml). 
4.8.2.2 Procedure 
Protein A was centrifuged at high speed to sediment any precipitate, and diluted 
to 100 ~g/ml with dist.H20. The gold colloid was adjusted to pH 6.0 with 0.1 M 
NaOH using pH paper, as the colloid will block a pH electrode. A dilution series 
was set up in flat-bot~omed microtitre plates (Table 4) and mixed by manual 
agitation. 
Table 4. Dilution series for the determination of the minimum protein A 
concentration for colloid stabilisation. 
protein A + dist.H2O protein A + dist.H2O 
(Ill) (Ill) (Ill) (Ill) 
- 10 0 5 5 
9 1 4 6 
8 2 3 7 
7 3 2 8 
6 4 1 9 
Colloidal gold was added to each well and mixed by agitation. Adsorption was 
allowed to proceed tor 2 min and the colloid was then challenged with 10% NaCI 
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(10 1-11). After agitation the plate was allowed to stand (5 min) and the colour 
change assessed visually. The highest dilution of protein A giving no colour 
change (pink to blue) represents the end point, and was used to calculate the 
amount of protein required to stabilise 200 ml of gold colloid. The calculated 
amount of protein A was added dropwise to the stirred gold colloid suspension. 
After 5 min, residual protein binding sites were quenched by the addition of 10% 
BSA in PBS-E, to a final concentration of 0.2% (4 ml added to 200 ml gold colloid). 
4.8.3 Purification and characterisation of gold probes 
The gold particles are first collected as a loose pellet, resuspended and centrifuged 
through a continuous glycerol gradient. The colloid fractionates in the gradient 
on the basis of size, the majority of particles of uniform size forming a band in 
the gradient and the aggregates passing through. Unbound protein is 
simultaneously removed. 
Once synthesised, colloidal gold preparations need to be evaluated 
ultrastructurally. This is accomplished by drying a small aliquot of the colloidal 
gold onto a coated grid, and transmission electron microscopy is used to evaluate 
the particle size, size distribution and the presence of clusters. As a rule, probes 
with at least 75% singlets and at the most 5% triplets are considered acceptable 
(Leunissen and De Mey, 1989). 
4.8.3.1 Reagents 
0.2% (m/v) BSA in PBS-E (BSA-PBS-E) . BSA (globulin-free, Sigma Chemical Co., 
St. Louis, Mo.) (0.2 g) was dissolved in PBS-E (Section 4.6) (100 ml). 
10% (v Iv) Glycerol in BSA-PBS-E. Glycerol (10 ml) was diluted in BSA-PBS-E 
(90 ml). 
30% (v Iv) Glycerol in BSA-PBS-E. Glycerol (30 ml) was diluted in BSA-PBS-E 
(70 ml). 
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0.1 % (m/v) Poly-L-Iysine. Poly-L-Iysine (1 mg) was dissolved in dist.H20 (10 ml) . 
4.8.3.2 Procedure 
Quenched colloidal gold particles were centrifuged (30 min, 4°C) in a Beckman 
70 Ti rotor (5 nm probe at 210 000 x g, 10 nm probe at 75 000 x g). The mobile 
pellet was resuspended in approximately 1 ml BSA-PBS-E and loaded onto a 
15 ml 10%-30% glycerol gradient and centrifuged (45 min, 4°C) in a Beckman S W 
40 rotor (5 nm probe at 240000 x g, 10 nm probe at 65 000 x g). The dark red band 
in the middle of the gradient was collected and its absorbance (520 nm) adjusted 
to 2.5-5. Particle size and size distribution was assessed by electron microscopy. A 
transmission electron microscopy grid was coated with a formvar support 
membrane (Section 4.7), and further coated with 0.1% poly-L-lysine. A thin layer 
of gold colloid was allowed to adhere and the photographed particles assessed for 
size. A size variation of less than 10% was considered acceptable. The binding 
activity of the probes was evaluated during immunolabeling procedures 
incorporating the appropriate controls (Section 4.9). Probes were stored st~d at 
4°C. 
4.9 Immunolabeling of Lowicryl-embedded sections 
Immunocytochemical labeling of ultrathin sections with protein A-gold, In 
general follows standard protocols (Merighi, 1992), with the manipulation of 
variables such as choice of blocking agent, length of incubation times, and length 
and stringency of washing. The protocol used was slightly modified from that of 
Roth (1986); foetal calf serum was used as a block and grids were washed in drops 
rather than by spraying. Double labeling was achieved by using the small probe 
first, followed by the large. This prevents steric hindrance and accessibility effects 
if the large probe were used first. Fixation with glutaraldehyde after the first of 
the two labelings and at the end of the protocol, ensures that the 
antigen/ antibody /protein A-gold complex is securely held together. 
Furthermore, the first fixation ensures that any antibody not bound to protein A 
in the protein A-gold complex is inactivated, so that it is not available for binding 
to the second protein A-gold probe, an event which would cause false positive 
second labeling. Antibodies used are described in Section 4.3. 
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4.9.1 Reagents 
5% (v Iv) foetal calf serum in PBS-E. Foetal calf serum (50 ~l) was diluted In 
PBS-E (Section 4.6) (950 ~l). 
0.1% (m/v) BSA-PBS-E. BSA (globulin-free, Sigma Chemical Co., St. Louis, Mo ., 
10 mg) was dissolved in PBS-E (Section 4.6) (10 ml). 
1 % (v Iv) Glutaraldehyde in PBS-E. Glutaraldehyde (40 ~l of 25% stock, Merck, 
Darmstadt) was diluted in PBS-E (Section 4.6) (960 ~). 
0.02 M Glycine in PBS-E. Glycine (0.015 g) was dissolved in PBS-E (Section 4.6) 
(10 ml). 
Antibodies. Chicken anti-porcine cathepsin D IgY was used at 250 ~g/rnl, rabbit 
anti-human cathepsin B IgG at 20 Ilg/m1, and rabbit anti-chicken IgY serum at a 
1/200 dilution. 
4.9.2 Procedure 
Immunolabeling was performed by incubation of grids, section-side down, on 
droplets of reagents on a layer of Parafilm spread onto a bench. Grids were 
transferred from reagent to reagent with a 1 mm nichrome wire loop on the end 
of a thin wooden splint. The same loop was used for each system optimised, as 
the loop carries a small volume of liquid over which introduces a dilution factor. 
Single immunogold labeling was performed according to the following regimen: 
1) Block: foetal calf serum in PBS-E (20 Ill, 15 min), 
2) Labeling: 10 antibody diluted in block (15 ~, 2 h), 
3) Wash: PBS-E (5 drops, 10 min total), 
4) Labeling: 20 antibody (if required) diluted in block (15 Ill, 1 h), 
5) Wash: PBS-E (5 drops, 10 min total), 
6) Labeling: protein A-gold ( 5 nm or 10 nrn, Section 4.8) diluted in BSA-PBS-E 
(15 Ill, 1 h) , 
7) Wash: PBS-E (5 drops, 10 min total) , 
8) Fix: glutaraldehyde in PBS (10 Ill, 5 min), 
9) Wash: 2 drops of PBS-E followed by 5 drops of dist.HzO, 
10) Gently blot grids and allow to dry. 
For double labeling, the following regimen was used: 
1) Protocol was followed as for single labeling to step 8), 
2) Block: glycine in PBS-E (5 drops, 10 min total) followed by BSA-PBS-E 
(5 drops, 10 min total), 
3) Wash: PBS-E (5 drops, 10 min total), 
4) Protocol was followed as for single labeling from steps 2)-10) . 
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As a control, all procedures were repeated with immune antibody substituted 
with a non-immune preparation, at the lowest dilution of immune antibody 
used. During optimisation of the gold probe level, antibody was additionally 
substituted with a diluting buffer only control. 
Double labeled (5 nm and 10 nm, Section 4.8) grids were incubated first in small 
probe, then large probe. Controls included single labeling with each probe for 
each antigen in the absence of primary antibody, single labeling with each probe 
for each antigen in the presence of primary antibody, and double labeling for both 
antigens with both sizes of probe. 
4.10 Counterstaining of Lowicryl K4M sections 
Counterstaining procedures for Lowicryl K4M are- similar as those for traditional 
electron microscope resins. Sections may be stained with either aqueous or 
alcoholic solutions of uranyl acetate and with lead citrate (Hobot, 1989). The use 
of Millonig's lead acetate (Millonig, 1961) in combination with uranyl acetate, has 
been suggested to provide superior quality of contrast and fine granular staining 
(Roth et al., 1985). Further improvement in the contrast of cellular structures 
embedded in Lowicryl K4M can be achieved by a contrasting method based on the 
uranyl acetate/methyl cellulose staining of thawed cryosections (Roth et al. , 1990) . 
It was found, however, that for MCF-10 cells staining with uranyl acetate and lead 
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citrate provided sufficient contrast. Since Lowicryl K4M is hydrophilic, the 
sections should be incubated on drops of stain for short periods of time. 
Prolonged staining may cause ccmtamination and distortion of the section. 
4.10.1 Reagents 
2% (m/v) uranyl acetate. Uranyl acetate (1 g) was dissolved in dist.H20 (50 ml), 
the addition of 95% ethanol (1 ml) assists solubility. The uranyl acetate solution 
was stored in the dark at 4°C. 
1 M NaOH. NaOH (0.4 g) was dissolved in dist.H20 (10 ml). 
Lead citrate. Lead nitrate (1.33 g) and trisodium citrate.2H20 (1.76 g) were added to 
freshly boiled and cooled dist.H20 and shaken intermittently for 30 min. NaOH 
(about 8 ml) was added to clear the milky solution. The solution was adjusted to 
50 ml with freshly boiled and cooled dist.H20 and stored in the dark at 4°C in an 
air-tight container. 
4.10.2 Procedure 
Dried grids were inverted onto uranyl acetate (4 min, .in the dark), washed with 
dist.H20 by gentle pipetting (500 ~l) and inverted onto lead citrate (30 s) in a 
closed dish containing NaOH pellets to remove CO2, The grids were again 
washed with gentle pipetting (500 ~l), blotted, allowed to air dry and viewed in a 
Jeol 100CX transmission electron microscope at 80 kV. 
4.11 Results 
This study was aimed at comparing the relative distributions of lysosomes and 
lysosomal proteinases in the normal human breast epithelial cell line, MCF-I0A, 
and the ras-transformed cell line, MCF-I0AneoT. 
Examination of the distribution of lysosomes as revealed by LysoTrackerTM, a 
fluorescent probe that accumulates in the low pH environment of lysosomes, 
shows a perinuclear distribution in MCF-I0A cells (Fig. 20A), with dark spaces 
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Figure 20. MCF-IOA and MCF-IOAneoT cells labeled for low pH compartments. 
(A) MCF-IOA and (B) MCF-I0AneoT cells were grown overnight on 
coverslips, incubated in LysoTrackerTM and viewed live by epi-
fluorescent microscopy (Section 4.4). 
Bar scales: (A and B) 10 1J.IIl. 
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between cells where the cell periphery and borders are located. In MCF-IOAneoT 
cells (Fig. 20B), however, lysosomal labeling can be found in the long, slender 
cellular processes that extend from the cells and cross each other in the contact 
uninhibited manner of transformed cells. Labeling for cathepsin D reveals a 
pattern similar to that of LysoTracker: generally perinuclear in MCF-IOA cells 
(Fig. 2IA) and more peripheral in MCF-IOAneoT cells (Fig.2IB). Furthermore 
labeling is profuse and strong, correlating with the abundance of this enzyme in 
cells and tissues. 
Cathepsins B, Hand procathepsin D immunofluorescent labeling was detected 
with a secondary antibody conjugated to TRITC which fluoresces red, a colour to 
which standard colour film is relatively insensitive. This was overcome by using 
the more sensitive Ilford XP2 400 film, in which punctate fluorescence is 
visualised as white dots. Cathepsin B fluorescence was localised around the 
nucleus on MCF-IOA cells (Fig. 22A & B), and more peripherally, to the cell 
membrane (Fig. 22C) and cellular extensions (Fig. 22D) in MCF-IOAneoT cells. 
There appeared also to be a greater number of fluorescent compartments in the 
transformed cells (compare Figs 22A & B and Figs 22C & D). Localisation of 
cathepsin H was characterised by highly defined small or larger compartments 
with bright fluorescence. In normal cells the distribution was generally 
perinuclear (Fig. 23B), but examples of a peripheral distribution were found 
(Fig. 23A). Transformed cells showed a sparse distribution of labeled vesicles 
which were mostly peripheral (Fig. 23C). In populations of both cell types only 
the occasional cell showed any labeling at all. 
Labeling of cathepsin L was unsuccessful in MCF-IOA cells, and very sparce and 
weak in MCF-IOAneoT cells. This is in contrast to similar experiments, using the 
same antibody, performed on the mouse embryo fibroblast line, NIH 3T3, and the 
B16-BL6 mouse melanoma cell line, where labeling was abundant (pers. com. 
with Frieda Dehrmann, Department of Biochemistry, University of Natal). 
Labeled vesicles appeared primarily perinuclear in the transformed cells 
(Fig. 24A). Proenzyme labeling was performed to assess any difference in 
distribution between proenzyme and mature enzyme and between the cell lines . 
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Figure 21. Immunofluorescent labeling of MCF-I0A and MCF-I0AneoT cells for 
cathepsin D. 
(A) MCF-I0A and (B) MCF-I0AneoT cells were grown overnight on 
coverslips, and labeled (Section 4.5) with chicken anti-porcine 
cathepsin D (200 j..lg/ml). 
Bar scales: (A and B) 10 j..lm. 
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Figure 22. Immunofluorescent labeling of MCF-IOA and MCF-I0AneoT cells for 
cathepsin B. 
(A, B) .MCF-IOA and (C, D) MCF-IOAneoT cells were grown overnight 
on coverslips, and labeled (Section 4.5) with affinity-purified rabbit 
anti-human cathepsin B (40 ~g/ml). 
Bar scales: (A-D) 10 ~m. 
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Figure 23. Immunofluorescent labeling of MCF-I0A and MCF-I0AneoT cells for 
cathepsin H. 
(A, B) MCF-I0A and (C) MCF-I0AneoT cells were grown overnight 
on coverslips, and labeled (Section 4.5) with rabbit anti-human 
cathepsin H anti-peptide antibody (300 ~g/ml). 
Bar scales: (A-C) 10 ~m. 
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Figure 24. Immunofluorescent labeling of MCF-I0AneoT cells for cathepsin L, 
and MCF-I0A and MCF-I0AneoT cells for pro cathepsin D. 
MCF-I0AneoT cells were grown overnight on coverslips, and labeled 
(Section 4.5) with (A) chicken anti-sheep cathepsin L (300 Ilg/ml), and 
MCF-I0A (B) and MCF-I0AneoT cells (C) with rabbit anti-human 
procathepsin D (300 Ilg/ ml). 
Bar scales: (A-C) 10 11m. 
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Labeling for procathepsins Band L was indistinct or absent, and that for 
procathepsin D was weak and sparse: labeled vesicles were generally near the 
nucleus or even closely associated with the nuclear membrane, pOSSibly in the 
RER in normal cells (Fig. 24B), but occasionally also in the cytoplasm. In 
transformed cells, compartments appeared to be peripheral, near the cell surface 
(Fig. 24C) . 
Double-labeling for cathepsins D and B at the electron microscope level revealed 
two features. First, these enzymes appear to co-localise in the same vesicles more 
often in MCF-IOA than MCF-IOAneoT cells and, secondly, both enzymes were 
found to be cell surface associated in the transformed cells but not in the normal 
cells. Some of the images presented are of labeled frozen thin sections of cells, 
. - - - - . --.. _",-
work performed by Dr Edith Elliott, Department of Biochemistry, University of 
Natal. 
When MCF-IOA cells were labeled for cathepsins D and B, both enzymes were 
found co-localised in perinuclear vesicles (Fig. 25A, B & C; Fig. 27 A). In 
MCF-IOAneoT cells, however, labeling appeared more peripheral and vesicles 
were generally labeled for either one or the other enzyme, and only occasionally 
for both (Fig. 26A & B; Fig. 27 B). Labeling for cathepsins D or B in Lowicryl 
embedded cells always occurred in translucent, asymmetrically rounded 
organelles, although not all such organelles were necessarily labeled. These 
vesicles were morphologically identical to vesicles which labeled for LAMP-2 
(Fig. 27C), a marker for lysosomes. It is possible, therefore, that most enzyme 
labeled ~esicles are lysosomes, and not endosomes, but this would need to be 
substantiated with double labeling experiments. Surface, microvillar labeling for 
cathepsin B was found to occur on the transformed cells (Fig. 28A & B), but this 
was not widespread. For cathepsin D some labeling was found on the surface of 
the MCF-IOA cells (not shown), but substantially more was observed on the 
surface of the transformed cells (Fig. 28B). For both enzymes, labeling was 
localised primarily to the apical surface although, due to the nature of the 
Lowicryl and ultracryo techniques used, this does not necessarily preclude 
basolateral labeling. 
'I 





Figure 25. Immunogold double-labeling of cryo-sections for cathepsin Band 
cathepsin D in MCF-I0A cells. 
Cathepsin B localisation was performed with a 10 nm gold probe and 
cathepsin D with a 15 nm probe (Section 4.9). (A) An MCF-I0A cell is 
show in transverse section, the basolateral surface indicated by open 
arrows. Cathepsins B -and D were "generally found in a perinuclear 
location (arrowheads). (B and C) Co-localisation of cathepsins Band 
D in electron-dense vesicles (arrowheads). Nu = nucleus; g = Golgi 
apparatus. 
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Figure 26. Immunogold double-labeling of cryo-sections for cathepsin Band 
cathepsin D in MCF-I0AneoT cells. 
Cathepsin B localisation was performed with a 10 nm gold probe and 
cathepsin D with a 15 nm probe (Section 4.9). MCF-I0AneoT cells (A 
and B) indicated -less To-localisation of cathepsin B -(A, arrowheads) 
and cathepsin D (A, arrows; B, arrowheads) in vesicles compared to 
MCF-I0A cells (cf Fig. 25). 
Bar scales: (A) 0.5 llm; (B) 0.25 llm. 
.. 
. . . 
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Figure 27. Immunogold double-labeling of lowicryl sections for cathepsin Band 
cathepsin D in MCF-I0A and MCF-I0AneoT cells, and labeling for 
LAMP-2 in MCF-I0AneoT cells. 
Cathepsin D was detected with a 5 nm gold probe, cathepsin B with a 
10 nm probe (A and B) and LAMP-2 with a 5 nm probe (C) 
(Section 4.9). Cathepsins B (arrows) and D (arrowheads) were found 
to typically co-localise in vesicles of MCF-I0A cells (A), while in the 
ras-transformed cells (B) little co-localisation was evident. 
Translucent vesicles, similar to those which typically label for 
cathepsins Band D (cf B), were labelled for the lysosomal marker, 
Lamp-2 (C, arrowheads). 
Bar scales: (A) 0.1 ~m; (B) 0.2 ~m; (C) 0.25 ~m. 
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Figure 28. Plasma membrane labelling for cathepsin B (lowicryl) and 
cathepsins D and B (cryo-section) in MCF-I0AneoT cells. 
Single labelling for cathepsin B was achieved with a 5 nm probe, and 
double labelling for cathepsin D with a 10 nm probe and cathepsin B 
with a 15 nm probe (Section 4.9). Association of (A) cathepsin B 
(arrows) and (B) cathepsins B (arrows) and D (arrowheads) with the 
microvillar projections of the plasma membrane of ras-transformed 
cells is evident. m = mitochondrion. 
Bar scale: (A and B) 0.25 !lm. 
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4.12 Discussion 
Transfection of MCF-I0A breast epithelial cells with oncogenic ras, produces 
altered trafficking of at least some lysosomal enzymes. Three important 
anomalous phenomena were found: 1) in ras-transformed cells lysosomal 
enzyme-containing vesicles were more peripherally distributed in the cytoplasm 
than in normal cells, where vesicles were predominantly perinuclear; 2) in 
transformed cells, labeled enzymes did not always co-localise in vesicles as would 
be expected of lysosomal enzymes; and 3) both cathepsins B and D were found to 
be membrane-bound in transformed cells. Indeed, membrane-associated 
cathepsin B is the mature double-chain form, and therefore functionally active 
(Sloane et al., 1994). Further studies have shown that the constitutive cathepsin 
B secretion is ,..,2.5-fold greater in the transfected cells (Rozhin et al., 1994) and , 
cathepsin L is also found more peripherally (Moin et al., 1994). These events are 
consistent with a metastatic phenotype. Peripherally situated lysosomes (labeling 
for LAMP-2 of morphologically identical vesicles as those labeled for enzymes, 
seems indicative of lysosomes, although other compartments cannot be ruled 
out) may be poised to secrete enzymes or deliver enzymes to the cell surface. 
Such altered trafficking is typical of metastatic tumour cells, and this may further 
be reflected by alterations in the enzyme complement of different lysosomes, 
leading to lysosomal sub-populations. Furthermore, membrane-bound cathepsin 
B is well situated for focal digestion of extracellular matrix or the activation of 
other proteases. Cathepsin D, on the other hand, may exert a mitogenic effect on 
the cell (Fusek and Vetvicka, 1994). 
These studies confirm those of Sloane et al. (1994) where, in MCF-I0AneoT cells, 
a more peripheral distribution of immunofluorescent staining for cathepsin B 
was demonstrated, and by immunogold labeling cathepsin B was localised to the 
cell membrane. Similar observations have been made in other models of 
malignant progression (Rempel et al., 1994; Rozhln et al., 1994): in the murine 
B16 melanoma lines that differ in their lung colonisation potential, and human 
KM12 colorectal carcinoma cell lines that differ in their metastatic capabilities, a 
more peripheral distribution of cathepsin B was found to be associated with the 
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more invasive phenotype. Cell surface labeling for cathepsin B has been 
observed in human lung carcinoma cells (Erdel et al., 1990), and in murine B16a 
cells (Honn et al., 1994). The association of cathepsin L with the surface of 
human colorectal cells has also been confirmed (Maciewicz et al., 1989), although 
in this study cathepsin L labeling proved too weak to confirm this for ras-
transformed human breast epithelial cells . The localisation of cathepsin D to the 
plasma membrane may, however, be a phenomenon unique to these cells as no 
similar observations have been made in other cells lines. Alterations in 
trafficking that lead to secretion of other lysosomal cathepsins have been widely 
reported and may be a feature of malignant transformation. Transfection of 
murine 3T3 fibroblasts with the ras oncogene elevates secretion of procathepsin L 
(Denhardt et al., 1987), transformation of murine BALB/3T3 fibroblasts by 
Moloney murine sarcoma virus elevates secretion of both procathepsin Land 
procathepsin B (Achkar et al., 1990), and in MCF-7 human breast cancer cells 
procathepsin D constitutes the major excreted proteinase (Rochefort, 1990). 
Indeed, the results presented in this study show transformed human breast 
-epi thelial -cells elaborating a perinuclear and also a significantly -more -peri pher-al 
distribution of compartments labeling not only for specific proteinases, but for 
low pH compartments in general This, and the lack of rabll labeling of 
peripheral cathepsins Band D labeled vesicles (a marker for the constitutive and 
regulated pathways) suggests that they are not part of the secretory pathway 
(Elliott et al., 1995). In contrast, in MCF-7 human breast carcinoma cells 
peripheral procathepsin B-containing vesicles are of a secretory nature (Elliott 
et al., 1995). This is consistent with the findings of Rochefort (1990) that MCF-7 
cells secrete a high proportion of cathepsin D in the precursor form. This 
indicates that cathepsins B and D may be trafficked by different pathways, 
dependent upon cell line or tissue. 
Lysosomal enzyme trafficking can occur in a M-6-P-independent manner as has 
been demonstrated in macrophages (Diment et al., 1988), HepG2 cells (Rijnbout 
et al., 1991), I-cell disease (Glickman and Kornfeld, 1993) and U937 monocytes 
(Braulke et aI., 1987), and may explain the differential trafficking of cathepsins D 
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and B in MCF-10 cells. This hypothesis is reinforced by the recent findings of 
Capony et al. (1994), who showed that cathepsin D secretion in some metastatic 
human breast cancer cell lines, contrary to normal mammary cells including 
MCF-10, is not increased by ammonium chloride treatment which totally 
abolishes the M-6-P-dependent pathway by preventing acidic pH dissociation of 
M-6-P receptor/lysosomal enzyme complexes. Procathepsin D, but neither 
cathepsin B nor ~-hexosaminidase, accumulated · in vesicles postulated to be 
phagosomes or large acid vesicles (Montcourrier et al., 1990). The routing of 
these enzymes was shown to involve interaction with membranes, but in the 
present study both cathepsins D and B were found membrane-bound. The 
presence of cellular lysosomal proenzyme receptors for cathepsins D and L has 
been proposed (McIntyre and Erickson, 1991) and active membrane-associated 
cathepsins D and B have been found in rat liver endosomes (Authier et al., 1995). 
It remains to be seen by which mechaIlism enzyme/membrane association occurs 
in ras-transformed MCF-10 cells, which may also have altered pH regulation 
(Sloane et al., 1994) and perhaps also modified procathepsin/membrane 
interactions. 
Evidence seems to suggest that the redistribution of lysosomes and the altered 
localisation of enzymes in tumour cells parallels malignant progression. 
Lysosomes are normally localised in the perinuclear region of cells. However, a 
redistribution of lysosomes to the cell periphery often occurs in cells that 
participate in invasive or degradative processes. Activated macrophages secrete 
lysosomal enzymes (Etherington et al., 1981) including cathepsin L (Reilly et al., 
1989); activated osteoclasts transport lysosomes toward the apical surface, where 
enzymes, particularly cathepsins Band L, are secreted into extracellular 
resorption lacunae formed between an osteoclast and bone (Vaes et aI., 1992). The 
universality of this phenomenon is reflected in the observation that recruitment 
of lysosomes and fusion with the plasma membrane is required for the invasion 
of epithelial cells by trypanosomes (Tardieux et al., 1992). Movement of 
lysosomes away from the cell centre can be experimentally induced by protocols 
that produce significant cytoplasmic acidification, to the range of ~pH 6.8 (Heuser, 
1989). In these studies macrophages and fibroblasts were used to demonstrate pH-
122 
dependent perturbation of microtubule-based motors, this effect being reversed 
byalkalisation. Similar results have been obtained with polarised MDCK cells 
(Parton et al., 1991), where lowering the cytosolic pH causes the movement of late 
endosomes to the base of the cell. It is well known that many tumours have a 
more acidic interstitial pH than normal tissues (Gerweck and Seetharaman, 1996), 
primarily due to the poorly organised vasculature of tumours, which gives rise to 
poor tissue oxygenation. This necessitates reliance on glycolysis, producing lactic 
acid which is inefficiently removed (Wike-Hooley et al., 1984). It would be 
interesting to speculate that such a low pH environment would be able to 
potentially induce a redistribution of lysosomes to the tumour cell periphery. 
Indeed, an acidic pericellular pH induced a redistribution of cathepsin B positive 
vesicles toward the cell periphery, and enhanced secretion of active cathepsin B 
(Rozhin et al., 1994). The pH values in human tumours are on average 
approximately 0.4 units lower than those observed in normal tissues, a value 
which appears to be low enough for redistribution to occur. 
Such a phenomenon, however, would only be relevant in the environment of 
the tumour mass, and not in the case of cells in culture or extra- or intravasation 
of single tumour cells. As has been demonstrated, however, transformation with 
the ras oncogene causes a more peripheral distribution of lysosomes. In the light 
of the findings of Heuser (1989), it may have been expected that if transformation 
resulted in intracellular pH perturbation, it would tend towards acidification. 
However, the opposite is seen: microinjection of oncogenic p21 into fibroblasts 
induces a rapid rise in intracellular pH (Hagag et al., 1987), and transformation of 
fibroblasts with ras _results in significant alkalisation of lysosomes Giang et al., 
1990). A similar increase was found in the ras-transformed epithelial cells 
(Sloane et al., 1994) and, in NIH 3T3 fibroblasts, is a result of ras-dependent 
activation of the Na+ /H+ antiporter (Maly et al., 1989). These effects suggest that 
the events demonstrated by Heuser (1989) are either as a result of a short-circuit 
of normal cellular controls, or the ras-induced effects demonstrated operate by a 
stronger and independent mechanism. Such a mechanism may be the 
downstream regulation by ras of the rae and rho pathways, which are known to 
affect the actin cytoskeleton. Indeed, in HEp-2 cells the movement and 
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localisation of endocytic compartments depends on microtubules and actin 
microfilaments (van Deurs et al., 1995), suggesting that oncogenic ras may perturb 
trafficking by affecting the cytoskeleton. 
The lysosomal alkalisation (pH 5.0 to 6.1) detected in Kirsten sarcoma virus (ras) 
transformed fibroblasts is comparable to that induced by chloroquine (pH 6.3) 
(Jiang et al., 1990). Treatment of cells with alkalisation agents such as 
chloroquine (or ammonium chloride), causes default misrouting of newly 
synthesised lysosomal enzymes to the cell exterior via the constitutive secretory 
pathway (Braulke et al., 1987). Yet, in a separate study, similarly transformed 
fibroblasts were reported to retain almost all lysosomal enzymes except 
procathepsin L, whose secretion is enhanced due to an intrinsic low affinity for 
the M-6-P receptor (Dong et aI., 1989). This apparent contradiction again serves to 
underscore the variable trafficking options available to cells, and the further 
complexity introduced by transformation. 
Perhaps the strongest candidate for mediating altered trafficking due to ras-
transfection, is phosphatidylinositol-3-kinase (PI 3-kinase). Rho, a .downstream 
target of ras, appears to mediate the activation of PI 3-kinase (Kumagai et al., 
1993), which in turn has been implicated in trafficking of M-6-P receptor-ligand 
complexes from the trans-Golgi network towards lysosomes (Davidson, 1995). 
Wortmannin, a PI 3-kinase inhibitor, causes almost complete extracellular 
mistargeting of procathepsin D which, in the cell line studied, is normally 
trafficked to lysosomes in a M-6-P receptor-dependent manner. The most 
probable explanation for this is that wortmannin directly interferes with M-6-P 
receptor trafficking by either the prevention of its recruitment into clathrin-
coated buds on the trans-Golgi network, inhibition of budding or fusion events, 
or the prevention of receptor recycling (Davidson, 1995). Presumably 
wortmannin has corresponding effects on similarly sorted lysosomal enzymes, 
implying a more general role for ras in lysosomal enzyme mistargeting. 
The work reported in this chapter has provided evidence for the association of 
some lysosomal proteinases with the plasma membrane of ras-transformed 
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human breast epithelial cells, and an abnormal distribution of compartments 
containing lysosomal proteinases in these cells. This, and other work already 
addressed, provides circumstantial evidence for a role of these enzymes in 
invasion and metastasis. The following chapter addresses the issue of the 
degradative events effected by the normal and transformed cell lines, as well as 
the proteinases implicated. 
CHAPTERS 
DEGRADATION AND INVASION OF EXTRACELLULAR MATRIX 
BY c-Ha-Ras TRANSFORMED BREAST EPITHELIAL CELLS 
5.1 Introduction 
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The interaction of tumour cells with the microvasculature constitutes a rate 
regulator for haematogenous metastasis (Weiss et al., 1989). Chapter 4 was 
concerned with changes brought on by ras-transformation which, at this point, 
are only circumstantially related to invasive ability. In this chapter studies are 
described that investigate more directly one aspect of this interaction, namely the 
proteolytic destruction of ECM proteins by the MCF-10 cell lines, a prerequisite for 
breaching the BM. 
Tumour cell adhesion to the endothelial cells of the target organ is the first 
important event in tumour cell-vessel wall interactions, and plays a decisive role 
in determining the organ preference of metastasis. The concerted action of a 
large array of cell surface adhesion molecules mediates the adhesive interactions 
of blood-borne tumour cells and endothelial cells (Honn and Tang, 1992). An 
orderly and reproducible sequence of events has been defined using the 
experimental metastasis of three murin~ tumour cell lines (Crissman et aI., 1988). 
First, initial tumour cell arrest with intimate contact between tumour cell and 
endothelial cell plasma membranes during the first 8 h; second, rapid platelet 
thrombus formation and association with arrested tumour cells (from 2 min. to 
1-4 h); third, endothelial cell retraction and extension of the tumour cell to the 
sub-endothelial matrix commencing at 4 h; fourth, dissolution of the tumour-
associated thrombus starting at 8 h and completed by 24 h to re-establish 
circulation; fifth, intravascular proliferation after 24 h, as reflected by the presence 
of mitotic figures, and the formation of intravascular tumour nodules; and sixth, 
dissolution of the BM by the attached tumour cells after 24-72 h. The final 
outcome of this interaction is the liberation (extravasation) of tumour cells from 
circulation into the target organ stroma. 
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The function of platelets and tumour cell-associated thrombosis in the 
extravasation steps remains unclear, although platelet involvement was 
indicated by experiments where induced thrombocytopenia resulted in decreased 
numbers of lung colonies after tail veil injection of tumour cells (Gasicet al., 
1973). Platelets are able to form adhesive bridges between tumour cells and the 
subendothelial matrix (Menter et al., 1987). It has been proposed that the platelet 
thrombus may be protective against mechanical forces which would tend to 
dislodge the apparently weakly attached tumour cell from the endothelial 
monolayer (Weiss et al., 1985). This is supported by the observation that the 
platelet thrombus remains until the tumour cell achieves contact with the 
subendothelial matrix (Crissman et al., 1988), presumably to secure a more firm 
attachment (Kramer et al., 1980). Another possibility is the facilitation of 
endothelial cell retraction and exposure of the subendothelial matrix (see below). 
In vitro studies have shown, however, that endothelial cell retraction in the 
presence of tumour cells can occur in the absence of platelets (Kramer and 
Nicolson, 1979). 
The physical and functional integrity of endothelial cell monolayers is critical to 
retarding the dissemination of metastasising tumour cells. The integrity of the 
endothelial layer can be perturbed as a result of destructive cell damage in 
response to a number of stimuli. These include vasoactive substances 
(e.g., bradykinin, histamine, serotonin), lipid mediators (e.g., platelet-activating 
factor, leucotriene C4), thrombin, tumour necrosis factor, serine proteases, 
y-radiation and endotoxins (Lafrenie et al. , 1992). Most of th~se stimulants are 
implicated in increasing vascular permeability and facilitating leucocyte 
transmission through endothelial monolayers during inflammation. So mOe 
types of tumour cells may extravasate by intravascular proliferation resulting in 
rupture of the vessel wall. However, the majority of studies both in vitro and in 
vivo have shown that endothelial cells retract prior to extravasation. Using an 
in vitro system, Kramer and Nicolson (1979) showed that tumour cells were able 
to attach to endothelial cell monolayers and cause morphological changes, such 
as a rupture of endothelial-endothelial cell interactions, leading to endothelial 
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cell retraction and exposure of ECM, and subsequent invasion and underlapping 
of retracted endothelial cells. Similar observations were made after the 
experimental metastasis of three tumour cell lines (Crissman et al., 1988). In 
contrast, entry into circulation of malignant cells from two metastasis forming 
tumour cell lines, occurred by penetrating the intact endothelial cell body (De 
Bruyn and Cho, 1982). The migration pore formed by the migrating tumour cell 
closed after the cell had reached the intravascular space. 
The factors responsible for endothelial cell retraction are not clearly defined, 
although a strong candidate is a lip oxygenase metabolite of arachidonic acid, 
12(S)-hydroxyeicosatetranoic acid (12(S)-HETE) (Honn et al., 1994a), which 
induces reversible, non-destructive and non-denuding endothelial cell 
retraction. Endothelial cell monolayers retract in response to the adhesion of 
tumour cells, but not in response to normal fibroblasts, suggesting a specific 
interaction between tumour cells and endothelial cells. Tumour cells synthesise 
12(S)-HETE in response to adhesion to endothelial cells, but a lack of detectable 
metabolite in the culture medium suggests metabolic transfer of 12(S)-HETE to 
endothelial cells. Indeed, this hypothesis is supported by the observation that 
tumour cells can establish gap junctional channels between their cytoplasms and 
those of endothelial cells, and easily transfer small molecules from the tumour 
cells to endothelial cells (EI-Sabban and Pauli, 1991). These authors speculate that 
the transfer of mediators, such as 12(S)-HETE, may playa critical role in tumour 
extravasation. In vivo, host platelets are an abundant source of 12(S)-HETE, 
which may be locally released. Platelet activation and aggregation to tumour cells 
occurs wi~ minutes of tumour cell arrest (Crissman et al., 1988), and platelet-
derived 12(S)-HETE may potentiate tumour cell-induced endothelial cell 
retraction. It is interesting to note that feeding a high fat diet, rich in linoleic acid, 
enhanced metastasis of a mouse mammary tumour cell line, compared with a 
diet containing the same quantity of fat, but of low linoleic acid content. Linoleic 
acid is metabolised to arachidonic acid, which is available for conversion to 
eicosanoids (Rose et al., 1994). It is interesting to speculate that a mechanism 
involving enhanced production of 12(S)-HETE may be at work. 
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The finding that 12(S)-HETE is an activator of protein kinase C in tumour cells 
(Liu et al., 1991), and that endothelial cell retraction induced by 12(S)-HETE is also 
protein kinase C-dependent (Tang et al., 1993), has lead to the formulation by 
Honn et al. 1994a of a hypothetical mechanism. Tumour cell adhesion to 
endothelial cells activates 12-lipoxygenase in tumour cells, leading to arachidonic 
acid metabolism to 12(S)-HETE which activates protein kina?e C and translocates 
it to the plasma membrane (Liu et al., 1991). Protein kinase C phosphorylates and 
reorganises cytoskeletal elements which mobilise ~Jb~ integrin-containing 
vesicles to the cell surface, where the integrin is required for tumour cell matrix 
adhesion (Honn et al., 1992). 12(S)-HETE also modulates tumour cell spreading 
on matrix and tumour cell motility (Timar et al., 1993). By its action on 
endothelial cells, 12(S)-HETE enhances a..,,~3 integrin surface expression and 
tumour cell adhesion (Honn et al., 1989), and protein kinase C mediated 
endothelial cell retraction (Honn et al., 1994a). Also, 12(S)-HETE can promote the 
release of cathepsin B in cancer cell lines, including the ras-transformed 
MCF-10A line (Honn et al., 1994b). Thus, 12(S)-HETE is able to mediate each of 
the three steps of invasion: adhesion, degradation and migration. 
Successful intravasation or extravasation requires directed migration of tumour 
cells towards or from a blood vessel, while simultaneously overcoming 
endothelial cell and BM barriers. During extravasation, this process is probably 
initiated by the preferential adherence of tumour cells to the ECM underlying the 
vascular endothelial cells. Fibronectin, associated with the endothelial BM may, 
in part, be responsible for establishing an adhesive gradient that could be 
important for tumour cell extravasation (Kramer et al., 1980). Similar haptotactic 
activity has been demonstrated for laminin, a glycoprotein also found in BM 
(McCarthy et al., 1983). Interestingly, both type I and IV collagenases have been 
found to manifest significant chemokinetic (random motility) and 
chemoattractive (directed motility) activity respectively (Terranova et al., 1989). 
Although an in vivo significance for this finding has not been established, even a 
small amount of collagenase in an extracellular compartment at the leading edge 
of a tumour cell can imply a high specific activity. Type I and IV collagens and 
their breakdown products are also chemoattractive (Terranova et al., 1989), 
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therefore the collagenolytic activity may provide an additional mechanism for in 
situ enhancement of tumour cell motility in a collagen-rich matrix. The 
migration of tumour cells can also be enhanced by the presence of uP A and 
plasminogen (Terranova et al., 1989). Immunohistochemical findings have 
shown that plasminogen is present throughout the thickness of capillary walls in 
tumour areas and in tumour stroma (Burtin et al., 1985). With this localisation 
plasminogen could guide tumour cells toward and into capillaries, and promote 
the spread of cancer. Changes in enzyme and matrix components can thus offer a 
fine control mechanism which elicits specific responses in tumour cells which 
can potentiate invasive and metastatic behaviour. 
It is clear that adhesive interactions playa critical role in the process of metastatic 
tumour dissemination. This topic is beyond the scope of this work, but it should 
be borne in mind when considering metastasis. Adhesion molecules can act as 
both positive and negative modulators of the metastatic process. Intercellular 
contacts that confine cells to the primary tumour site are mediated by homotypic 
adhesion molecules, such as E-cadherin, which are negatively correlated with 
metastatic potential (Takeichi, 1991). Tumour ·cells already in circulation may 
specifically adhere to endothelial . cells in selected organs, a process mediated by 
molecules such as the VLA-4 (a.4~J integrin or molecules containing the Sialyl 
Lewis X carbohydrate determinant (Zetter, 1993), which bind to endothelial 
adhesion molecules such as E-selectin (Bevilacqua et al., 1989) or the vascular cell 
adhesion molecule, VCAM-1 (Osborn et al., 1989). Preferential adhesion and 
subsequent site-specific metastasis of particular tumour types, may be specified by 
endothelial determinants such as lung endothelial cell adhesion molecule, 
LuECAM. After adherence to endothelial cells and endothelial cell retraction, 
metastatic cells must adhere to elements of the subendothelial BM such as 
laminin and type IV collagen (Terranova et aI., 1982), interactions frequently 
mediated by a laminin receptor (Castronovo et al., 1991) and members of the ~l 
and ~4 integrin families (Zetter, 1993). Finally, for movement into the 
subendothelial stroma, tumour cell adhesion to connective tissue elements such 
as fibronectin, type I collagen and hyaluronan is mediated by molecules such as 
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the ~1 integrins (Zetter, 1993) and the CD44 cell surface adhesion molecule 
(Gunthert et al., 1991). 
5.2 Cell culture 
The MCF-10A and MCF-10AneoT cell lines were maintained as described in 
Section 4.2. Serum free medium (SFM) was prepared as before (Section 4.2) 
except that equine serum was replaced with sterile 0.1 % (m/v) BSA and medium 
with human serum was prepared as before except that equine serum was replaced 
with 5% (v Iv) complement-inactivated (56°C, 30 min) human serum (volunteer 
donor). Mouse embryo fibroblasts (NIH 3T3) were cultured as previously 
described (Section 4.2), except that RPMI-1640 medium (Sigma Chemical Co., St. 
Louis, Mo.) and 10% (v Iv) foetal calf serum (Gibco, Paisley) were used as the 
culture medium. Fibroblast-conditioned medium (FCM) was prepared by 
switching the NIH 3T3 cells to MCF-10 cell culture medium (Section 4.2) for 
3 passages, and then to conditioning medium (50 ~g/ml ascorbic acid in SFM) for 
48 h. The conditioned medium was adjusted to pH 7.4 with sterile 0.1 M NaOH, 
cell debris removed by centrifugation, and stored at -70°C. Where required, cells 
were assessed for viability and counted by trypan dye exclusion using an 
Improved Neubauer haemocytometer. 
5.3 In vitro matrix degradation 
A number of in vitro assays for tumour cell-dependent proteolytic activity rely 
on the degradation of insoluble ECM proteins. These are usually quantitative, as 
in the measurement of released radiolabel from metabolically labeled 
subendothelial matrix, produced by endothelial cell monolayers (Kramer et al., 
1982). A less frequently used approach is fluorescent microscopy of tumour cell-
mediated matrix proteolysis. Fibronectin, immobilised as a uniform layer on an 
appropriate substratum, has been used as a substrate for tumour cell adhesion 
and proteolysis, degradation being detected by immunofluorescent microscopy 
(McCarthy et al., 1985; Chen and Chen, 1987; Campbell and Campbell, 1988; 
Wakabayashi and Kawaguchi, 1992). Chen et al. (1994) have also similarly used 
rhodamine-labeled ECM produced by chicken embryonic fibroblasts, or 
fluorescein conjugates of type I and IV collagen, laminin (McCarthy et aI., 1985; 
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Kelly et al., 1994) and matrigel (Monsky et al., 1994) co-coupled to the surface of a 
cross-linked gelatin film, while Montcourrier et al. (1990) used fluorescein-
labeled ECM produced by endothelial cells. In the present study direct fluorescent 
microscopy of FITC-Iabeled ECM was used to characterise the degradative 
characteristics of MCF-10A cell lines. Biomatrix I, a proprietary name and 
equivalent to the reconstituted BM, matrigel, was used as ECM. 
5.3.1 Preparation of FITC-matrix 
Biomatrix I labeled with FITC was produced by the method of Homer and 
Beighton (1990), where the method was used to generate protein substrates with 
fluorescent leaving groups. 
5.3.1.1 Reagents 
75 mM Sodium carbonate, pH 9.5. NaHC03 (0.315 g) and Na2C03 (0.387 g) were 
each dissolved in dist.H20 (50 ml). The Na2C03 solution was titrated with 
NaHC03 to pH 9.5. 
5.3.1.2 Procedure 
Biomatrix I (5 mg in 511.2 ~l, Biomedical Technologies, Inc., Stoughton, Ma.) was 
diluted with sodium carbonate buffer (1 ml), and FITC-celite (1.7 mg, Sigma 
Chemical Co., St. Louis, Mo.) added and stirred (2 h, 4°C). Celite was removed by 
centrifugation and the supernatant applied to a column of Sephadex G-25 
(1,0 x 19 cm = 15 ml) equilibrated (10 ml/h) with ultrapure water. The V 0 fraction 
was collected as FITC-matrix, which was aliquoted and stored at -70°C. 
5.3.2 FITC-matrix degradation assay 
5.3.2.1 Materials 
Serum free medium. Prepared as in Section 5.2. 
Complete medium with equine serum. Prepared as in Section 5.2. 
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Complete medium with human serum. Prepared as in Section 5.2. 
5.3.2.2 Procedure 
Round coversiips (22 mm) were rinsed in ethanol, dist.H20 and ultrapure water, 
and allowed to dry under ultraviolet light in a laminar flow hood. FITC-matrix 
was diluted to 30 ).1g/50 ).11 with ultrapure water, and deposited as a drop (50 ).11, 
ca. 13 mm in diameter) on the coverslips and allowed to dry under ultraviolet 
light in a laminar flow hood. Coverslips were plac~d in 35 mm cell culture petri 
dishes, and the FITC-matrix allowed to rehydrate in the appropriate medium 
(5 min; SFM, complete medium with equine serum or complete medium with 
human serum). Cells (MCF-10A and MCF-10AneoT) were trypsinised 
(Section 4.2), suspended in complete medium, washed three times in HBSS, and 
resuspended in the appropriate medium. Protease inhibitors used are indicated 
in the results (Section 5.6.1), and were made up as in Section 5.4.2. Cells were 
seeded into petri dishes at low density (5 x 103) and incubated (16 h) as before 
(Section 4.2). A coverslip was placed cell-side down into a custom-designed 
holder (Mechanical Instrument Workshop, University of Natal, 
Pietermaritzburg) which is able to accommodate pre-warmed medium. This 
allows cells to be viewed live under the epifluorescent microscope (Olympus 
BH-2 equipped with an Olympus BH-2 RFC epifluorescence attachment). 
Representative cells were photographed under phase-contrast and 
epifluorescence using an Olympus PM-20 exposure control unit, with llford XP-2 
film . 
5.4 In vitro tumour invasion models 
Evidence for the involvement of proteinases in tumour cell invasion, is derived 
from various experimental approaches quantifying the degradation (using 
metabolically ·radiolabeled ECM formed by cultured cells) and/or invasion of BM 
and interstitial stroma by tumour cells. The effect of specific inhibitors or 
antibodies to selected proteinases is measured in these assays. The modified 
Boyden chamber invasion system used in some of the SEM studies (Section 5.4.1) 
and used for quantifying the effects of various proteinase inhibitors, is discussed 
in Section 5.4.2. 
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5.4.1 Scanning electron microscopy 
Scanning electron microscopy (SEM) has been used recently to visualise the 
penetration of invasive cells through proteinaceous barriers. Human amniotic 
membrane was used to demonstrate the invasion of B16-BL6 mouse melanoma 
cells (Mignatti et al., 1986) and polymorphonuclear leucocytes (Bakowski and 
Tschesche, 1992), and matrigel-coated filters were used to investigate invasion of 
human cytotrophoblasts (Librach et al., 1991) and hamster melanoma cells 
(Thomas et al., 1993). In the present study the methods of Neumtiller (1990) and 
Arro et al. (1981) were used. These are designed for cultured cells and to 
minimise artefacts due to imperfect fixation, shrinkage during dehydration and 
drying, or uneven metal coating. 
5.4.1.1 Reagents 
Complete medium with equine serum. Prepared as in Section 5.2. 
Serum free medium. Prepared as in Section 5.2. 
Fibroblast conditioned medium. Prepared as in Section 5.2. 
Wash buffer (0.1 M sodium cacodylate, pH 7.2). Sodium cacodylate (5.35 g) was 
dissolved in about 200 ml of dist.H20, titrated to pH 7.2 with HCl and made up to 
250 ml. 
Fixative (0.1 M sucrose, 2% (v Iv) glutaraldehyde, 0.1 M sodium cacodylate, 
pH 7.2). Sodium cacodylate (1.07 g) and sucrose (1.71 g) were dissolved in about 
40 ml of dist.H20, glutaraldehyde (4 ml of 25% stock, Merck, Darmstadt) was 
added, the solution titrated to pH 7.2 with HCI and made up to 50 ml. 
0.2 M Sodium cacodylate, pH 7.2. Sodium cacodylate (2.14 g) was dissolved in 
about 40 ml of di:st.H20, titrated to pH 7.2 with HCl, and made up to 50 ml. 
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post-fixative (1% (v Iv) osmium tetroxide in 0.2 M sodium cacodylate, pH 7.2) . 
Osmium tetroxide (1.875 ml of 4% stock) was added to 0.2 M sodium cacodylate 
(3.75 ml) and made up to 6 ml with dist.H20. 
30% (v Iv) Ethanol. Ethanol (6 ml, AR) was made up to 20 ml with dist.H20. 
50% (v Iv) Ethanol. Ethanol (10 ml, AR) was made up to 20 ml with dist.H20 . 
70% (v Iv) Ethanol. Ethanol (14 ml, AR) was made up to 20 ml with dist.H20 . 
80% (v Iv) Ethanol. Ethanol (16 ml, AR) was made up to 20 ml with dist.H20. 
90% (v Iv) Ethanol. Ethanol (18 ml, AR) was made up to 20 ml with dist.H20. 
95% (v Iv) Ethanol. Ethanol (19 ml, AR) was made up to 20 ml with dist.H20. 
5.4.1.2 Procedure 
Biomatrix I (Biomedical Technologies, Inc., Stoughton, Ma.) was thawed on ice 
and diluted with cold ultrapure water (20 J.1g in 50 J.1l). Polycarbonate filters 
(Nuclepore, Costar, Cambridge, Ma., 13 mm, 8 J.1m pores) were placed on a plastic 
petri-dish, coated (dull side up) with diluted Biomatrix I (50 J.1l), allowed to dry in 
a laminar-flow bench with the ultraviolet light on, and the coating procedure 
repeated. For chemotaxis control experiments, filters were coated (dull side up) 
with type VI collagen_ (10 J.1g in 10 J.1l, prepared in this laboratory by Dr Theresa 
Coetzer). Coated filters were covered with a large drop of SFM (5 min) to 
reconstitute the ECM proteins. The bottom-half of the Boyden chambers was 
filled with FCM (200 J.1l, chemotaxis control or invasion) or complete medium 
(morphological characterisation), and the filters carefully placed over the 
medium, taking care not to trap air-bubbles. The upper chamber was screwed on, 
and cells (MCF-I0A and MCF-I0AneoT) were trypsinised (Section 4.2), suspended 
in complete medium, washed three times in HBSS, resuspended in SFM or 
complete medium, assessed for >98% viability, counted and added (5 x 104 in 
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800 III SFM or complete medium) to the upper chamber. Boyden chambers were 
placed in the cell culture incubator (16 h), and at timed intervals (40 min, 2 h, 
16 h) a chamber was removed, disassembled and processed for SEM. Control 
chambers (16 h incubation) were assessed for chemotaxis and invasion 
(Section 5.4.2). 
For SEM processing, removed filters were gently placed in an equal volume 
mixture of SFM and fixative and allowed to stand undisturbed (5 min, 37°C). The 
mixture was replaced with fixative (1 h, 37°C) which was periodically agitated and 
allowed to cool to RT. Fixative was replaced and cells fixed overnight (4°C). 
Filters were rinsed with wash buffer (3 x 2 min.), post-fixed (1 h, RT), rinsed again 
(3 x 2 min.) and dehydrated in an increasing ethanol series. Cells were critical 
point dried (Hitachi HCP-2) from liquid C02r filters cut into -3 mm 3 squares and 
mounted, upper surface exposed, onto copper stubs. Some of the filter squares 
derived from invasion experiment were mounted bottom side up, and others 
were stripped of cells by gently laying a filter onto the adhesive on a stub and 
pulling away. This leaves cells, ventral-side up, on the stub. Filters were sputter-
coated (Polar son SEM coating unit) with gold/palladium (80/20). Cells were 
viewed and representative photographs taken in an Hitachi S-570 scanning 
electron microscope at 8 k V. 
5.4.2 Modified Boyden chamber invasion assays 
In vitro invasion studies utilise either natural BM, or reconstituted BM. Three 
different types of natural BM have been used: the human amniotic membrane 
(Thorgeirsson et al., 1982), the bovine lens capsule (Starkey et ai., 1984) and the 
chorioallantoic membrane of the chicken embryo (Ossowski and Reich, 1983). 
The amniotic membrane, obtained from human term placentas, is the most 
commonly used of these natural substrates for cell invasion studies. Soluble 
ECM from the Englebreth-Holm-Swarm murine sarcoma cell line (matrigel or 
Biomatrix I), containing laminin, type IV collagen, fibronectin, elastin, entactin 
and nidogen (Orkin et al., 1977; Kleinman et al., 1986), is the most widely used 
substrate for invasion studies, as it is considered to be biochemically almost 
identical to BM. 
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The assay is conceptually, but not practically, simple. In general, polycarbonate 
filters with 5-8 ~ diameter pores are coated with the matrix, to form an artificial 
BM. The filters are inserted into chemotaxis chambers consisting of a top and 
bottom compartment separated by the matrix-coated filter. Culture medium is 
added to both compartments, and the tumour cells seeded onto the upper, matrix 
coated, surface of the filter. Protease inhibitors may be included in the media to 
investigate the contribution of various proteases to invasion. During incubation 
(6-24 h) the cells infiltrate the matrix coating, migrate and adhere to the bottom 
surface of the filter. At the end of the incubation the material on the top surface 
is removed, the filter stained and the number of cells on the bottom surface 
counted with a microscope (Albini et al., 1987). The blind well Boyden chambers 
used in this study were manufactured by the Mechanical Instrument Workshop, 
University of Natal, Pietermaritzburg. The protease inhibitor concentrations 
used in this study were based on the work of Mignatti et al. (1986) and Yagel et al. 
(1989b). 
5.4.2.1 Reagents 
HBSS. Prepared as in Section 4.2. 
Complete medium with equine serum. Prepared as in Section 5.2. 
Serum free medium. Prepared as in Section 5.2. 
Fibroblast conditioned medium. Prepared_as in Section 5.2. 
1, 10-Phenanthroline (10 mg/ml) in dimethyl sulfoxide (DMSO). 
I, 10-Phenanthroline A (Sigma Chemical Co., · St. Louis, Mo.) (5 mg) was 
dissolved in DMSO (0.5 ml) and diluted to a final concentration of 10 ~g/ml in 
SFM and FCM (Section 5.4.2.2). 
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Pepstatin A (7.0 mg/ml) in DMSO. Pepstatin A (Sigma Chemical Co., St. Louis, 
Mo.) (1.05 mg) was dissolved in DMSO (150 ~l) and diluted to a final 
concentration of 10 ~g/ml in SFM and FCM (Section 5.4.2.2) . 
L-trans-epoxysuccinyl-Ieucylamido(4-guanidino)butane (E-64) (7.5 mg/ml) in 
DMSO. E-64 (Sigma Chemical Co., St. Louis, Mo.) (0.75 mg) was dissolved In 
DMSO (100 ~) and diluted to a final concentration of 36 ~g/ml in SFM and FCM 
(Section 5.4.2.2). 
Fixative (2 mglml malachite green in methanol). Malachite green (2 mg) was 
dissolved in methanol (1 ml). 
Stain 1 (0.1% (v Iv) eosin Y, 0.1 % (v Iv) formaldehyde, 0.4% (m/v) N aliPO~, 0.5% 
(m/v) KH2PO,J. Na2HP04 (0.2 g) and KH2P04 (0.25 g) were dissolved in dist.H20, 
eosin Y (50 ~) and formaldehyde (50 ~l) were added and the solution made up to 
50 ml. 
Stain 2 (0.047% (m/v) methylene blue, 0.4% (m/v) Na2HPOM 0.5% (mlv) KH2P0,1 
Na2HP04 (0.2 g) and KH2P04 (0.25 g) were dissolved in dist.H20, methylene blue 
(23.5 mg) was added and the solution made up to 50 ml. 
5.4.2.2 Procedure 
For invasion and control random migration and chemotaxis experiments, 
polycarbonate filters were coated as described in Section 5.4.1. Coated filters were 
covered with a large drop of SFM with protease inhibitor, DMSO or HBSS 
solvent when appropriate, and placed in a cell culture incubator (60 min). Cells 
(MCF-10A and MCF-10AneoT) were trypsinised (Section 4.2), suspended in 
complete medium, washed three times in HBSS, resuspended in SFM, assessed 
for >98% viability and counted. The bottom-half of the Boyden chamber was 
filled with SFM (200 ~l, random migration control) or FCM (200 ~l, chemotaxis 
control or invasion), and the filters carefully placed over the medium, taking care 
not to trap air-bubbles. The upper chamber was screwed on, and cells (3 x 105 in 
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800 ).11 SFM, with inhibitor, DMSO or HBSS when appropriate) added to the upper 
chamber. Boyden chambers were placed in the cell culture incubator (16 h) for 
migration and invasion to occur. Filters were removed, the upper surface 
allowed to adsorb onto paper towelling, and the filter gently laterally pulled away 
to remove adherent cells. Cells on the filter underside were fixed (5 x 1 s), 
drained, and stained (5 x 1 s) in each of Stain 1 and Stain 2, rinsed in dist.H20 and 
allowed to dry. An image analysis system (Kontron Vidas, Kontron Elektronik, 
Germany), in tandem with a light microscope, was used to determine cell surface 
area, which was used as a measure of the number of invaded cells The use of cell 
surface area as a representation of cell number, was validated by comparison with 
scores obtained by manual cell counting. A total of 10 fields of vision per filter, 
4 bisecting the invasion area and 3 on either side, were used to determine cell 
surface area. Image analysis was not able to discriminate between cells and pores 
in the filter, and so the program was modified to eliminate any surface area 
smaller than 200 pixels, which was found to be larger than a pore but smaller 
than a cell. Invasion was determined by calculating cell surface area of a treated 
experiment as a percentage of an untreated positive control, which was taken as 
100% invasion. Each assay was performed in duplicate, repeated either two or 
three times. 
5.5 Gelatin-substrate SDS-PAGE 
Substrate zymograms combine the molecular weight-dependent resolving power 
of SDS-P AGE, with detection based on the activity of the enzyme of interest. 
Incorporation of gelatin (denatured type I collagen) into gels allows for the 
detection of a variety of proteinases (Heussen and Dowdle, 1980). Following SDS-
PAGE, proteinases are renatured by substitution of SDS in the gel by Triton X-100. 
Gels are then incubated in . assay buffer containing the relevant activators and 
inhibitors, to ensure specific enzyme activity. Proteinase activity is visualised, 
after staining of gels, by clear bands of digested gelatin. The assay buffer of Brooks 
et al. (1996) was used in this study. 
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5.5.1 Reagents 
1 % (m/v) Gelatin in running gel buffer. Gelatin (0.1 g) was dissolved in running 
gel buffer (solution B, Section 2.3.2) (10 ml) with gentle heating. 
2.5% (v Iv) Triton X-100. Triton X-100 (5 rnl) was diluted to 200 rnl with dist.H20. 
Assay buffer (50 mM Tris, 200 mM NaCl, 10 mM CaCl2< pH 7.5. Tris (3.03 g), NaCl 
(5.84 g) and CaC12 (0.74 g) were dissolved in 450 ml of dist.H20, titrated to pH 7.5 
with HCI and made up to 500 ml. When required the metalloproteinase 
inhibitor, 1,10-phenanthroline, was added to the assay buffer to a concentration 
of 10 llg/ml from a 100 mg/ml stock solution (Section 5.4.2). 
0.01 M p-aminophenylmercuric acid (APMA) in 0.05 M NaOH. p-aminophenyl-
mercuric acid (35 mg) was dissolved in 10 ml of 0.05 M NaOH (0.02 g dissolved in 
10 ml of dist.H20) just before use. 
0.1% (m/v) Amido black. Amido black (0.1 g) was dissolved in methanol:acetic 
acid:dist.H20 (30:10:60) (100 ml), and filtered through Whatrnan No.1 filter paper 
before use. 
5.5.2 Procedure 
Serum free medium (8 ml) was conditioned (72 h) by confluent MCF-10A and 
MCF-10AneoT cells grown in 75 cm2 flasks, and concentrated to 1 ml. The total 
number of cells in each flask was counted (Section 5.2), and the relative volumes 
of conditioned medium added to treatment buffer adjusted to account for 
differences in cell number. This allows direct quantitative comparison of 
clearing by enzyme activity from the two cell lines. The procedure for preparing 
SDS-PAGE gels (Section 2.3.2) was modified by adding 1% (m/v) gelatin (1.5 ml) 
to the running gel buffer (2.25 ml), and reducing and increasing the respective 
volumes of acrylamide monomer (solution A) and dist.H20, to produce a 7.5% 
gel. When necessary, latent collagenases were activated with APMA (0.01 M 
stock diluted to 0.5 mM in conditioned medium, 37°C, 30 min) . Samples were 
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prepared in treatment buffer (Section 2.3.2) without ~-mercaptoethanol and 
without boiling, and run as normal. 
After electrophoresis, the running gel was soaked in two changes of 2.5% (v /v) 
Triton X-100 (50 ml) over 1 h at RT. The gel was incubated in assay buffer (16 h) 
at 37°C, stained in 0.1% (m/v) amido black (1 h) and destained in several changes 
of methanol:acetic acid:dist.H20 (30:10:60). 
5.6 Results 
It is established that MCF-10AneoT, in contrast to MCF-10A cells, are able to 
invade artificial basement membrane in vitro (Ochieng et al., 1991), and are able 
to form sustainable xenografts in mice (Miller et al., 1993). No attempt, however, 
has been made to characterise the proteolytic episodes, elaborated by ras-
transformed breast epithelial cells, which occur during these events, and the 
present study begins to address this question. 
5.6.1 Extracellular matrix _degradation 
There are a few reports that growth of transformed cells on a substratum of 
fluorescently-Iabeled extracellular matrix results in discrete spots lacking 
fluorescence beneath the cells · (McCarthy et al., 1985; Chen and Chen, 1987; 
Campbell and Campbell, 1988). To determine whether ras-transformation of 
human breast epithelial cells increases the expression of proteolytic enzymes at 
the cell surface or in the extracellular milieu capable of degrading artificial BM, 
the effect of cells grown on FITC-matrix was investigated by visualising 
degradation under the ventral surface of cells. After 16 h in SFM, MCF-10A cells 
had effected degradation mostly corresponding to the cell circumference and 
pseudopodial projections (Fig.29A & B). Transformed cells, in contrast, were 
capable of extensive matrix degradation (Fig. 29C & D and Fig. 30A & B), which 
appeared to originate at the cell periphery, proceeding inwards (results not 
shown) (initial degradation was almost always observed peripheral to a cell). 
Degradation associated with cellular motility was observed (Fig. 29D), and matrix 
removal was also visible under phase-contrast optics (Fig. 29C). It was common 
to observe phagocytosed matrix in the form of bright fluorescent spots, where 
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Figure 29. Behaviour of MCF-10A and MCF-10AneoT cells, in SFM, on 
fluorescently labeled Biomatrix I coated substrata. 
(A, B) MCF-10A and (C, D) MCF-10AneoT cells were seeded onto 
FITC-matrix, incubated (16 h) and observed live by (A, q phase 
contrast and (B, D) epifluorescent microscopy (Section 5.3.2). 
Bar scales: (A- D) 40 ~. 
I . 
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Figure 30. Behaviour of MCF-I0AneoT cells, in SFM, on fluorescently labeled 
Biomatrix I coated substrata. 
MCF-I0AneoT cells were seeded onto FITC-matrix, incubated (16 h) 
and .observed live by (A) phase contrast and (B) epifluorescent 
microscopy (Section 5.3.2). 
Bar scales: (A and B) 10 flIn . 
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matrix has been concentrated in intracellular vesicles (Fig.29C & D and Fig. 30A 
& B) . 
Tumour cells, during in vivo metastasis, are in contact with interstitial tissue 
fluids or plasma which are rich sources of proteinase inhibitors, and it was 
therefore of interest to ascertain the behaviour of the transformed and normal 
breast epithelial cells in the presence of serum. The most notable effect is the 
increase in cellular motility and the concomitant destructive effects on the 
matrix. T~s effect, in equine serum, is manifest even by the MCF-I0A cells 
(Fig. 31A & B), but is more pronounced with the transformed cells (Fig. 31C & D). 
Human serum accentuates the effect in the transformed cells (Fig. 31E & F), and 
cells appear very rounded, probably due to their increased motility. A dominant 
. feature is the accumulation of matrix around motile cells (Fig. 31A & Band 
Fig. 31E & F), especially at the leading edge of the cell, and the presence of strands 
of matrix emanating from cells, suggesting that mechanical events may also play 
a role in matrix disruption in this assay system. Cells may be invading under the 
matrix layer and by moving along the surface of the cover-slip may disrupt and 
become entangled in matrix. In the presence of human -serum, MCF-I0A cells 
were observed to contain phagocytosed matrix, in the form of many small dim 
perinuclear vesicles, while transformed cells demonstrated fewer, larger and 
brighter vesicles (see Fig. 32C & D). Both cell lines were able to 'track' over the 
substratum leaving a path denuded of matrix, but MCF-I0A cells were able to 
accomplish this only when the matrix was thin and patchy (results not shown) . 
Transformed cells, in contrast, effectively cleared matrix in their path (Fig.31G 
&H). 
The effect of various protease inhibitors on degradation was tested. All inhibitors 
used (pepstatin A, I, 10-phenanthroline, E-64, leupeptin, antipain, £-amino 
caproic acid, aprotinin, soybean trypsin inhibitor) were unable to extinguish 
degradation to any noticeable degree. In the presence of the metalloproteinase 
inhibitor, 1,10-phenanthroline, transformed cells were as able to disrupt the 
matrix layer (Fig. 32A & B), and in the presence of leupeptin many instances of 
matrix phagocytosis were seen (Fig. 32C & D), typical, in this case, of the extensive 
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Figure 31. Behaviour 'of MCF-10A and MCF-10AneoT cells, in medium 
supplemented with horse or human serum, on fluorescently labeled 
Biomatrix I coated substrata. 
(A, B) MCF-10A and (C-H) MCF-10AneoT cells were seeded onto 
mC-matrix, incubated (16 h) and observed live by (A, C, E, G) phase 
contrast and _(B,.-V, F, H) epifluorescent microscopy (Section 5.3.2). 
Cells were grown in the presence of (A-D) equine serum and (E-H) 
human serum. 
Bar scales: (A-H) 40 ~m. 
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Figure 32. Behaviour of MCF-10AneoT cells, in the presence of protease 
inhibitors, on fluorescently labeled Biomatrix I coated substrata. 
MCF-I0AneoT cells were seeded onto FITC-matrix, incubated (16 h) 
and observed live by (A, C, E) phase contrast and epifluorescent (B, D, 
F) microscopy (Se£tion 5~3.2) . Cells were -grown in the presence of (A, 
B) 1, 10-phenanthroline, (C, D) leupeptin and (E, F) aprotinin. 
Bar scales: (A-F) 40 J..lffi. 
146 
phagocytosis "that appears to occur in areas where matrix is deposited sparsely. In 
the presence of the serine proteinase inhibitors aprotinin and £-amino caproic 
acid, cells were occasionally observed beneath the layer of matrix, as reflected by 
the blurred regions corresponding to the position of cells when focus is in the 
plane of the deposited matrix layer, in some cases without disrupting it (Fig. 32E 
& F). A similar lack of proteolytic inhibition was observed with normal breast 
epithelial cells in the presence of inhibitors (results not shown). 
To ascertain whether any matrix-degrading activity was released into the culture 
medium, conditioned medium (48 h) from normal and transformed cells, 
adjusted to pH 5 or 7.2, was incubated (72 h) with FITC-matrix coated cover-slips, 
and the supernatant tested for released matrix by fluorimetry. No significant 
increase in fluorescence over control medium was detected for either cell line 
(results not shown). 
5.6.2 SEM characterisation of cell morphology and invasion 
A SEM morphological characterisation of the MCF-10A cell line has been 
reported (Tait et al., 1990), but no such study has been performed on the ras-
transformed counterpart, MCF-10AneoT. MCF-10A cells grown, in the presence 
of serum, on Biomatrix I do not differ appreciably from those grown on glass 
(Tait et al., 1990). The cells form flat monolayers, are closely apposed and roughly 
polyhedral in shape, and the surface is covered by sparse short microvilli 
(Fig. 33A). The transformed cells are irregularly shaped, ranging from dome to 
spindle, to stellar shaped. They are thicker in the centre, have well defined cell 
borders and at high density overlap one another and thereby do not form a 
continuous monolayer (Fig. 34B). The surface is covered with abundant long, 
slender microvilli or filopodia and occasional cells have membrane blebs 
(Fig.33B & C). Long, thin horizontal extensions, up to one cell diameter long, 
project from the cells (Fig. 33B and C). In SFM, MCF-10AneoT cells lack long 
extensions, but still possess numerous microvilli and blebs (Fig. 33D). 
Little is known about the morphological changes undergone by metastasising 
tumour cells during extravasation. Although this question cannot be adequately 
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Figure 33. Morphology of MCF-10A and MCF-10AneoT cells, grown on 
Biomatrix I, determined by SEM (Section 5.4.1). 
(A) MCF-10A cells, grown in the presence of equine serum, form a flat 
monolayer of which the surface is covered with short microvilli. 
(B) MCF-10AneoT cells, also in the presence of equine serum, 
elaborate long cellular extensions and microvilli, while some cells 
were -.S.een to feature large blebs ~(upper cell) . (C) Enlargement of the 
lower cell in (B). When the cell density is high, the transformed cells 
are able to overlap one another (see Fig. 34B). (D) An MCF-10AneoT 
cell grown in SFM, showing numerous microvilli and blebs. 
Bar scales: (A) 21 ~m; (B) 10 ~m; (C) 4.1 ~m; (D) 2.1 ~m . 
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addressed in IJztro, it is important to characterise the events occurrmg during 
modified Boyden chamber invasion assays, as the quantitative results from these 
assays are used to help define proteolytic mechanisms which may be relevant in 
vivo. To this end the invasive MCF-10AneoT cell line was allowed to invade in 
vitro and then subjected to SEM characterisation. Cells were firmly attached to 
the Biomatrix I 40 min after seeding and had begun to spread (Fig. 34A). 2 h after 
seeding, cells were fully spread (Fig. 34B) but there were no signs of invasion, 
while at 4 h invasion had begun (Fig. 34C). In response to the chemoattractant, 
cells were able to deform their leading edge into a narrow extension that 
projected into a pore in the filter (Fig. 34C). On emerging on the filter underside 
the extension immediately spread over the surface into a thin sheath already 
elaborating some microvilli (Fig. 34D). After 16 h many cells had emerged 
underneath the filter, and all appeared firmly attached and spread (Fig. 34E). In 
an attempt to visualise the pseudopodial extensions which are, presumably, 
responsible for breaching the Biomatrix I barrier, cells were stripped from their 
filter after 4 h and viewed upside down. At the point of adherence to the stub, 
cells appear to be damaged, but the putative pseudopodia appear intact, and 
display microvilli and membrane folds (Fig. 34F). 
5.6.3 In vitro invasion assays 
The in vitro invasion assay was used to study the role of proteinases in ras-
transformed cell invasion by attempting to inhibit specific proteases. As the 
proteases mediating cell invasion are probably localised in regions of close contact 
between the cells and matrix substratum, inhibitors were pre-adsorbed onto the 
filter-borne matrix, to ensure the pr~sence of inhibitors in regions of cell 
substratum adhesion. Furthermore, unlike the case with the FITC-matrix assays, 
inhibitors have access from the lower half of the Boyden chamber to the 
underside of the matrix, via the pores in the filter. This assumes that the 
inhibitors are able to penetrate through matrix in and coating the pores. The 
validity of invasion experiments is dependent upon pores of the filter being 
evenly and completely coated with reconstituted BM matrix. It has been reported 
that complete coating is attainable down to 25 Ilg/13 mm filter (Mackinnon et al., 
1992), thus proper coating was assumed at the 40 Ilg/13 mm filter used in this 
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Figure 34. Attachment of MCF-10AneoT cells to Biomatrix I and subsequent 
invasion as demonstrated by SEM (Section 5.4.1). 
(A) 40 min after seeding cells are firmly attached and beginning to 
spread. (B) After 2 h cells are spread and (C) invasion begins. 
(D) After 6 h a cell emerges through a pore in the filter and attaches to 
the underside. (E) After 16 h many cell have invaded and are 
adherent to the filter under-surface. (G) Cells stripped from a filter in 
the process.of invasion (4 h), showing the dorsal aspect revealing 
invadopodia (F) which were, presumably, extracted from a pore in the 
filter. 
Bar scales: (A) 6.6 /-lm; (B) 10.1 /-lm; (C) 7.5 /-lm; (D) 5.5 /-lm; (E) 40 /-lm; 
(F) 5.5 /-lm. 
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study. Coating heterogeneity appears to be the most significant problem, and 
manifests itself as a heterogenous population of stained cells across the underside 
of a filter. This makes cell quantification difficult, and sometimes impossible, 
stressing the need for quantification in many fields of vision across a filter 
surface. 
As shown in this study, both cathepsins B and D are present on the surface of 
MCF-10AneoT cells. To ascertain if their presence assisted in vitro invasion, 
inhibitors to aspartic and cysteine proteinases, i.e. pepstatin A and E-64, were used 
in Boyden chamber assays. Neither inhibitor effected significant inhibition of 
invasion relative to control invasion in the absence of an inhibitor (100% 
invasion), indeed inhibition of cathepsin D potentiated invasion (Fig. 35). 
1,10-P chemotaxis (10 Jlg/ml) 
Figure 35 
Control invasion 
Pepstatin A (10 Jlg/ml) 
E-64 (36 Jlg/ml) 
1,10-P (10 Jlg/ml) 
o 20 40 60 80 100 120 140 160 
Invasion (%) 
Effect of aspartic, cysteine and metalloproteinase inhibitors on in vitro basement 
membrane invasion by MCF-lOAneoT cells. 
Inhibitors (at the concentration indicated in the figure) were incubated with 
Biomatrix I coated filters 1 h prior to cells being added to the chambers, as described 
in Section 5.4.2. Invasion in the absence of inhibitor was normalised to 100%. Error 
bars represent the standard deviation of the invasion mean of the assays performed. 
Each assay was performed in duplicate and each experiment repeated either two or 
three times. 
Significant inhibition of invasion of ras-transformed cells was achieved with the 
MMP inhibitor, l,10-phenanthroline, implicating this class of enzymes as the 
15 1 
rate-limiting proteolytic facilitators of in v itro invasion (Fig. 35). To ensure that 
I, 10-phenanthroline does not perturb cell viability and motility at the 
concentration used, cell chemotaxis was measured in the presence and absence of 
inhibitor, and each assay normalised to control (100%) invasion. The presence of 
the inhibitor only slightly decreases the rate of chemotaxis (Fig. 35), indicating 
that the inhibitory effect it has in the invasion assay is specific to proteolytically 
mediated invasion. 
5.6.4 Metalloproteinase gelatin-substrate gel electrophoresis 
Gelatin-substrate gel electrophoresis was used to ascertain the extent to which 
normal and ras-transformed breast epithelial cell lines express MMPs into the 
culture supernatant and, in the light of inhibition of in vitro invasion by the 
MMP inhibitor, I, 10-phenanthroline, the degree to which this expression differs. 
Both cell lines, in the absence of the metalloproteinase activator APMA, express a 
minor band of activity at 120-150 kDa, and a major band at 100-110 kDa (Fig. 36A). 
A major band at 80-85 kDa is, however, significantly more active in the 
supernatant of the transformed cells. A further minor band of activity is present 
-at 55-60 kDa in the MCF-10A cell line supernatant. 
In the presence of APMA (Fig. 36B), the 100-110 kDa band migrated as a doublet, 
consistent with activation of type IV collagenases (Marbaix et al., 1996). The 
upper band represents the latent proform and the lower band the activated 
enzyme. The latent proform is rendered active under the conditions of this 
assay, probably as a result of the activating power of SDS, which presumably 
induces _a conformational change in type IV collagenases, removing the . 
inhibiting propiece from the active site (Birkedal-Hansen and Taylor, 1982). A 
faint band of activated 80-85 kDa protease is present in the MCF-IOAneoT lane, 
probably due to incomplete activation under the assay conditions used. 
Incubation of gels in assay buffer in the presence of 1, 10-phenanthroline 
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Gelatin-substrate SDS-PAGE of SFM conditioned by MCF-10A and MCF-10AneoT 
cells. I 
Non-reduced samples (normalised by cell number) were loaded onto a 7.5% gelatin-
containing gei, and following electrophoresis proteases were renaturedj the gels 
incubated in assay buffer, stained and destained as in Section 5.5. A) Samples 
prepared in the absence of APMA and the gel incubated with assay buffer 
(a) molecular weight markers (phosphorylase b, 93 kDa; BSA, 68 kDa; civalbumin, 
45 kDa; carbonic anhydrase, 29 kDa) . (b) MCF-10A conditioned \ medium; 
(c) MCF-10AneoT conditioned medium. B) Samples prepared in the p}esence of 
\ 
APMA and the gelmcubated with assay buffer, "(d) MCF-10A conditioned medium; 
(e) MCF-10AneoT conditioned medium. C) Samples prepared in the absence: of APMA 
and the gel -incubated with assay buffer in the presence of 1, 10-phenanthroline, 
I 
(f) MCF-10A conditioned medium; (g) MCF-10AneoT conditioned medium. I 
5.7 Discussion 
Tumour cell metastasis 1S dependent upon -breaching the BM, which \implies 
ECM degradation, a process facilitated by localised proteolysis. Two 
morphological approaches have been used to access cell invasion in the present 
study. 1) By using a substratum of immobilised ECM coupled to a fluorescent 
marker, it has been shown that ras-transformed human breast epitheli:al cells 
I 
produce proteases that are capable of degrading ECM. 2) An SEM inves~igation 
has shown that these cells are capable of ECM invasion by elaborhting a 
pseudopodial structure by virtue of which, presumably, invasion mayl occur. 
I 
Furthermore, it has been demonstrated that a metalloproteinase is largely -
responsible for this invasive process. 
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Up-regulation of proteolytic capacity due to ras-transformation is clearly evident 
from the more profound clearing of immobilised matrix, and the higher 
invasive ability of these cells. Normal breast epithelial cells do, however, exhibit 
some degradative and invasive ability, but this is probably a reflection of a 
requirement for mammary gland involution (Larsson et aI., 1984) and tissue 
remodelling, which is essential for morphogenesis during development and 
wound healing. 
In the presence of SFM, zones of proteolysis appear as sharply demarcated areas 
directly subjacent to the cells. Larger zones represent the confluence of a number 
of smaller zones of proteolysis. The mechanism giving rise to this pattern may: 
1) be as a result of the release of soluble proteases from vesicles, and/or 2) occur at 
sites of close contact between the cell and the matrix substratum. Evidence for an 
intimate association between the cell and the matrix comes from the fact that 
inhibitors of all classes of proteases were unable to inhibit degradation of coated 
ECM. 
Similar phenomena have been observed with other invasive cells. Chen and 
Chen (1987), using Rous sarcoma virus-transformed chicken embryo fibroblasts, 
showed that a 6 h preincubation with the metalloproteinase inhibitor 
1,10-phenanthroline was required to inhibit clearing. Polymorphonuclear 
neutrophils were shown to exclude a-I-proteinase inhibitor from areas subjacent 
to the cells (Campbell and Campbell, 1988). Unlike in this case, the inhibitors 
used by Chen and Chen (1987) and in the present study were almost all of a very 
low molecular weight, which emphasises the closeness of the contact between 
cell and substratum. 
The nature of such close contacts is not clear. Cells could form, at their periphery, 
a band of close contact to delineate an area under the cell which could serve as an 
"extracellular lysosome", as has been suggested for macrophages (Reilly et al., 
1989) and osteoclasts (Vaes et al., 1992). Alternatively, cancer cells, at their 
basolateral surface, may elaborate invasive pseudopodia or "invadopodia" (Kelly 
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et al., 1994) which are formed at contact sites (Chen et al., 1994). Focal contacts, in 
fibroblasts, have a 10-15 nm separation between cell membrane and substrate 
(Izzard and Lochner, 1980). Given that cathepsin D, a relatively small molecule at 
45 kDa, has a length of about 7 nm along its longest axis (Cantor et al., 1992), it 
w.ould be reasonable to assume that cell membrane- or receptor-associated 
proteases would be intimately accommodated in such a gap but, due to . steric 
hindrance, small inhibitors would have difficult access. Indeed, uP A has been 
localised to discrete focal adhesion contact sites in the human fibrosarcoma cell 
line, HT-1080 (P6IHinen et al., 1987), while the 72 kDa type IV collagenase 
(Monsky et al., 1993) and seprase, a neutral gelatinase (Monsky et al., 1994), were 
localised on invadopodia. 
The present studies have shown that medium conditioned by MCF-10AneoT 
cells and adjusted to pH 5 or 7.2, was unable to release more ECM than a control. 
This indicates that either insufficient or no low or neutral pH proteolytic activity 
capable of ECM degradation, under the assay conditions used, is released. It 
would appear, then, that the proteolytic activity is either released as a latent 
proform, or is cell-associated and not released as soluble -enzyme. 
The involvement of pseudopodial extensions, which may, in the context of the 
leading edge of an invasive cell, form specialised invadopodia, is apparent from 
SEM micrographs of invading cells. It is difficult to discern, under the 
experimental conditions used, to what degree the chemoattractive forces are 
responsible for these structures. A cell would not be able to pass through the 
narrow pores of the filter without constricting at that point, but it is likely that 
-
proteases required for degradation of · ECM prior to entering the pores are 
elaborated on the invadopodia. Proteases expressed on invadopodia, are found 
in close contact with planar ECM substratum. The mechanism for this 
preferential targeting is, at present, unknown, but may be by virtue of higher 
concentrations of MMP receptors at the ventral surface of cells. Indeed, integrins 
have been found to localise to the invadopodia of Rous sarcoma virus-
transformed chicken embryo fibroblasts (Mueller and Chen, 1991), and the 72 kDa 
type IV collagenase can be localised in a proteolytically active form on the surface 
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of invasive cells,· based on its ability to directly bind integrin a ... ~ (Brooks et al., 
1996). Furthermore, a novel family of membrane proteins has been identified 
containing both integrin binding sequences and a metalloproteinase catalytic 
domain (Wolfsberg et al., 1995). 
It was shown that ras-transformed cells (Fig. 29), as well as normal cells but to a 
lesser degree, often display vesicles which contain phagocytosed ECM. This is 
unusual in that this activity is thought to occur mostly in specialised phagocytic 
cells, such as polymorphonuclear neutrophils and macrophages. However, other 
instances of this activity are found: the oestrogen-dependent breast cancer cell 
line MCF-7 (Montcourrier et al., 1990), and murine melanoma and fibrosarcoma 
cell lines (McCarthy et al., 1985) were found to phagocytose ECM, while the 
hormone-independent breast cancer cell line, MDA-MB 231, phagocytosed ECM 
and latex beads during in vitro invasion (Montcourrier et al., 1994). Some breast 
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cancer cell lines (Montcourrier et aI., 1994), as well as paraffin sections of invasive 
ductal breast carcinoma (Roger et al., 1994), have shown the presence of large 
acidic vesicles in which ECM can be digested. It has been suggested that these 
compartments may be important for the complete digestion .of phagocytosed 
material which, in turn, may be of critical importance for successful invasion 
(Montcourrier et al., 1994). The ECM-containing compartments in the 
transformed cells in this study, were generally larger than those of the normal 
cells. 
In addition to proteolysis, it is well known that cell motility is closely related to 
the pathogenesis of cancer. It is of interest, therefore, that the addition of equine 
serum and, even more successfully, homotypic human serum greatly enhanced 
cellular motility on ECM. This was associated with increased destruction of ECM, 
apparently by both proteolysis and mecharucal action. Although the increase in 
motility was most likely due to an increase in random migration, it is interesting 
to note that a preliminary experiment showed that serum-containing medium 
was very chemoattractive in a Boyden chamber assay (results not shown). It may 
be speculated that blood plasma in capillaries could have similar activity, and 
could contribute to tumour extravasation, assuming the active molecule is 
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present in lower amounts in interstitial tissue fluid. Furthermore, breaching the 
basement membrane may, mechanistically, be as a result of a combination of 
proteolysis and mechanical disruption, although the nature of the interaction in 
vitro, between the cell surface and the matrix, which causes this disruption is 
unknown, and nor is it known whether it has any physiological equivalent. 
Although localised degradation assays are able to provide insight into cell-matrix 
interactions, such as the proteolytic capacity of cells, it must be remembered that 
this is a purely experimental system, perhaps with little direct physiological 
relevaI!ce. The addition of protease inhibitors, for example, had little effect on 
ECM proteolysis, probably because of a lack of access from underneath the matrix 
layer. In vivo, BM is bathed in extracellular fluid from both sides. This is also a 
feature of the in vitro Boyden chamber system, hence its success as a method for 
helping determine the proteases involved in invasion, with the use of protease 
inhibitors. 
This approach was used to begin to determine the proteinase requirement for in 
vitro invasion through reconstituted BM by ras-transformed breast epithelial 
cells. Type IV collagen appears to be one of the major barriers to invasion of the 
BM, since the extent of invasion often correlates well with the extent of collagen 
type IV degradation (Liotta et al., 1980). This implies the involvement of type IV 
collagen-degrading proteinases, such as type IV collagenases and cathepsins L 
and B (Maciewicz et al., 1987). It is not surprising, therefore, that the highest 
inhibitory activity was displayed by an inhibitor of MMPs, which is consistent 
with the findings of other workers using a variety of cell lines (Mignatti et al., 
1986; Reich et al., 1988; Yagel et al., 1989b). 
However, due to the complexity of proteolytic events, it is unlikely that only a 
single extracellular proteinase can be responsible for invasion. It appears that, in 
many cases, the uP A system is linked to type IV collagenase activation, as 
inhibitory antibodies to this enzyme produce a partial inhibition of invasion 
which can be circumvented by the addition of organomercurial activators of type 
IV collagenases (Reich et al., 1988). Furthermore, uz-antiplasmin, a specific 
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inhibitor of plasmin, was also found to significantly inhibit invasion (Ylignatti 
et al., 1986). This has led to the proposal of a proteolytic cascade: cell-associated 
uP A activates plasminogen (found in abundance in plasma), and the resulting 
plasmin activates type IV procollagenase. In the present study, preliminary 
experiments using serine proteinase inhibitors, indicated no apparent inhibition 
of invasion, although this remains to be confirmed. Also, the addition of 
plasminogen did not potentiate invasion (results not shown). Were this the case, 
another mechanism of type IV collagenase activation would be required. 
Cathepsin B, a cysteine proteinase, is able to activate latent collagenase (Sloane 
and Honn, 1984), and Yagel et al. (1989a) have shown that inhibitors of 
cathepsin L, also a cysteine proteinase, retard in vitro invasion in a murine 
melanoma and mammary carcinoma cell line, but to a lesser extent than 
metalloproteinase inhibitors. They suggest that this may reflect a role for 
metalloproteinase activation. In the present study however, E-64, a class 
inhibitor of cysteine proteinases, afforded no significant inhibition of invasion. 
Similar results have been demonstrated with mouse melanoma Bl6-F10 celis, 
where the serine/ cysteine proteinase inhibitor, leupeptin, afforded no significant 
decrease in invasion (Persky _et ..ilL, 1986). .Ibis is. surprising -as .se.cretion of.both 
uPA (Wang et al., 1980) and cathepsin B (Sloane and Honn, 1984) has been 
correlated with metastatic potential in this celiline. 
Similarly, pepstatin A, a class inhibitor of aspartic proteinases, caused no 
inhibition, but rather a small increase in invasion (Fig. 35), a result similarly 
found by Johnson et al. (1993) with the human breast carcinoma cell line, MCF-7. 
This may be due to the inhibition of cathepsin D-dependent inactivation of other 
proteinases that are important in invasion. This data appears to support 
evidence that cathepsin D does not have an important extracellular role in the 
invasive phenotype of invasive cells, at least not in Boyden chamber assays. 
Such a conclusion should, however, be treated with circumspection as a role for 
the enzyme in metastasis has been shown (Garcia et al., 1990), although it is 
unknown what its function is. 
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The demonstration of the involvement of an MMP in in vitro invasion 
prompted the question whether such activity could be detected in cell culture 
supernatants. Zymographic analysis indicated three MMP activities, two of 
which were significant at a Mr of 100-110 kDa and 80-85 kDa and a third minor 
band at 120-150 kDa. A high molecular weight MMP has been identified in 
extracts of a human melanoma cell line, which runs as a doublet at 170 and 
150 kDa on gelatin substrate gels (Monsky et al., 1994). Significantly, the 80-85 kDa 
band appears more active in the supernatant medium of the transformed cells 
than in that of the normal cells, which could be a reflection of the higher 
invasive activity of the transformed cells. It is unknown at present whether this 
increased activity is due to induction of the enzyme, or other events such as 
reduction in secreted endogenous inhibitor levels. At present, the identity of 
these MMPs is unknown. H-ras-transformed human bronchial epithelial cells 
have been shown to secrete the 72 kDa type IV collagenase (Collier et al., 1988), 
and the 92 kDa type IV collagenase can be induced in a squamous cell carcinoma 
cell line by fibroblasts (Lengyel et al., 1995). The molecular weights of the 
identified bands do not correspond to these enzymes, but it is possible that these 
enzymes form complexes with other molecules. 
The metastatic potential of neoplastic cells is most commonly assessed by 
injection into a host animal, with subsequent monitoring of tumour growth and 
metastasis. Invasion is pathologically considered the hallmark of a malignant 
tumour, hence the .development of in vitro assays which specifically test this 
process. However, while this assay is appealing because it is rapid and 
quantitative, it should not be used as the sole criterion for predicting in v i va 
-
invasion, as cells derived from normal tissues are able to penetrate the matrix, 
and some cells with in vivo invasive capacity cannot do so in vitro (Mackinnon 
et al., 1992). Furthermore, tP A (McGuire and Seeds, 1989) and the 72 and 92 kDa 
type IV collagenases (Mackay et al., 1993) have both been found to be associated 
with laminin in the basement membrane-like matrix from the Englebreth-Holm-
Swarm tumour. Although the effect of the presence of these enzymes on 
invasion is unknown, these findings should be borne in mind in the 
interpretation of invasion results. 
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The present study has clearly demonstrated that ras-transformation of breast 
epithelial cells confers a phenotype characterised by increased extracellular 
proteolytic activity, which is reflected in ECM degradation and in vitro invasion. 
A preliminary study has shown that MMPs are probably the rate-limiting 
proteases in this invasion assay system, which is corroborated by the increased 
activity of an MMP in the culture supernatant of transformed cells. The precise 
role of other proteases, modes of activation of proteases and the contribution of 




Prot eases and cancer 
The aggressiveness of a tumour is primarily dependent on its ability to invade 
adjacent tissue and then metastasise to distant sites. During these processes 
natural barriers such as interstitial connective tissue and BM must be degraded. 
It is now widely believed that enzymes released from the primary tumour are an 
absolute requirement for the successful development of most cases of metastatic 
disease. There is substantial evidence implicating proteases in invasion and 
metastasis, including the following: 
• proteases are involved in normal tissue destructive events, 
• levels of specific proteases correlate with metastatic potential in model 
systems, 
• inhibitors and antibodies to various proteases inhibit invasion in model 
systems, 
• transfection of cells with cDNA encoding specific proteases increases the 
metastatic activity of these cells and, 
• transfection of cells with cDNA encoding specific protease inhibitors decreases 
the metastatic activity of these cells. 
These enzymes, by virtue of the nature of the required degradative activity, must 
be active extracellularly, in close proximity to the malevolent cells. Indeed, there 
are now tangible clues as to the identity of some of these proteases, although it 
would be misrepresentative not to include the potential role of endogenous 
protease inhibitors. A protease/protease inhibitor imbalance could just as easily 
be as a result of suppression of inhibitor activity as of the induction of protease 
activity. Nevertheless, knowledge of the identity of rate-limiting proteases 
provides a potential avenue for the development of a treatment strategy aimed at 
preventing the life-threatening metastatic process. 
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Invasive cells probably have many ways of degrading ECM. They are able to 
increase proteolytic activity without necessarily increasing their own production 
and secretion of proteases, probably by cytokine-mediated recruitment of enzymes 
from adjacent stromal cells (Dan.0 et al., 1996). Optimal matrix degradation is also 
achieved by producing a variety of proteases, which can be concentrated and 
activated in the pericellular space. Thus, tumour cell proteolysis could probably 
only be controlled by targeting more than one family of proteases. 
Protease inhibitors 
For many years, prevention of cancer cell dissemination has ' been the primary 
potential target for the therapeutic use of protease inhibitors in cancer. Inhibitors 
of proteases are either physiological inhibitors naturally present in tissues, or 
non-physiological inhibitors produced by micro-organisms or chemically 
synthesised. Endogenous inhibitors appear always to be proteins, and thus have 
the advantage that they can be produced in recombinant form, their activity 
modified by site-directed mutagenesis, and their expression in cells altered by 
genetic manipulation. Moreover, as the three dimensional structure and active-
site configuration of many proteases is unveiled by X-ray crystallographic studies, 
synthetic inhibitors can be engineered to optimise potency and bioavailability. 
Unfortunately, the application of protease inhibitors to prevent cancer spread is 
limited, as most patients, at the time of cancer diagnosis, already have detectable 
or microscopic metastases. Possibly inhibitors could be used prophylactically in 
hig,h risk groups, such as with patients after resection of tumours . However, as 
understanding of the biological activity of proteases and their inhibitors has 
increased, new therapeutic roles have been suggested. The mitogenic action of 
proteinases is well known, and includes trypsin which cleaves a domain of the 
thrombin receptor resulting in G-protein-dependent cellular signalling (Bratt and 
Scott, 1995). A similar explanation has been offered for the mitogenic action of 
uP A and tP A. The lysosomal proteinases, cathepsins L and D, have also been 
associated with growth promotion (Berquin and Sloane, 1994). This may occur by 
the release of growth factors from extracellular matrices (Whitelock et al., 1996), 
or by a direct mitogenic effect as has been proposed for cathepsin D (Fusek and 
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Vetvicka, 1994). In favour of a role of cysteine proteinases in growth promotion, 
E-64-d, a membrane permeable derivative of E-64, causes arrest of epidermoid 
cancer cells in the metaphase (Shoji-Kasai et al., 1988). It is clear that protease 
inhibitors could have a significant cytostatic activity on a primary tumour and 
established metastatic lesions. Furthermore, the ability to block extracellular 
proteolytic events in tumours could stimulate encapsulation of invasive 
tumours, which would allow later resection. Tumour angiogenesis could also be 
retarded by inhibitors, as proteases are well known to playa role in this process. 
A further area of importance of protease inhibitors in cancer, is their ability to 
prevent carcinogenesis in vivo and in vitro (Kennedy, 1994). The Bowman-Birk 
soybean proteinase inhibitor, a serine proteinase inhibitor, has been shown to 
suppress carcinogenesis induced by several different carcinogens in different 
species, tissues and involving different types of tumours. The mechanism of 
action is unknown, but is thought to stop the initiating event in carcinogenesis. 
This is probably related to the ability of this inhibitor to inhibit the expression of 
the c-fos and c-myc proto-oncogenes (Kennedy, 1994). Indeed, the Bowman-Birk 
soybean proteinase inhibitor (Bratt and Scott, 1995), u1-antitrypsin, hirudin, .a 
thrombin inhibitor (DeClerck and Irnren, 1994) and batimastat (Brown, 1994), a 
metalloproteinase inhibitor, have undergone limited clinical trials as anti-
tumour drugs. 
However, it is likely that these approaches would require prolonged 
administration of inhibitors which may lead to toxicity. For example, serine 
protease inhibitors, due to their involvement in blood coagulation, would be 
difficult to administer systemically. Matrix metalloproteinases are involved with 
tissue remodelling and repair, reproduction and menstruation (Marbaix et aI., 
1996), and would be susceptible to similar problems. Therefore, targeting 
inhibitors either specifically to tumours or to specific proteinases may be 
important. This approach is most readily realised by directing antibodies to 
predominantly tumour antigens, and loadu:,.g such antibodies with a cytotoxic 
compound such as a radioisotope (Larson, 1990). A novel approach utilises 
prodrugs designed for activation by proteases (Panchal et aI., 1996). This approach 
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exploits one of the phenotypes of malignant cancer cells, the presence of cell 
surface proteases, in this case cathepsin B, to trigger activation of a pore-forming 
toxin, a mutation of a-haemolysin. a-Haemolysin causes tumour cell 
permeability leading to cell death. Another interesting approach is the use of 
drugs that prevent protease secretion instead of inhibiting protease activity. One 
such drug, estramustine (Wang and Stearns, 1988), prevents invasion thorough 
ECM barriers of a human prostatic carcinoma and mouse melanoma cell line, by 
preventing secretion of type IV collagenase due the effects of the drug on the 
microtubular system which is involved with vesicular trafficking. Other anti-
proliferative drugs and alkylating agents (5-fluoracil, cisplatin and 
L-phenylalanine mustard) were ineffective blockers of invasion. 
Inhibitory antibodies targeting cathepsin D and other proteases 
In the present study a different approach to protease inhibition has been pursued. 
By recruiting the immune system to produce antibodies against "self" antigens, 
such as proteases thought to be relevant to malignancy, these proteases should be 
neutralised with concomitant benefit (Dennison, 1989). This is done by 
challenging the immune system with a peptide derived from a sequence of a 
relevant protease. This effectively "tricks" the immune system into producing 
antibodies which should cross-react with the protease. The peptide chosen is 
usually part of a sequence important to the activity of the enzyme, thereby 
optimising the chances of inhibitio~ . of activity. Of course, although preferred, 
inhibition, is not absolutely necessary for the success of this approach. Opsonised 
protease molecules, although possibly still active, will be removed by phagocytic 
cells of the immune system. 
Cathepsin D was used, in this study, as the protease of choice as a target in breast 
cancer therapy. Much circumstantial evidence had indicated, at the outset of the 
present study, that this enzyme was involved in breast cancer dissemination 
(Rochefort, 1990; Rochefort, 1992). Currently, the contribution that cathepsin D 
makes to this process is uncertain. Overexpression of human cathepsin D in rat 
embryo cells appeared to correlate with an increased propensity to form Ii ver 
metastases when injected into athymic mice (Garcia et al., 1990). In subsequent 
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experiments cathepsin D was modified in an attempt to change the cellular 
compartment in which it is expressed (Liaudet et al., 1994). Cathepsin D 
containing the endoplasmic reticulum retention signal peptide, KDEL, at the 
C terminus was expressed in 3Y1-Ad12 cells. Cells expressing cathepsin D with 
the control KDAS peptide were highly metastatic, while the metastatic potential 
of cells expressing the KDEL cathepsin D construct was significantly reduced 
concomitant with a dramatic reduction of the processing of procathepsin D into 
mature enzyme. The present study suggests that the involvement of cathepsin D 
in metastasis requires mature (proteolytic ally active?) enzyme. In contrast, 
Johnson et al. (1993) used in vitro invasion experiments, in the presence of the 
aspartic protease inhibitor pepstatin, to show that secretion of procathepsin D by 
MCF-7 cells is not correlated with invasion. Rather than indicating that 
cathepsin D has no role in invasion, these results may emphasise the importance 
of the processing and maturation of cathepsin D. In fact, the observation that 
secreted procathepsin D levels are not correlated with invasion is in agreement 
with the data of Liaudet et al. (1994), which shows the ineffectiveness of 
intracellular unprocessed procathepsin D in promoting metastasis. It is evident 
that cathepsin D does have a major influence on metastasis in some cell lines . 
What remains in question, however, is how, and is the effect intracellular, 
extracellular or both, bearing in mind the acidic pH optimum for the enzyme? 
Until such time as these questions are addressed, it is difficult to know whether 
cathepsin D would make a good target for enzyme immunoinhibition. 
Cathepsin D may, however, possess mitogenic activity extracellularly (Fusek and 
Vetvicka, 1994), although the overall importance of this in relation to growth 
factors remains in question. The anti-peptide antibodies raised during this study 
could not be shown to inhibit the enzyme, probably as a result of the insensitivity 
of available enzyme assays for cathepsin D. Inhibition of mitogenic activity does 
not necessarily require abolishment of protease activity, but rather the 
perturbation of binding of the enzyme to a putative receptor. It would be of 
interest to ascertain whether the antipeptide antibodies against cathepsin D, 
which successfully bind cathepsin D, would have an effect on mitogenic activity. 
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Despite the lack of immediate success of the immunoinhibition approach \\-ith 
cathepsin D as a tool for cancer therapy, it is proposed that this approach could, 
nevertheless, be used to target enzymes that have been shown to be involved in 
the promotion of invasion and metastasis, such as the MMPs and uP A. 
Judiciously chosen pep tides could target anti-peptide antibodies to determinants 
on the enzyme critical for activity, while simultaneously ensuring a high degree, 
if not complete, specificity for the chosen enzyme. This would alleviate, to a 
large degree, cytotoxicity and other metabolic problems that would probably be 
associated with the prolonged administration of broad spectrum inhibitors, as has 
been previously discussed. Furthermore, the action of the immune system, being 
systemic and continued, is probably more powerful than using exogenous drugs_ 
Indeed, peptides or a cocktail of peptides specific to different proteases or even 
more than one region on the same protease, could be used as an anti-cancer 
vaccine_ 
To make such an approach feasible, an intimate knowledge of trafficking and 
behaviour of proteases in transformed cells, and the inter-relationship between 
proteases and transformation is required. The remainder of this discussion will 
address aspects of these questions in the context of the normal and ras-
transformed human breast epithelial cells used in this study. 
Ras-transformation 
It is clear, from the present studies and others, that ras-transformation of 
MCF-10A cells induces a number of changes in the proteolytic capacity of these 
cells, which is, in part, reflected in the induction of the invasive phenotype. 
Furthermore, not only is an altered status quo of proteolysis required, but an 
overall change in the disposition of the transformed cell. Transformation with 
the ras oncogene causes alterations in disparate cellular systems, including cell 
architecture (Symons, 1996), translation, transcription, the cell cycle and 
differentiation (Prendergast and Gibbs, 1993). Of particular interest in the context 
of invasion and metastasis, are the effects of ras on the cytoskeleton, as the 
cytoskeleton is integral to processes such as cell motility, the formation of 
specialised structures at the invasive front of invasive cancer cells, and the 
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expression and transport of proteolytic enzymes at times and to places which are 
inappropriate. 
Normal epithelia, as has been shown by SEM in this study, are organised into 
closely associated, largely immobile cells. During normal development, 
transitions from epithelia to fibroblastic cells or mesenchyme can occur, and 
mesenchyme can differentiate into new epithelia (Birchmeier and Birchmeier, 
1993). Such transitions are not confined to development. Malignant carcinomas 
lose their epithelial character, which results in the appearance of invasive, motile 
cells, resembling the fibroblastic phenotype and morphology, as was evident in 
ras-transformed cells in this study. It is believed that soluble mesenchymally 
derived factors lead to the dissociation and scattering of epithelial colonies. The 
factor, identified as hepatocyte growth factor or scatter factor, in addition to EGF, 
induces these effects by elevating protein tyrosine phosphorylation, by virtue of 
their tyrosine kinase receptors (Weidner et al., 1991). 
The intercellular junctions of epithelia are composed of a complex of cell surface 
and cytoskeletal elements .which stabilise cell-cell adhesion. These junctions, 
termed adherens, are specialised regions of the epithelial plasma membrane 
where transmembrane cadherin molecules located on opposing cells contact each 
other (Takeichi, 1990). The cytoplasmic portion of E-cadherin is associated with a 
group of proteins, catenins, that interact with components of the actin 
cytoskeleton (Birchmeier and Birchmeier, 1993). Together, these proteins form 
the adherens-type junctions, which encircle the apical perimeter of epithelial 
cells thereby stabilising them. 
Focal adhesions are sites of cell adhesion to ECM, and these increase in number 
with a concomitant decrease in adherens junctions during the change from 
epithelial to fibroblastic morphology (Burridge and Connell, 1983). Where in 
adherens junctions the primary cell adhesion molecule is cadherin, in focal 
adhesions it is generally an integrin. 
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Ras-transformed MCF-10AneoT cells reveal increased numbers of focal 
adhesions and altered cell-cell adhesions, which is accompanied by elevated 
levels of protein phosphotyrosine (Kinch et al. , 1995). The modification of the 
adherens-type junctions is, in most part, due to the decreased interaction between 
E-cadherin, ~-catenin and the actin cytoskeleton. Furthermore, elevated levels of 
tyrosine-phosphorylated ~-catenin and p120 Cas, sequentially similar to ~-catenin, 
are found. Instead of tyrosine-phosphorylated ~-catenin being detected in 
E-cadherin complexes, tyrosine-phosphorylated p120 Cas is found. It is suggested 
that elevated tyrosine phosphorylation of proteins such as ~-catenin and p120 Cas 
contribute to the altered junctions of the ras-transformed epithelial cells, as both 
isoforms show decreased association with the actin cytoskeleton (Kinch et al., 
1995). Indeed, herbimycin A, an inhibitor of protein tyrosine kinase activity, 
abolishes tyrosine phosphorylation of ~-catenin and restores binding to 
E-cadherin. This, in turn, restores adherens junctions and reverts the 
morphology from fibroblastic to epithelial (Kinch et al., 1995) . 
In question, however, is how ras-transformation is able to mediate these events, 
considering that ras is thought to act downstr.eam of tyrosine kinases, such as 
receptors for growth factors . It has recently been found that MCF-10AneoT cells 
display increased levels of amphiregulin, a member of the EGF family 
(Normanno et al., 1994). Amphiregulin is able to bind to and activate the EGF 
receptor, which exhibits tyrosine kinase a~tivity. It is possible, therefore, that 
amphiregulin may be acting through an autocrine mechanism to stimulate 
tyrosine phosphorylation. 
Another intriguing relationship is that between focal adhesions and, proteases 
and phosphorylated proteins localised in these structures in some transformed 
cell types. Chen (1989) has proposed a scheme to explain the alterations found to 
occur at fibroblast-ECM contact sites upon Rous sarcoma virus-induced 
transformation. In normal cells, the formation of the closest contacts with ECM, 
focal adhesions, involves end-on and lateral attachments of both microfilaments 
and ECM fibres to membrane associated proteins. Transformation induces cell 
surface changes, such as the reorganisation of microfilaments and adhesion 
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plaques, as well as the formation of invadopodia. Cells may then recruit 
membrane-bound proteases to invadopodia for local ECM degradation. This 
would allow protrusive activities for directed migration and invasion of cell into 
the surrounding ECM. The recruitment of these membrane-bound proteases 
may be regulated by tyrosine kinase activity, as a Rous sarcoma virus src gene 
product, the protein tyrosine kinase pp6Ov'src, is localised to invadopodia. Indeed, 
both the degradative and motile activities of the invadopodia were inhibited by 
genistein, an inhibitor of tyrosine-specific kinases (Mueller et al., 1992). 
Given that ras transformed breast epithelial cells elaborate elevated 
phosphotyrosine in many proteins, it would be interesting to speculate that a 
similar mechanism may be applicable. Although proteases have not yet been 
localised to invadopodiain MCF-10AneoT cells, circumstantial evidence, 
collected in this study, seems to suggest that these structures are important in 
ECM degradation by MCF-10AneoT cells. First, in non-transformed cells matrix 
degradation was localised in discrete patches predominantly at the cell periphery, 
where focal adhesions are found (Monsky and Chen, 1993). In the transformed 
cells, degradation was _evident beneath _the whole lower surface -of the cell, which 
is consistent with the localisation of invadopodia (Monsky et al., 1993). Secondly, 
the lack of demonstrable inhibition of coated ECM degradation by protease 
inhibitors suggests a close association between the cell membrane and the ECM, 
also consistent with invadopodia-ECM interaction (Chen et al., 1994). Thirdly, 
invadopodia-like structures were found beneath MCF-10AneoT cells invading 
through ECM-coated filters. Interestingly, the focal adhesion kinase is tyrosine-
specific and has, as the name suggests, been identified in focal adhesions (Hanks 
et al., 1992), structures which are more numerous in MCF-10AneoT cells (Kinch 
et al., 1995). 
Rho, one of the ras-related GTPases essential for ras-transformation, appears to be 
involved in the control of focal adhesion kinase (Symons, 1995), thereby 
providing a link between ras-transformation and tyrosine kinase activity in focal 
adhesions. An alternative link is that pp6(}:-src, a tyrosine kinase associated with 
focal adhesions in normal cells and, as the virally-derived counterpart, with 
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invadopodia of transformed cells (Mueller et al., 1992), has been shown to 
suppress N-cadherin-mediated cell-cell adhesion in virally transformed cells 
(Hamaguchi et al., 1993). At present, however, the c-sre family of kinases appears 
to act by a pathway different from that of ras (Prendergast and Gibbs, 1993). 
Focal adhesions provide not only the starting point for invadopodium 
formation, but are areas where integrins connect to the ECM and provide the 
traction that is required for migration. Ras-transformation probably affects cell 
motility through rho, which initiates the formation of filopodia, lamellipodia 
and focal adhesions at the leading edge of the cell and is implicated in adhesive 
release at the rear of the cell (Huttenlocher et al., 1995). 
Degradation and motility are both essential to invasion. Integrins participate in 
the adhesion of invadopodia during cellular invasion, and it is likely that 
integrins and membrane-associated proteases co-localise in invadopodial 
membranes (Mueller and Chen, 1991). The 72 kDa type IV collagenase interacts, 
at the surface of invasive cells, with an integrin (Brooks et al., 1996), and integrin-
ECM binding and integrin aggregation at the cell surface stimulates production of 
MMPs (Werb et al., 1989). Furthermore, membrane protein trafficking through 
the cell such as endocytosis (Glenney et al., 1991), has been associated with 
tyrosine phosphorylation. 
Ras-and its related GTPases could also be implicated in other aspects of the 
malignant phenotype. Rae has been shown to be necessary for the activation of 
arachidonic acid metabolism by EGF and insulin (Symons, 1995). Release of 
arachidonic acid and subsequent production of leucotrienes leads to rho-
dependent stress-fibre formation. It is further possible that the induction of 
leucotrienes may result in the production of 12(S)-HETE, a lipoxygenase 
metabolite of arachidonic acid, which has been proposed to modulate various 
events during tumour cell extravasation from blood circulation (Honn and Tang, 
1992). Transformation with oncogenic ras could also provide potential tumour 
angiogenesis inducers. Vascular endothelial growth factor expression is 
enhanced in v-Ha-ras transformed NIH 3T3 fibroblasts (Grugel et al., 1995), and 
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has been localised to the plasma membrane of tumour-associated microvascular 
endothelial cells (Hong et al., 1995). Vascular endothelial growth factor is one of 
the most potent inducers of angiogenesis known, and probably by acts as an 
endothelial cell mitogen. It also enhances microvascular hyperpermeability. 
Angiogenesis is vital for tumour growth and dissemination, while vascular 
hyperpermeability, characteristic of the microvasculature of tumours, may aid 
the escape of tumour cells from the mass into circulation. 
It is clear that transformation of cells with the ras oncogene has ramifications in 
many aspects of cellular control, which together gives rise to an invasive 
phenotype. Activated forms of the p21 ras gene product have been found in 20% 
of all types of human cancer, and in 90% of pancreatic and >50% of colon 
carcinomas (Gibbs, 1991). This suggests that manipulation of the ras signal 
transduction pathway may provide a useful approach to control cancer. 
The ras gene product, p21 ras, is cell membrane associated, a localisation required 
for efficient transforming activity. Preceding membrane association, p21 ras is 
.post-translationally modified. The C-terminal sequence CAAX (where C is 
cysteine, A is any aliphatic amino acid, and X is any amino acid) determines 
which lipid moiety is to be added to the protein. Farnesyltransferase mediates 
farnesylation of the cysteine residue if X is methionine or serine, while if X is 
leucine or isoleucine, a geranylgeranyl moiety is added. Normal ras proteins are 
famesylated, and this has led to the development of farnesyltransferase inhibitors 
(Gibbs, 1991). 
Farnesyltransferase inhibitors can be divided into two classes, based on the two 
substrates of the reaction. For example, L-739, 749 is a competitive inhibitor of 
the farnesyltransferase substrate, famesyl diphosphate, and suppresses the growth 
of tumours arising from ras-transformed Ratl cells in nude mice by 66% (Kohl 
et al., 1994). The second substrate is the CAAX tetrapeptide, the portion of the ras 
protein that is sufficient for interaction with the enzyme. Analogs of CAAX have 
been synthesised that are potent inhibitors of farnesyltransferase, because they are 
able to block ras farnesylation. They have been shown to modulate critical 
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aspects of ras-transformation, including tumour cell growth (Kohl et al., 1994; 
Garcia et al., 1993). A question arises as to the biological specificity of these 
compounds, as other proteins such as retinal transducin and nuclear lamin are 
also"famesylated (Gibbs, 1991). 
Achievements of this study 
Embarking on new areas of investigation often requires the development of new 
methodologies, a process which can be hampered by technical difficulties. The 
present study has made a number of methodological contributions, among which 
are PLT embedding in Lowicryl resin, the use of fluorescently-Iabeled ECM for 
cell-mediated degradation studies, in vitro cell invasion assays and scanrung 
electron microscopy of invading cells. 
To assess the role of proteolytic enzymes in invasive cells, an 
immW1ocytochemical approach was decided upon. Dr Edith Elliott (of this 
laboratory) was central to establishing the hydrated ultracryo-section technique, 
and the refinement of labeling methodologies. However, this technique 
although sensitive and rapid, suffers from several drawbacks. lt requires highly 
skilled manipulations, requires sample blocks to be permanently stored in liquid 
N 2, and limits the degree to which a sample can be orientated P!ior to sectioning, 
when special requirements are needed. In situ sample embedding in Lowicryl 
resin overcomes these problems, simplifying cell orientation when transverse 
sections are required for protease distribution studies. To this end a PLT 
embedding system was devised, which required the design of a cabinet which 
could maintain a temperature of -35°C under a N2 environment in the presence 
of ultraviolet radiation. Optimal resin polymerisation conditions required that 
the resin was not too rubbery, due to slow polymerisation, but without bubbles 
and distortions due to too rapid polymerisation. This could be attained by 
adjusting the distance between the sample and the ultraviolet radiation lamps. 
Labeling protocols also had to be adjusted from cryo-section labeling protocols, 




The use of in vitro invasion assays became central to the present study to 
morphologically characterise invasion by ras-transformed cells, and to investigate 
the proteases involved in this process. This technique appears simple, but due to 
the large number of variables involved, is temperamental. Invasion within an 
experiment can vary a great amount, probably due to factors such as stage of the 
cell cycle at which cells are used, homogeneity of the coated ECM barrier which 
appears to be dependent upon the consistency of the coating technique and batch-
batch variation of ECM. Indeed, the method has associated with it many small 
"tricks", some which were learned first hand in the laboratory of Dr Josef Giossl 
(Zentrum fiir Angewandte Genetik, Universitat fur Bodenkultur, Vienna), but 
remains somewhat tedious and intensive. However, with perseverance and 
some help this powerful assay has been developed in this laboratory to the stage 
where it can now be used routinely to address questions relating to the invasive 
phenotype. 
A number of important elements emerged from the present study, in terms of 
scientific impact. The first is the formulation of a strategy for an imm uno-
therapeutic approach to combating cancer. This involves synthesising and 
raising antibodies to peptides chosen from proteases thought to be involved in 
tumour progression. Although not necessarily a prerequisite, peptides 
generating antibodies inhibitory to protease activity, could be tested in in v i v 0 
tumour metastasis models for inhibition of metastasis. Since most of the 
methodological and conceptual pioneering work for this strategy has already been 
completed, this avenue can now be rapidly pursued. 
The second is the demonstration, by immunofluorescence and immunoelectron 
microscopy, of a more peripheral cellular distribution of low pH and protease-
containing compartments in ras-transformed breast epithelial cells compared to 
normal cells. Furthermore, cathepsins Band D were found to be cell surface 
associated. These results give rise to the question of the involvement of 
lysosomal proteinases, especially cathepsins Band D, in the metastatic phenotype 
of ras-transformed cells. 
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Thirdly, studies were undertaken to assess the matrix degrading and invasive 
capabilities of the ras-transformed cells. These cells exhibited increased 
degradation of ECM in SFM, and increased motility and disruption of ECM in 
serum-containing ' medium. Protease inhibitors were used to preliminarily 
identify the proteases involved in in vitro invasion by transformed cells. An 
inhibitor of MMPs was found to give the most prominent inhibition, and 
overexpression of an MMP in the ras-transformed cells was demonstrated by 
zymography. These results demonstrate that transformation of human breast 
epithelial cells with the ras oncogene confers characteristics of the metastatic 
phenotype. Cells are morphologically fibroblastic, appear to have lost contact 
inhibited growth, and appear to demonstrate increased motility in the presence of 
serum. They have an enhanced disposition for ECM proteolysis which, in part, 
translates into an accentuated invasive capacity. 
Remaining questions 
As is often the case when one sets out to address specific issues, the result is that 
more questions than answers are generated. These may include: 
• what is the -role of cathepsin B in tumour invasion, and is the redistribution 
of this enzyme merely an epiphenomenon . of ras-transformation? This 
question probably cannot be simply answered by in vitro invasion studies, but 
may ultimately require a more elaborate approach such as gene knockout or 
gene antisense technology. 
• similarly for cathepsin D, does the enzyme have an extracellular function In 
cancer, or does it function intracellularly by digesting phagocytosed ECM? 
• do ras-transformed breast epithelial cells elaborate invadopodia, and are 
proteolytic enzymes concentrated on the surface of these structures? This may 
be best addressed by confocal immunofluorescent microscopy of cells invading 
ECM in vitro. In confocal microscopy cells can be viewed in the z axis. This 
may help to identify proteases found at the invasive edge of invading cells. 
• what role do protein tyrosine kinases play in the invasive and proteolytic 
capacities of these cells? Tyrosine kinase-specific inhibitors could be used in 
conjunction with in vitro invasion assays and ECM degradation assays to 
address this question. 
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• what is the identity and cellular location of the MMP shown, in this study, to 
be overexpressed in the transformed cells, and what is the nature of this 
overexpression, i.e is it at the transcriptional or translational level or due to a 
reduction in endogenous inhibitor levels? This could be pursued by western 
and northern blotting and immunofluorescent microscopy with specific 
antibodies against the most likely candidates, namely the 72 kDa and 92 kDa 
type IV collagenases. 
• what is the status of endogenous MMP inhibitors, namely the TIM:Ps? This 
could be ascertained by reverse zymography. 
• what role do serine proteinases play in in vitro invasion? This question 
could be addressed with serine proteinase inhibitors and immunoinhibitory 
antibodies against uP A. 
• based on the proteinase profile of invading cells, these enzymes could, first in 
vitro and then in vivo, be targeted with anti-peptide antibodies designed to 
inhibit activity to assess the feasibility of an immunotherapeutic approach to 
cancer intervention. 
Perhaps, from a more philosophical perspective, the most significant outcome -of 
work in this field over the last decade is a collective paradigm shift giving rise to 
a new model for cancer therapy. Scientists now speak not of necessarily killing 
cancer cells, but of reining them in, perhaps rehabilitating them and tricking 
them into dying naturally. After all, no cure exists for diseases such as 
hypertension and diabetes, yet these are eminently controllable - why not cancer? 
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POSSIBLE SECONDARY FUNCTION OF SPLENIC ENDOTHELIAL STAVE 'CELLS 
REVEALED BY IMMUNOLABELLING STUDIES 
E. Elliott, P.H. Fortgens and C. Dennison 
Department of Biochemistry, University of Natal, Pietermaritzburg 
The reticular meshwork of the cord cells and the phagocytic macrophages in the sinuses I 
of the red pulp of the spleen (fig. 1), are thought to be responsible for the removal of aged 
erythrocytes from the blood. Phagocytosis, and hence removal of ageing, more rigid, 
erythrocytes may be f~voured by prolonged exposure to the high concentrations of hydrolytic 
enzymes in extracellular fluids in the sinuses!. Such exposure may lead to the observed loss 
of sialic acid residues and the exposure of galactose sugars on outer membranes of ageing I 
cells, possibly leading to phagocytosis by phagocytic cells!. In the present study, 
immunolabelling of human splenic tissue for elastase and cathepsin D has revealed that I 
regulation of the levels of extracellular hydrolytic enzymes may be achieved by pinocytosis 
by splenic endothelial stave cells. 
Human spleen (2 x 2 mm) was fixed in 8% paraformaldehyde in 0,1 M sodium cacodylate 
(pH 8,0, 20 min), cyroprotected by infusion with 2,1 M sucrose (30 min), mounted on a copper 
stub and frozen in liquid nitrogen2• Sections were double immunolabelled for elastase and 
cathepsin Dusing 3 nm and 10 nm ,protein A gold probes. Control labellings consi~ted of I 
omitting the primary antibody, substituting pre-immune or pre-adsorbed serum or IgG at the I 
same concentration as the test, and performing labellings for one antigen at a tim.e (single I 
labelling). After labelling, sections were contrasted by a "positive-negative" contrast 
procedure, using uranyl acetate and methyl cellulose2• . 
Cathepsin D has not previously been localised in neutrophils by immunocytochemistry. 
The present labelling indicates that cathepsin D is present at a concentration approximately 
ten fold lower than that of the enzyme elastase, and is co-localised with elastase in the 
azurophil granulesofneutrophils (figs 2 and 3). This concurs with biochemical findings. The 
presence of elastase and cathepsin D, in some pinocytotic vesicles of endothelial stave cells, 
adjacent to stimulated neutrophils (fig. 3), suggests the co-secretion of these enzymes by 
neutrophils and simultaneous uptake by endothelial stave cells. The smaller stave cell I 
vesicles, are probably pinocytotic vesicles (figs 2 and 3), due to their size, relatively low 
cathepsin D content (non-lysosomal nature), and, in the absence ofneutrophils, their usually 
low content of the enzyme elastase. The relatively high content of cathepsin D (usually a 
lysosomal marker enzyme) in larger stave cell vesicles, present adjacent to the pinocytotic I 
vesicles, indicate that the larger organelles are possibly lysosomes. The uptake of enzymes I 
and hence regulation of the level of enzyme concentration in extracellular fluids in the 
splenic sinuses, by pinocytosis, may be a mechanism by which endothelial cells may perform 
a secondary function, the control of levels of extracellular enzymes. 
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Fig 1. An area of red pulp from a human spleen showing endothelial stave cells (e), 
macrophages (m), basement membrane (arrows), sinuses (s) and neutrophijs (n). ' 
Fig 2. Enlargeme~t of vesicle populations seen in the section of the endothelial stave cell 
(lower right, fig. 3 below). The smaller, pinocytotic vesicles contain mainly elastase 
(3 nm gold label, small arrow), while larger vesicles (lysosomes) contain only 
cathepsin D (10 nm gold label, large arrow). 
Fig 3. Neutrophil (Nu) and adjacent endothelial stave cell (e) labelled for cathepsin D (10 
nm gold label, large arrow) and elastase (3 nm gold probe, small arrow). Note 
pinocytotic vesicles (open arrow head) and lysosomal compartments (medium arrow) 
and co-localisation of elastase and cathepsin Din azurophil granules of Nu and som~ 
pinocytotic vesicles (double arrow head). 
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Anti-peptide antibodies to cathepsins B, Land D 
and type IV collagenase 
Specific recognition and inhibition of the enzymes 
Theresa H.T. Coetzer, Edith Elliott, Philip H. Fortgens, Robert N. Pike and Clive Dennison 
DeparlllJcnl 0/ Biochcmistry, University 01 Nalal, P.o.Box 375, PielCflllaritzburg 3200, Rcpublic of South A/rica 
(Received 20 July .1990, revised received 19 September 1990, accepted 15 October 1990) 
I 
Anti-peptide antibodies were raised against synthetic pep tides selected from the sequences of human 
cathepsins Band L, porcine cathepsin D and human type IV collagenase. Sequences were selected from 
the active site clefts of the cathepsins in the expectation that these would elicit immunoinhibitory 
antibodies. In the case of type IV collagenase a sequence unique to this metalloproteinase subclass and 
I 
suitable for immunoaffinity purification, was chosen. Antibodies against the chosen cathepsin B sequence 
were able to recognize the peptide but were apparently unable to recognise the whole enzyme. Antibodies 
against the chosen cathepsin L sequence were found to recognise and inhibit the native enzyme arid were 
also able to discriminate between denatured cathepsins Land B on Western blots. Antibodies ag~inst the 
chosen cathepsin D sequence recognised native cathepsin D in a competition ELISA, but did not inhibit 
the enzyme. Native type IV collagenase was purified from human leukocytes by immunojaffinity 
purification with the corresponding anti-peptide antibodies. 
Key words: Anti-peptide antibody; Cathepsins B, L, D; Type IV collagenase; Immunoinhibition 
Introduction 
Cathepsins B, Land D and type IV collagenase 
have been implicated in tumour invasion and 
Correspondence 10: C. Dennison, Department of Biochem-
istry, University of Natal, P.O. Box 375, Pietermaritzburg 
3200, Republic of South Africa. 
Abbreviations: ABTS, 2,2'-azino-di(3-ethyl)-benzthiowline 
sulphonic acid; BSA, bovine serum albumin; ELISA, enz.yme-
linked immunosorbent assay; HRPO, horseradish peroxidase; 
KLH, keyhole limpet haemocyanin; MBS, IIJ-maleimidoben-
zoic acid N-hydroxysuccinimide ester; M" relative molecular 
weight; NHMec, 7-(4-methyl)coumarylamide; PBS, phosphate-
buffered saline; SBT!, soybean trypsin inh.ibitor; SDS-PAGE, 
sodium dodecyl sulphate polyacrylamide gel electrophoresis; 
TBS, Tris-buffered saline; Z-, benz.yloxycarbonyl. 
metastasis (Liotta et aI., 1980; Sloane and Honn, 
1984; Denhardt et aI., 1987; Spyratos et al!, 1989). 
The role of these enzymes in tumour invas~on may 
be explored using specific antibodies and in this 
context anti-peptide antibodies (Briand I et aI., 
1985) have many advantages. A sequence of ten or 
more amino acids has a very high probability of 
being unique to a particular protein and the corre-
sponding anti-peptide antibody is, therefote, also 
likely to . allow highly specific detection ' of the 
protein. Moreover, for immunocytochemis1try, for 
example, with polyclonal anti-peptide an(ibodies 
against a linear peptide sequence, there is' an in-
trinsically lower probability of the epitope(s) being 
destroyed during tissue processing, than I in the 
case of a monoclonal antibody which may be 
targeted at a single, labile, discontinuous epitope. 
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The utility of anti-peptide antibodies may be 
increased if these arc additionally able to inhibit 
enzymic activity. In the case o[ the cysteine 
cathepsins, B, Hand L, [or example, inhibiting 
anti-peptide antibodies might constitute tools with 
a unique ability to discriminate between these 
enzymes, and might thus aid in their identifica-
tion. I t has also been suggcsted (Dennison, 1989) 
that inhibiting anti-proteinase anti-peptide anti-
bodies might be therapeutically useful. 
To raise anti-peptide antibodies against the 
cathepsins, peptide sequences were selected from 
their primary sequences, mainly by consideration 
of their 3-dimensional structure, but also with 
reference to the mobility and hydrophilicity of the 
chosen peptide sequence. The cathepsins are in-
volved in an tigen processing (Takahashi et ai., 
1989; Van Noort and Van der Drift, 1989) and 
consequently may be regarded as integral parts of 
the immune system. The question thus arises as to 
whether there is any prejudice against production 
of anti-peptide antibodies to these proteinases, 
especially against their conserved sequences. As a 
basis for comparison, therefore, anti-peptide anti-
bodies were also raised against a sequence in a 
non-lysosomal proteinase, type IV collagenase, 
similar to that previously shown to successfully 
elicit anti-peptide antibodies (Hoyhtya et aI., 
1988). We report here our observations on raising 
antibodies to the selected peptides and on the 
effectiveness of the resulting antibodies in binding 
to, and inhibiting, the target enzymes. 
Materials and methods 
Reagents 
KLH and MBS were obtained from Sigma. 
Glutaraldehyde .(E.M. grade) and cyanogen 
bromide were from Merck and ABTS was from 
Boehringer Mannheim. Human liver cathepsin B 
was a gift from Dr. D. Buttle, Strangeways 
Laboratory, Cambridge, U.K. Sheeps' liver 
cathepsin L was isolated by a modification of the 
method of Pike and Dennison (1989); chromatog-
raphy on S-Sepharose, at pH 4.5, being sub-
stituted by chromatography on Sephadex G-75. 
Human spleen cathepsin L was similarly isolated, 
though in the form o[ a complex with cystatin, in 
a study to be reported elsewhere. Human kidney 
cathepsin L was purchased frol11 Novabiochem, 
U.K. Cathepsin D was isolated from human, 
porcine and bovine spleens by the method of 
1 , 
Jacobs et al. (1989). Type IV collagenase was 
purified from human leukocytes by immunoaffin-
ity chromatography with the anti-peptide ' anti-
body iml110bilised on CNBr-activated Sepharose 
4B. Z-Phe-Arg-NHMec and Z-Arg-Arg-NHMec 
were obtained from Cambridge Research Bio-
chemicals. 
Se/ec/ioll of pep/ides 
The peptide sequences from cathepsins Band L 
(Table I) were selected by considerations of 3-di-
mensional structure, based on a published struc-
ture of the analogous enzyme, papain (Wolthers et 
aI., 1970). The 3-dimensional structures I of 
cathepsins B, Hand L have been deduced, frlom 
amino acid sequence information, to be compara-
ble to that of papain (Kamphuis et aI., 1985; 
Dufour, 1988). 
The sequence selected for cathepsin B, corre-
sponds to residues 13-22 in the structure .of hu-
man liver cathepsin B (Turk et iL, 1986). This 
sequence is in an accessible position, at one end of 
I 
the substrate-binding cleft of the enzyme (Wolthers 
TADLE I 
THE PEPTIDE SEQUENCES SELECTED FOR THE GEN-
ERATION OF ANTI-PEPTIDE ANTIBODIES, FROM THE 
AMINO ACID SEQUENCES OF THE PROTEINASES IN-
DICATED 
Peptide Sequence Corresponding 
proteinase 
1313-22 Q-C-I'-T-I-K-E-I-R-D Human 
(+ C)' cathepsin D 
Ll53-165 E-P-D-C-S-S-E-D-M- !'!uman 
D-H-G-V cathepsin L 
D1I2-122 T-K-Q-P-G-L-T-F-I- Porcine 
A-A (+C) cathepsin D 
COL476-490 M-G-P-L-L-V-A-T-F- Human 
W-P-E-L-P-E collagenase IV 
• The selected pep tides were modified for synthesis by the 
substitution of the cysteine residues in pcp tides B13-22 and 
Ll53-165 with a-amino butyric acid and by the addition of an 
extra cysteine residue to the C termini of B13-22 and D112-p2 
respectively, in addition to the acetylation of the N terminus of 
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Fig. 1. Hydrophilicity and segmental mobility profiles of the selected pep tides .•• hydrophilicity. calculated according to H pp and 
Woods (1981.1983); D. segmental mobility. calculated according to Westhof el aL. (1986). Profiles indicated are (or the peptia<;s: (a) 
B13-22; (b) Ll53-165; (e) D1l2-122; and (d) COL476-490. 
et aI., 1970). It also corresponds to a peak of both 
hydrophilicity (Hopp and Woods, 1981, 1983) and 
segmental mobility (Westhof et aI., 1984) (Fig. 
1a). ' 
A sequence different from that for cathepsin B 
was chosen for cathepsin L, to potentially maxi-
mise the information gained from the experiments. 
Also, the region chosen for cathepsin B is not a 
I 
suitable choice for human cathepsin L since the 
human cathepsins Land H have analogous se-
quences in this region, with seven ,out of ·the 11 
amino acids being similar or identical (Ritonja et 
aI., 1988). There is thus an increased probability 
I 
that an I anti-peptide antibody to the sequence in 
cathepsin L may cross-react with cathepsin H. 
By contrast, the loop of amino acids containing 
the active site histidine is also accessible (Wolthers 
et aL, 1970), and there are , marked :differences in 
the seqJences in this region betweeri the diffe;ent 
cysteine cathepsins. The presence or'the active-site 
histidine in this sequence was also thought to 
increase the probability that antibodies targeting 
this region might be inhibitory. The chosen se-
quencc corresponds to residues 153-165 in the 
amino acid sequence of human c'athepkin L 
(Ritonja et aI., 1988); in papain the comp~rable 
residues are 150-161. The sequence is large~y hy-
drophilic but has a cluster of hYdrOPhO~liC re-
sidues towards its C terminus (Fig. 1b). The 
L153-165 sequence is also relatively con~erved 
between species and may be expressed as Oly-Pro-
Asx -Cys-Ser -Ser -A -Asx -B-Asp-His-G ly-V al, where 
Asx is either Asp or Asn, A is Glu or Lys an:d B is 
Met or Leu (Dufour et aL, 1987; Ishidoh et 
aL,1987; Ritonja et aL, 1988). An additionall crite-
rion in its selection, therefore, was its potenFal to 
target cathepsin L across species. I 
The sequence chosen for cathepsin D (Table I) 
was based on the 3-dimensional structure of, a 
related aspartic protein;1se, penicillinopepsin (Hsu 
et aL, 1977), since no 3-dimensional struct re of 
cathepsin D has been published. The seqhence 
corresponds to residues 112-122 in p6rcine 
cathepsin D (Faust et aL, 1985), and corres~onds 
to a loop on the rim of the substrate-bihding 
groove of penicillinopepsin. It has low . hYdro-
202 
philicity and mobility (Fig. Ic) and differs from 
• human cathepsin D in a single, conservative, sub-
stitution of leucine for isoleucine at position 117 
(Faust et aI., 1985). 
The sequence chosen for human type IV col-
lagenase (Table I) is based on the sequence of a 
CNBr-generated fragment of this enzyme from 
human melanoma A2058 cells (CB4 peptide), re-
ported by Hoyhtya et al. (1988) to elicit antibodies 
which bind only to type IV collagenase and not to 
related, secreted, extracellular matrix metallopro-
teinases, such as interstitial collagenase and 
stromelysin. The sequence corresponds to residues 
476-490 in human type IV procollagenase (Collier 
et aI., 1988) and is hydrophilic towards its C 
terminus and mobile in its centre (Fig. 1d). In the 
present study the C terminal Lys was omitted 
[rom the CB4 peptide to ensure that glutaralde-
hyde conjugation was effected exclusively through 
the N terminus, thereby exposing the hydrophilic 
part of the peptide. 
Synthesis of peptides 
The selected peptides were modified, before 
synthesis, by the substitution of the cysteine re-
sidues in pep tides B13-22 and Ll53-165 with 
a-amino butyric ' acid and by the addition of an 
extra cysteine residue to the C-termini of B13-22 
and D112-122 respectively. The resulting peptides 
were custom synthesised by Multiple Peptide Sys-
tems, San Diego, CA. 
Conjugation 
All four peptides were conjugated to KLH, 
using two different conjugation methods. Pep tides 
B13-22 and D112-122 were conjugated, through 
their C termini to KLH, using MBS (Robertson 
and Liu, 1988). The maleimide content of KLH-
MBS was determined by the addition of 
mercaptoethanol and subsequent assay for re-
duced thiol content (Kitagawa and Aikawa, 1976). 
Due to their solubility differences, it 'was neces-
sary to treat B13-22 and D112-122 differently. 
B13-22 was dissolved in 200 i mM sodium phos-
phate buffer, pH 8.0, and D112-122 was dissolved 
in the same buffer, but containing 8 M urea, 
before reduction and conjugation. The: method of 
Sedlak and Lindsay (1968) wa~ used t6 determine 
the peptide reduction. Pep tides Ll53-165 and 
COL476-490 were conjugated to KLH, through 
TABLE II 
INOCU LATION PROTOCOL 






adj ll va llt 
Complete s.c .• 
Incomplete s.c. 
Incomplete s.c. 
200 JLg conj ugated pep tide 
200 JLg conjugated peptide 
Blced ' 
200 I"g conjuga ted peptide 
Bleed 
10 I ncomplcte s.c. 
i.v. b 
I 
200 JL g conjugated peptide or' 
1 mg free pep tide 
12 Bleed 
Month ly boos ters as indicated for 10 weeks 
• s,c. = subcutaneous injection on the back at each of five si les. 
h i.v. = in travenous in marginal car vein. 
theirN termini, using 1% (v/ v) glutaraldehyde, 
according to Briand et al. (1985). A carrier p '0-
tein-to-peptide ratio of 1 : 40 was used. 
Inoculation protocol 
For each peptide two rabbits were inoculat1ed 
with peptide conjugate according to the protoc6ls 
summarized in Table II . For comparison the pto-
tocol of Richardson et al.(1985) was followed, lin 
which conjugate was replaced by free peptide from 
. I 
week 10. B13-22 was only subjected to the latter 
protoco!. 
ELI SA for Gnti-peptide antibodies 
Wells of microtitre plates (Nunc Immunopla e) 
were coated overnight at room temperature w~th . 
peptide solution in PBS, pH 7.2, at 5 ,ug/ml 
I 
(B13-22 and Ll53-165), 0.5 ,ug/ml (D112-1 ~2) 
and 1 ,ug/ ml (COL476-490). Wells were blocked 
with 0.5 % BSA in PBS for 1 h at 37°C and washbd 
3 X with 0.1% Tween 20 in PBS (PBS-Twee?'). 
Dilutions of the primary antiserum in 0.5% BS -
PBS were then added, incubated at 37°C for 2 h, 
and excess antiserum was again washed out 3 X 
with PBS-Tween. A 1/ 200 dilution of sheep anti-
rabbit IgG-horseradish peroxidase conjugate, ~n 
0.5% BSA-PBS, was added and incubated for 30 
min at 37°C. The ABTS substrate (0.05% in 150 
mM citrate-phosphate buffer, pH 5.0, containihg 
. I 
0.0015% H 20 2 ) was added and ll1cubated for p 
min. The enzyme reaction was stopped by tpe 
addition of 0.1 % NaN3 in citrate-phosphate buffer I 
and the absorbance was read at' 405 nm III a 
Bio-Tek EL307 ELISA plate reader. 
ELISA for immobilized enzyme 
The ability of anti-peptide antibodies to cross-
react with the respective whole enzymes (not nec-
essarily in their native form) was measured by 
coating the wells of microtitre plates with either 
cathepsin B or L (5 ILg/ml and l ' ILg/ml, respec-
tively, in 50 mM carbonate buffer, pH 6.0, for 3 h 
at 37°C, followed by overnight at 4°C) or cathep-
sin D (2 ILg/ml in PBS, pH 7.2, overnight at room 
temperature). The remainder of the procedure was 
as outlined above except that IgG was purified 
from serum, by the method of Polson et al. (1964), 
to remove serum inhibitors of the enzymes (e.g. 
cystatin). Species cross-reactivity of anti-peptide 
antibodies was measured using the same ELISA 
. by coating with cathepsins purified from various . 
sources: I ,I I 
, ' I 
Competition ELISA for native enzyme 
The binding of the anti-peptide antibodies to 
the native cathepsins was tested i~ an ELISA in 
which free enzyme was permitted t~ compete with 
immobilized peptide for binding to the antibody 
and thus prevent a fraction of the antibody from 
being' immobilized. Microtitre plates were coated 
with peptide as described above. Various amounts 
of antibody (between 10 and 450 ILg/ml IgG) 
were pre-incubated at 37.o C for 30 min ·with differ-
ent levels of enzyme (molar ratios lof peptide-to-
enzyme from 1: 24 to 1 : 0.5), before the incuba-
tion mixture was transferred to the peptide coated 
wells. After a further 1 h ,incubation at 37 0 C, \ the 
ELISA was developed as described above. 
I 
Removal of anti-KLH antibodies I 
KLH was coupled to cyanogen bromide 
activated Sepharose-4B according to Kohn and 
Wilchek (1982). Anti~KLH antibodies were ' re-
moved from immunoglobulin fractions, purified 
from serum according to Polson et al. (1964), by 
passage through KLH-Sepharose. 
I mmunoblotting 
The different enzymes were subjected to reduc-
ing SDS-PAGE (Laemmli, 11970), before transfer 
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to nitrocellulose membranes (Schleicher and 
Schull, BA 85,0.45 p.m) essentially as described by 
Towbin et al. (1979). Following electro-tilotting 
fo~ 16 h, the nitrocellulose membrane 1as, air 
dned for 1.5 h and non-specific binding sites were 
blocked with low-fat dried milk powder ts% in 
TBS) for 1 h. After trus, and at all subslequent 
steps, the membrane was washed (3 X 5 mi~) with 
TBS. Anti-peptide antibodies, from wrucA anti-
KLH antibodies had been removed, were tIiluted 
in 0.5% BSA-TBS and incubated with thel mem-
brane (2 h), followed by sheep anti-rabbit IgG-
HRPO conjugate (1 h). All incubation step1s were 
. d I carne out at room temperature. The HRP<D reac-
~ion was detec~e~ with 0.06% 4-chloro-1-na~hthol 
111 TBS, contalll1l1g 0.0015% H 20 2 • The reaction 
was stopped by rinsing in TBS containin~ 0.1 % 
NaN). Targeting of sheep and human cathepsin L 
by anti-Ll53-165 antibodies was also visJalised 
by protein A-gold labelling with silver am~lifica-
tion (Moeremans et al., 1984). I 
Immunoinhibition assays 
Assays for the immunoinrubition of cathepsins 
Band L were carried out usi~g the sub~ trates 
Z-Arg-Arg-NHMec and Z-Phe-Arg-NHMJc, re-
spectively, as described by Barrett and K.it~chke 
(1981). C~thepsin B (250 ~g) or cathepsin IL (25 
ng) were 1l1cubated at 30°C for 15 min witli anti-
peptide IgG, or normal rabbit IgG, at tHe ap-
propriate concentration in 400 mM Na-pho~phate 
buffer, pH 6.0, containing 1 mM EDTA and 0.1% 
Tween 20. Assays against 'the Z-Phe-Arg-NHMec 
substrate revealed that the IgG fractions h~d in-
trinsic activity against trus substrate whlch is 
. ' I 
pro?abl,Y att.nbutable to. contaminating p1asma 
kallikre1l1 which cleaves this substrate (Barrett and 
Kirschke, 1981). This activity was controll~d by 
the addition of 40 ILg/ml of SBTI, and b~ sub-
t~acting the residual activity in the antibod frac-
~lO~s .from t~e m.easured cathepsin L activity. ISBTI 
I~hibIts kallikrem but not cathepsin L. Stopped 
tIme assay~ were carried out over the range olf IgG 
con.cent:atlOns, and the inhibition by anti-p6ptide 
antIbodles was calculated in comparison td nor-
mal rab~it IgG. Immull,oinrubition of c~thep~in p 
was carned out using acid denatured hemoglobin 






Anti-peptide antibody production 
All four peptide conjugates elicited 'antibodies, 
which reacted with the corresponding immobilized 
peptides in an ~LISA (Fig. 2). In each case, it 
appears that the antibody titer peaked a t about 
8-12 weeks. No significant difference could be 
observed in titer obtained with the two inocula-
tion protocols (using conjugate throughout or 
changing to free peptide after 10 weeks) when 
tested against immobilized peptide .. Anti-B13-22 
antibodies ,showed a decline after f2 weeks, but 
this could not be attributed to changing to inocu-
lation with free peptide since anti-D1l2-122 anti-
bodies, for instance, showed a similar decline in 
ti ter after 8 weeks wi th both inoculation protocols. 
Recognition 0/ enzymes coat.ed to ELISA plates 
The anti-B13-22 antibodies, although able to 
recognize the peptide B13-22, were unable to 
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plate at pH 6.0, 7.2 or pH 9.6 (results not shown). 
By contrast, anti-L153-165 antibodies were a~le 
to recognize both human and sheep cathepsin IL, 
immobilised on ELISA plates (Fig. 3a). Th,ey , 
apparently reacted more strongly with the sheep 
than the human enzyme, from which the peptide 
sequence was selected, but this may merely be:. a 
concen tra tion phenomenon. Human splern 
cathepsin L, used in this test, was complexed Ito 
cystatin and the measured protein concentration 
was therefore not a 'true reflection of the amou~t 
of catl~epsin L present per se. Al1ti-porcihe 
cathepsin D, was able to recognize whole human, 
porcine and bovine cathepsin D enzymes, ixh-
mobilised on an ELISA plate (Fig. 4). The peptide 
antibodies, raised against D112-122 (a sequenhe 
from porcine cathepsin D), apparently reacted 
better with human than with porcine or boviAe 
cathepsins D. In the region corresponding to the 
chosen peptide, the human cathepsin D sequente 
shows a single subs titution of leucine for is6-
leucine, at position 117, compared to .the porciAe 
1.4 

















· 4 .5 · J .5 ·2. 5 ·1.5 ·0.5 
-log(Antiserum d il ution) 
I , 
Fig. 2. Progress of immunisation with peptide conjugates as determined by ELISA. Peptides were coated to microtitre plates, (al) 
ll13-22; (b) Ll53-165; (c) D112-122; and (d) COL467-490 and incubated with serial two-fold dilutions of antisera collected after 
3 (_), 8 (0). 12 (~), 30 (A) and 32 weeks (x). Normal rabbit serum con trol (0). This was followed by ine~bation with H~PO-linkef 
secondary antibody and AllTS as a chromogenic substrate, as described under materials and methods seClion. Each POlntlS the mean 
absorbance at 405 nm of duplicate samples. 
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Fig. 3. ELISA of binding of anti-peptide antibodies to whole immobilised cathepsin L. Cross-reaction of anti-L153-165 antibodies 
with human (+) and sheep (A) cathepsin L"and peptide L153-165 (.). Normal rabbit IgG (0). Experimental procedure as In Fig. 2 
and in the materials and methods section. (a) anti-L153-165 antibod ies elicited by use of conjugated peptide throug10Ul. (b) 
anti-L153-165 antibodies elicited by use of conjugated peptide followed by free peptide in the inoculation prOCedUre) 
enzyme, and it may be inferred from the results D (result not shown). Anti B13-22 antibodies, 
that the bovine enzyme must also be very similar tested against whole cathepsin B, ' did not \give a 
in this region. Due to the lack of sufficient en- positive reaction at any stage, including at 8 iWeeks, 
zyme, the anti-COL476-490 antibodies could not before the switch to free peptide. 
be tested against the collagenase IV enzyme, in an 
ELISA. ' I 
Although antibodies raised using the two dif-
ferent immunisation protocols apparently had the 
same' titer against immobilised peptide, a clear 
differerice wa:s sometimes seen in their ability to 
target. t~e immobilised whole enzyme. In the case 
of anti-Ll53-165 peptide antibodie~, for example, 
where conjugate was used throughout, the result-
ing antibodies cross-reacted with the whole pro-
tein to a much higher degree (Fig. 3). This phe-
nomenon was less marked in the case of cathepsin 
log {[IgG] (~lg/ml)} I 
Fig. 4. ELISA of binding of anti-peptide antibodies to whole 
immobilised cathepsin O. Cross-reaction of anti-0112-122 
antibodies with human (+). porcine (A) 'and bovine (A) 
cathepsin 0, and peptide 0112-122 (0). Normal rabbi t IgG 
(0). Experimental procedure as in IFig. 2 and in the matcrials 
I ' 
andmcthods section. ! 
Specificity of anti-peptide antibodies: wester\n blot 
analyses 
In Western blot analyses it was found Ithat a 
more specific reaction was obtained if anti-KLH 
antibodies were removed by passage thr~ugh a 
column containing immobilised KLH. Anti-L153-
165 antibodies targeted human cathepsin L to a 
I much higher degree than the sheep enzyme and 
protein A-gold labelling with silver amplifibation 
was required to show the targeting of isheep 
cathepsin L (Fig 5A). The specificity of tlus target-
ing was evidenced by the fact that there Jas no 
cross-reactivity with human cathepsin B. Anti-
B13-22 and D1l2-122 antibodies did not show. 
any reaction with the corresponding enzymes on a 
Western blot (result not shown). The I anti-
COL476-490 antibodies detected a Mr 66,000 
band of type IV collagenase purified from h~man 
leukocytes (Fig. 5B). 
Recognition of native enzymes 
Anti-B13-22 antibodies did not interact with 
the native form of cathepsin B when teste in a 
competition ELISA and immunoinhibition absays [ , 
all at pH 6.0 (results not shown). Cathepsin D 
inhibited the binding of anti-D1l2-122 antib'odies 
(250 p.g/ ml) to the peptide coated to mul ititer 
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Fig. 5. Targeting of cathepsin Land Iype IV collagcnase by 
:lnli-pcpliuc <lntibouics on WCSlcrn blols. A: samples ((I) 
sheep cathepsin L; (2) human cathepsin L; (3) human cathep-
sin B) were subjected to 12.5% reducing SDS-PAGE, e1ectro-
blollcd onto nitrocellulose and then incubated with anti-
KLH-purified anti-Ll53-165 IgG, before developing with (a) 
protein A-gold with silver amplification or, (b)' sheep anti-rab-
bit-HRPO conjugate as describcd in the materials and methods 
section. B: human type IV collagenase was electrophorescd on 
a 7.5% SDS-polyacrylamide gcl with reduction, transferred 10 
nitrocellulose and immunologically stained with anti-KLH-
purified anti-COL476-490 IgG as described in the materials 
. and melhods section. 
446 ,ug/ml (Fig. 6), suggesting that the antibody 
recognizes the native enzyme. Because of the rela-
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Fig. 6. Competition ELISA for native cathepsin D. The ability 
of cathepsin ,D to inhibit the binding of anti-D1l2-122 anti-
bodies to immobilised D1l2-122 was measured by pre-in-
cubating various amounts of IgG with different levels of en-
zyme befoie , transfer of the incubation mixture to peptide 
coaled plates. The ELlSA was developed as in the materials 
and mcthods section. The pcrccntage inhibition was calculated 
from control incubations containing either norlllal rabbit IgG 
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Fig. 7. Immllnoinhibition of hUlllan and shcep cathcpsin L by 
<lnti-L153-165 antibodies. Stoppcd limc assays were carried 
out using human (0) and shecp (6) cathepsin L as describ1ed in 
the materials and mcthods section and the percentage inhibi-
tion calculatcd relative to control assays with normal rhbbit 
IgG. 
this assay, cathepsin Land type IV collagenase 
were not included in these tests. Cathepsiri D 
activity was, however, not inhibited by d~ti­
D1l2-122 antibodies 111 the enzyme I·m _ 
munoinhibition test. 
An indication that anti-COL476-490 antibod-
ies bind to native type IV collageJiase is giveJ by 
their effectiveness in immunoaffinity purifica{ion 
o[ the enzyme. Type IV collagenase thus purified 
[rom human leukocytes showed gelatinolytic 'adtiv-
ity on a gelatin zymogram (result not shown). 
The L153-165 antibodies almost completely in-
hibited human cathepsin L at high antibody crn-
centrations and inhibition decreased with decreas-
ing antibody concentration until a plateau I as 
reached at low antibody concentration (Fig. 7). 
Sheep liver cathepsin L was also inhibited, but to 
I 
a lesser extent than the human enzyme. Thlese 
results therefore show that the antibody was able 
to bind to and inhibit native human and sheep 
cathepsin L. Anti-L153-165 antibodies did ~ot 
inhibit cathepsin B (results not shown), showing 
I 
the specificity of this immunoinhibition for 
cathepsin L. 
Disclission 
The failure of the anti-B13-22 peptide antibod-
ies to recognize whole human cathepsin B was Jlot 
expected since the peptide corresponds to peaks of 
both hydrophilicity and mobility in the sequence 
'.1 
of cathepsin B (Fig. 1a) and, from a consideration 
of the 3-dimensional stru~ture of papain, it would 
also appear to be on the surface of the molecule. It 
has been reported that, in general, segmental mo-
bility is an important criterion for the recognition 
of the native protein by I anti-peptide antibodies 
(Van Regenmortel, 1988a). This d,oes not appear 
to hold for the peptide B13-22, and it may be 
speculated that the presence of a disulfide bridge 
might, perhaps, constrain the peptide in a particu-
lar way in the native protein. There is thus an 
apparent conflict between the high mobility value 
assigned to Cys-14, by Westhof et ,aI. (1984) anti-
genicity prediction profile, and its participation in 
a cons~rained disulfide bridge. Comparison with 
the results obtained for the cathepsin L peptide, 
Ll53-165, may be instructive. The peptide Ll53-
165 was conjugated through its N terminus, which 
is close to the Cys residue involved in a disulfide 
bridge, and in this case antibodies to the peptide 
were able to recognize the' native protein. In both 
cases, the Cys residue was substituted by an a-
amino butyric residue, but since the peptide 
Ll53-165 elicited competent antibodies, this sub-
stitution per se is probably not the reason why the 
peptide Bl3"':22 failed to raise antibodies able to 
recognize the native enzyme. It may be interesting 
to examine the possible recognition of the native 
protein by antibodies rai.s7d against B13-22, but 
conjugated through its Cys resi9ue, or its N 
terminus. 
It must be noted that cathepsin B is generally a 
refractory enzyme with regard to antibody 'pro-
duction and normal polyclonal antibodies, raised 
against whole cathepsin B, are only able to recog-
nize denatured forms of the enzyme (Barrett, 
1973). I Monoclonal antibodies against native 
cathepsin B have been reported (Wardale et al., 
1986). Monoclonal antibodies are produced in 
vitro, however, and it may be speculated that there 
is a prejudice against production of, anti-cathepsin 
B antibodies in vivo, due to its involvement in 
antigen, processing. By contrast, . antibodies , are 
easily raised against native cathepsin L, and it is 
interesting to note, in this regard, ~hat Takahashi 
et ai. (1989) have concluded that cathepsin B, and 
not cathepsin L, might be, the major enzyme in-
volved' in antigen processing. Therefore, if human 
B13-22 shares sequence homology with its rabbit 
! I 
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counterpart, any rabbit B cell clones prqducing 
anti-Bl3-22 antibodies capable of recognis'ng na-
tive cathepsin B may be suppressed. 
The cathepsin L peptide, Ll53-165, is much 
less hydrophilic and mobile at its exp6sed C 
terminus, than at its N terminus (Fig. 1b)! but it 
was decided to conjugate it through its N t~rminus 
so as to expose the active site histidine. This 
stratagem appears to have been successful i I' elicit-
ing anti-peptide antibodies able to inhibit native 
human and sheep cathepsin L (Fig. 7). Du~ to the 
specificity of ' this inhibition, anti-Ll53-165 
peptide antibodies may be useful researcB tools, 
since the inhibitors currently in use are unkble to 
discriminate qualitatively between cathep~sins B 
and L (Kirschke et aI., 1988). Anti-Ll53-165 anti-
bodies also discriminate very specifically bf tween 
cathepsins Band L on Western blots (Fig. SA), 
which suggests that they may also be uSf ful in 
immunocytochemistry. They may also be useful as 
therapeutic agents in pathologies arising frbm ex-
cessive cathepsin L activity. I 
A criterion in the selection of the peptide 
LlS3-16S was the potential of antibodies Ito this 
peptide to target cathepsin' L across speci~s. The 
cross-reactivity between anti-L153-165 antibodies 
I 
and sheep cathepsin L, immobilised in ELISAs 
and on Western blots, and in the enzyrite im-
I 
munoinhibition assays (Fig~. 3, SA and 7), con-
firms this expectation. ' I 
Anti-D112-122 antibodies recognizetl the 
peptide as well as whole human, porcide and 
bovine cathepsin D enzymes,' immobilised oh mul-
tititer wells (Fig. 4). Nevertheless, the coloJr took 
a relatively long time (about 1 h) to developl in the 
ELISA assay against immobilised whole enzymes. 
There is evidence (Van Regenmortel, 1988b) that 
proteins become partially denatured or u?dergo 
conformational changes when adsorbed to solid 
phases, so the slow colour development ma~ indi-
cate that anti-D112-122 antibodies recognize the 
partially denatured enzymes only weakly dr that 
only a small percentage of the enzyme adbpts a 
conformation suitable for antibody bindin~. The 
antibody clearly recognizes the native fo~m of 
human cathepsin D, as evidenced from the cbmpe-
tition ELISA results (Fig. 6), but does not I target 
the fully denatured enzyme on a Western blot.' It 




tope in the native enzyme, recognized by anti-
D112-122 antibodies, may be a continuous but 
conformationally specific ep itope which is dc-
stroyed by reducing SDS-PAGE. Consideration of 
the 3-D structure of penicillinopepsin reveals a 
prominent spiral turn in the region corresponding 
to the 1;)112-122 sequence and suggests that this 
may constitute such a conformational epitope. 
Conjugation of the peptide DIl2-122, to KLH, 
was effected through its C terminus, since these 
residues appear to be less accessible in the native 
protein; I a situation which may therefore be 
mimicked in the conjugate by the presence of the 
' carrier protein. The more exposeq . N terminal 
residues proved to be antigenic and the resulting 
anti-peptide antibodies were able to bind to the 
native protein, but were not able to inhibit the 
enzyme. The paratope-epitope interaction is possi-
bly too distant to occlude the substrate binding 
cleft. 
From a methodological point of view it is of 
interest that although peptide D1l2-122 is largely 
hydrophobic, and was initially insoluble in all 
solvents tested except 8 M urea, it remained in 
solution after subsequent removal of the urea and 
could successfully elicit antibodies able to recog-
nize the native enzyme. The significance of this is 
that many enzymes apparently have hydrophobic 
binding sites. From the results obtained using 
peptide D112-122, it would appear that genera-
tion of peptide antibodies against such hydro-
phobic sites is not impossible. 
Omission of the CD4 C terminal Lys-residue 
(Hoyhtya et aI., 1988), in COL476-490, used in 
the present study, ensured glutaraldehyde conju-
gation exclusively via the N terminus. This presen-
tation, exposing the more hydrophilic C terminus, 
proved to be sufficiently immunogenic to elicit 
anti-peptide antibodies which are able to interact 
with native type IV collagenase from human 
leukocytes in immunoaffinity purification. This 
result confirms the finding of Hoyhtya et aJ. (1988) 
that the anti-CD4 antibody specifically im-
munoprecipitated native type IV collagenase from 
a mixture of metalloproteinases secreted by hu-
man melanoma cells and also recognized the dena-
tured proteinase (Mr 68,000) on Western blots 
following SDS-PAGE. Targeting of a 67,000 band 
on a Western blot by anti-CB4 antibodies was also 
I 
used by Spinucci et al. (1988) to positively idehtify 
the proteinase purified from c-Ha-ras oncogene 
transformed mouse NIH 3T3 fibroblasts. 10' the 
I , 
present s tudy anti COL476-490 antibodies irni-
larly recognized the denatured Mr 66,000 pro-
teinase [rom human leukocytes (Fig. SB). ~rom 
these results it may be inferred that these f nti-
peptide an tibodies recognize native and denatured 
I 
type IV collagenase from both normal (leukocyte) 
and malignant (melanoma) human sources as Iwell 
as oncogene transformed mouse NIH 3T3 fibro-
blasts. , I ' 
From this study it is clear that there is as yet no 
reliable basis on which to predict which pep (ides 
will sucessfully elicit antibodies capable of r'ebog-
ni si ng the ;1ative target protein. Consideratioll of 
the 3-D st ructure, when this is available, app1ears 
to be the most promising approach and was ~uc­
cessful wilh cathepsin L, though nol with cathep-
si n B. It will be inleresting, 'in .future, to fur;ther 
explore the structures of cathepsins Band D with 
a view to finding inhibitory peptide antibodies to 
these proteinases. 
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Paraformaldehyde (PFA) fixation was optimized to facilitate 
the immobilization and labeling of multiple granule anti-
gens, using short fixation regimens and cryoultramicrotomy 
of unembedded neutrophils (PMNs). In the optimal pro-
tocol, extraction of azurophil ' granule antigens (especially 
of the ~bundant elastase) was obviated by manipulating the 
polymeric state of PFA, and hence its rate of cross-linking, 
by altering its concentration and pH in a1multistep process. 
Primary fixation conditions used (4% PFA, pH 8.0, 5 min) 
favor fixative penetration and rapid cross-linking. Stable cross-
linking of the. antigen was achieved in a secondary fixa-
I 
Introduction 
The invasive movement of activated polymorphonuclear leukocytes 
(PMNs) and monocyte/macrophages through barrier membranes 
is believed to be facilitated by hydrolytic enzymes, including pro-
teases (Faurie et aI., 1987;Johnson and Varani, 1981). Initially our 
investigations, aimed at identifying and defining the origin of 
such proteas~s, were frustrated by extraction and translocation of 
azurophil granules and their antigens, reportedly a common prob-
lem in immunolabeling studies ofPMNs (Hibbs and Bainton, 1989; 
Damiano et aI., 1986; Cramer et aI., 1985; Ganz et aI., 1985). This 
problem prompted the present investigation oflJaraformaldehyde 
(PF-A) fixation regimens. 
In this study, brief fixation with PFA, one of the least cross-linking 
(Tokuyasu, 1986) and denaturing fixatives (Larsson, 1988; Tokuyasu , 
1986), was used to preserve maximal antigenicity and allow the de-
tection of low levels of antigens in some granule populations. Com-
plete immobilization of all antigens and the preservation of the 
integrity of all granule types is also required, however. To achieve 
this, the concentration (Griffiths, 1993; Walker, 1964) and pH of 
I Supported by grants from the University of Natal Research Fund and 
the Foundation for Research Development. 
1 Correspondence to: Dr. E. Elliott, Dept. of Biochemistry, University 
of Natal, Pvc' Bag X01, Scottsville, Pietermaritzburg 3209 South Africa. 
tion step using conditions that favor larger, more cross-' . g 
polymeric forms of PFA (8% PFA, pH 7.2, 15 mid). Im-
mobilization of granule antigens was enhanced by fl6tation 
of cut sections on fixative (8% PFA, pH 8.0) before I~beling 
and by using post-labeling fixation with 1% glutaraldehyde. 
The optimized protocol facilitated immobilization ahd im-
munolabeling of elastase, myeloperoxidase, lactoferrih, and 
cathepsin D in highly hydrated, unembedded PMNs. (J 
HistochclIl Cytochcm 43:1019-1025, 1995) . I· 
KEY WORDS: Paraformaldehyde fixation; Cryoultramicrotomy; 
Elastase; Cathepsin D; Mycloperoxidase; Lactofcrrin; Neut lophils. 
the fixative (Griffiths, 1993; Bourgnon and CharitOn, 1987; Eldred 
et aI., 1983; Berod et aI., 1981) were varied to alter fhe degree of 
penetration and cross-linking, and hence optimal conditions were 
found . 
Infiltration of the fixative through the newly cut Side of the sec-
tion, by flotation of the section on fixative before lab~ling, was also 
found to improve the immobilization of granule antigens and pres- . 
ervation of granule morphology. 
Materials and Methods 
Different preparations of stock PFA were used in repeat exp,eriments, and 
cell isolation, processing, and immunolabeling procedures Jere performed 
at least five times for each protocol described. I 
Separation ofPMNs. Blood drawn from healthy volunteers was collected 
into lithium-heparin tubes and the PMN fraction .was se~arated within 
1 hr by the Pcrcoll (Pharmacia; Uppsala, Sweden) gradient ciethod of Has-
lett et al. (1985). Cells were washed (400 x g, 10 min, 2p,·C) with 2% 
bovine serum albumin (BSA, fraction V; Boehringer, Mannheim, Germany) 
in PBS, pH 7.2 (Slot and Geuze, 1985), and prepared for spe~ ificity testing 
of antisera by Western blotting, or were fixed for immunblabcling. 
Preparation of Paraformaldchydc Fixative. Paraformald1ehyde powder 
(BDH; Poole, UK) (16 g) was added to distilled water (100 ful), heated to . 
GO·C. and cleared by the dropwise addition of 1 M NaOH (Hayat, 1981). 
The stock solution was diluted with concentrated buffer sol ~ tion, titrated 
to the requlfed pH, diluted to yield the required strength .yf both buffer 
(0.2 M HEPES) and fixative, and stored frozen until requ red. 
1020 
T:lblc 1. Protocols tCI/ed lor F\'iltiol/ oillciltro/)hds" 
~roto(ol Prilllacy li.'(:uion condirions Sc(ol1dar), fix;Hion condirions 
110.
/1 pll 'VuPFA Min I'll %PFA Min 
I 7.2 ~ 30 
2 0.0 30 1-
3 7.2 H }O 
~ 8.0 H 30 
5 7.2 4 7.2 8 15 
6 8.0 4 7.2 8 15 
7.2 ~ 8.0 8 15 
8 8.0 4 8.0 8 15 
, In eyery case. pOSl.l.beling fix"ion wilh 1% glul>r,ldeh),de was addilion,lly 
ustd 10 stabilize an ligen-antibody-label complexes. 
" If nOlation fixation was addition,ll), used. Ihis is indicated in the text by, 
" + .. afler (he prolOcoi number and means flot;uion on dlC highest conccmr;uion 
of PFiI used. al the pH at which Ihe primary fix>lion was carried out. 
Fixation and Processing for Electron Microscopy. PMN pellets were fixed 
at room temperature in either 4 % or 8% PFA (30 min) or in 4 % PFA (5 
min) followed by 8% PFA (15 min), at pH 7.2 or pH 8.0. This gave eight 
combinations. denoted protocols I to 8 (Table I). Wheri reference to con· 
centration and pH is made in the text, the dboye values' will be described 
as either "high" or "low" concentration or pH. 
After fixation the pellet was infiltrated with 2.1 M sucrose in PBS, fro· 
zen in liquid nitrogen, and sectioned with a tungsten·coated (RobertS, 1975) 
glass knife (Morewood ct al.. 1992) in an RMC·MT.6000XL ultramicro· 
come fitted with a CR·2000 cryoattachmenc.' Sections (100-150 nm thick) 
were retrieved on 2.3 M sucrose (Tokuyasu, 1986; Griffiths et aI., 1983), 
placed on a 100·mesh hexagonal, [ormvar. and carbon·coated grid, and 
floated out onto chilled PBS or fixative for 30 min. This procedure of ex· 
tending fixation by flotation o[ the section ontO fixative will be termed 
"flotation fixation" (sec T.1ble I,Fooenote b). 
Antibodies. The specificity of all antibodies was assessed by Western 
blotting of crude white·cell homogenates and pure antigen. These were 
probed with immune and pre·immune sera/antibodies at the same level 
as lIsed in the electron microscopy immunolabeling procedure. 
The rabbit anti·human cathepsin D antibody, raised against human 
spleen cathepsin D purified by the method of Jacobs et al. (1989), was tested 
against homogenates of human PMNs ("'80 ~g) and purified spleen frac · 
.".-.. : 
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tlons (5 ~g). separated by SDS·PAGE on 12.5 % gels, and electro blotted 
as described preyiously (Coetzer et aI., 1991). The blot was Iprobed with 
the ami·cathepsin D antiserum (dilllted I:~O in 5 % fetal calf serum (Gibco; 
Paisley. UK) in PBS]. ;\f1d labeling located with a sheep anti.r~bbit peroxi. 
dase label and an H101 /4.chloro·l·naphthol derection system \Hudson and 
l-la)', 1980). . I 
The rabbit ami·hllman leukocyte elastase (HLE) antibody,' obtained from 
Athens Research and Technology (Athens, GA), was similarl ~rcsted with 
Western blotting of HLE (3 ~g), isolated as described by Baugh and Travis 
(1976), and a hllman PMN homogenate ("'80 ~g). Binding lof the anti· 
HUj: antibody (88 ~g/ml) was detected with a biotinylated goal anti·rabbit 
and stfeptavidin-biotin-peroxidase system (Amersham; Poole. UK). 
The anti·hllman catl~epsin D antiserum located the 30 KD heavy chain 
of the two·chain form of human cathepsin D (Figure lA, a) ahd the anti· 
HLE antibody located the characteristic closely associated subunib of elastase 
(M'. 27.000 and 29,000) in the puri.fied fractions (Figure lB, la). Neither 
antibody located equivalent bands 111 the crude PMN homogenate, even 
when crude extracts were overloaded ("'80 ~g of total proteiri) .and over-
developed to revcal any reactivity against proteins present at vdry low con-
(Clltfations. Control blots probed with pre·immune rabbit seLm or IgG 
showed no (;Hgeling of the purified antigen or the crude exJracc. 
The ami.cathepsin D antiserum, pre.adsorbed with I nmoillmi of hu· 
man cathepsin D, showed almost tOtal extinction of labeling ~Figure lA, 
b). 13~callse of limits to the amounts of HLE antigen avaiiable' ladsorption 
controls were performed only in the immunolabeling procedures. All con· 
trol Iabelings confirmed the specificity of the antibody and Jdbeling sys· 
tems used and indicated that the Western blotting systems us2d were too 
insensitive to detect the target antigens in crude PMN fractidns. 
Antibodies used to confirm labeling results. included :i chicken anti· 
porcine cathepsin D antibody raised and characterized as described, by Sameni 
et al. (in press) and a sheep anti·HLE antibody from Serotec (Oxford, UK). 
Other 'lntibodies used included a rabbit anti·human lactoferrirl IgG from 
Sigma Chemical (St Louis, MO) and a rabbit anti-human mYeloberoxidase 
IgG from Dakopatts (Glostfup, Denmark). I. , 
Immunogold Labeling for Electron Microscopy. Gold labeling was per· 
formed with 5·nm protein A-gold labels purchased from JanJsen Phar-
maceutica (Beerse, Belgium) or produced according to the l1'\et~od of Slot 
and Geuze (1985). Antibodies and gold labels were diluted in lglobulin. 
free bovine serum albumir; (Sigma) or 5% fetal calf serum (Gibco) in PBS. 
Sections were blocked by incubation in 0.02 M glycine (10 rin) and 
by 2% 13S1\ or 5% fetal calf serum in PBS (15-30 min). Incubation (I hr) 








Figure 1. Western blot for (A) Ithe anti· 
human cathepsin 0 antibody and (6) the 
anti·human leucocyte elastase (~nti.HLE) 
antibody. (A) Purified human sPleep cathep· 
sin 'O probed with the anti·cathepsin 0 anti· 
body (a), pre·adsorbed anti.cathep:sin 0 (b), 
and pre·immune serum (c). (6) Purified HLE 
probed with the anti·HLE antibody (a) and 
pre·immune serum (b). I 
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(0.36 ~tg in 10 ~d), rabbit anti-human mycloperoxidase (0.5 ~g in 10 ~I), 
,or rabbit anti-cathepsin D antiserum (1:40) was followed by washing in PBS 
(20 min total), and incubation with a 5-nm protein A-gold probe (10 Ill, 
AllO 0.1-0.5). Post-labeling fixation to stabilize the binding of the final 
antigen-antibody-gold label complexes was effected, with 1% glutaralde-
hyde in PBS (5 min) (Tokuyasu, 1986). 
Double labeling was performed as described by Slot et al. (1991). Sec-
tions were blocked, incubated in primary antibody and 5-nm protein A-gold 
probe as described above, and mated with 1% glutaraldehyde in PBS (5 
min) to eliminate reactivity between the primary antibody and the second-
ary (10-nm) pr~tcin A-gold probe. Residual reactive fixative groups were 
quenched by blocking as before and sections were incubated in the second-
ary antibody and gold label (10 nm) as described above. Sections were re-fixed 
with 1% glutaraldehyde, washed, and contrasted in acidic uranyl acetatel 
methyl cellulose (Tokuyasu, 1986), and ~iewed 'in aJeol 100CX transmis-
sion elewo~ ~icroscope at 80 kY. 
"Controls included the substitution of pre-immune IgG or ,serum for 
antibodies usee! in the labeling scheme, ' omitting ·the primary antibody 
and, in the case of the anti-HLE antibody, labeling was also performed with 
pre-adsorbed a~tibody (88 Ilg/ml antibo'dy adsorbed with 1-5 nmolcs of 
I 
HLE). , I, j 
In double-labeling procedures, the adequacy of quenching of reactiv-
ity between the 'primary antibody and the secondary gold probe was estab-
lished by performing the labeling procedure but omitting the secondary 
antibody. Labeling was also validated by \varying the10rder in which anti-
gens were labeled. I . 
Cathepsin D and elastase labeling resul,ts were confirmed using a chicken 
anti-porcine cathepsin D and a sheep aini-HLE antibody, respectively. , I I . I 
I 
Results I , I 
, I I 
In assessing different fixation regimens, their ~uccess in meeting 
the following criteria were considered': (a) preservation of the anti-
I 
gcnicity of multiple granule antigens; (b) preservation of granule 
ultrastructure (especially of elastase-containing azurophil granules); 
and (c) immobilization of target antigens, especially HLE. All pro-
tocols mentioned refer to those outlined in Table L 
Representative micrographs for presentation were selected from 
at least 10 micrographs of random sections of PMNs, each fixed 
with one of the different fixation regimes. 
" i I I 
Pr'eservati~~ of Antigenicity a~d Verification of 
Labeling Specificity !,' I ' 
In all PFA fixation protocols, high-density immunolabeling was 
observed for all antigens tested except where ehensive extraction 
of antigen occurred (e.g., with prot?coll; Figur~ 2a) orwher~ anti-
gen was over fixed (e.g., using Protqcol 8; results not shown). 
The labeling system used was judged to be free of nonspecific 
interactions, '~ substitution of pre-immune IgG at the same level 
of antibody usrd or omission of the priIl"!ary antibody gave low back-
ground counts (6-10 gold probes/cell section, dssessed on a mini-
mum of 10 cells for each fixation protocol). I~ double-labeling 
regimens, only five large (10 nm) gold labels werCfseen to be nonspe-
cifically bound per cell (averaged over 10 cells), 'indicating the sig-
nificance of the double labeling shown in Figure 3b. 
The labeling specificity of the anti-HLE antibody used was con-
firmed by adsorption of the antibody with 1 nmole or 5 nmoles 
of HLE, which resulted in a reduction in immunolabeling for elastase 
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(by 75 % or 99%, respectively), a~d by similar granule labeling pat-
terns seen using an unadsorbed antibody raised in sheep (results 
not shown). The anti-human cathepsin D antibody I ~beling speci-
ficity was confirmed usi?g a chicken anti-po.rcine cat~epsi? D an~i­
body that crossreacts With the human antigen'(Samenl ,et aI., 10 
press) (results n'ot shown) and by adsorption control~ on Western 
blots. The specificity of the antibodies and labcling!systems used 
in double and single labelings was thus confirmed b all .controls. 
I
I 
Effect of PFA Concentration and pH on 
Ultrastructure and Antigen Immobilization 
The apparent shape of granules may be influenced by the plane 
of sectioning but, on the basis of morphology and elastase con-
tent, three types of azurophil granules were distinguishable: ap-
proximately spherical, electron-dense, elastase-conra+ng,granules , 
of "'350 nm diameter; elongated, dumbbell-shapdl granules of 
approximately 200 x 60p nm; and smaller, less electron-dense 
spherical granules 100-200 nm in diameter. These \morphologi-, 
cally distinct "azurophil" g~anule types resemble those described 
by Pryzwansky and Breton-Gorius (1985). All three krariule types 
were best preserved and the elastase antigen best immobilized by 
Protocol 6 +, using a combination of rapid fixation wlth a low con-
centration ofPFA at a high pH, followed by longer fi~ation at high 
concentration and at a low pH, and flotation fixatiob (Figure 3c). 
All protocols using fixation only at a low pH gave p~or immobili-
zation of the elastase antigen (Protocois I, 3, and 1;Figures 2a, 
2c, and 2e, respectively). High pH fixation for mory than 5 min. 
(Protocol 2 or 4, results not shown; Figure 2d, arrow?eads) gener-
ally gave poor preservation of small and dumbbell-shaped gran- · 
ules (and hence poor antigen immobilization) but bletter granule 
preservation (and hence superior antigen immobilizatio~) in larger 
azurophil granules than equivalent low pH fixation Iprotocols. In 
the high pH double-fixation Protocol 8, however, all granules were 
well preserved but labeling density was extremely 10w,I pos~ibly due 
to overfixation of membranes resulting in limited anti~ody penetra-
tion (results not shown). I 
Lactoferrin-containing specific granules were adequately pre-
served and labeled in all fixation regimens used in t~is st~dy. Sin-
gle labeling for myeloperoxidase- (Figure 3a, inset) ~nd ~athepsin 
D-containing granules (Figure 3 b) was similar to that' observed for ' . 
elastase. Cathepsin D-Iabeled granules appeared to deef1ease in num-
ber from "'8 granules/section in less mature PMNs (assessed on 
sections of 10 cells showing ·two nuclear lobes or less), to 2-4 gran-
ules/section in more mature cells (with two or more nuclear lobes). 
I 
T~ese re~ults, however, c?nfirm the observatio~s of 'shikawa and 
Clmasonl (1977), Barabasl and Nassberger (1994), Levy' et aI. (1989), 
"d R,id " ,,- (1986) 'h" "">op,i, D "'"" i, lMNi' 
II 
II 
Flotation Fixation and Post-immunolabelzrg :!. 
Fixation I' I 
Where the initial fixation was relatively weak, e.g., P1roto'cols 1, 5, 
and 6, immobilization of the elastase antigen was imp,roved by pre-
labeling flotation fixation (compare Fi~ures 2a and ~b, Figures 2e 
and 2f, and Figures 3a and 3c, respectively). The preservation of 
dumbbdl-,h'p,d go,"ul" ... d ... ,ig<n immUbili"ti'l in Fro,ocu. 
Figure 2. CrYOultra~icrotomy se~ ';;~'ns' of unembedded PMNs labeled for HLE after fixation (for 30 min unless o'therwise 'indicated) with (a) 4% PFA, JH 7.2, (b) 
4% PFA, pH 7.2, followed by pre-labeling lateral fixation, (e) 8% PFA, pH 7.2, (d) 8% PFA pH 8.0, (e) 4% followed by 8% PFA, pH 7.2 (for 5 and 15 min, respectively), 
and (f) 4% followed by 8% PFA pH 7.2 (for 5 and 15 n:in, respectively) and lat.eral fixation of the section. Small arrowheads indicate extracted granyfes (a) or 
translocalion of elastase due to Inadequate membrane fixation (d). Large arrows indicate reasonably well-preserved dumbbell-shaped or large elastase-containing 
granules (c-f). Original magnif ications: a x 33,000; b-f x 50,000. Bars = 0.2 ~m . 
I 
I 1 
Figure 3. (a-c) Cryoullramicrotomy sections of unembedded PMNs fixed with 4% PFA, pH B.O (5 min) followed by B% PFA, pH 7.2 (15 min), I with and (a,b) 
without flotation fixation prior to labeling. (a) Large azurophil granules labeled for elastase (5·nm gold probe) appear shrunken, partially (arrows), and 
show antigen translocation. Inset shows similar extraction of myeloperoxidase. (b) Large (possibly azurophil) granules labeled for cathepsin I gold probe) 
(large arrow) show partial extraction, whereas smaller cathepsin D·labeled granules and specitic granules labeled for lactoferrin (10·nm gold (arrowheads) 
remain unextracted. (c) Flotation tixation allows most precise immobilization ot elastase, even in swollen, yet unextracted granules (large arrow). Inset shows 
labeling of specific granules for lactoferrin. Original magnifications: a,c x 26,000; b x 50,000; Insets x 33,000. Bars = 0.25 Ilm. 
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6 + and 5 +, however, was enhanced by flotation fixation (compare 
Figu res 3a and 3c and Figl'.fes 2e and 2f, respectively). 
Discussion 
In this study, conditions required for optimal fixation of HLE-
containing granules appeared to vary among the three types of such 
granules. This may reflect differences i~ membrane composition 
and hence in reactivity with the PFA polymers, which vary in length 
and reactivity at the different concentrations and pHs used. 
Solid PFA consists largely of polymeric species that dissolve in 
alkaline solutions by slowly depolymerizing to smaller, more pen-
etrating polymers but which arc less able 'to cross-link residues some 
distance apart (Larsson, 1988; Walker, 1964). Increasing dilution 
has a similar effect on polymer size. Above a 2% (\v/v) concentra-
tion the degree of polymerization of PFA increases progressively 
and the fixative molecules become less penetrating, more able to 
cross-link distant residues (Walker, 1964). 
At low concentrations, PFA reacts mainly and most rapidly with 
deprotonated primary or secondary amines to form hydroxymethy-
lene bridges (Kallen andJencks, 1966), and hence should react best 
at higher pHs. A~ higher concentrations, however, PFA reacts with 
both protonated and unprotonated amines (Kallen and Jencks, 
1966), hence being more reactive over a wider pH range, including 
physiological pH, and presumably produces a more extensive cross-
linking of reactive residues owing to the increased polymer lengths. 
In this study, as predicted, fixation was facilitated by the in-
creased length of PFA polymers and the greater reactivity of PFA 
at high concentrations. High concentrations ofPFA alone, at phys-
iological pH, however, appear not to be adequate to prevent the 
translocation of azurophil antigens, possibly indicating that fixa-
tion is too slow and reversible at this pH, 'or that polymers arc too 
large to penetrate tissues quickly to effect fixation. 
Fixation with a low concentratiol:J ofPFA, to ensure ~rapid penetra-
tion of fixative, followed by a high concenuation ofPFA, to ensure 
adequa~e tissue cross-linkage (a 5 + 15-min fixation procedure), 
was found to give better containment of elastase and slightly bet- . 
ter ultrastructural preservation of granules than any single concen -
tration of fixative (applied for 30 min). PFA's affin;ity for protq-
nated amines is,however, two to three orders of magnitude less 
than for the non-protonated amine (Kallen andJencks, 1966). Fix-
ation with a low c~ncentration of PFA at high pH was therefore 
also attempted. Under these conditions the fixative was more 
penetrating but fixation was more rapid and effective than at higher 
concentrations and lower pH. This gave the best antigen immobili-
zation in large but not in small azurophil granules. . 
To prevent premature fixation of the outer membranes (e.g., 
of the smaller granules) impeding fixative penetration, the pH shift 
method of Berod et a!. (1981) and Eldred et a!. (1983) has been 
proposed. This uses fixation with low PFA at a low
l 
pH to allow 
rapid penetration, followed by fixation with the same low concen: 
tration of PFAbut ,at a high pH to facilitate rapid cross-linkage 
and immobilization of the antigen. In the present study, however, 
a reverse pH shift strategy, a high to low pH shift, combined with 
an increase in PFA concentration, was most successful in immobiliz-
ing azurophil antig~ns in all granule types: provided the high pH 
fixation period was kept brief. In this case, the low' penetration, 
I 
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caused by increased efficiency of fixation of the azurophil granule 
membranes at the higher pH was possibly partially offset by the 
shorr period of fixation and the low concentration of PFC and the 
decreased size of the polymers present at the higher pill used for 
initial fixation. I. ' 
Lastly, the results of flotation of the newly cut section10llto fixa-
tive suggest that this is an effective way of additionally fixing PMN 
granule contents and preserving the ultrastructure of cer~ain gran-
ules and stabilizing c),toskelctal elements responsible for 'the main-
taining of granule shape. I 
Initially, PMN granules were classified into two gro~ps, larger 
"primary" or "azurophil," peroxidase-positive, hydrolytic enzyme-
containing granules, and smaller "secondary" (specific) Idctoferrin-
containing granules (Bretz and Baggiolini, 1974). Subpo~ulations 
of azurophil granules, differing in levels of myeloperoxidase and 
elastase (Damiano et a!., 1988; Przywansky and Breto I -Gorius, 
1985), and specific granules, varying in their gclatinase content 
(Hibbs and Baimon, 1989), have since been discovered. ~mmuno­
cytochemical classificat,ion of granules is difficult, however, If granule 
antigens arc extracted. The optimal fixation regimen described here 
(4% PFA at pH 8.0,5 min, followed by 8% PFA, pH 7.2 15 min, 
followed by flotation fixation) preserves maximal antig~nicity of 
a wide range ofPMN antigens, facilitating the simultanedus label-
ing of myeloperoxidase, lacroferrin, elastase, and catheps'ih D. An-
tigens arc immobilized without compromising antibody Ipenetra-
tion and the structure of three azurophil granules is pre~ervdd; hence 
opening the wa), for multiple simultaneous labeling sthdies on 
PMNs and accurate classification of granule subtypes. 
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Cathepsin Band D are Localized at the Surface 
of Human Breast Cancer Cells* 
, 
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Bonnie F. SLOANE' ' 
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Alterations in trafficking of cathepsins Band D . transfected cells. By immunofluorescence sta~ning, 
have been reported in human and animal tumors. cathepsin B can be localized on the outer surface ~f 
In MCF-IO human breast epithelial cells, altered the cells. Similar patterns of periPheral \intracel-
trafficking of cathepsin B occurs during their pro- lular and surface staining for cathepsin B an! seen 
gression from a preneoplastic to neoplastic state. in the human breast carcinoma lines MCF-7 and 
We now show that this is also the case for altered BT20. We suggest that the altered traffiFking of 
trafficking of cathepsin D:I Nevertheless, the two cathepsins Band D may be of functional signifi-
cathepsins are not necessarily trafficked to the cance in malignant progression of hum~n breast 
same vesicles. Perinuclear vesicles of immortal epithelial cells. Translocation of vesicles !contain-
MCF-IOA cells label for both cathepsins Band D, ing catl:epsins Band D to,:ard. the cell Pjeriphery 
yet the peripheral vesicles found in ras-transfected . occurs 111 human breast eplthelIal cells tHat are at 
MCF-IOAneoT cells label for cathepsin B, cathep- the point of transition between the pre-nkoplastic 
sin D <;>r, both enzymes. Studies at Ithe electron mi- and neoplastic state and remains part of t~e malig-
croscopic level confirm these findings and show in nant phenotype of breast carcinoma cells. (Patho-
addition surface labeling for both enzymes in the logy Oncology Research Vol I, Nol, 43-53, 1995~ 





Expression, redistribution andlor secretioh of the lysosomal 
proteases cathepsins B, D and L have ' been reported to 
parallel malignant progression.32 Redistribution of cathep-
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sin B has been observed in human colon carcinomas,5 
prostate carcinomas31 and gliomas;27 ' this red~stribution 
parallels increased malignancy. and/or 'decreas~d patient I' 
survival. Recently, the distribution of cathepsin D in ph a-
golysosomcs has been suggested to be a progndstic indi-
cator for human breast carcinoma.6•3o In macrophages and 
I 
osteoclasts, i.e., cells that like ' tumqr cells particip~te in 
degradative or invasive processes, lysosomes l uddergo 
translocation from the perinuclear region to the cell peri-
phery. This redistribution is induced by cytoskeletal alte-
rations associated with membrane ruffling. Lhosomes 
redistribute' toward the ruffling membrane of lactivated 
osteoclasts and lysosomal enzymes are secreted.3 , 
The study of breast cancer progression has been facili- .1 I 
tated by the development of the diploid MCF- ~O human 
breast epithelial cell lines. These cells were obtainbd duri~g 
d 
. I 
re uctlOn mammoplasty from a patient with fibrocystic 
breast disease and underwent spontaneous immohalization 
in culture.35 Transfection of immortal MCF-lOA t ells with 
mutated ras
4 
results in cells (neoT) that have S11 e of the 
c~aracteristics of atypical breast epithelial stem ceiis. In I i 
vitro they are capable of indefinite proliferation d invade ' 
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Figllre 1. IlIlll1UnOCljtochemical localization of illtmcellular 
cathepsin D in parental lOA cells (A) and their neoT cOlllltapart 
transfected with mutated ms (B). The primary antibody lUns 
mOllse anti-hllman cathepsin D IgG1. Catliepsill D staining ill 
the lOA cells (A) was concentrated in the perirwe/ear regioll, 
whereas in the ras-transfeeted cells (B) the distribution of cathep-
sill D stainillg was 1710re peripheral. The secondary anli/lOdy wns 
Texas red-colljugated dOllkey allti-mouse IgG. The staining for 
cathepsin 0 has been repeated tell tillles 10 dnle witiz cOlllpnmble 
results. Only a weak background fluorescence was observed ill 
controls ill which mouse or rabbit pre-il111ml11e IgG replaced the 
primanj antibodies (1I0t illustrated) . Bars, 10 /1111. 
through Matrigel25 and ill vivo they form persistcnt palpable 
nodules that exhibit three pathologicentities: 1) benign ductal 
aggregates, sometimes with mild hyperplastic changes; 2) 
atypical hypcrplastic lesions; and 3) carcinoma in sitll and 
invasivc carcinomas.2o ras-transfection of the MCF-IO lines 
rcsults in altered trafficking of cathepsin B,)) such thdt this 
enzyme is localized in the cell periphery and on th6 cell 
I . 
surface. As ras-transfection of breast cancer cells increases 
thcir invasivcncss ' and metastatic ability, ') the observations 
on altered trafficking of cathepsin B in ras-transfected 
MCF-!o cells may be of functional significance in the early 
. I 
progressIon of breast cancer. In the present study, we deter-
mined whether transfection of MCF- J 0 human breast\ epi-
thelial cells with the c-Ha-ras oncogene affects the traffick-
ing of cathepsin D as well as that of cathepsin B, whJther 
cathepsins Band D are trafficked to the same vesicles I and 
whether altered trafficking of these enzymes also is charac-
teristic of fully malignant human breast carcinoma cellliries. 
Materials alld Methods 
Materials 
Saponin, Dulbccco's modified Eagle's medium and 
Ham's F-12 nutrient mixture, minimal essential medi~m, 
HEPES, BSA, insulin, hydrocortisone, antibiotics, fish skin 
gelatin and methylcellulose were from Sigma (St L06is, 
MO); equine scrum and fetal bovine serum from GIBCO 
. I 
(Grand Island, NY); epIdermal growth factor from UBI 
I 
(Lakc Placid, NY); and 4,6-diamidin-2-phenylindol-dihy-
drochloride from Boehringer-Mannheim (Indianapolis, IN). 
A monoclonal antibody to human breast cancer cathepsid D 
was purchased from BioSys (Compiegne, France). FIJo-
rescein-conjugated affinity-purified donkey anti-rabbit IgG, 
Texas red-conjugated affinity-purified donkey anti-moJse 
IgG and normal donkey scrum were obtained from Jacksbn 
ImmunoResearch (Wcst Grove, PA); formaldehyde fr~m 
Polyscienccs (Warrington, PA); and SlowFade anti-fade 
reagent from Molecular Probes (Eugene, OR). The micrp-
biological grade gelatin used for embedding of tissues aryd 
glutaraldehyde were purchased from Merck (Darmstadt, 
Germany); para formaldehyde from BDH (Poole, Unit~d 
Kingdom); fraction V BSA from Boehringer-Mannheim 
I 
(Mannhcim, Germany); and 10 and 15 nm protein A-golp. 
probes from Drs. Slot and Posthuma, Department of Cell 
I 
Biology, University of Utrecht, The Netherlands. The rabbit 
an ti-ch icken Ig Y used in immunogold labeling was raise~ 
against Jg Y isolated from eggs of non-immunized chickens 
using polyethylene glycol precipitation.26 Rabbit anti-chick-
cn IgY-horseradish peroxidase was prepai'ed as previousl~ 
describcd.s All other chcmicals were of reagent grade and 
were obtained from commercial' sources. \ 
Cell lilies alld cultllre 
MCF-IO is a diploid human breast cpithelial cell line 
derived from a patient with fibrocystic breast disease. This! 
line underwent spontaneous immortalization in culture llnd\ 
grows attached in the presence of calcium or floating in l 
the absence of calciulll. J5 Transfcction and cotransfcctions \. 
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Figure 2. Immunocytochemical colocalizatioll of intracellular 
cathepsin Band cathepsin ·D in immortal MCF-I0A'cells (A) 
and their counterpart transfected with ollcogenic ras (B). 
Vesicles staining for cathepsin B alone are indicated with 
arrowheads and those staining for cathepsin D alone are indi-
cated with arrows. Vesicles staining yellow indicate possible 
colocalization. Primary antibodies were rabbit anti-human 
cathepsin B IgG and mouse anti-human cathepsin D IgGl . 
Fluorescein-conjugated affinity-purified donkClj anti-rabbit 
. IgG and Texas red-conjugated affinity-purified donkey anti-
mouse IgG were used as secondary antibodies. The double 
labelillg for catlzepsins Band D has been repeated six times to 
date with comparable results. Only a weak background fluores-
~ence was observed in controls in which rabbit or mouse pre-
Immune IgG replaced the primanj antibodies (not illustrated). 
Bars, 10 )-1m. 
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were performed using the calcium phosphate ~lethod with 
a plasmid containing the neomycin resistance gene as a 
transfeclion vector either alone (MCF-lOAneo) or with 
conslructs containing wild-type (MCF-lOAnebN) or mu-
tated (MCF-IOAneoT) c-Ha-ras.4 The MCF-lO lines were 
grown in Dulbecco's modified Eagle's m~dium and 
Ham's F-12 nutrient mixture, containing 5%\ equine se-
rum, supplemented with insulin, hydrocOltis6ne, epider-
mal growth factor, antibiotics and fungizOlie,4.25.35 but 
I 
without amphotericin and cholera toxin.33 The MCF-7 and 
BT20 human breast carcinoma lines were gro~n in mini-
mal essential medium containing 10% fetal bo1vine serum 
as recommended by the ATCC (Rockville, MD). All cell 
lines were screened on a routine basis with 4' ,6-diami-
din-2-phenylindol-dihydrochloride and shownl to pe free, 
of Mycoplasma, 
Immunochemical studies 
Preparation of monospecific anti-cathepsin BIgGs and 
anti-cathepsin D Ig y" Cathepsin B antisera wete raised in 
rabbits as described.21 An IgG fraction was phrified and 
stored at -20°C. The specificity of the IgG use~ for immu-
nofluorescence labeling of cathepsin B has been confirm-
ed by slotblotting and immunoblotting against! crude and 
purified cathepsin B fractions from hpman live~ and sarco-
ma,21 acetone fractions of human colonic mucosa and 
·colon tumors5 and cell homogenates of hurhan breast 
epithelial cells?) Immunogold labeling for dthepsin B 
was performed using an affinity purified anti-hhman liver 
cathepsin B antibody, kindly supplied by Drs. L~kas Mach 
and Josef GlOssl, Zentrum filr Angewandte Gehetik, Uni-
versiUit fUr Bodenkultur, Vienna, Austria. The production 
and specificity of this antibody was reported previously. I? 
Cathepsin D was purified from porcine spleen: according 
III the method of Jacobs et a1. 14 Laying hens wer~ immuniz-
ed with 100 flg of porcine cathepsin D (50 flg into each 
breast muscle). The antigen was triturated in f 1:1 ratio 
with Freund's complete adjuvant at 0 wk and in Freund's 
incomplete adjuvant at 1, 2, 4 and 6 wk and f6r monthly 
I 
boosters thereafter. Eggs were collected on a daily basis. 
IgY was isolated from the yolks by precipit~tion with 
polyethylene glycol as described.26 The specificity of the 
Ig Y for cathepsin D was confirr~ed by immupoblotting 
agmnst crude and pUrIfied cathepslI1 D fractions (data not 
shown). I .1: 
Immunofluorescent staining: Intracellular cathepsins B 
and D and surface cathepsin B were localizeb using a 
modification33 of the general immunocytochemibal metho-
dologies described by Willingharn.36 Cells grown to 
60-80% confluence on glass coverslips were fixed with 
3.7% formaldehyde in phosphate-buffered salinb, pH 7.4. 
Fixation and subsequent steps were performed at 25°C for 
intracellular labeling and at 4 °C for surfacel labeling. 
After washing with phosphate-buffered saline, bells were 
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blocked with phosphate-buffered saline-2 mg/ml BSA. 
For intracellular labeling, all subsequent antibody and 
wash solutions contained 0.1 % saponin; saponin was not 
used in the surface labeling studies. Cells were incubatcd 
with primary antibody (rabbit anti-human liver cathepsin 
S, mouse anti-human breast cancer cathepsin D IgG I) for 
2h and washed. Surface labeling was performed on cells 
incubated with primary and secondary antibodies at 4°C 
prior to fixation for the breast epith~lial cells. For .the 
breast carcinoma cells, surface labeling was performed 
subsequent to fixation at 4°C as these cells detached from 
I 
I . 
the substratum at 40°C. In contro s, I prelmmune serum 
(rabbit or mouse) was substituted for the primary anti-
body. After blocking with normal donkey serum (5 % in 
phosphate-buffered saline-O.l % saponin for intracellular 
staining l and without saponin for surface staining), cells 
were incubated for 60 min with fluorescein-conjugated 
affinity-purified donkey anti-rabbit IgG or Texas red-
conjugated affinity-purified donkey anti-mouse IgG at 20 
).1g1ml. After washing, the coverslips were mounted upside-
down on slides with SlowFade anti-fade reagent and ob-
I 
served with a Zeiss LSM 310 confocal microscope. 
111ll1lunogold stainillg: Cells grown to 60-80% conflu-
ence in T-25 flasks were fixed and processed by a modi-
fication of the method of Griffiths et at'. 10 Cells were fixed 
I , 
in 2% paraformaldehyde containing 0.02% glutaraldehyde 
in 200 mM HEPES buffer, pH 7.3, at 4°C for Ih. After 
washing in phosphate buffer containing 20 mM glycine, 
the fixed monolayers were infiltrated with gelatin [10% 
(mass/vol) bacteriological gelatin phoJphate buffer, Ih at 
37°C] and crosslinked with the primar~ fixative (10 min at 
room temperature). The crosslinked, gelatin-infiltrated cell 
layers were stripped off the plastic and cryoprotected by 
infiltration with 2.1 M sucrose. Block~ were cut, oriented 
for vertical sectioning of cells, frozen in liquid nitrogen 
and ultra-thin frozen sections were cut using an RMC 
MT6000XL ultramicrotome fitted with a CR2000 cryo-
attachment. Sections were collected on 2.3 M sucrose, 
, I 
thawed and mounted on 100 mesh hexagonal copper grids, 
previously formvar- and carbon-coated and glow-discharg-
ed. Thawed, grid-mounted sections were collected on 
I 
, 
O.l % f,.,,,;on V BSA ;0 pho,ph", bn rro< pdm fo l'b'Hng. 
The grids were labeled as described by Slot et al. 34 Non-
. I 
specific binding sites on the sections were plocked by 
incubation in 2% fish skin gelatin and 20 111M glycine in 
phosphate buffer. Incubation on primar~ antibody 
(chicken anti-porcine spleen cathepsin D IgY or rabbit 
anti-human liver cathepsin B IgG, 10 ).1g/ml) w:as for Ih at 
25°C. Incubation in the anti-porcine spleen 'iath~psin D 
IgY required an additional incubation step wah a rabbit 
anti-chickcn linker antibody (1: 100 dilution! for Ih at 
25°C). For single labeling, the grids were then incubated 
for 30 min at 25°C with a I :40 dilution of protein A-gold 
probe (mean particle size of 10 nm) before bei~1 g washed, 
fixed with 2% glutaraldehyde, counterstained and sealed 
in a uranyl acetate/methyl cellulose mixture a described 
I 
by Slot et al. 34 Double labeling was performe1 by r,epeti-
tion of the blocking and labeling regime described, the 
detection of antibody-binding to the second anfigen being 
detected using a 1 :55 dilution of a second protein A-gold 
probe (mean particle size of 15 nm). Labeling specificity 
was verified by the omission of primary and secondary 
antibodies in various labeling schemes, and t~e perform-
ance of labeling for the two different antigens In different 
orders, using detection with first the small a~d then the 
large gold labels, according to Slot et a1.34 Grids were 
viewed and photographed in a Jeot 100 CX ttansmission 
electron microscope, at 100 kY. 
Results 
We have previously established that the lys9somal cys-
teine protease cathepsin B is distributed more perfpherally in 
MCF-lOA human breast epithelial cells transfected with 
oncogenic !"as. 33 Rochefort and colleagues havJ shown an 
I 
association between the presence of cathepsin [i) in ph ago-
Iysosomes near the cell surface of human breast f arcinomas 
and prognosis.30 Therefore, we determined whether the 
subcellular localization of cathepsin D also wad altered .. In . 
the parental lOA cells, the staining for catheJsin ', D was 
I 
localized primarily to the perinuclear region (Fig.) A); a 
localization consistent with cathepsin D being di~tributed in 
Figure 3. I1I1111l1nogoid labeling for cathepsin B and cathepsin D in immortal MCF-lOA cells. Cell monolayers were fixed with 2% 
paraformaldehyde containing 0.02% g!utaraldehyde, ell1~edded .with gelatin, refixed, and the gelatin-infiltrated mondlayer, cryo-
protected w.lth 2.1 M sucrose, was stripped off the pla~tlc, cut 11110 bloc~s, mounted for vertical sectioning of cells an~1 frozen for 
cryoultr~l1l1crotoI11Y·. ll11l11LlI1~labelmg for c~tlzepsll1 ~ and p on the sectlOlls ~as pe1formed u~ing all affinity, purified rabbit anti-
hUl11an IlVcr cathcps1ll B antibody and a chicken antl-porcme cathepsl1l D antIbody. For protel11 A gold labcllng using the chicken 
al1ti-po~c!ne D all~ibody, a lillk~r (ra~bit i anti-chick~n antibody) was used. Labeling was pelformed for cathepsin r and then 
cathep~1Il D, alld vice ve~'sa, labelll1g bell1g ~elecle1 uS.l11g a small (10 11111) followed by a larger (15 nm) protein A gold probe, in each 
case. Sll1l1lar colocail~atlOlI results were. observed II: either case. C01:tro!s for dOllble labelillg indicated adequate blockins 'of sections . 
between dou~le labellllg steps. In the 1I~lcrographs Illu~trated, 10calizatlOIl of cathepslIl B was performed first and de!ecfed with the 
10 111n protel1l .A gold probe and labell~1g for cathepsll1 D was pelfo1'11~ed ~lIbsequently and detected with a 15 nm gqld probe. A 
transverse sectIOn of aJl MCF-lOA cell IS shown (A; basolater~l surface IIldlcated With open arrows). Generally, cathepsins Band D 
'f!lere fou~'ld to co!ocallze III th~. l11ore electron-~ense, larger veSicles (presulllably late endosol1!al or lysosomal ~ompartn1eltts) ~ituated 
III a perl11uclem locatIOn (allowheads). V,eslcles selected for enlargement (B and C) mdlcate colocalzzatlOn more clearly. Nu = 
lIucleus, g = Golgi apparatus . Bars, 1/-1111 (A) and 0.2 /.11ll (B alld C). . 
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lysosomes. In the ras-transfected neoT cells (Fig.} B), both 
perinuclear and peripheral staining for cathepsin D was 
observed . Thus, cathepsin D exhibited a more peripheral 
subcellular distribution in the neoT cells, a pattern similar to 
. I • • 
" \ . ' I 
that observed previously for cathepsin B.3;! In order to 
whether the two enzymes were distributed in the same 
les, we perfonned double labeling studies. In the i 
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colocalized in perinuclear vesicles (Fig.2 A). A different pat-
tern was observed in the neoT cells transfected with mutated 
ras (Fig.2 B). The distribution of both enzymes was more 
peripheral and three patterns of vesicular staining were 
observed: I) vesicles staining for both enzymes, 2) vesicles 
staining for only cathepsin B, and 3) vesicles staining for 
only cathepsin D. Vesicles staining for cathepsins Band D, 
cathepsin B or cathepsin D appeared to be of similar sizes. 
The peripheral vesicles staining for cathepsin D may be 
endosomes as endosomes containing cathepsin D have been 
observed in macrophages29 and hepatocytes7 or may be the 
phagolysosomes described by Rochefort and colleagues.23.30 
In order to determine the localization of cathepsins Band 
D at the ultrastructural level, we employed immunogold 
double~ labeling. In the immortal lOA cells, cathepsins B 
and D were largely colocalized in ' perinuclear vesicles 
(Figs.3 A, B, alld C, arrowheads). In contrast, in the neoT 
I 
cells transfected with mutated ras, a more peripheral dis-
I 
tribution of the gold labeling for both enzymes was observ-
ed, including increased labeling on the cell surface (Figs.4 
A and B): The majority of Iperipheral vesicles exhibited 
label for only one of the two cathepsins (Fig.4 A, C and 
D). Gold particles representing cathepsin D protein could 
be observed apparently in the procds of being secreted 
from surface protrusions of the neoT 'cells ( Fig.4 B). The 
I 
most numerous cathepsin D- and B-Iabeled organelles in 
the immortal . lOA cells (!fig.3) we~e of the order of 
0.14-0.19 )lm in diameter, whereas in the ras-transfected , 
neoT cells these vesicles were 0.1-0.13 )lm in diameter 
(Fig.4). In the lOA cells, occasional vesicles (0.5-0.54)lm 
in diameter) were observed that resembled phagolyso-
somes and labeled heavily for cathepsin D. Larger phago-
lysosomes (0.5-1 )lm in diameter) were observed in the 
neoT cells where they labeled more heavily for cathepsin 
B than for cathepsin D (Fig.4 C). 
Cell surface labeling for cathepsin B has been observed 
by immunofluorescence techniques i~ human lung carci-
noma cells9 and murine B16 amelanotic melanoma cells. 12 
In order to evaluate whether, the. imm\mogold labeling for 
cathepsjn B observed in ras transfecte~ neoT cells33 (Fig.4) 
was on the external surface of the cells. we performed im-
munofl~orescence staining I i~ non-permeabilized cells. 
Staining for cathepsin B was not observed on the surface of 
the immortal lOA cells (Fig.5 A), but was present on the 
I 
I 
I I. I 
I 
sUiface of the ras-transfected neoT cells ( Fig. 511 B). In these 
latter cells, the staining for cathepsin B was localized to 
discrete regions on the basal surface. For cathepsin D, some 
cell surface labeling was observed on immortal lOA cells, 
yet substantially more cell surface labeling on the ras-trans-
fected neoT cells (data not shown). As indicat~d above, in 
these confocal studies, the cell surface labelink was local-
ized primarily to the basal surface of the cell~ with apical 
labeling only in a few cells. By the immunogold method, 
apical labeling was observed rather than baSal\ (Figs.3 and 
4). However, this latter technique may not be optimal for 
examining basal membrane expression of cathepsins as the 
surface-bound cathepsins may be lost when t~e cells were 
stripped off the plates (see Materials and ~ethods). By 
contrast, in the immunofluorescence method, the cells were 
examined without removal from the coverslips. ! 
Studies in human colon carcinomas,s prostate carci-
nomas31 and gliomas27 suggest that altered trhltIcking of 
cathepsin B is part of the malignant phenotypb. Rochefort 
and colleagues.3o have shown that altered trkfficking of 
cathepsin D rriay be of prognostic significan2e in human 
breast carcinomas. As similar studies have n6t been per-
formed for cathepsin B, we analyzed the intra'cellular and 
surface distribution of cathepsin B in two h~man breast 
carcinoma lines, MCF-7 and BT2D. In both lihes, cathep-
sin B was found to be distributed througho~t the cyto- . 
plasm rather than being restricted to the perinu:clear region 
(Fig.6 A alld C). The sizes of the vesicles labeling for 
cathepsin B could not be accurately determirled in these 
immunofluorescen.t images. In ?oth MCF-71 and BT20 
cells. surface labelIng for catheps111 B was observed (Fig.6 
B and D). As in the ras-transfected MCF-lOtneoT cells 
(Fig.5 B), surface staining for cathepsin B wlas found at' 
discrete regions on the basal surface of the-cells . . -
Discussion 
Trafficking by two distinct pathways might be respon-
sibl.e for cath~psin~ Band D being localized I in separate 
penpheral veSIcles 111 the ras-transfected neoT cells (Figs.2 
I 
and 4). Studies to date suggest that cathepsin B tS trafficked 
to the Iysosomes via a MPR-dependent pathway."·17 On 
the other hand, cathepsin D has been shown tolbe traffick-
ed by both MPR-dependenr2,16.19 and MPR-independent 
. .' I 
Figure 4. Immun~gold labeling for cathepsin B Imd ca~hepsin D ill MCF-lOAneoT cells transfected with oncogenic ras. Cell 
lIlol/olayers were fixed,. embedded, and proces~ed f~r vertical cryoultrall1icrotomy sectioning and immunolabeling for tathepsins B . 
and 0 was perfol~lI1ed, m both orders,.as described m theJegend to Fig. 3. In the micrographs illustrated, localization o/Jcathepsin 0 
was pl!lformed first and dete~te4 wIth a 10 nll1 protem A gold probe (A and B) and labeling for cathepsin B was performed 
subsequ.ently ~nd detected U!'th a 15 n111 gold probe. Immuno!abelin$ was also performed in the reverse sequencel (C 'and D), I 
catheps.m B being detect~d with the sl1~all go!d probe an.d cathepsm 0 with the larger probe. A transverse section of a cell, shows less 
col~callzatlol1 at cathepsllls Band 0 III perlph~ral regl~l1s (A) [basolateral surface .indicated with ~n open ar!'ow (A)], and in sub-
permuclear regIOns of the cell (C an~ f!), than m the fmental MCF-lOA cells (cf. Fig. 3). Some penpheral veSicles appear caught in 
th~ proc~ss of secretIOn (A). ASSOCIatIOn of cathepsm B (arrows) and cathepsin 0 (arrowheads) with the surface alii cells is also 
eVldellt 111 the ras-transfected neaT cells (A and B). g = Golgi apparatus. Bars, 0.25 flm (A, B and D) and 0.51w1 (C). 
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pathways.2H.31 Although the peripheral vesicles labeling for 
either cathepsin B or cathepsin D might represent two 
different vesicular compartments, this would appear to be 
unlikely as the sizes of the vesicles are similar. Another 
possibility is that one compartment might contain only pro 
forms of the two cathepsins and the other mature forms. 
However, as the antibodies used in the present study rec-
ognize both pro and mature forms of cathepsins Band D, 
both compartments should stain ' for the two enzymes. 
Thus, at present the identity of the peripheral vesicles 
staining for only cathepsin B or for only cathepsin D is 
unknown. Studies to establish the molecular forms of 
cathepsins Band D associated with the cell surfac~ and 
thcse peripheral vesicles and the identity of these I peri-
pheral vesicles are in progress. I 
Rochefort and colleagues have proposed that intracellu-
lar cathepsin D plays a functional role in breast carcinoma, 
specifically in the degradation of extracellular n\atrix 
proteins in a peripheral compartment of phagolysosorlles.23 
In the present study by immunogold labeling, we locdlized 
Figllre 5. 11;1II1l1110cytpcltelllienllocnlizlltioll of enl~lepsill BOil tlte s~lrfn~e of 1101I-jJerllleabilized MCF-lO Itlllllnn 
brenst epitltelinl cells. SlIrfnce stnillillg for entlll:pS111 B wns prescllt III dls~rete reS/oII~ on tlte bnsnl slIrfnce of lite 
cells trallsfeeted witlt /nlltnted ras (B) . SlIrfnce stnillillg cOllld lI?t be V1SIl11f1z~d 011 tlte 11!ll1lOrtnll0A cells (A). Tlte 
covers lips were 1II0uI/ted upside-dowII 011 slides. Tilus, the Inbcl111g observed 111 pnllel ~ /s tII/demenllt the ce!ls. Tlte 
primnry nlltibody wns rabbit nllti-lllIlllnll cnllll:psill B IgG nlld Ihe secoII~nry nlll/body .Texns red-colIJllgnted 
dOl/key nllti-rabbit IgG. The sit/iII illS for cnlhepsill B hn.s been repen!ed tll1.'ec tlllles.lo dnt~ wllh cOlI/pnrable reslIlts. 
Gilly n wenk bnckgroUlld f/llorescellce wns observed III cOlllrols III which ~nbbll pre-IIl1l11l1l1e IgG replnced the 
primnry nntibody (1101 illllstrated). Pallcls C alld 0 arc the phnse cOlltmst l1IInges correspolldlllg 10 Ihe flllores-
cence illlages of pn II cls A nnd 8, n:spcctir'cly. Bnrs, 10 /'111. 
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cathepsin D to phagolysosomes primarily in immortal lOA 
cells and cathepsin 13 to phagolysosomes primarily in ras-
transfected neoT cells. We also localized both cathepsins 
Band D to smaller peripheral vesicles and to surface 
membranes of the ras-transfected neoT cells. To our know-
ledge, the present study is the first to localize cathepsin 
D to the cell surface by immunogold techniques. Three 
lysosomal proteases have now been localized to the sur-
face of malignant cells: cathepsin D to the surface of ras-
transfected neoT cells by immunogold microscopy (pre-
sent study) ; cathepsin B to the surface of I) human lung 
I 
adenocarcinoma cells by immunofluorescenc<f microsco-
py,9 2) murine B 16 amelanotic melanoma cells and ras-
transfected neaT cells by immunofluoresence Imicroscopy 
and flow cytometric analysis,12 3) ras-trans~ected neoT 
cells by immunogold microscopy33 (present study), and 4) 
ras-transfected neoT cells and MCF-7 and B human 
breast carcinoma cells by immunofl 
copy (present study); and cathepsin L to 
human colon adenocarcinoma cells by 
Figllre 6. Immullocytochemicallocalization i~ MCF-7 (A, B) and BT20 (C D) human breast carcinom.a 
intracellula: cathep~in B (A and C) and cell surface cathepsin B (B and D). In'tracellular cathepsin B stain 
breast ~arcllloma lmes was present throughout the cytoplasm and at the cell periphery. Surface sta 
cath~psm .B was preswt 0~1 the bas,al surface of both cell .lines (see legend to Fig. 5). The primary antibody . 
rab?l~ antI-human c~thepsm B IgG and the secondary antIbody Texas red-conjugated dOl1key anti-rabbit IgG. The 
stal~lIlg for cathepsin .B ha~ been repe~ted tI~ree tim~s to ~ate with comparable results. Only a weak backgrolmd 
f/uolescence was observed III controls In whIch rabbit prel1l1111Une IgG replaced the pril11al'y antibody (not illus-
trated). Bars, 10 ].1m. i I 
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cence microscopy. We do not yet know whether surface 
associated lysosomal proteases playa functional role in 
tumor progression. This possibility is suggested by the 
ability to induce concomitantly in malignant cells the 
surface expression of cathepsin B, the integrin UllbPJ ' and 
the autocrine motility factor receptor. These three proteins 
could mediate the three putative steps in tumor invasion: 
adhesion, local degradation andmigration. t5 Furthermore, 
the localization of cathepsin B to discrete regions on the 
basal surface of ras-transfected human breast epithelial 
cells and breast carcinoma cells resembles the localization 
of proteases to the invadopodia described by Chen and 
colleagues,22 a structure shown to be involved in cell adhe-
sion, focal degradation and invasion.24 , 
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Anti-catheI sin D chicken IgY antibodies: Characterisation, 
cross-species : ·ec.ctivity and application in imrnunogold labelling 
of h .1nlan splenic neutrophils and fibroblasts 
Pllilip H. Fortgens, Clive Dennison, Edith Elliott • 
Otparrm.enl uf Bioc 'lemi ;try. Ullit!(rsity of NaUlI. Prit:art Bag X01 . ScallJL!ille 3209, Pimrl?Ulril1.burg. South Africa 
Abstract 
Hyperexpression, alter;;ltl )O (If trafficking and secretion of cathepsin D has been linked wirh rumour invasion and 
inflammation. TO srudy thne J:hc:nomcna in a valiety of cells large quantitie~ of anti·cathepsin D antibodies and the 
appropriate immunogen arc required. As the h\lman immunogen for studies on human tissue is less easily accessed. 
antibodies to both human lin I pOl cine cathepsin D were raised in chickem, <I~ high levels of antibody may ~ recovered from 
egg yolks, and the potential ero is-reactivity of the anti-porcine cathepsin D IgY antibody was assessed. This preparation 
cross-reacted strongly with lUm ill cathepsin D, comparing favourably with the reactivity of the chicken antibody to the 
human immunogen. The ne 'essity for isolating human immunogen can thu~ be circumvented. The cross-species-reacting 
chicken IgY was successful y used to localise cathepsin D in immunogold labelling of human tissues, To Our knowledge. 
IgY antibodies have no! pr !vio Jsly been used by other rese~rchers for this PUIlJOSe, Application of rhe cross-r~<lt:ljng 
antibody to human splenic neulfophils (PMNs) has conflmled I..'le presence of cathepsin D in some granules. D(,ubk 
labelling has shown these to be. Ilove! subpopuiations of az.urophil granules. Cathepsin D may. therefore. be relevant in the 
invasive and inflammatory < ;tivities of PMNs and it tatgel for therapeutit: strategies. 
K<y ..... vrlis ; Chicken .mti-{;a:he~ ,n 0 I¥Y ; Cro~~·spe.;ies reacuvit)'; lnununogold labctlin&; Ncutrophil~; Fibroblasts 
1. Introduction 
Our interest in cathep! ill I) , a lysosomal aspartic 
proteinase, centres on the Dos)ible common role that 
this enzyme may play i 1 tr.e invasion process of 
me:.astatic tumours (Liaut et (t ai. , 1994; Rochefort, 
Abbrevialiom: AlHS. 2,2 · azino·di-()~thyl)..henzthiozolin, 
.ulpl1onic acid; BSA-PBS. bovir ~ Strum albumin in PBS; EL.ISA. 
enzyrn.:·Ii.nXed imrnunosorbent 115$9.J; FeS. foetal calf serum: 
PBS. phosphate buffered s.alinc. PB~ ·Tw~.n , Tween 20 in PBS; 
PEG. polyethyletlt. glycol; PM!'; polJmorphonuclear neutrophil 
• Com:spondini author, Tel. +::7·331·2605455; fax: +27-
331·2605462: e·mail: cllion~ur :)sunl .cc.unp. at;.z.a. 
1992) and in inflammatory leucocytes such as 
macrophages (Bever et aJ.. 1989) and polymor-
phonuclear neutrophils (PMNs) (Ishikawa and Cirna-
soni, 1977; Barabasi and Nassberger, 1994; Elliott et 
al., 1995), We have elected to study the relevance of 
cathepsin D in this phenomenon, by screening a 
large variety of tumour and innamrnatory ti$sues, 
using immunocytochemical te(.:hniques . For such a 
screening programme a primary requirement is a 
large quantity of anti-carh.epsin D antibody, capable 
of strong, specific recognition of the enzyme in 
human tissue . 
Human tissue, as a SOurce material for immuno-
0162·3109 / 97 / $)S ,OO Copyrig: [ ;C' 1997 El~vier S~ience S.v , All rights resel'fed. 
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gcn isolation, is problemat c \\ ith respect to accessi-
bility and disease risk. Thi i provided the motivation 
for the present investigatio I of the cross-reactivity of 
anti-cathepsin D antibodi< s, raised against the en-
2:yme isolated from anima . tis$ues, with the human 
enzyme. 
In this study antibodies Igainst human and porcine 
cathepsins D rai.$ed in cl ,ick'ms (IgY) were com-
pared with respect to t.h ~jr ability to react with 
human cathepsin D. The r ltiollale of the latter com-
bination was that the soure! (pig) and target (human) 
species are relatively clo ! ~ , in phylogenetic terms, 
which should favour anti >od;! cross-reactivity, but 
are distant from the spt.ci ~s (;hicken) in whkh the 
antibodies were raised, ' ,hich should favour im-
. munogenicity. Chicken an :i-porcine 19Y was subse-
quently used to probe f( r c.lthepsin D ' in human 
spleen tissue, using immuJ oge ld. To our knowledge, 
IgY has not previously b :<!n used for irrununogold 
labelling studies. An adv(lltage of IgY antibodies is 
that milligram amounts of IgY can be isolated from 
each egg. 
CathepSin D has previc :.I~l) been demonstrated to 
occur in PMNs (Ishika1/a and Cimasoni, 1977; 
Barabasi and Niissberger, 1994; Elliott et aI. , 1995) 
and fibroblast.'> (Mort et (I. , 1981). This study COn-
firms the presence of cat \ep! in D in fibroblasts . It 
also describes double la >elling studies of PMNs. 
using immunogold probes of different size. the anti· 
porcine cathepsin D IgY c e$clibed in this paper. and 
a previously characterised anti-elastase antibody (EI· 
liott et al" 1995). Labdling re.su!ts suggest tliat 
cathepsin D occurs in Sl bpopulations of azurophil 
granules. How such sub\ opulations may arise and 
the possible relevance of ' ath~psin D in the inv&ive 
activities of inflammatory PMNs is discussed. 
2. MateriaJ~ and methoo s 
2.1. Cathepsin D purifica 'ion 
Cathepsin D was pur; fied from human , porcine 
and bovine spleens as pI !vic usly described (Jacobs 
et aL 1989). 
Purified human and porcine cathepsins D (100 
~g) were each triturated with adjuvant and injected 
mto the breast muscle: of two laying hens (Polson el 
aI., 1980). Freund's complete adjuvant (Difco) was 
used for the first immunisation and Freund's im:om-
plete adjuvant (Difco) at 1, 2, 4.6 and 10 weeks and 
for monthly boosters thereafter. Eggs were collected . 
on a daily basis. 
2.3. Isolation of Ig Y 
Egg yolks were freed of adherinll albumin the .. . , 
yolk sac was punctured and its contents diluted in 2 
volumes of 100 mM Na-phosphate buffer (pH 7.6) 
and precipitated with PEG-6000 (polyethylene gly-
col-6(00), added to 3.5% (w I v). After centrifuga-
tion (4420 X g , 30 min, room temperature) the su-
pernatant was filtered through a loose plug of collon-
wool and the concentration of PEG-6000 in the clear 
filtrate was increased to 12% (w/ v). The precipitate 
was harvested by centrifugation (12000 X g I 10 min. 
room temperature) and redissolved in phosphate 
buffer (Polson et aI .. 1985; Rowland et aI., 1986). 
An extinction coefficient of 1.2.5 mljrng/cm at 280 
nm was used to detennine IgY concentration. 
Chicken antibodies were diluted I: 1 with glycerol 
and stored at - 20¢C. Exposure to low temperature 
often resulted in the formation of a lipid precipitate 
which could be filtered off, with no loss of antibody 
yield or titre. 
2.4. Enzyme-linked immlmosorbent assay (ELISA) 
The progress of inoculation or the ability of anti-
bodies to cross-react with cathepsin D from different 
species was measured by ELISAs. Microtitre plate 
wells (Nunc Immunoplate) were coated overnight at 
room temperature with enzyme (2 J,tg/mD in phos-
phate-buffered saline (PBS), pH 7.2. Wells were 
blocked with 0.5% (w / v) bovine serum albumin.PBS 
(BSA-PBS) (200 }.(oJ) for 1 h at 37°C and washed 
3 X with 0.1 % (v I v) Tween 20 in PBS (PBS-
Tween). Dilutions of the primary antibody in BSA-
PBS (100 ~d) were added, incubated at 37°C for 2 h 
and excess antibody washed out with PBS-Tween. 
A 1/750 dilution of rabbit anti-chicken IgY-
horseradish peroxidase (120 j.l.J) was added and incu-
P.H. Fongtns el al. / lmmuT'.Cphannaco(ogy 00 (19971000-000 3 
bated at 37"C for 30 mi J. T'he ABTS substrate 
(0.05% (w/v) in 150 mM cirruc-phosphate buffer, 
pH 5.0, containing 0.0015~ ) (v Iv) H20 2) (150 ,un 
' was added and incubated ' or (5 min. The enzyme 
re:action was stopped by the addition of 0.1 % (w Iv) 
NaN) in citrate-phosphate buffer (50 ,ul) and the 
absorbance read at 405 nm n all ELISA plate reader. 
2.5. Immunob/otting 
Antibody specificity wa: asc;ertained by immuno· 
blotting, essentially as pre, IOU! ly described (Coetzer 
et al., 1991). 
2.6. Immunogold labelling '11 hun-w.n splenic tissues 
Gold probes were prod\! ~ed by the method of Slot 
and Geuze (1985) and befl ·re lise were diluted to an 
absorbance of between 0 05 and 0.1 at 520 nm. 
Samples of red pulp from a spleen provided by the 
Depanment of Surgery. 1 iniversity of Natal, were 
fixed (20 min) in a mixturE of ·1% (w/v) paraformal-
dehyde and 0.1% (v/v) 8Iut3\'aldehyde in 100 mM 
sodium cacodylate, pH 7.1. cr in 8% (w/v) para-
formaldehyde in )0 roM Na-phosphate, 150 roM 
NaCI, 2.5 mM KCl, pH 9.11. Tissue blocks (ca. 1 mm 
cubes) were infiltrated wid 2.3 M sucrose and rapidly 
frozen in liquid nitroge 1 fl)[ cryoultrasectioning 
(Griffiths et aL, 1983). Sf ~tio\,s (approximately 100 
nm thick) were cut using in RMC MT6000XL ultra· 
microtome fitted with a CF 2000 cryoattacrunent. 
Sections were collected (n 2.3 M sucrose, thawed 
and mounted on ) 00 me5 ~ h,~xagona1 copper grids, 
previously fonnvar- and c. trbon·coated and glow·dis-
charged. Thawed, grid-m .JUnfed sections were col· 
lected on 20 mM glycin ~ in PBS and labeiled as 
described by Slot et al. (I }9t). Non-specific binding 
sites on the sections were bl()cked by jncubation in 
10% (v Iv) foetal calf ! ~ruIn (FeS) and 20 mM 
glycine in PBS. For singe labelling. incubation on 
primary antibody (226 J.I. ~/Dll chicken anti-porcine 
cathepsin D 19Y diluted i \ 5% (v /v) FeS in PBS, 1 
h) was followed by inc ubs':ion on a rabbit anti-
chicken IgY linker antise urn (l/200 dilution in 5% 
FeS in PBS. 1 h). After wa:;hing. grids were incu-
bated (30 min) on a gc at ,nti·rabbit immunogold 
probe. 
Double labelling was l-erfc1nned using the method 
of Slot e.t al. (1991). The first and linker antibodies 
(chicken anti-porcine cathepsin D IgY and rabbit 
anti-IgY antiserum, diluted as before) were detected 
using a 3 nm protein A-gold probe. A fixation step 
(1 % glutaraldehyde in PBS, 5 min) was included 
before the blocking and labelling regime were re-
pealed. this time with rabbit anti-human elastaSe 
(Athens Research and Technology, Athens, GA) di-
luted to 88 ,ug/mt and detected using a 10 nm 
protein A·gold probe. Grids were washed, counter· 
stained and sealed in a uranyl acetate/methyl cellu-
lose mixture (Griffiths et aL, 1983). Sections were 
viewed and photographed in a Jeol lOOCX transmis-
sion electron microscope, at 100 kY. 
For controls for single labellings, pre-immune 
IgY antibodies were substituted into the labelling 
regime, at the same level of IgY as in the test. For 
double labelling, specificity was verified by the 
omission of primary and secondary antibodies and 
by labelling for the two different antigens in differ-
ent orders, using detection with first the small and 
then the large gold labels (Slot et aI., 1991). 
3. Results 
3.1. Chicken anti· human and anti-porcine cathepsin 
D 19 Y production 
Immunisation of hens with human cathepsin D 
resulted in a peak of antibody production at 8 weeks 
and a plateau until 12 weeks (Fig. J). Porcine 
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Fii· 1. ELISA at' the progress of immunisation of:! representative 
etu(;k~n inocu\a[ed with human cathepsin D. Human cathepSin D 
Wl\$ coated at 2 jJ.g/mJ. incubated wilh serial two-fold dilutions 
of chicken anti-human cathepSin D and the microtitre plate devel-
oped as descnbed in Section 2. Chicken IiY from week 4 (u). s 
(5). 12 (x) and pre-immune liY (D). 
-~-.. . -----











-I o I 2 
log{[: ;V) ':I-Lg/ml)} 
Fig. 2. ELISA of the progress of 'Jllm misation of a representath'c 
chicken inoculated with porcine athe )sin D. Porcine cathepsin D 
was COaled at 2 JL8 / ml. incuba ~ I'.ith serilll two·fold dillltions 
of chicken anri-porcine cathepsi \ D ~nd the plate developed as 
described ;n Section 2. Chicken IgY from week 4 (u). g (s). 12 
( X) OVId pre-immune I,y (D). 
significant titre apparent! fter 4 weeks (Fig. 2). The 
titre peaked at 8 weeks. \\ ith H slight reduction at 12 
weeks. Eetween 50 and 150 mg of IgY could be 
purified per yolk, depenc ing on the yolk size and 
differences between indiv dual chickens. 
3.2. Specificity of chickel Gnti-porcine cathepsin D 
IgY 
Western blot analyses of the antibody revealed 
high potency and specific: ty: fhe 45 kDa singJe-chain 
cathepsin D was targeted n tlle TPP fraction and the 
30 kDa heavy chitin of r No-·~hain cathepsin D was 
recognised even in the m.)St ;rude fraction (Fig. 3). 
3.3. Homologous chicke,l. aNi· human cathepsin D 
reactivity compared to th' cross-species reactitlity of 
chicken anti-porcine cath Ipsi"! D 
Human and bovine (ath( psin D were strongly 
targeted by chicken anti- >orcine cathepsin D IgY in 
an ELISA and only slig Itly more wea.l.dy than the 
porcine antigen, or the h Iman antigen when probed 
with chicken anti·human catl.epsin D IgY (Fig. 4). 
3.4. Immllnogold labcIIin ~ of human splenic Tissues 
Lysosome-like vesicl( $ it: many cells of the red 
pulp tissue labelled for ell :hepsin D. using the chicken 
anti'porcine cathepsin D [gY preparation. Some sub· 




Fig. l Western blot of pu~ and, crude frllcoons of porcino 
cathepsin D incubated with chicken anti·porcine cathepsin D. The 
blot was incubated in 20 J.4g/ ml of immune IgY. Samplc5 were: 
(,,) erode ~upemnrant ; (b) acid supernatant; (c) TPP fraction and 
(d) pwified porcine c,Uhepsin D (JlIcobs tlt aJ .• 1989). The pre.im-
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Fig. 4. ELISA of cros5-ipc:cies reactivjty of chicken anti-por~ine 
c:u~psin D with bovine, porcine and !JUlTWl cathepsin D and a 
comparative reaction of chicken anti-human cathepsin D with 
hUITlllll cathepsin D. The enzyme prep;lT1l1ions were collted ~t"Z 
JLg / ml. incubated with soritU two-fold dilutions of antibody and 
the microtille plate dc:velop<:d as de~cribed in Section 2. CrosNc.-
action of chicken anti-pol\.ine cathepsin 0 IgY witll bovine (n). 
porcine «() and human cathepsin 0 (X); chicken anti·human 
co\thepsjn D with human cathepsin D (=> and pre-irrunune IltY 
with bovine (1/). porcine (~) Md human ;;U~psin D (D), 
P,H, Fongtns II ai, /lmrrumopluJl77UlcQlogy 00 (j997) 000-000 5 
double labelling for catl epsln D and elastase, while 
fibroblasts (Fig, 5b) lab :l1ed for cathepsin D, show 
the. highest labelling d ;nsi'.y, Labelling density is 
apparently not affected ))' the fixation regime used 
(compare Figs, 5 and 5( )), 
4. Discussion 
Cathepsin D immuno ocalisation studies based on 
the cross-species reacti\ :ty I)f antibodies, have been 
previously reported (D< rn Ilt al.I 1986; Andujar et 
aI ., 1989; SaXu et al., 1991)) and the phylogenetic 
distance between marDl1als and chickens has aho 
previously been exploi ted to generate high titre 
chicken antibodies (Vie a el al., 1984; Song el al., 
1985; Stuart et aL, 1988), 
A previous extensive cross-species study of anti· 
cathepsin D antibodies (W!ston and Poole, 1973) 
revealed no cross-reacti< n where the immunogen and 
antigen were from distru tly "elated species, but com-
plete identity among dif 'ere1t bird species when the 
immunogen was chickel . ca\bepsin D, These studies 
employed immunodiffusion techniques, which have 
now been superceded by the more sensitive ELISA 
and western blotting technologies used here, Never-
theless, the general conclusions are supported by the 
results of the present study, 
In the present study, a rabbit anti-bovine catheJr 
sin D antiserum targeted the human eIl2.yme more 
weakly than the porcine enzyme, presumably be-
cause of the greater evolutionary distance of bovines 
from humans than porcines (result not shown). How-
ever, when the immunogen and antigen are from 
more closely relate.d species, and phylogenetically 
distant from the inoculated species, there seems to be 
significant recognition of enzymes across species, 
Thus, chicken anti-porcine cathepsin D recognised 
both the bovine and human enzymes essentially to 
the same degree and similarly to the homologous 
reaction between chicken anti-human cathepsin D 
and human cathepsin D. Furthermore, the chicken 
anti.porcine cathepsin D IgY cross-reacts with mouse 
cathepsin D on westem blOtS, and with rat cathepsin 
D in immunofluorescent labelling (unpublished re-
sults). Comparison of the amino acid sequence of the 
~~~ .. , .' 
Fi\t. 5. 1mmunOj:old labdling )f CTloultrascctions of c~lls in a biopsy of hun\;lll splenic ~<J pilIp ti$$II(: . (3) Section of a human neutrophil 
sho~lng double labelling of • . 1 az lrophil granule for C;lthcpsin D (3 nm prutic!e) and elilSl<lSe (10 nm particle), Tissue flxed \l~;Oi 8% 
pwaformaJdchyde at pH 9.0, 20 jnin. Original magnit\catiOl\ ~O.OOO X , (b) High rnagnifj~~tioll micrOiTBPh of coUagen fibres and a 
lys05omc~likc vesicle in a spIt ue f brobla,${ labelled for cathepsin D (j 0 nm particle). Ti'i5UC: was fixed in 4% paIll.fonnllld~h)'de containing 
0,1 ~ il,u~dehyde at pH 7" , 20 mjn. OTi¥ipa.! ma~ficarion 66,000 X . All controls (nol shown) were ~tisfactory. jn(lic;ating labellin!l 
specificity. Bar scale: 0.1 /Lrn 
6 P.H. FOr1gens el al. / lmmunopitarmacology 00 (1997) 000-000 
human enzyme with tho: e oj' other species. ar~ con-
sistent with these results, with 87% sequence homol-
ogy obtaining between thl~ human and porcine 
cathepsins D (Faust et al. 19 ~5) 81 % homology with 
mouse cathepsin D (Gn sby et aI ., 1990) and 83% 
with rat cathepsin D (I irct, and Lok, 1990). The 
sequence of bovine cath !psin D has not been pub-
lished , 
Cathepsin D has pre' iou:;ly been reponed in fi-
broblasts (Mort et at, J 981) and PMNs (Ishikawa 
and Cimasoni, 1977; Bar tbasi and Nassberger, 1994; 
Elliott et 411., 1995) and is ,)ften used as a marker 
enzyme for the Iysosorr.! oj' the cell (Araki et aI., 
1995). The organelles iT ununolabelled in the colla-
gen-secreting fibroblast: re, by this definition, lyso-
somal compartments. In . he neutrophil. however. the 
double labelling. using t Ie anti-porcine cathepsin D 
IgY and anti-elastase IS J, :.'ep<lrted he.re. has pro-
vided the first indicati, lO ,)f the identity of the 
cathepsin D-containing g 'am: Ie. 
Initially, PMN granul!s \l/ere classilied into two 
groups, the larger '>rimary' or 'azurophi]' , 
myeloperoxidase-contain ng granules and the smaller 
'secondary' (specific) 101< (oferrin-coTltaining granules 
(Bretz and Baggiolini, 197 n. Sub-populations of 
azurophil granules, differ ng J n levels of myeloperox-
id3lie and elastase (Dam ano el aI., 1988; Pryzwan-
sky and Breton-Gorius, : 985) and specific granules, 
varying in their gelatina.!.! C('"tent (Hibbs and Bain-
ton. 1989). have since be 'n discovered, however. We 
have used elastase as a IT ark(:r enzyme for a subpop-
ulation of the azurophil ! ranlJle. 
We have preyjously ;hown that cathepsin D is 
present in early myeloid , :ell~ (unpublished data) and 
using an anti-huma.n catl eps: n D antibody, we have 
also reported that cathe~ ,in D-labelled granules ap-
pear to decrease. relative ~o the total number of other 
granules, with maturatio 1 0 : PMNs (Elliott et aI,. 
1995). In this study. w~ sh(,w that these cathepsin 
D-Iabelled granules are ;ubpopulations of the elas-
tase-labelled subpopulati( n of the aiourophil granules. 
As only SOme popuiatiol S oj" elast4lSe-labelled gran-
ules also labelled for ca hepsin D and cathepsin D 
labelled granules seem te decrease with cell matura· 
tion, we also suggest tl at I:athepsin D expression 
may slowly decrease as • nye(oid differentiation pro-
gresses and elastase exp ession increases. The sub-
population of cathepsin [ -collt.a.ining a2urophil gran-
ules may , therefore, arise at some early period when 
the first population of azurophil granules is synthe-
sised during the early promyelocytic-PMN differenti-
ation phase. At such a time, cathepsin D expression 
may be diminishing as elastase expression is increas-
ing. The overlapping synthesis of these marker en-
zymes for these different slates of differentiation 
may, therefore, co-exist in these early granules. 
The existence of other subpopulations of the dif-
ferent granule types would suggest that this may be a 
phenomenon conunon to all granule types. Our pre-
liminary data supportS such a hypothesis, but further 
quantitative data and cell maturation studies are re-
quired to substantiate these results. It is irnportant'to 
identify the different enzymes present in various 
granule populations and hence classify the popula-
tions and to study the order of their release in 
response to various stimuli in order to devise thera-
peutic strategies for the control of PMN infiltration 
and hence some inflammatory conditions. As neu-
trophils and cancer cells may invade via a common 
mechanism. involving proteolysis, the enzyme in-
volved may be a commonly expressed enzyme such 
as cathepsin D and this enzyme may, therefore, 
constitut~ a target for therapeutic intervention. 10is 
manuscript reports the first of the multiple labelling 
experiments which will be utilised to classify the 
various subpopulations of PMN granules and an 
additional cross-species-reacting antibody that . will 
be used in further studies . 
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